{"07f290f8b7a17164c93fa80eb98ccae4fa503a22": [["Early epidemiological studies suggest the most important predictor of severity of COVID-19 disease course is age.", [["Early epidemiological studies", "TEST", 0, 29]]], ["Pre-existing conditions, including diabetes, CVD, hypertension, obesity and other consequences of an unhealthy lifestyle are also associated with increased mortality, indicating that the biological age is more relevant than the chronological age.", [["diabetes", "DISEASE", 35, 43], ["CVD", "DISEASE", 45, 48], ["hypertension", "DISEASE", 50, 62], ["obesity", "DISEASE", 64, 71], ["Pre-existing conditions", "PROBLEM", 0, 23], ["diabetes", "PROBLEM", 35, 43], ["CVD", "PROBLEM", 45, 48], ["hypertension", "PROBLEM", 50, 62], ["obesity", "PROBLEM", 64, 71], ["increased mortality", "PROBLEM", 146, 165], ["diabetes", "OBSERVATION", 35, 43], ["hypertension", "OBSERVATION", 50, 62], ["obesity", "OBSERVATION", 64, 71], ["unhealthy lifestyle", "OBSERVATION", 101, 120], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["mortality", "OBSERVATION", 156, 165]]], ["Because a reliable COVID-19 vaccine is unlikely to available before the maximal infection of COVID-19 has occurred, it is essential to establish reliable tools for patient stratification and identification of individuals at high risk of severe disease.", [["infection", "DISEASE", 80, 89], ["COVID-19", "CHEMICAL", 93, 101], ["COVID-19", "CELL", 93, 101], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["a reliable COVID-19 vaccine", "TREATMENT", 8, 35], ["the maximal infection", "PROBLEM", 68, 89], ["COVID", "TEST", 93, 98], ["individuals", "PROBLEM", 209, 220], ["severe disease", "PROBLEM", 237, 251], ["severe", "OBSERVATION_MODIFIER", 237, 243], ["disease", "OBSERVATION", 244, 251]]], ["A number of biomarkers aimed at objective estimation of biological age have been developed in the past several years, the most prominent ones being the epigenetic clock and the glycan clock.", [["most prominent", "OBSERVATION_MODIFIER", 122, 136]]], ["A key feature of a good biomarker of biological age is that the difference between chronological and biological age should correlate with known biomarkers of unhealthy lifestyle and that increased biological age should predict future disease development.", [["future disease development", "PROBLEM", 227, 253], ["good", "OBSERVATION_MODIFIER", 19, 23]]], ["The original epigenetic clock relied, in part, on chronological age, so several alternative epigenetic clocks, such as the GrimAge methylation clock, were developed.", [["GrimAge methylation clock", "DNA", 123, 148], ["several alternative epigenetic clocks", "TREATMENT", 72, 109], ["the GrimAge methylation clock", "TREATMENT", 119, 148], ["epigenetic clock", "OBSERVATION", 13, 29]]], ["This has been demonstrated for both methylation and glycans.", [["both methylation and glycans", "TREATMENT", 31, 59]]], ["The difference between glycan age and chronological age Editorial associates with biomarkers of unhealthy lifestyle [1] , while changes in glycans predict future diabetes and cardiovascular events [2] .", [["cardiovascular", "ANATOMY", 175, 189], ["diabetes", "DISEASE", 162, 170], ["cardiovascular", "ANATOMICAL_SYSTEM", 175, 189], ["diabetes", "PROBLEM", 162, 170], ["cardiovascular events", "PROBLEM", 175, 196]]], ["Several different epigenetic clocks were recently also shown to predict prevalence and incidence of leading causes of death and disease [3] .", [["death", "DISEASE", 118, 123], ["Several different epigenetic clocks", "PROBLEM", 0, 35], ["death", "PROBLEM", 118, 123], ["disease", "PROBLEM", 128, 135], ["epigenetic clocks", "OBSERVATION", 18, 35]]], ["Glycans, or polysaccharides, are carbohydrate-based polymers that regulate a variety of processes, including immunity [4] .", [["Glycans", "CHEMICAL", 0, 7], ["carbohydrate", "CHEMICAL", 33, 45], ["Glycans", "SIMPLE_CHEMICAL", 0, 7], ["Glycans", "TEST", 0, 7], ["polysaccharides", "PROBLEM", 12, 27], ["carbohydrate-based polymers", "TREATMENT", 33, 60]]], ["In fact, glycan diversity represents one of the main defenses of all higher organisms against pathogens, and the repertoire of glycans changes with age, especially in the age ranges that are most susceptible to SARS-CoV2.", [["SARS", "DISEASE", 211, 215], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 211, 220], ["pathogens", "PROBLEM", 94, 103], ["glycan diversity", "OBSERVATION", 9, 25], ["main", "OBSERVATION_MODIFIER", 48, 52], ["defenses", "OBSERVATION_MODIFIER", 53, 61], ["all", "OBSERVATION_MODIFIER", 65, 68], ["higher organisms", "OBSERVATION_MODIFIER", 69, 85], ["glycans", "OBSERVATION", 127, 134]]], ["Furthermore, both the SARS-Cov-2 virus and its principal cellular target ACE2 are known to be highly glycosylated [5] , a pattern that likely changes with age.", [["cellular", "ANATOMY", 57, 65], ["SARS-Cov-2 virus", "ORGANISM", 22, 38], ["cellular", "CELL", 57, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 73, 77], ["ACE2", "PROTEIN", 73, 77], ["SARS-Cov-2 virus", "SPECIES", 22, 38], ["the SARS", "TEST", 18, 26], ["Cov", "TEST", 27, 30]]], ["Recent study analysed site-specific N-linked glycosylation of MERS and SARS S glycoproteins, indicating that each of these glycosylation sites can be occupied by up to ten different glycans (called glycoforms), which greatly extends epitope diversity [6] .", [["N", "CHEMICAL", 36, 37], ["MERS", "GENE_OR_GENE_PRODUCT", 62, 66], ["SARS S glycoproteins", "GENE_OR_GENE_PRODUCT", 71, 91], ["MERS", "PROTEIN", 62, 66], ["SARS S glycoproteins", "PROTEIN", 71, 91], ["glycosylation sites", "PROTEIN", 123, 142], ["Recent study", "TEST", 0, 12], ["MERS", "PROBLEM", 62, 66], ["SARS S glycoproteins", "TREATMENT", 71, 91], ["these glycosylation sites", "PROBLEM", 117, 142]]], ["Glycans are the primary molecular basis inter-individual differences within the human population, including the ABO blood groups.", [["blood", "ANATOMY", 116, 121], ["Glycans", "GENE_OR_GENE_PRODUCT", 0, 7], ["human", "ORGANISM", 80, 85], ["ABO", "GENE_OR_GENE_PRODUCT", 112, 115], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["the ABO blood groups", "TREATMENT", 108, 128], ["human population", "OBSERVATION", 80, 96]]], ["Furthermore, glycans are one of the principal regulators of antibody effector functions and many other aspects of the immune system.", [["immune system", "ANATOMY", 118, 131], ["antibody effector functions", "PROBLEM", 60, 87], ["antibody effector", "OBSERVATION", 60, 77]]], ["Based on www.aging-us.com 6490 these and other findings, we believe that glycans should be in the focus of biomarker discovery in COVID-19 cases.", [["COVID", "TEST", 130, 135]]], ["Since glycans are structurally complex and their analysis is technically challenging, until recently they were largely ignored by clinical researchers.", [["structurally complex", "PROBLEM", 18, 38], ["structurally", "OBSERVATION_MODIFIER", 18, 30], ["complex", "OBSERVATION_MODIFIER", 31, 38]]], ["However, the situation changed dramatically in the last few years and through the Human Glycome Project over 100,000 glycome profiling has been performed, resulting in many prominent discoveries of promising glycan biomarkers.Biomarkers of biological age as predictors of COVID-19 disease severityGlycans are inherited as complex traits and also affected by epigenetic memory of environmental factors [7] .", [["Human", "ORGANISM", 82, 87], ["Glycans", "GENE_OR_GENE_PRODUCT", 297, 304], ["Glycans", "PROTEIN", 297, 304], ["Human", "SPECIES", 82, 87], ["glycome profiling", "TEST", 117, 134], ["promising glycan biomarkers", "PROBLEM", 198, 225], ["Biomarkers", "TEST", 226, 236], ["COVID", "TEST", 272, 277], ["19 disease severity", "PROBLEM", 278, 297], ["complex traits", "PROBLEM", 322, 336], ["dramatically", "OBSERVATION_MODIFIER", 31, 43], ["prominent", "OBSERVATION_MODIFIER", 173, 182], ["glycan biomarkers", "OBSERVATION", 208, 225]]], ["Environmental factors such as smoking and diabetes could alter the glycan repertoire directly or by increasing biological (Figure 1 ), [2, 8] .Biomarkers of biological age as predictors of COVID-19 disease severityReports from Italy and US indicate that in case of insufficient ICU capacity triage of COVID-19 patients is based on subjectively defined criteria that are not based on strong data.", [["smoking", "CHEMICAL", 30, 37], ["diabetes", "DISEASE", 42, 50], ["patients", "ORGANISM", 310, 318], ["patients", "SPECIES", 310, 318], ["diabetes", "PROBLEM", 42, 50], ["Biomarkers", "TEST", 143, 153], ["COVID", "TEST", 189, 194], ["19 disease severity", "PROBLEM", 195, 214]]], ["At present, we still do not understand the molecular basis of severe COVID-19 symptoms, so research is urgently needed to identify biomarkers that could enable early identification of high-risk individuals.", [["COVID", "DISEASE", 69, 74], ["severe COVID-19 symptoms", "PROBLEM", 62, 86], ["high-risk individuals", "PROBLEM", 184, 205]]], ["Therefore, it is of utmost importance to biobank large number of plasma samples of both severe and mild cases, so that modern profiling technologies can be used to identify molecular risk factors during this and for future outbreaks.", [["plasma samples", "ANATOMY", 65, 79], ["plasma samples", "ORGANISM_SUBSTANCE", 65, 79], ["plasma samples", "TEST", 65, 79], ["both severe and mild cases", "PROBLEM", 83, 109], ["modern profiling technologies", "TREATMENT", 119, 148], ["molecular risk factors", "PROBLEM", 173, 195], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["mild", "OBSERVATION_MODIFIER", 99, 103]]], ["We understand that our colleagues at the frontlines of this pandemics are overwhelmed with saving lives, but biobanking samples has a potential to save many more lives in the future.", [["pandemics", "DISEASE", 60, 69]]]], "b6b042e7716276b7d09f27cb3ed8f74d0f455e69": [["a b s t r a c tThis is the first report of an acute and fatal outbreak of bovine diarrhea virus (BVDV)-2 infection in Israel.", [["bovine diarrhea virus (BVDV)-2 infection", "DISEASE", 74, 114], ["bovine diarrhea virus", "ORGANISM", 74, 95], ["BVDV)-2", "ORGANISM", 97, 104], ["bovine", "SPECIES", 74, 80], ["diarrhea virus", "SPECIES", 81, 95], ["BVDV", "SPECIES", 97, 101], ["bovine diarrhea virus", "SPECIES", 74, 95], ["BVDV", "SPECIES", 97, 101], ["an acute", "PROBLEM", 43, 51], ["bovine diarrhea virus", "PROBLEM", 74, 95], ["BVDV", "PROBLEM", 97, 101], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["fatal", "OBSERVATION_MODIFIER", 56, 61]]], ["The clinical presentation varied with the age of the affected animals with a bovine-respiratory-complexlike syndrome in young stock, and diarrhea and dysentery only in the lactating stock.", [["respiratory-complexlike syndrome", "DISEASE", 84, 116], ["diarrhea", "DISEASE", 137, 145], ["dysentery", "DISEASE", 150, 159], ["bovine", "ORGANISM", 77, 83], ["bovine", "SPECIES", 77, 83], ["a bovine-respiratory-complexlike syndrome", "PROBLEM", 75, 116], ["diarrhea", "PROBLEM", 137, 145], ["dysentery", "PROBLEM", 150, 159], ["respiratory", "ANATOMY", 84, 95], ["complexlike syndrome", "OBSERVATION", 96, 116], ["dysentery", "OBSERVATION", 150, 159], ["lactating stock", "OBSERVATION", 172, 187]]], ["Enteritis first appeared in one shed of post-parturient cows; it spread for 6 weeks, until at least 30% of the lactating stock contracted enteritis or dysentery.", [["Enteritis", "DISEASE", 0, 9], ["enteritis", "DISEASE", 138, 147], ["dysentery", "DISEASE", 151, 160], ["cows", "ORGANISM", 56, 60], ["cows", "SPECIES", 56, 60], ["Enteritis", "PROBLEM", 0, 9], ["post-parturient cows", "PROBLEM", 40, 60], ["the lactating stock contracted enteritis", "PROBLEM", 107, 147], ["dysentery", "PROBLEM", 151, 160], ["contracted", "OBSERVATION_MODIFIER", 127, 137], ["enteritis", "OBSERVATION", 138, 147], ["dysentery", "OBSERVATION", 151, 160]]], ["At the same time, dairy calves aged 10-90 days exhibited severe respiratory disease.", [["respiratory", "ANATOMY", 64, 75], ["respiratory disease", "DISEASE", 64, 83], ["calves", "ORGANISM", 24, 30], ["calves", "SPECIES", 24, 30], ["severe respiratory disease", "PROBLEM", 57, 83], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["respiratory disease", "OBSERVATION", 64, 83]]], ["Of 79 animals that died, 13/350 (3.7%) were adult lactating cows, and 66/1100 (6%) were young feedlot calves.", [["animals", "ORGANISM", 6, 13], ["cows", "ORGANISM", 60, 64], ["calves", "ORGANISM", 102, 108], ["cows", "SPECIES", 60, 64], ["calves", "SPECIES", 102, 108], ["adult lactating cows", "TEST", 44, 64], ["feedlot calves", "OBSERVATION", 94, 108]]], ["Phylogenetic analysis of the isolated virus revealed a 95% identity with the corresponding genome parts of various BVDV type 2 sequences.", [["BVDV", "ORGANISM", 115, 119], ["BVDV type 2 sequences", "DNA", 115, 136], ["BVDV type 2", "SPECIES", 115, 126], ["Phylogenetic analysis", "TEST", 0, 21], ["the isolated virus", "PROBLEM", 25, 43], ["various BVDV", "OBSERVATION", 107, 119]]], ["The route of introduction of BVDV-2 into Israel could not be elucidated.a b s t r a c t\u00d3 2010 Elsevier Ltd.", [["BVDV-2", "CHEMICAL", 29, 35], ["BVDV", "ORGANISM", 29, 33], ["introduction of BVDV", "TREATMENT", 13, 33]]], ["All rights reserved.a b s t r a c tBovine viral diarrhea virus (BVDV), a member of the genus Pestivirus, comprises two distinct species, BVDV-1 and BVDV-2 (Heinz et al., 2000) .", [["viral diarrhea", "DISEASE", 42, 56], ["c tBovine viral diarrhea virus", "ORGANISM", 32, 62], ["BVDV", "ORGANISM", 64, 68], ["BVDV-1", "ORGANISM", 137, 143], ["BVDV-2", "ORGANISM", 148, 154], ["tBovine viral diarrhea virus", "SPECIES", 34, 62], ["BVDV", "SPECIES", 137, 141], ["BVDV", "SPECIES", 148, 152], ["tBovine viral diarrhea virus", "SPECIES", 34, 62], ["BVDV", "SPECIES", 64, 68], ["BVDV-1", "SPECIES", 137, 143], ["a c tBovine viral diarrhea virus", "PROBLEM", 30, 62], ["BVDV", "PROBLEM", 64, 68], ["the genus Pestivirus", "PROBLEM", 83, 103], ["two distinct species", "PROBLEM", 115, 135], ["BVDV", "TEST", 137, 141], ["BVDV", "TEST", 148, 152], ["genus Pestivirus", "ANATOMY", 87, 103]]], ["Post-natal infection elicits a wide range of clinical manifestations and pathological conditions.", [["infection", "DISEASE", 11, 20], ["natal infection", "PROBLEM", 5, 20], ["clinical manifestations and pathological conditions", "PROBLEM", 45, 96], ["infection", "OBSERVATION", 11, 20], ["wide range", "OBSERVATION_MODIFIER", 31, 41]]], ["Additionally, infection in the first trimester of pregnancy can result in persistent infection (PI) of the offspring, which is often unnoticed (Radostits et al., 2007) .a b s t r a c tIn the non-pregnant animal, exposure to BVDV-1 often elicits no or only mild clinical signs, but may cause susceptibility to other pathogens, most of which have a tropism to the respiratory tract (Baker, 1995) .", [["respiratory tract", "ANATOMY", 362, 379], ["infection", "DISEASE", 14, 23], ["infection", "DISEASE", 85, 94], ["BVDV-1", "CHEMICAL", 224, 230], ["tropism to the respiratory tract", "DISEASE", 347, 379], ["BVDV-1", "ORGANISM", 224, 230], ["respiratory tract", "ORGANISM_SUBDIVISION", 362, 379], ["BVDV-1", "SPECIES", 224, 230], ["infection", "PROBLEM", 14, 23], ["persistent infection", "PROBLEM", 74, 94], ["BVDV", "PROBLEM", 224, 228], ["mild clinical signs", "PROBLEM", 256, 275], ["susceptibility to other pathogens", "PROBLEM", 291, 324], ["infection", "OBSERVATION", 14, 23], ["persistent", "OBSERVATION_MODIFIER", 74, 84], ["infection", "OBSERVATION", 85, 94], ["respiratory tract", "ANATOMY", 362, 379]]], ["Severe courses of BVDV infection in adult animals, characterized by thrombocytopenia and high mortality (hemorrhagic syndrome) have been linked exclusively to BVDV-2 infection (Ridpath et al., 1994) , but Lunardi et al. (2008) recently described a wild-type BVDV subtype 1b that caused an acute outbreak in beef cattle in Brazil.", [["BVDV infection", "DISEASE", 18, 32], ["thrombocytopenia", "DISEASE", 68, 84], ["hemorrhagic syndrome", "DISEASE", 105, 125], ["BVDV-2 infection", "DISEASE", 159, 175], ["BVDV", "ORGANISM", 18, 22], ["BVDV-2", "ORGANISM", 159, 165], ["BVDV subtype 1b", "ORGANISM", 258, 273], ["beef", "SPECIES", 307, 311], ["cattle", "SPECIES", 312, 318], ["BVDV", "SPECIES", 18, 22], ["BVDV-2", "SPECIES", 159, 165], ["beef", "SPECIES", 307, 311], ["cattle", "SPECIES", 312, 318], ["BVDV infection", "PROBLEM", 18, 32], ["thrombocytopenia", "PROBLEM", 68, 84], ["high mortality (hemorrhagic syndrome", "PROBLEM", 89, 125], ["BVDV", "PROBLEM", 159, 163], ["infection", "PROBLEM", 166, 175], ["type BVDV subtype 1b", "PROBLEM", 253, 273], ["BVDV", "OBSERVATION_MODIFIER", 18, 22], ["infection", "OBSERVATION", 23, 32], ["thrombocytopenia", "OBSERVATION", 68, 84], ["high", "OBSERVATION_MODIFIER", 89, 93], ["mortality", "OBSERVATION_MODIFIER", 94, 103], ["hemorrhagic syndrome", "OBSERVATION", 105, 125], ["BVDV", "OBSERVATION", 159, 163], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["outbreak", "OBSERVATION", 295, 303], ["beef cattle", "OBSERVATION", 307, 318]]], ["It elicited similar clinical signs to BVDV-2 infection, from which it could be distinguished only by molecular analysis.a b s t r a c tHere we present the first report of acute BVDV-2 infection in Israel.", [["BVDV-2 infection", "DISEASE", 38, 54], ["BVDV-2 infection", "DISEASE", 177, 193], ["BVDV-2", "ORGANISM", 38, 44], ["BVDV-2", "ORGANISM", 177, 183], ["BVDV-2", "SPECIES", 38, 44], ["BVDV-2", "SPECIES", 177, 183], ["BVDV", "PROBLEM", 38, 42], ["2 infection", "PROBLEM", 43, 54], ["molecular analysis", "TEST", 101, 119], ["acute BVDV", "PROBLEM", 171, 181], ["infection", "OBSERVATION", 45, 54], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["BVDV", "OBSERVATION", 177, 181], ["infection", "OBSERVATION", 184, 193]]], ["The progress of the disease was severe as expected, but predominantly with enteritis and respiratory symptoms rather than a hemorrhagic syndrome.", [["respiratory", "ANATOMY", 89, 100], ["enteritis", "DISEASE", 75, 84], ["respiratory symptoms", "DISEASE", 89, 109], ["hemorrhagic syndrome", "DISEASE", 124, 144], ["the disease", "PROBLEM", 16, 27], ["enteritis", "PROBLEM", 75, 84], ["respiratory symptoms", "PROBLEM", 89, 109], ["a hemorrhagic syndrome", "PROBLEM", 122, 144], ["disease", "OBSERVATION", 20, 27], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["enteritis", "OBSERVATION", 75, 84], ["respiratory symptoms", "OBSERVATION", 89, 109], ["hemorrhagic", "OBSERVATION_MODIFIER", 124, 135], ["syndrome", "OBSERVATION", 136, 144]]], ["The location was a BVD-unvaccinated mixed farm which housed approximately 350 lactating Israeli Holstein-Friesian cows and 300 heifers; it also raised male calves that were acquired at 1 week of age from five other dairy herds, and had a feedlot of 1100 mixed-breed calves that were bought from several sources.a b s t r a c tIn March 2008, the first noticeable problems, namely, fever, lack of appetite, and agalactia, were seen.", [["fever", "DISEASE", 380, 385], ["agalactia", "DISEASE", 409, 418], ["BVD", "ORGANISM", 19, 22], ["cows", "ORGANISM", 114, 118], ["calves", "ORGANISM", 156, 162], ["calves", "ORGANISM", 266, 272], ["cows", "SPECIES", 114, 118], ["calves", "SPECIES", 156, 162], ["calves", "SPECIES", 266, 272], ["Holstein-Friesian cows", "SPECIES", 96, 118], ["a BVD", "PROBLEM", 17, 22], ["the first noticeable problems", "PROBLEM", 341, 370], ["fever", "PROBLEM", 380, 385], ["lack of appetite", "PROBLEM", 387, 403], ["agalactia", "PROBLEM", 409, 418], ["BVD", "OBSERVATION", 19, 22]]], ["Enteritis first appeared in one shed of post-parturient cows, and by early-September 2008, at least 30% of the lactating stock contracted enteritis or dysentery, and dairy calves aged 10-90 days exhibited severe respiratory discomfort.", [["respiratory", "ANATOMY", 212, 223], ["Enteritis", "DISEASE", 0, 9], ["enteritis", "DISEASE", 138, 147], ["dysentery", "DISEASE", 151, 160], ["respiratory discomfort", "DISEASE", 212, 234], ["cows", "ORGANISM", 56, 60], ["calves", "ORGANISM", 172, 178], ["cows", "SPECIES", 56, 60], ["calves", "SPECIES", 172, 178], ["Enteritis", "PROBLEM", 0, 9], ["the lactating stock contracted enteritis", "PROBLEM", 107, 147], ["dysentery", "PROBLEM", 151, 160], ["severe respiratory discomfort", "PROBLEM", 205, 234], ["contracted", "OBSERVATION_MODIFIER", 127, 137], ["enteritis", "OBSERVATION", 138, 147], ["dysentery", "OBSERVATION_MODIFIER", 151, 160], ["severe", "OBSERVATION_MODIFIER", 205, 211], ["respiratory discomfort", "OBSERVATION", 212, 234]]], ["The lactating stock, were located less than 50 m from the gravid dry cows, among which clinical signs were first noted, and young stock (aged 1-3 months) were 50 m from the gravid dry cows and 100 m from the lactating cows.", [["cows", "ORGANISM_SUBDIVISION", 218, 222], ["cows", "SPECIES", 69, 73], ["cows", "SPECIES", 184, 188], ["cows", "SPECIES", 218, 222], ["The lactating stock", "TREATMENT", 0, 19], ["the gravid dry cows", "PROBLEM", 54, 73]]], ["Calves were moved to the feedlot at 90 days of age and these calves (aged 3-10 months) were less affected, if at all.a b s t r a c tEach affected lactating cow exhibited temperatures of 41-41.5\u00b0C for 4-5 days accompanied by diarrhea.", [["diarrhea", "DISEASE", 224, 232], ["Calves", "ORGANISM", 0, 6], ["calves", "ORGANISM", 61, 67], ["cow", "ORGANISM", 156, 159], ["Calves", "SPECIES", 0, 6], ["calves", "SPECIES", 61, 67], ["cow", "SPECIES", 156, 159], ["cow", "SPECIES", 156, 159], ["temperatures", "TEST", 170, 182], ["diarrhea", "PROBLEM", 224, 232], ["diarrhea", "OBSERVATION", 224, 232]]], ["Overall, dysentery was present in the adult animal stock for approximately 3 months.", [["dysentery", "DISEASE", 9, 18], ["dysentery", "PROBLEM", 9, 18], ["dysentery", "OBSERVATION", 9, 18]]], ["The lactating cows were first diagnosed via the milking records, when milk yield decreased.", [["milk", "ANATOMY", 70, 74], ["cows", "ORGANISM", 14, 18], ["milk", "ORGANISM_SUBSTANCE", 70, 74], ["cows", "SPECIES", 14, 18], ["decreased", "OBSERVATION_MODIFIER", 81, 90]]], ["Tentative treatment of the young stock that exhibited respiratory distress achieved no clinical improvement, in spite of routine administration of 'preventive respiratory' doses of tetracycline (Aurofac Aureomycin, Alphparma) before the outbreak, and of therapeutic doses of enrofloxacin (Baytril, Bayer) during prevalence of the respiratory symptoms.", [["respiratory", "ANATOMY", 54, 65], ["respiratory", "ANATOMY", 159, 170], ["respiratory", "ANATOMY", 330, 341], ["respiratory distress", "DISEASE", 54, 74], ["tetracycline", "CHEMICAL", 181, 193], ["Aurofac Aureomycin", "CHEMICAL", 195, 213], ["Alphparma", "CHEMICAL", 215, 224], ["enrofloxacin", "CHEMICAL", 275, 287], ["Baytril", "CHEMICAL", 289, 296], ["respiratory symptoms", "DISEASE", 330, 350], ["tetracycline", "CHEMICAL", 181, 193], ["Aurofac Aureomycin", "CHEMICAL", 195, 213], ["enrofloxacin", "CHEMICAL", 275, 287], ["tetracycline", "SIMPLE_CHEMICAL", 181, 193], ["Aurofac Aureomycin", "SIMPLE_CHEMICAL", 195, 213], ["Alphparma", "SIMPLE_CHEMICAL", 215, 224], ["enrofloxacin", "SIMPLE_CHEMICAL", 275, 287], ["Baytril", "SIMPLE_CHEMICAL", 289, 296], ["respiratory distress", "PROBLEM", 54, 74], ["'preventive respiratory' doses", "TREATMENT", 147, 177], ["tetracycline", "TREATMENT", 181, 193], ["Aurofac Aureomycin", "TREATMENT", 195, 213], ["Alphparma", "TREATMENT", 215, 224], ["enrofloxacin", "TREATMENT", 275, 287], ["Baytril", "TREATMENT", 289, 296], ["the respiratory symptoms", "PROBLEM", 326, 350], ["respiratory distress", "OBSERVATION", 54, 74], ["respiratory symptoms", "OBSERVATION", 330, 350]]], ["This wave killed 79 animals, comprising 13 adult cows out of 120 affected lactating cows (i.e. a case mortality rate of approximately 0.09), and 66 calves under than 90 days of age (i.e., 3.7 and 6% of the respective populations).a b s t r a c tFive heifers had tested negative for antibodies against BVDV in November 2007, indicating that no persistently infected (PI) animals were present, the lack of clinical BVD-infection-related manifestations suggested there was no latent or acute infection in this herd (Lindberg and Alenius, 1999) .", [["BVD", "DISEASE", 413, 416], ["infection", "DISEASE", 417, 426], ["infection", "DISEASE", 489, 498], ["cows", "ORGANISM", 49, 53], ["cows", "ORGANISM", 84, 88], ["calves", "ORGANISM", 148, 154], ["BVDV", "ORGANISM", 301, 305], ["BVD", "ORGANISM", 413, 416], ["antibodies", "PROTEIN", 282, 292], ["cows", "SPECIES", 49, 53], ["cows", "SPECIES", 84, 88], ["calves", "SPECIES", 148, 154], ["BVDV", "SPECIES", 301, 305], ["BVD", "SPECIES", 413, 416], ["a case mortality rate", "TEST", 95, 116], ["a b s t r a c tFive heifers", "TEST", 230, 257], ["antibodies", "PROBLEM", 282, 292], ["BVDV", "PROBLEM", 301, 305], ["persistently infected (PI) animals", "PROBLEM", 343, 377], ["clinical BVD-infection", "PROBLEM", 404, 426], ["acute infection", "PROBLEM", 483, 498], ["no", "UNCERTAINTY", 340, 342], ["persistently", "OBSERVATION_MODIFIER", 343, 355], ["infected", "OBSERVATION", 356, 364], ["infection", "OBSERVATION", 417, 426], ["no", "UNCERTAINTY", 470, 472], ["latent", "OBSERVATION_MODIFIER", 473, 479], ["acute", "OBSERVATION_MODIFIER", 483, 488], ["infection", "OBSERVATION", 489, 498]]], ["BVDV virus was first isolated on 17 July 2008 at the Kimron Veterinary Institute (KVI), during a pathological investigation of colon-sections of adult animals that had died.", [["colon-sections", "ANATOMY", 127, 141], ["BVDV virus", "ORGANISM", 0, 10], ["colon-sections", "MULTI-TISSUE_STRUCTURE", 127, 141], ["animals", "ORGANISM", 151, 158], ["BVDV virus", "SPECIES", 0, 10], ["BVDV virus", "SPECIES", 0, 10], ["BVDV virus", "PROBLEM", 0, 10], ["a pathological investigation", "TEST", 95, 123], ["colon", "ANATOMY", 127, 132]]], ["Previously, 60 young calves aged 10-90 days had succumbed and the fresh carcass of a young calf was taken to KVI for post mortem examination.", [["carcass", "ANATOMY", 72, 79], ["calves", "ORGANISM", 21, 27], ["carcass", "ORGANISM_SUBDIVISION", 72, 79], ["calf", "ORGANISM", 91, 95], ["calves", "SPECIES", 21, 27], ["calf", "SPECIES", 91, 95], ["post mortem examination", "TEST", 117, 140], ["calf", "ANATOMY", 91, 95]]], ["The carcass exhibited severe pneumonia; 70% of the lung parenchyma was severely affected, and consolidation, color changes and micro-abscess were scattered on much of the lung mass.", [["carcass", "ANATOMY", 4, 11], ["lung parenchyma", "ANATOMY", 51, 66], ["micro-abscess", "ANATOMY", 127, 140], ["lung mass", "ANATOMY", 171, 180], ["pneumonia", "DISEASE", 29, 38], ["micro-abscess", "DISEASE", 127, 140], ["carcass", "ORGANISM_SUBDIVISION", 4, 11], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 51, 66], ["lung", "ORGAN", 171, 175], ["severe pneumonia", "PROBLEM", 22, 38], ["severely affected", "PROBLEM", 71, 88], ["consolidation", "PROBLEM", 94, 107], ["color changes", "PROBLEM", 109, 122], ["micro-abscess", "PROBLEM", 127, 140], ["the lung mass", "PROBLEM", 167, 180], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["pneumonia", "OBSERVATION", 29, 38], ["lung", "ANATOMY", 51, 55], ["parenchyma", "ANATOMY_MODIFIER", 56, 66], ["severely", "OBSERVATION_MODIFIER", 71, 79], ["affected", "OBSERVATION", 80, 88], ["consolidation", "OBSERVATION", 94, 107], ["color", "OBSERVATION_MODIFIER", 109, 114], ["scattered", "OBSERVATION_MODIFIER", 146, 155], ["lung", "ANATOMY", 171, 175], ["mass", "OBSERVATION", 176, 180]]], ["No other changes were noted in the internal organs, but the stomach and the fore-stomachs were empty.", [["internal organs", "ANATOMY", 35, 50], ["stomach", "ANATOMY", 60, 67], ["fore-stomachs", "ANATOMY", 76, 89], ["organs", "ORGAN", 44, 50], ["stomach", "ORGAN", 60, 67], ["stomachs", "ORGAN", 81, 89], ["other changes", "PROBLEM", 3, 16], ["internal organs", "ANATOMY", 35, 50], ["stomach", "ANATOMY", 60, 67], ["stomachs", "ANATOMY", 81, 89], ["empty", "OBSERVATION", 95, 100]]], ["Histological examination revealed multifocal necrosis, and massive infiltration of alveoli and bronchi, neutrophils and histiocytosis.", [["alveoli", "ANATOMY", 83, 90], ["bronchi", "ANATOMY", 95, 102], ["neutrophils", "ANATOMY", 104, 115], ["necrosis", "DISEASE", 45, 53], ["histiocytosis", "DISEASE", 120, 133], ["alveoli", "MULTI-TISSUE_STRUCTURE", 83, 90], ["bronchi", "MULTI-TISSUE_STRUCTURE", 95, 102], ["neutrophils", "CELL", 104, 115], ["neutrophils", "CELL_TYPE", 104, 115], ["Histological examination", "TEST", 0, 24], ["multifocal necrosis", "PROBLEM", 34, 53], ["massive infiltration of alveoli and bronchi", "PROBLEM", 59, 102], ["neutrophils", "PROBLEM", 104, 115], ["histiocytosis", "PROBLEM", 120, 133], ["multifocal", "OBSERVATION_MODIFIER", 34, 44], ["necrosis", "OBSERVATION", 45, 53], ["massive", "OBSERVATION_MODIFIER", 59, 66], ["infiltration", "OBSERVATION", 67, 79], ["alveoli", "ANATOMY_MODIFIER", 83, 90], ["bronchi", "ANATOMY", 95, 102], ["neutrophils", "OBSERVATION_MODIFIER", 104, 115], ["histiocytosis", "OBSERVATION", 120, 133]]], ["Eleven additional lungs from calves aged 8 to 12 weeks, also had severe lung affections (Table 1) .a b s t r a c tAdditionally, part of the intestine of the dead cow was available and exhibited discernable mucosal hemorrhages ('zebra stripes').", [["lungs", "ANATOMY", 18, 23], ["lung", "ANATOMY", 72, 76], ["intestine", "ANATOMY", 140, 149], ["mucosal", "ANATOMY", 206, 213], ["lung affections", "DISEASE", 72, 87], ["hemorrhages", "DISEASE", 214, 225], ["lungs", "ORGAN", 18, 23], ["calves", "ORGANISM", 29, 35], ["lung", "ORGAN", 72, 76], ["intestine", "ORGAN", 140, 149], ["cow", "ORGANISM", 162, 165], ["mucosal hemorrhages", "PATHOLOGICAL_FORMATION", 206, 225], ["calves", "SPECIES", 29, 35], ["cow", "SPECIES", 162, 165], ["cow", "SPECIES", 162, 165], ["severe lung affections", "PROBLEM", 65, 87], ["discernable mucosal hemorrhages", "PROBLEM", 194, 225], ["lungs", "ANATOMY", 18, 23], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["lung", "ANATOMY", 72, 76], ["affections", "OBSERVATION", 77, 87], ["intestine", "ANATOMY", 140, 149], ["mucosal", "ANATOMY", 206, 213], ["hemorrhages", "OBSERVATION", 214, 225]]], ["The tissue was suitable for virus isolation and identification, but not for histopathological examination.", [["tissue", "ANATOMY", 4, 10], ["tissue", "TISSUE", 4, 10], ["virus isolation", "TREATMENT", 28, 43], ["identification", "TEST", 48, 62], ["histopathological examination", "TEST", 76, 105], ["tissue", "ANATOMY", 4, 10]]], ["The attending veterinarian had reported that all five adult cows examined had presented with a congested intestinal tract, bloody feces and intestinal hemorrhages.a b s t r a c tTwo commercial BVDV antigen (BVDVAg) detection kits, the HERDCHEK BVDV Ag/Leukocytes, and the HERDCHEK BVDV Ag/serum plus (IDEXX Laboratories), were used, and virus was isolated using Madin-Darby Bovine Kidney Cells (MDBK).", [["intestinal tract", "ANATOMY", 105, 121], ["bloody feces", "ANATOMY", 123, 135], ["intestinal", "ANATOMY", 140, 150], ["Leukocytes", "ANATOMY", 252, 262], ["serum", "ANATOMY", 289, 294], ["Kidney Cells", "ANATOMY", 381, 393], ["MDBK", "ANATOMY", 395, 399], ["bloody feces", "DISEASE", 123, 135], ["intestinal hemorrhages", "DISEASE", 140, 162], ["Ag", "CHEMICAL", 286, 288], ["Ag", "CHEMICAL", 286, 288], ["cows", "ORGANISM", 60, 64], ["intestinal tract", "ORGANISM_SUBDIVISION", 105, 121], ["feces", "ORGANISM_SUBDIVISION", 130, 135], ["intestinal", "ORGAN", 140, 150], ["BVDV", "ORGANISM", 193, 197], ["BVDV", "ORGANISM", 244, 248], ["Leukocytes", "CELL", 252, 262], ["BVDV", "ORGANISM", 281, 285], ["Ag", "GENE_OR_GENE_PRODUCT", 286, 288], ["serum", "ORGANISM_SUBSTANCE", 289, 294], ["Bovine", "ORGANISM", 374, 380], ["Kidney Cells", "CELL", 381, 393], ["MDBK", "CELL", 395, 399], ["BVDV antigen", "PROTEIN", 193, 205], ["BVDVAg", "PROTEIN", 207, 213], ["HERDCHEK BVDV Ag", "PROTEIN", 235, 251], ["Leukocytes", "CELL_TYPE", 252, 262], ["HERDCHEK BVDV Ag", "PROTEIN", 272, 288], ["cows", "SPECIES", 60, 64], ["Bovine", "SPECIES", 374, 380], ["BVDV", "SPECIES", 193, 197], ["BVDV", "SPECIES", 244, 248], ["BVDV", "SPECIES", 281, 285], ["MDBK", "SPECIES", 395, 399], ["a congested intestinal tract", "PROBLEM", 93, 121], ["bloody feces", "PROBLEM", 123, 135], ["intestinal hemorrhages", "PROBLEM", 140, 162], ["a b s", "TEST", 163, 168], ["a c tTwo commercial BVDV antigen", "TEST", 173, 205], ["detection kits", "TEST", 215, 229], ["the HERDCHEK BVDV Ag", "TEST", 231, 251], ["Leukocytes", "TEST", 252, 262], ["the HERDCHEK BVDV Ag", "TEST", 268, 288], ["serum plus (IDEXX Laboratories", "TEST", 289, 319], ["virus", "PROBLEM", 337, 342], ["Madin", "TREATMENT", 362, 367], ["Darby Bovine Kidney Cells", "TREATMENT", 368, 393], ["congested", "OBSERVATION", 95, 104], ["intestinal tract", "ANATOMY", 105, 121], ["intestinal", "ANATOMY", 140, 150], ["hemorrhages", "OBSERVATION", 151, 162], ["Leukocytes", "ANATOMY", 252, 262], ["Kidney", "ANATOMY", 381, 387]]], ["Cell-culture supernatants from infected cells were used for reverse transcription polymerase chain reaction (RT-PCR) and subsequent genotyping.a b s t r a c tTwelve blood samples and the intestinal section (Table 2 ) yielded BVDV RNA, which was confirmed by RT-PCR.", [["Cell", "ANATOMY", 0, 4], ["supernatants", "ANATOMY", 13, 25], ["cells", "ANATOMY", 40, 45], ["blood samples", "ANATOMY", 165, 178], ["intestinal section", "ANATOMY", 187, 205], ["Cell", "CELL", 0, 4], ["cells", "CELL", 40, 45], ["intestinal section", "MULTI-TISSUE_STRUCTURE", 187, 205], ["BVDV", "ORGANISM", 225, 229], ["infected cells", "CELL_TYPE", 31, 45], ["BVDV RNA", "RNA", 225, 233], ["BVDV", "SPECIES", 225, 229], ["Cell-culture supernatants", "TEST", 0, 25], ["infected cells", "PROBLEM", 31, 45], ["reverse transcription polymerase chain reaction", "PROBLEM", 60, 107], ["RT-PCR", "TEST", 109, 115], ["subsequent genotyping", "TEST", 121, 142], ["a b s", "TEST", 143, 148], ["blood samples", "TEST", 165, 178], ["the intestinal section", "TREATMENT", 183, 205], ["BVDV RNA", "PROBLEM", 225, 233], ["PCR", "TEST", 261, 264], ["infected cells", "OBSERVATION", 31, 45], ["intestinal", "ANATOMY", 187, 197], ["BVDV RNA", "OBSERVATION", 225, 233]]], ["RNA was extracted from cell-culture supernatants with the QIAamp Viral RNA Kit (Qiagen).", [["cell", "ANATOMY", 23, 27], ["supernatants", "ANATOMY", 36, 48], ["cell", "CELL", 23, 27], ["RNA", "RNA", 0, 3], ["culture supernatants", "TEST", 28, 48], ["the QIAamp", "TEST", 54, 64], ["cell", "OBSERVATION", 23, 27]]], ["The following primers were used: B3 5 0 -GGT-AGC-AAC-AGT-GGT-GAG-3 0 /B4 5 0 -GTA-GCA-ATA-CAG-TGG-GCC-3 0 and B5 5 0 -ACT-AGC-GGT-AGC-AGT-GAG-3 0 /B6 5 0 -CTA-GCG-GAA-TAG-CAG-GTC-3 0 , for BVDV-Typ I and BVDV-Typ II, respectively.", [["BVDV", "ORGANISM", 189, 193], ["BVDV", "ORGANISM", 204, 208], ["GCC-3 0", "DNA", 98, 105], ["B5 5 0 -ACT-AGC-GGT-AGC-AGT-GAG-3 0 /B6 5 0 -CTA-GCG-GAA-TAG-CAG", "DNA", 110, 174], ["GTC-3 0", "DNA", 175, 182], ["BVDV-Typ I", "DNA", 189, 199], ["BVDV-Typ II", "DNA", 204, 215], ["BVDV-Typ I", "SPECIES", 189, 199], ["BVDV-Typ II", "SPECIES", 204, 215], ["The following primers", "TEST", 0, 21], ["B3", "TEST", 33, 35], ["-GGT-AGC-AAC-AGT-GGT", "TEST", 40, 60], ["GAG", "TEST", 61, 64], ["B4", "TEST", 70, 72], ["-GTA-GCA-ATA-CAG-TGG", "TEST", 77, 97], ["GCC", "TEST", 98, 101], ["B5", "TEST", 110, 112], ["-ACT-AGC-GGT-AGC-AGT", "TEST", 117, 137], ["GAG", "TEST", 138, 141], ["B6", "TEST", 147, 149], ["-CTA-GCG-GAA-TAG-CAG", "TEST", 154, 174], ["GTC", "TEST", 175, 178], ["BVDV", "TEST", 189, 193], ["BVDV", "TEST", 204, 208]]], ["RT-PCR revealed a typical 220-bp band with the BVDV-2-specific primers but not with the BVDV-1-specific primers (Letellier et al., 1999; Vilcek et al., 2003) .", [["BVDV-2", "GENE_OR_GENE_PRODUCT", 47, 53], ["BVDV-1", "GENE_OR_GENE_PRODUCT", 88, 94], ["BVDV-2-specific primers", "DNA", 47, 70], ["BVDV-1", "SPECIES", 88, 94], ["RT-PCR", "TEST", 0, 6], ["bp band", "TEST", 30, 37], ["the BVDV", "TEST", 43, 51], ["the BVDV", "TEST", 84, 92]]], ["We used the following sequence: TAG-CAGTGAGTTCATTGGATGGCCGAATCCCTGAGTACAGGGAAGTCGTCA TGGTTCGACACTCCATCAGTTGAGGAGTCTCGAGATGCCATCATAGGT GAAAGCGCCATTCGTGGTGCTATGGACACAGCCTGATAGGGTGTAG\u00d3 TAGCAGTGAGTTCA TTGGATGGCCGAATC, for the BLAST nucleotide search and it revealed a 98% nucleotide identity with the following BVDV-2 strains: EU224225.1, AY379543.1, AY379544.1, AY379545.1, and AJ304381.1.", [["nucleotide", "CHEMICAL", 228, 238], ["nucleotide", "CHEMICAL", 268, 278], ["nucleotide", "CHEMICAL", 228, 238], ["nucleotide", "CHEMICAL", 268, 278], ["BVDV-2", "ORGANISM", 307, 313], ["the BLAST nucleotide search", "TEST", 218, 245], ["a 98% nucleotide identity", "PROBLEM", 262, 287], ["BVDV", "TEST", 307, 311], ["AJ", "TEST", 375, 377]]], ["The products were sequenced by Eurofins MWG Operon, Martinsried, Germany.a b s t r a c tFourteen sera from adult animals were tested with the commercial BVD antibody (BVDV-Ab) SVANOVIR kit (Svanova Biotech).", [["sera", "ANATOMY", 97, 101], ["sera", "ORGANISM_SUBSTANCE", 97, 101], ["BVD", "ORGANISM", 153, 156], ["BVDV", "ORGANISM", 167, 171], ["BVD antibody", "PROTEIN", 153, 165], ["BVDV-Ab) SVANOVIR kit", "PROTEIN", 167, 188], ["BVD", "SPECIES", 153, 156], ["BVDV", "SPECIES", 167, 171], ["a c tFourteen sera", "TEST", 83, 101], ["the commercial BVD antibody", "TEST", 138, 165], ["BVDV", "TEST", 167, 171]]], ["Sera were taken from seven convalescent, four clinically affected, and three apparently healthy cows.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["cows", "ORGANISM", 96, 100], ["cows", "SPECIES", 96, 100], ["Sera", "TEST", 0, 4]]], ["Five of the seven convalescent animals were BVDV seropositive, compared with only 2/4 diseased animals and 0/3 apparently healthy cows.", [["animals", "ORGANISM", 31, 38], ["BVDV", "ORGANISM", 44, 48], ["cows", "ORGANISM", 130, 134], ["cows", "SPECIES", 130, 134], ["BVDV", "SPECIES", 44, 48], ["BVDV seropositive", "PROBLEM", 44, 61]]], ["Interestingly, one of the seropositive cows had tested sero-negative a month previously, which led to the present diagnosis of BVDV seroconversion.", [["BVDV", "DISEASE", 127, 131], ["cows", "ORGANISM", 39, 43], ["BVDV", "ORGANISM", 127, 131], ["cows", "SPECIES", 39, 43], ["BVDV", "SPECIES", 127, 131], ["the seropositive cows", "PROBLEM", 22, 43], ["BVDV seroconversion", "PROBLEM", 127, 146], ["BVDV seroconversion", "OBSERVATION", 127, 146]]], ["All other adult cows had been tested only once.a b s t r a c tThe relevant hematological outcomes (ranges) of seven blood samples of cows with pale mucosa were: RBC 5.2-6.85 \u00c2 10 6 (reference, 7.4-11.6 \u00c2 10 6 ); hemoglobin 7.4-7.8% (9.8-15.3%); hematocrit (packed cell volume) 21.0-28.9% (reference, 25.8-40.1%); leukocytes 0.82-5.8 \u00c2 10 3 (reference, 6.2-13.6 \u00c2 10 3 ); and thrombocytes; 45-384 \u00c2 10 3 (reference, 412-1003 \u00c2 10 3 ).a b s t r a c tBVDV infection is an important infectious disease of cattle worldwide.", [["blood samples", "ANATOMY", 116, 129], ["pale mucosa", "ANATOMY", 143, 154], ["RBC", "ANATOMY", 161, 164], ["cell", "ANATOMY", 264, 268], ["leukocytes", "ANATOMY", 313, 323], ["thrombocytes", "ANATOMY", 375, 387], ["infection", "DISEASE", 453, 462], ["cows", "ORGANISM", 16, 20], ["blood samples", "ORGANISM_SUBSTANCE", 116, 129], ["cows", "ORGANISM", 133, 137], ["pale mucosa", "MULTI-TISSUE_STRUCTURE", 143, 154], ["RBC", "CELL", 161, 164], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 212, 222], ["cell", "CELL", 264, 268], ["leukocytes", "CELL", 313, 323], ["thrombocytes", "CELL", 375, 387], ["cattle", "ORGANISM", 501, 507], ["hemoglobin", "PROTEIN", 212, 222], ["leukocytes", "CELL_TYPE", 313, 323], ["cows", "SPECIES", 16, 20], ["cows", "SPECIES", 133, 137], ["cattle", "SPECIES", 501, 507], ["cattle", "SPECIES", 501, 507], ["blood samples", "TEST", 116, 129], ["pale mucosa", "TEST", 143, 154], ["RBC", "TEST", 161, 164], ["hemoglobin", "TEST", 212, 222], ["hematocrit", "TEST", 245, 255], ["packed cell volume", "TEST", 257, 275], ["leukocytes", "TEST", 313, 323], ["thrombocytes", "TEST", 375, 387], ["a b s", "TEST", 433, 438], ["tBVDV infection", "PROBLEM", 447, 462], ["mucosa", "ANATOMY", 148, 154], ["thrombocytes", "ANATOMY", 375, 387], ["infection", "OBSERVATION", 453, 462], ["important", "OBSERVATION_MODIFIER", 469, 478], ["infectious", "OBSERVATION", 479, 489]]], ["Recognized syndromes associated with BVDV infection include subclinical infection, reproductive disturbances, and gastrointestinal and respiratory diseases.", [["gastrointestinal", "ANATOMY", 114, 130], ["respiratory", "ANATOMY", 135, 146], ["BVDV infection", "DISEASE", 37, 51], ["subclinical infection", "DISEASE", 60, 81], ["reproductive disturbances", "DISEASE", 83, 108], ["gastrointestinal and respiratory diseases", "DISEASE", 114, 155], ["BVDV", "ORGANISM", 37, 41], ["gastrointestinal", "ORGANISM_SUBDIVISION", 114, 130], ["BVDV", "SPECIES", 37, 41], ["BVDV", "SPECIES", 37, 41], ["Recognized syndromes", "PROBLEM", 0, 20], ["BVDV infection", "PROBLEM", 37, 51], ["subclinical infection", "PROBLEM", 60, 81], ["reproductive disturbances", "PROBLEM", 83, 108], ["gastrointestinal and respiratory diseases", "PROBLEM", 114, 155], ["associated with", "UNCERTAINTY", 21, 36], ["BVDV", "OBSERVATION_MODIFIER", 37, 41], ["infection", "OBSERVATION", 42, 51], ["subclinical", "OBSERVATION_MODIFIER", 60, 71], ["infection", "OBSERVATION", 72, 81], ["reproductive disturbances", "OBSERVATION", 83, 108], ["gastrointestinal", "ANATOMY", 114, 130], ["respiratory diseases", "OBSERVATION", 135, 155]]], ["Fatal mucosal disease has been known as an acute syndrome characterized by gastrointestinal lesions, which occur only in PI animals (Ellis et al., 1998; Sreerma et al., 2008) .", [["mucosal", "ANATOMY", 6, 13], ["gastrointestinal lesions", "ANATOMY", 75, 99], ["mucosal disease", "DISEASE", 6, 21], ["gastrointestinal lesions", "DISEASE", 75, 99], ["mucosal", "MULTI-TISSUE_STRUCTURE", 6, 13], ["gastrointestinal lesions", "PATHOLOGICAL_FORMATION", 75, 99], ["Fatal mucosal disease", "PROBLEM", 0, 21], ["an acute syndrome", "PROBLEM", 40, 57], ["gastrointestinal lesions", "PROBLEM", 75, 99], ["mucosal", "ANATOMY", 6, 13], ["disease", "OBSERVATION", 14, 21], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["syndrome", "OBSERVATION", 49, 57], ["gastrointestinal", "ANATOMY", 75, 91], ["lesions", "OBSERVATION", 92, 99]]], ["A specific form (the hemorrhagic syndrome) is predominantly linked to BVDV-2 infection.", [["hemorrhagic syndrome", "DISEASE", 21, 41], ["BVDV-2 infection", "DISEASE", 70, 86], ["BVDV-2", "ORGANISM", 70, 76], ["BVDV-2", "SPECIES", 70, 76], ["the hemorrhagic syndrome", "PROBLEM", 17, 41], ["BVDV", "PROBLEM", 70, 74], ["2 infection", "PROBLEM", 75, 86], ["hemorrhagic", "OBSERVATION_MODIFIER", 21, 32], ["syndrome", "OBSERVATION", 33, 41], ["BVDV", "OBSERVATION", 70, 74], ["infection", "OBSERVATION", 77, 86]]], ["Since no BVDV type 2 hemorrhagic infections had been observed in Israel before the present episode, acute severe BVDV-1 infection was suspected as the cause of respiratory and enteric symptoms in this affected herd.a b s t r a c tPreviously, only BVDV-1 has been found in Israel.", [["respiratory", "ANATOMY", 160, 171], ["hemorrhagic infections", "DISEASE", 21, 43], ["BVDV-1 infection", "DISEASE", 113, 129], ["respiratory and enteric symptoms", "DISEASE", 160, 192], ["BVDV type 2", "ORGANISM", 9, 20], ["BVDV-1", "ORGANISM", 113, 119], ["BVDV-1", "ORGANISM", 247, 253], ["BVDV-1", "SPECIES", 113, 119], ["BVDV", "SPECIES", 9, 13], ["BVDV-1", "SPECIES", 113, 119], ["BVDV-1", "SPECIES", 247, 253], ["BVDV type 2 hemorrhagic infections", "PROBLEM", 9, 43], ["acute severe BVDV", "PROBLEM", 100, 117], ["1 infection", "PROBLEM", 118, 129], ["respiratory and enteric symptoms", "PROBLEM", 160, 192], ["BVDV", "PROBLEM", 247, 251], ["no", "UNCERTAINTY", 6, 8], ["BVDV", "OBSERVATION_MODIFIER", 9, 13], ["type", "OBSERVATION_MODIFIER", 14, 18], ["hemorrhagic", "OBSERVATION_MODIFIER", 21, 32], ["infections", "OBSERVATION", 33, 43], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["BVDV", "OBSERVATION", 113, 117], ["infection", "OBSERVATION", 120, 129], ["respiratory", "ANATOMY", 160, 171], ["enteric", "OBSERVATION_MODIFIER", 176, 183], ["symptoms", "OBSERVATION", 184, 192]]], ["We collected and analyzed samples taken during the years 1996-2007 in various locations, and sequenced and analyzed them in order to characterize and map the isolates.", [["samples", "ANATOMY", 26, 33]]], ["Further analyses revealed that the isolates could be subtyped into BVDV type 1b (unpublished data).a b s t r a c tViruses tend to exacerbate other latent bacterial and viral pathogen infections.", [["pathogen infections", "DISEASE", 174, 193], ["BVDV type 1b", "ORGANISM", 67, 79], ["BVDV type 1b", "SPECIES", 67, 79], ["Further analyses", "TEST", 0, 16], ["the isolates", "PROBLEM", 31, 43], ["a b s", "TEST", 99, 104], ["t r a c tViruses", "TREATMENT", 105, 121], ["latent bacterial and viral pathogen infections", "PROBLEM", 147, 193], ["viral", "OBSERVATION_MODIFIER", 168, 173], ["pathogen", "OBSERVATION_MODIFIER", 174, 182], ["infections", "OBSERVATION", 183, 193]]], ["Mycoplasma bovirhinitis, an apathogenic bacterium, was isolated from the lung of the dead calf, but is unlikely to have contributed to the severe pneumonia or dysentery manifestations.", [["lung", "ANATOMY", 73, 77], ["Mycoplasma bovirhinitis", "DISEASE", 0, 23], ["pneumonia", "DISEASE", 146, 155], ["dysentery", "DISEASE", 159, 168], ["Mycoplasma bovirhinitis", "ORGANISM", 0, 23], ["lung", "ORGAN", 73, 77], ["calf", "ORGANISM_SUBDIVISION", 90, 94], ["Mycoplasma bovirhinitis", "SPECIES", 0, 23], ["calf", "SPECIES", 90, 94], ["Mycoplasma bovirhinitis", "SPECIES", 0, 23], ["Mycoplasma bovirhinitis", "PROBLEM", 0, 23], ["an apathogenic bacterium", "PROBLEM", 25, 49], ["the severe pneumonia", "PROBLEM", 135, 155], ["dysentery manifestations", "PROBLEM", 159, 183], ["apathogenic bacterium", "OBSERVATION", 28, 49], ["lung", "ANATOMY", 73, 77], ["dead calf", "ANATOMY", 85, 94], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["pneumonia", "OBSERVATION", 146, 155], ["dysentery", "OBSERVATION_MODIFIER", 159, 168]]], ["BRSV or other latent viruses were not found in any of the seven lungs submitted.", [["lungs", "ANATOMY", 64, 69], ["BRSV", "ORGANISM", 0, 4], ["lungs", "ORGAN", 64, 69], ["BRSV", "SPECIES", 0, 4], ["BRSV", "SPECIES", 0, 4], ["BRSV", "PROBLEM", 0, 4], ["other latent viruses", "PROBLEM", 8, 28], ["latent", "OBSERVATION_MODIFIER", 14, 20], ["viruses", "OBSERVATION", 21, 28], ["lungs", "ANATOMY", 64, 69]]], ["Although any strains of bovine respiratory coronaviruses could be involved in winter dysentery (WD), exacerbation of such viruses is very unlikely in this case, since the WD syndrome is not present in Israel.", [["respiratory coronaviruses", "DISEASE", 31, 56], ["dysentery", "DISEASE", 85, 94], ["WD", "DISEASE", 96, 98], ["WD syndrome", "DISEASE", 171, 182], ["bovine", "ORGANISM", 24, 30], ["respiratory coronaviruses", "ORGANISM", 31, 56], ["bovine", "SPECIES", 24, 30], ["bovine respiratory coronaviruses", "SPECIES", 24, 56], ["bovine respiratory coronaviruses", "PROBLEM", 24, 56], ["dysentery", "PROBLEM", 85, 94], ["exacerbation", "PROBLEM", 101, 113], ["such viruses", "PROBLEM", 117, 129], ["the WD syndrome", "PROBLEM", 167, 182], ["respiratory coronaviruses", "OBSERVATION", 31, 56], ["viruses", "OBSERVATION", 122, 129]]], ["Therefore, these findings could not explain the marked difference between clinical signs shown at different ages observed in this descriptive study of BVDV-2.", [["BVDV-2", "ORGANISM", 151, 157], ["BVDV-2", "SPECIES", 151, 157], ["clinical signs", "TEST", 74, 88], ["this descriptive study", "TEST", 125, 147], ["BVDV", "TEST", 151, 155], ["could not explain", "UNCERTAINTY", 26, 43], ["marked", "OBSERVATION_MODIFIER", 48, 54]]], ["To our knowledge this is the first description of a fatal outbreak of acute BVD related to BVDV-2 infection in Israel.", [["BVD", "DISEASE", 76, 79], ["BVDV-2 infection", "DISEASE", 91, 107], ["BVD", "ORGANISM", 76, 79], ["BVDV-2", "ORGANISM", 91, 97], ["BVDV", "SPECIES", 91, 95], ["BVD", "SPECIES", 76, 79], ["BVDV-2", "SPECIES", 91, 97], ["acute BVD", "PROBLEM", 70, 79], ["BVDV", "PROBLEM", 91, 95], ["fatal", "OBSERVATION_MODIFIER", 52, 57], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["BVD", "OBSERVATION", 76, 79], ["BVDV", "OBSERVATION", 91, 95], ["infection", "OBSERVATION", 98, 107]]], ["This case was characterized by a clinical dichotomy: a bovine-respiratory-complex-like syndrome (BRCS) was noted only in young stock, whereas diarrhea or dysentery was observed only in the lactating stock.", [["bovine-respiratory-complex-like syndrome", "DISEASE", 55, 95], ["BRCS", "DISEASE", 97, 101], ["diarrhea", "DISEASE", 142, 150], ["dysentery", "DISEASE", 154, 163], ["bovine", "ORGANISM", 55, 61], ["bovine", "SPECIES", 55, 61], ["syndrome", "PROBLEM", 87, 95], ["BRCS", "PROBLEM", 97, 101], ["diarrhea", "PROBLEM", 142, 150], ["dysentery", "PROBLEM", 154, 163], ["respiratory", "ANATOMY", 62, 73], ["dysentery", "OBSERVATION", 154, 163], ["lactating stock", "OBSERVATION", 189, 204]]], ["Remarkably, the clinical signs presented by the adult animals did not resemble published descriptions of severe infection with BVDV genotype 2 Flores et al., 2000; Ode\u00f3 n et al., 2003) .", [["infection", "DISEASE", 112, 121], ["BVDV", "ORGANISM", 127, 131], ["severe infection", "PROBLEM", 105, 121], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["infection", "OBSERVATION", 112, 121]]], ["For 15 months 45/615 (7.3%) calves aged 3-5 weeks old tested were categorized as PI.", [["calves", "ORGANISM", 28, 34], ["calves", "SPECIES", 28, 34]]], ["In addition, to the immediate losses of animals during the acute stage of the outbreak, the productive and reproductive damages are shown in Table 3 .a b s t r a c tAll of the herds from which young male calves were purchased claimed not to be BVD positive.", [["calves", "ORGANISM", 204, 210], ["BVD", "ORGANISM", 244, 247], ["calves", "SPECIES", 204, 210], ["calves", "SPECIES", 204, 210], ["BVD", "SPECIES", 244, 247], ["the outbreak", "PROBLEM", 74, 86], ["the productive and reproductive damages", "PROBLEM", 88, 127], ["BVD positive", "PROBLEM", 244, 256], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["productive", "OBSERVATION_MODIFIER", 92, 102]]], ["This claim had been based on periodic voluntary serial serological sampling of their lactating and young stocks (Lindberg and Alenius, 1999) .", [["periodic voluntary serial serological sampling", "PROBLEM", 29, 75]]], ["Only after about a year following diagnosis of the BVDV-2 acute infection in the studied herd, BVDV-2 was found in the neonate farm of one of the six suppliers.", [["infection", "DISEASE", 64, 73], ["BVDV-2", "ORGANISM", 51, 57], ["BVDV-2", "ORGANISM", 95, 101], ["BVDV", "SPECIES", 95, 99], ["the BVDV", "PROBLEM", 47, 55], ["2 acute infection", "PROBLEM", 56, 73], ["BVDV", "PROBLEM", 95, 99], ["BVDV", "OBSERVATION", 51, 55], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["infection", "OBSERVATION", 64, 73]]], ["Diarrhea and pneumonia were the only clinical signs noted at this source and no other signs were reported in the lactating stock.", [["Diarrhea", "DISEASE", 0, 8], ["pneumonia", "DISEASE", 13, 22], ["Diarrhea", "PROBLEM", 0, 8], ["pneumonia", "PROBLEM", 13, 22], ["clinical signs", "PROBLEM", 37, 51], ["other signs", "PROBLEM", 80, 91], ["pneumonia", "OBSERVATION", 13, 22]]], ["Table 3 Average milk yield and conception rates in lactating cows on the farm before, during and after the BVD type 2 outbreak.YearAverage milk yield per cow (kg)", [["milk", "ANATOMY", 16, 20], ["milk", "ORGANISM_SUBSTANCE", 16, 20], ["cows", "ORGANISM", 61, 65], ["milk", "ORGANISM_SUBSTANCE", 139, 143], ["cow", "ORGANISM_SUBDIVISION", 154, 157], ["cows", "SPECIES", 61, 65], ["cow", "SPECIES", 154, 157], ["cow", "SPECIES", 154, 157], ["the BVD type 2 outbreak", "PROBLEM", 103, 126]]]], "PMC2957997": [["The StudyNPA samples were collected from 235 children hospitalized with ARTI at the First Hospital of Lanzhou University, Gansu Province, China during December 2007\u2013November 2008.", [["StudyNPA samples", "ANATOMY", 4, 20], ["ARTI", "DISEASE", 72, 76], ["StudyNPA samples", "CANCER", 4, 20], ["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["The StudyNPA samples", "TEST", 0, 20]]], ["All patients were <15 years of age, and informed consent was obtained from their parents.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Demographic data and clinical findings were recorded.", [["Demographic data", "TEST", 0, 16], ["clinical findings", "TEST", 21, 38]]], ["The study protocol was approved by the hospital ethics committee.The StudyDNA and RNA were extracted from the NPAs by using QIAamp DNA and QIAamp viral RNA mini kits (QIAGEN, Beijing, China).", [["NPAs", "ANATOMY", 110, 114], ["NPAs", "SIMPLE_CHEMICAL", 110, 114], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["StudyDNA and RNA", "RNA", 69, 85], ["NPAs", "DNA", 110, 114], ["The study protocol", "TEST", 0, 18], ["QIAamp DNA", "TEST", 124, 134]]], ["The cDNA sample was synthesized by using random hexamer primers.", [["cDNA sample", "DNA", 4, 15], ["The cDNA sample", "TEST", 0, 15], ["random hexamer primers", "TREATMENT", 41, 63]]], ["A standard reverse transcription\u2013PCR was used to screen for human rhinovirus, respiratory synctial virus (RSV), influenza virus A, influenza virus B, parainfluenza virus 1\u20133, human metapneumovirus, human coronavirus (HCoV)\u2013NL63, and HCoV-HKU1, and PCR method was used to screen for adenovirus (ADV) (7\u201311).To screen for HBoV, PCR was performed by using primers 188F and 542R, as described by Allander et al. (2).", [["respiratory synctial virus", "DISEASE", 78, 104], ["influenza virus", "DISEASE", 112, 127], ["influenza virus B", "DISEASE", 131, 148], ["human metapneumovirus", "DISEASE", 175, 196], ["human", "ORGANISM", 60, 65], ["rhinovirus", "ORGANISM", 66, 76], ["respiratory synctial virus", "ORGANISM", 78, 104], ["RSV", "ORGANISM", 106, 109], ["influenza virus A", "ORGANISM", 112, 129], ["influenza virus B", "ORGANISM", 131, 148], ["parainfluenza virus 1\u20133", "ORGANISM", 150, 173], ["human", "ORGANISM", 175, 180], ["metapneumovirus", "ORGANISM", 181, 196], ["human coronavirus", "ORGANISM", 198, 215], ["HCoV", "GENE_OR_GENE_PRODUCT", 217, 221], ["NL63", "GENE_OR_GENE_PRODUCT", 223, 227], ["HCoV-HKU1", "CELL", 233, 242], ["adenovirus", "ORGANISM", 282, 292], ["HBoV", "ORGANISM", 320, 324], ["HKU1", "DNA", 238, 242], ["primers 188F and 542R", "DNA", 353, 374], ["human", "SPECIES", 60, 65], ["respiratory synctial virus", "SPECIES", 78, 104], ["influenza virus A", "SPECIES", 112, 129], ["influenza virus B", "SPECIES", 131, 148], ["parainfluenza virus 1\u20133", "SPECIES", 150, 173], ["human", "SPECIES", 175, 180], ["metapneumovirus", "SPECIES", 181, 196], ["human", "SPECIES", 198, 203], ["coronavirus", "SPECIES", 204, 215], ["human rhinovirus", "SPECIES", 60, 76], ["respiratory synctial virus", "SPECIES", 78, 104], ["RSV", "SPECIES", 106, 109], ["influenza virus A", "SPECIES", 112, 129], ["parainfluenza virus 1\u20133", "SPECIES", 150, 173], ["human metapneumovirus", "SPECIES", 175, 196], ["human coronavirus", "SPECIES", 198, 215], ["HCoV", "SPECIES", 217, 221], ["HCoV", "SPECIES", 233, 237], ["adenovirus", "SPECIES", 282, 292], ["ADV", "SPECIES", 294, 297], ["HBoV", "SPECIES", 320, 324], ["A standard reverse transcription\u2013PCR", "TEST", 0, 36], ["human rhinovirus", "PROBLEM", 60, 76], ["respiratory synctial virus", "PROBLEM", 78, 104], ["RSV", "TEST", 106, 109], ["influenza virus", "PROBLEM", 112, 127], ["influenza virus B", "PROBLEM", 131, 148], ["parainfluenza virus", "PROBLEM", 150, 169], ["human metapneumovirus", "TEST", 175, 196], ["human coronavirus", "TEST", 198, 215], ["HCoV", "TEST", 233, 237], ["HKU1", "TEST", 238, 242], ["PCR method", "TEST", 248, 258], ["adenovirus", "PROBLEM", 282, 292], ["HBoV", "PROBLEM", 320, 324], ["PCR", "TEST", 326, 329]]], ["For HBoV2, nested PCR was performed with sf1/sr1 and sf2/sr2 primers, which amplified a 455-bp fragment of the partial NS1 gene, as described (6).The StudyIn addition, we designed HBoV2 forward (SN1: 5\u2032-ACCAGTGGGAGAACCACAAG-3\u2032) and reverse (SN2: 5\u2032-GGCATTTGTTTCCATGCTTT-3\u2032) primers, which produced a 563-bp fragment of the NP1 gene of HBoV2.", [["sf1", "GENE_OR_GENE_PRODUCT", 41, 44], ["sr1", "GENE_OR_GENE_PRODUCT", 45, 48], ["sf2", "GENE_OR_GENE_PRODUCT", 53, 56], ["sr2", "GENE_OR_GENE_PRODUCT", 57, 60], ["NS1", "GENE_OR_GENE_PRODUCT", 119, 122], ["NP1", "GENE_OR_GENE_PRODUCT", 323, 326], ["HBoV2", "GENE_OR_GENE_PRODUCT", 335, 340], ["HBoV2", "DNA", 4, 9], ["sf1", "DNA", 41, 44], ["sr1", "DNA", 45, 48], ["sf2", "DNA", 53, 56], ["sr2", "DNA", 57, 60], ["455-bp fragment", "DNA", 88, 103], ["NS1 gene", "DNA", 119, 127], ["HBoV2 forward", "DNA", 180, 193], ["563-bp fragment", "DNA", 300, 315], ["NP1 gene", "DNA", 323, 331], ["HBoV2", "DNA", 335, 340], ["HBoV2", "TEST", 4, 9], ["nested PCR", "TEST", 11, 21], ["sf1", "TEST", 41, 44], ["sf2/sr2 primers", "TEST", 53, 68], ["SN1", "TEST", 195, 198], ["ACCAGTGGGAGAACCACAAG", "TEST", 203, 223], ["SN2", "TEST", 241, 244], ["GGCATTTGTTTCCATGCTTT", "TEST", 249, 269], ["primers", "TEST", 274, 281], ["partial", "OBSERVATION_MODIFIER", 111, 118], ["NS1 gene", "OBSERVATION", 119, 127]]], ["Positive and negative controls were included for each PCR.", [["each PCR", "TEST", 49, 57], ["negative controls", "OBSERVATION_MODIFIER", 13, 30]]], ["Purified PCR products were sequenced by using SinoGenoMax.", [["Purified PCR products", "TREATMENT", 0, 21], ["SinoGenoMax", "TREATMENT", 46, 57]]], ["ClustalX (ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX) was used to align the obtained sequences with sequences available in GenBank.The StudyIn total, 260 viruses were identified in 196 (83.4%) of the 235 children.", [["children", "ORGANISM", 203, 211], ["children", "SPECIES", 203, 211], ["ClustalX (ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX)", "TREATMENT", 0, 52]]], ["Using nested PCR, we found 21 positive specimens; further nucleotide sequence analysis showed that 10 (4.3%) were HBoV2 and 11 were HBoV (Figure, panel A).", [["specimens", "ANATOMY", 39, 48], ["nucleotide", "CHEMICAL", 58, 68], ["HBoV", "ORGANISM", 132, 136], ["HBoV", "SPECIES", 132, 136], ["nested PCR", "TEST", 6, 16], ["21 positive specimens", "PROBLEM", 27, 48], ["further nucleotide sequence analysis", "TEST", 50, 86], ["HBoV2", "TEST", 114, 119], ["HBoV", "TEST", 132, 136]]], ["All 11 HBoV strains detected by using HBoV2 nested-PCR were included in the 18 HBoV-positive patients as determined by PCR using primers 188F and 542R.", [["HBoV", "ORGANISM", 7, 11], ["HBoV", "ORGANISM", 79, 83], ["patients", "ORGANISM", 93, 101], ["primers 188F and 542R", "DNA", 129, 150], ["patients", "SPECIES", 93, 101], ["HBoV", "SPECIES", 7, 11], ["All 11 HBoV strains", "PROBLEM", 0, 19], ["HBoV2 nested-PCR", "TEST", 38, 54], ["primers", "TEST", 129, 136], ["HBoV strains", "OBSERVATION", 7, 19]]], ["Of the 10 HBoV2-positive patients, 7 (70%) were co-infected with other respiratory viruses, including 4 patients with RSV.", [["respiratory viruses", "DISEASE", 71, 90], ["RSV", "DISEASE", 118, 121], ["HBoV2", "GENE_OR_GENE_PRODUCT", 10, 15], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 104, 112], ["RSV", "ORGANISM", 118, 121], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 104, 112], ["RSV", "SPECIES", 118, 121], ["other respiratory viruses", "PROBLEM", 65, 90], ["RSV", "PROBLEM", 118, 121], ["respiratory viruses", "OBSERVATION", 71, 90]]], ["Of the 18 HBoV-positive patients, 12 (66.7%) displayed co-infections.", [["co-infections", "DISEASE", 55, 68], ["HBoV", "ORGANISM", 10, 14], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["the 18 HBoV", "TEST", 3, 14], ["co-infections", "PROBLEM", 55, 68], ["co-infections", "OBSERVATION", 55, 68]]], ["There were no statistically significant differences in the HBoV2 and HBoV detection (p = 0.119 by \u03c72 test) and co-infection (p = 1.000 by Fisher exact test) rates.The StudyOf the 10 HBoV2-positive patients, 9 were male and 1 was female (\u03c72 = 1.957, p = 0.162).", [["co-infection", "DISEASE", 111, 123], ["HBoV", "ORGANISM", 69, 73], ["HBoV2", "GENE_OR_GENE_PRODUCT", 182, 187], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["the HBoV2", "TEST", 55, 64], ["HBoV detection", "TEST", 69, 83], ["p", "TEST", 85, 86], ["co-infection", "PROBLEM", 111, 123], ["Fisher exact test", "TEST", 138, 155], ["The StudyOf", "TEST", 163, 174], ["no", "UNCERTAINTY", 11, 13], ["statistically", "OBSERVATION_MODIFIER", 14, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["differences", "OBSERVATION_MODIFIER", 40, 51]]], ["HBoV2 infections were detected throughout the year.", [["HBoV2 infections", "DISEASE", 0, 16], ["HBoV2", "GENE_OR_GENE_PRODUCT", 0, 5], ["HBoV2", "SPECIES", 0, 5], ["HBoV2 infections", "PROBLEM", 0, 16], ["infections", "OBSERVATION", 6, 16]]], ["Of the 18 patients who were HBoV positive, 11 were male and 7 were female (\u03c72 = 0.084, p = 0.772).", [["patients", "ORGANISM", 10, 18], ["HBoV", "ORGANISM", 28, 32], ["patients", "SPECIES", 10, 18], ["HBoV", "TEST", 28, 32]]], ["The median age of patients was 11.5 months, and 16/18 (88.9%) were <3 years old.The StudyHBoV infections were detected in every month except August, with peaks in December (3 cases) and January (4 cases).", [["infections", "DISEASE", 94, 104], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["The StudyHBoV infections", "PROBLEM", 80, 104], ["infections", "OBSERVATION", 94, 104]]], ["The main diagnoses of the 3 patients with HBoV2 monoinfection were acute asthmatic bronchopneumonia, bronchopneumonia, and acute upper respiratory tract infection in 1 patient each.", [["upper respiratory tract", "ANATOMY", 129, 152], ["monoinfection", "DISEASE", 48, 61], ["asthmatic bronchopneumonia", "DISEASE", 73, 99], ["bronchopneumonia", "DISEASE", 101, 117], ["acute upper respiratory tract infection", "DISEASE", 123, 162], ["patients", "ORGANISM", 28, 36], ["upper", "ORGANISM_SUBDIVISION", 129, 134], ["respiratory tract", "ORGANISM_SUBDIVISION", 135, 152], ["patient", "ORGANISM", 168, 175], ["patients", "SPECIES", 28, 36], ["patient", "SPECIES", 168, 175], ["HBoV2 monoinfection", "PROBLEM", 42, 61], ["acute asthmatic bronchopneumonia", "PROBLEM", 67, 99], ["bronchopneumonia", "PROBLEM", 101, 117], ["acute upper respiratory tract infection", "PROBLEM", 123, 162], ["main", "OBSERVATION_MODIFIER", 4, 8], ["HBoV2", "ANATOMY", 42, 47], ["monoinfection", "OBSERVATION", 48, 61], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["asthmatic", "OBSERVATION_MODIFIER", 73, 82], ["bronchopneumonia", "OBSERVATION", 83, 99], ["bronchopneumonia", "OBSERVATION", 101, 117], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["upper", "ANATOMY_MODIFIER", 129, 134], ["respiratory tract", "ANATOMY", 135, 152], ["infection", "OBSERVATION", 153, 162]]], ["For the 6 patients with HBoV monoinfection, the main diagnoses were acute asthmatic bronchopneumonia (4 cases) and bronchopneumonia (2 cases).", [["HBoV monoinfection", "DISEASE", 24, 42], ["asthmatic bronchopneumonia", "DISEASE", 74, 100], ["bronchopneumonia", "DISEASE", 115, 131], ["patients", "ORGANISM", 10, 18], ["HBoV", "ORGANISM", 24, 28], ["patients", "SPECIES", 10, 18], ["HBoV", "SPECIES", 24, 28], ["HBoV monoinfection", "PROBLEM", 24, 42], ["acute asthmatic bronchopneumonia", "PROBLEM", 68, 100], ["bronchopneumonia", "PROBLEM", 115, 131], ["monoinfection", "OBSERVATION", 29, 42], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["asthmatic", "OBSERVATION_MODIFIER", 74, 83], ["bronchopneumonia", "OBSERVATION", 84, 100], ["bronchopneumonia", "OBSERVATION", 115, 131]]], ["The clinical signs and symptoms of HBoV2 and HBoV positive patients included cough, fever, sputum production, crackles, wheezing, rhinorrhea, cyanosis, vomiting, and diarrhea (Table 1).", [["sputum", "ANATOMY", 91, 97], ["HBoV positive", "DISEASE", 45, 58], ["cough", "DISEASE", 77, 82], ["fever", "DISEASE", 84, 89], ["sputum production", "DISEASE", 91, 108], ["wheezing", "DISEASE", 120, 128], ["rhinorrhea", "DISEASE", 130, 140], ["cyanosis", "DISEASE", 142, 150], ["vomiting", "DISEASE", 152, 160], ["diarrhea", "DISEASE", 166, 174], ["HBoV2", "GENE_OR_GENE_PRODUCT", 35, 40], ["HBoV", "ORGANISM", 45, 49], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["The clinical signs", "TEST", 0, 18], ["symptoms", "PROBLEM", 23, 31], ["HBoV2", "PROBLEM", 35, 40], ["HBoV positive patients", "PROBLEM", 45, 67], ["cough", "PROBLEM", 77, 82], ["fever", "PROBLEM", 84, 89], ["sputum production", "PROBLEM", 91, 108], ["crackles", "PROBLEM", 110, 118], ["wheezing", "PROBLEM", 120, 128], ["rhinorrhea", "PROBLEM", 130, 140], ["cyanosis", "PROBLEM", 142, 150], ["vomiting", "PROBLEM", 152, 160], ["diarrhea", "PROBLEM", 166, 174], ["crackles", "OBSERVATION", 110, 118], ["rhinorrhea", "OBSERVATION", 130, 140], ["cyanosis", "OBSERVATION", 142, 150]]], ["For patients with HBoV2 monoinfection, the median hospital stay was 11.3 days (range 4\u201323 days), and 2 had underlying illnesses (idiopathic pulmonary hemosiderosis and iron deficiency anemia).", [["pulmonary", "ANATOMY", 140, 149], ["HBoV2 monoinfection", "DISEASE", 18, 37], ["idiopathic pulmonary hemosiderosis", "DISEASE", 129, 163], ["iron deficiency anemia", "DISEASE", 168, 190], ["iron", "CHEMICAL", 168, 172], ["patients", "ORGANISM", 4, 12], ["pulmonary", "ORGAN", 140, 149], ["patients", "SPECIES", 4, 12], ["HBoV2", "SPECIES", 18, 23], ["HBoV2 monoinfection", "PROBLEM", 18, 37], ["underlying illnesses", "PROBLEM", 107, 127], ["idiopathic pulmonary hemosiderosis", "PROBLEM", 129, 163], ["iron deficiency anemia", "PROBLEM", 168, 190], ["monoinfection", "OBSERVATION", 24, 37], ["illnesses", "OBSERVATION", 118, 127], ["idiopathic", "OBSERVATION_MODIFIER", 129, 139], ["pulmonary", "ANATOMY", 140, 149], ["hemosiderosis", "OBSERVATION", 150, 163], ["iron deficiency", "OBSERVATION", 168, 183]]], ["The chest radiograph of 1 patient showed upper middle zone air-space shadows.", [["chest", "ANATOMY", 4, 9], ["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["The chest radiograph", "TEST", 0, 20], ["upper middle zone air-space shadows", "PROBLEM", 41, 76], ["chest", "ANATOMY", 4, 9], ["upper", "ANATOMY_MODIFIER", 41, 46], ["middle", "ANATOMY_MODIFIER", 47, 53], ["zone", "ANATOMY_MODIFIER", 54, 58], ["air", "OBSERVATION", 59, 62], ["space shadows", "OBSERVATION", 63, 76]]], ["For patients with HBoV monoinfection, the median hospital stay was 7.8 days (range 6\u201310 days), and none had underlying illnesses.", [["HBoV monoinfection", "DISEASE", 18, 36], ["patients", "ORGANISM", 4, 12], ["HBoV", "ORGANISM", 18, 22], ["patients", "SPECIES", 4, 12], ["HBoV", "SPECIES", 18, 22], ["HBoV monoinfection", "PROBLEM", 18, 36], ["underlying illnesses", "PROBLEM", 108, 128], ["HBoV monoinfection", "OBSERVATION", 18, 36], ["illnesses", "OBSERVATION", 119, 128]]], ["Chest radiographs of 2 patients showed shadows in the left lung zone.The StudyTen HBoV2 NS-1 sequences (455 bp) shared 98%\u201399% and 95%\u201396% nucleotide sequence identity and 99%\u2013100% and 98%\u201399% deduced amino acid sequence identity with HBoV2 strain PK-2255 (FJ170279) and HBoV2 strain W153 (EU082213), respectively; These sequences also shared 81%\u201382% and 83.3%\u201384.4% nucleotide sequence identity and 90% and 88% deduced amino acid sequence identity with the HBoV prototype strain ST1 or ST2 (DQ000495 and DQ000496) and human bocavirus 3 strain W471 (EU918736), respectively.", [["left lung zone", "ANATOMY", 54, 68], ["nucleotide", "CHEMICAL", 139, 149], ["amino acid", "CHEMICAL", 201, 211], ["nucleotide", "CHEMICAL", 367, 377], ["amino acid", "CHEMICAL", 420, 430], ["amino acid", "CHEMICAL", 201, 211], ["amino acid", "CHEMICAL", 420, 430], ["patients", "ORGANISM", 23, 31], ["lung", "ORGAN", 59, 63], ["amino acid", "AMINO_ACID", 201, 211], ["HBoV2 strain W153", "ORGANISM", 271, 288], ["amino acid", "AMINO_ACID", 420, 430], ["HBoV", "ORGANISM", 458, 462], ["ST2", "CELL", 487, 490], ["human", "ORGANISM", 519, 524], ["bocavirus 3", "ORGANISM", 525, 536], ["StudyTen HBoV2 NS-1 sequences", "DNA", 73, 102], ["patients", "SPECIES", 23, 31], ["human", "SPECIES", 519, 524], ["PK-2255", "SPECIES", 248, 255], ["human bocavirus 3 strain W471", "SPECIES", 519, 548], ["Chest radiographs", "TEST", 0, 17], ["shadows in the left lung zone", "PROBLEM", 39, 68], ["The StudyTen HBoV2 NS", "TEST", 69, 90], ["bp", "TEST", 108, 110], ["nucleotide sequence identity", "TEST", 139, 167], ["amino acid sequence identity", "TEST", 201, 229], ["HBoV2 strain PK", "TEST", 235, 250], ["HBoV2 strain", "TEST", 271, 283], ["These sequences", "TEST", 315, 330], ["nucleotide sequence identity", "TEST", 367, 395], ["88% deduced amino acid sequence identity", "PROBLEM", 408, 448], ["the HBoV prototype strain ST1", "PROBLEM", 454, 483], ["ST2", "TEST", 487, 490], ["human bocavirus", "TEST", 519, 534], ["shadows", "OBSERVATION", 39, 46], ["left", "ANATOMY_MODIFIER", 54, 58], ["lung", "ANATOMY", 59, 63], ["zone", "ANATOMY_MODIFIER", 64, 68]]], ["The 4 HBoV2 NP-1 sequences shared 98%\u201399% and 97.6%\u201398.3% nucleotide sequence identity and 98%\u2013100% and 97%\u2013100% deduced amino acid sequence identity with HBoV2 strain PK-2255 and HBoV2 strain W153, respectively, and shared 74%\u201378% and 69.7%\u201370.3% nucleotide sequence identity and 69%\u201373% and 58%\u201362% deduced amino acid sequence identity with the prototype strain ST1 or ST2 and human bocavirus 3 strain W471, respectively.", [["nucleotide", "CHEMICAL", 58, 68], ["amino acid", "CHEMICAL", 121, 131], ["nucleotide", "CHEMICAL", 248, 258], ["amino acid", "CHEMICAL", 309, 319], ["amino acid", "CHEMICAL", 121, 131], ["amino acid", "CHEMICAL", 309, 319], ["amino acid", "AMINO_ACID", 121, 131], ["PK-2255", "CELL", 168, 175], ["HBoV2 strain W153", "CELL", 180, 197], ["amino acid", "AMINO_ACID", 309, 319], ["ST2", "CELL", 371, 374], ["human", "ORGANISM", 379, 384], ["bocavirus 3 strain W471", "ORGANISM", 385, 408], ["4 HBoV2 NP-1 sequences", "DNA", 4, 26], ["ST2", "PROTEIN", 371, 374], ["human", "SPECIES", 379, 384], ["PK-2255", "SPECIES", 168, 175], ["human bocavirus 3 strain W471", "SPECIES", 379, 408], ["nucleotide sequence identity", "TEST", 58, 86], ["\u2013", "TEST", 107, 108], ["amino acid sequence identity", "TEST", 121, 149], ["HBoV2 strain PK", "TEST", 155, 170], ["HBoV2 strain", "TEST", 180, 192], ["nucleotide sequence identity", "TEST", 248, 276], ["\u2013", "TEST", 296, 297], ["deduced amino acid sequence identity", "PROBLEM", 301, 337], ["the prototype strain ST1", "PROBLEM", 343, 367], ["ST2", "PROBLEM", 371, 374], ["human bocavirus 3 strain", "PROBLEM", 379, 403]]], ["The nucleotide and deduced amino acid sequences of NS-1 and NP-1 shared high identities (>97%) with the HBoV2 and HBoV sequences (Table 2).", [["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 27, 37], ["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 27, 37], ["amino acid", "AMINO_ACID", 27, 37], ["NS-1", "GENE_OR_GENE_PRODUCT", 51, 55], ["NP-1", "GENE_OR_GENE_PRODUCT", 60, 64], ["HBoV", "ORGANISM", 114, 118], ["NS-1 and NP-1", "DNA", 51, 64], ["HBoV2 and HBoV sequences", "DNA", 104, 128], ["The nucleotide and deduced amino acid sequences", "TEST", 0, 47], ["NS", "TEST", 51, 53], ["NP", "TEST", 60, 62], ["the HBoV2 and HBoV sequences", "TEST", 100, 128]]], ["Phylogenetic analysis indicated that HBoV2 is more closely related to HBoV (Figure).ConclusionsUsing nested PCR and sequencing, we identified HBoV2 infections in 10 (4.3%) of 235 NPAs from children hospitalized with ARTI.", [["NPAs", "ANATOMY", 179, 183], ["HBoV2 infections", "DISEASE", 142, 158], ["NPAs", "DISEASE", 179, 183], ["ARTI", "DISEASE", 216, 220], ["HBoV2", "GENE_OR_GENE_PRODUCT", 37, 42], ["HBoV", "ORGANISM", 70, 74], ["HBoV2", "GENE_OR_GENE_PRODUCT", 142, 147], ["NPAs", "CANCER", 179, 183], ["children", "ORGANISM", 189, 197], ["HBoV2", "DNA", 37, 42], ["children", "SPECIES", 189, 197], ["Phylogenetic analysis", "TEST", 0, 21], ["HBoV2", "PROBLEM", 37, 42], ["HBoV", "PROBLEM", 70, 74], ["ConclusionsUsing nested PCR", "TEST", 84, 111], ["HBoV2 infections", "PROBLEM", 142, 158], ["ARTI", "PROBLEM", 216, 220], ["HBoV", "OBSERVATION", 70, 74], ["infections", "OBSERVATION", 148, 158]]], ["Most of the patients were <3 years old.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["In HBoV2-positive patients, co-infection was high (70%), with RSV being the most common co-pathogen.", [["co-infection", "DISEASE", 28, 40], ["HBoV2", "GENE_OR_GENE_PRODUCT", 3, 8], ["patients", "ORGANISM", 18, 26], ["RSV", "ORGANISM", 62, 65], ["patients", "SPECIES", 18, 26], ["RSV", "SPECIES", 62, 65], ["HBoV2", "TEST", 3, 8], ["co-infection", "PROBLEM", 28, 40], ["RSV", "PROBLEM", 62, 65], ["positive patients", "OBSERVATION_MODIFIER", 9, 26], ["co-infection", "OBSERVATION", 28, 40]]], ["Primers SN1 and SN2 were designed to detect the NP1 gene in the 10 HBoV2-positive patients.", [["SN1", "GENE_OR_GENE_PRODUCT", 8, 11], ["NP1", "GENE_OR_GENE_PRODUCT", 48, 51], ["HBoV2", "GENE_OR_GENE_PRODUCT", 67, 72], ["patients", "ORGANISM", 82, 90], ["SN1", "DNA", 8, 11], ["SN2", "DNA", 16, 19], ["NP1 gene", "DNA", 48, 56], ["patients", "SPECIES", 82, 90], ["Primers SN1", "TEST", 0, 11]]], ["However, only 4 gave positive results, which occurred because of the low PCR sensitivity with this pair of primers and because the NP1 gene of HBoV2 is divergent, as described (6).", [["NP1", "GENE_OR_GENE_PRODUCT", 131, 134], ["HBoV2", "GENE_OR_GENE_PRODUCT", 143, 148], ["NP1 gene", "DNA", 131, 139], ["HBoV2", "DNA", 143, 148], ["the low PCR sensitivity", "PROBLEM", 65, 88], ["this pair of primers", "PROBLEM", 94, 114], ["divergent", "OBSERVATION_MODIFIER", 152, 161]]], ["Furthermore, as previous studies (6,12) pointed out, potential recombination upstream from the NP1 gene may explain the lower detection.", [["NP1", "GENE_OR_GENE_PRODUCT", 95, 98], ["NP1 gene", "DNA", 95, 103], ["previous studies", "TEST", 16, 32], ["the lower detection", "PROBLEM", 116, 135]]], ["Phylogenetic analysis showed that the NS-1 region of the HBoV2 strain (LZ480 and LZ578) clustered closely with that of the HBoV2 PK-2255 strain (FJ170279), and the NP-1 region clustered closely with that of the HBoV2 W153 strain (EU082213), suggesting potential recombination in the HBoV2 strains (Figure).", [["NS-1", "GENE_OR_GENE_PRODUCT", 38, 42], ["HBoV2 strain", "ORGANISM", 57, 69], ["HBoV2 PK-2255 strain", "ORGANISM", 123, 143], ["NP-1", "GENE_OR_GENE_PRODUCT", 164, 168], ["HBoV2 W153 strain", "ORGANISM", 211, 228], ["HBoV2", "GENE_OR_GENE_PRODUCT", 283, 288], ["NS-1 region", "DNA", 38, 49], ["NP-1 region", "DNA", 164, 175], ["HBoV2 PK-2255 strain", "SPECIES", 123, 143], ["Phylogenetic analysis", "TEST", 0, 21], ["the NS", "TEST", 34, 40], ["the HBoV2 strain", "PROBLEM", 53, 69], ["the HBoV2 PK", "TEST", 119, 131], ["strain", "PROBLEM", 137, 143], ["the NP", "TEST", 160, 166], ["the HBoV2 strains", "PROBLEM", 279, 296]]], ["In addition, 11 HBoV sequences were amplified by using nested-PCR for HBoV2.", [["HBoV", "ORGANISM", 16, 20], ["HBoV2", "GENE_OR_GENE_PRODUCT", 70, 75], ["HBoV sequences", "DNA", 16, 30], ["HBoV2", "PROTEIN", 70, 75], ["HBoV", "SPECIES", 16, 20], ["11 HBoV sequences", "TEST", 13, 30], ["nested-PCR", "TEST", 55, 65], ["HBoV2", "TREATMENT", 70, 75]]], ["In the future, HBoV2-specific primers should be designed to investigate the prevalence of HBoV2 and its potential association with disease.ConclusionsWe found no difference in the clinical symptoms or length of hospital stay between the groups with HBoV2 and HBoV monoinfection, as well as between the groups with HBoV2 monoinfection and HBoV2 co-infection (Table 1).", [["HBoV monoinfection", "DISEASE", 259, 277], ["HBoV2 co-infection", "DISEASE", 338, 356], ["HBoV2", "GENE_OR_GENE_PRODUCT", 15, 20], ["HBoV2", "GENE_OR_GENE_PRODUCT", 90, 95], ["HBoV", "ORGANISM", 259, 263], ["HBoV2", "DNA", 15, 20], ["HBoV", "SPECIES", 259, 263], ["HBoV2", "TEST", 15, 20], ["HBoV2", "PROBLEM", 90, 95], ["disease", "PROBLEM", 131, 138], ["the clinical symptoms", "PROBLEM", 176, 197], ["HBoV2", "TREATMENT", 249, 254], ["HBoV monoinfection", "PROBLEM", 259, 277], ["HBoV2 monoinfection", "PROBLEM", 314, 333], ["HBoV2 co-infection", "PROBLEM", 338, 356], ["no", "UNCERTAINTY", 159, 161], ["difference", "OBSERVATION_MODIFIER", 162, 172], ["HBoV monoinfection", "OBSERVATION", 259, 277], ["HBoV2", "ANATOMY", 314, 319], ["monoinfection", "OBSERVATION", 320, 333]]], ["Statistical analysis indicated that HBoV2 and HBoV co-infection obviously did not correlate with disease severity (data not shown).", [["HBoV co-infection", "DISEASE", 46, 63], ["HBoV2", "GENE_OR_GENE_PRODUCT", 36, 41], ["HBoV", "ORGANISM", 46, 50], ["HBoV", "SPECIES", 46, 50], ["Statistical analysis", "TEST", 0, 20], ["HBoV2", "TEST", 36, 41], ["HBoV co-infection", "PROBLEM", 46, 63], ["disease severity", "PROBLEM", 97, 113], ["HBoV co-infection", "OBSERVATION", 46, 63]]], ["Two of 3 patients with HBoV2 monoinfection had diarrhea with no vomiting (Table 1), and only 1 of 10 patients who were HBoV2 positive vomited.", [["monoinfection", "DISEASE", 29, 42], ["diarrhea", "DISEASE", 47, 55], ["vomiting", "DISEASE", 64, 72], ["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 101, 109], ["HBoV2 monoinfection", "PROBLEM", 23, 42], ["diarrhea", "PROBLEM", 47, 55], ["vomiting", "PROBLEM", 64, 72], ["HBoV2 positive vomited", "PROBLEM", 119, 141], ["monoinfection", "OBSERVATION", 29, 42]]], ["Further investigation is needed to exclude oral or inhaled gastric viruses as possible sources of NPA-associated HBoV2.", [["oral", "ANATOMY", 43, 47], ["gastric", "ANATOMY", 59, 66], ["NPA", "CHEMICAL", 98, 101], ["NPA", "CHEMICAL", 98, 101], ["oral", "ORGANISM_SUBDIVISION", 43, 47], ["gastric", "ORGAN", 59, 66], ["NPA", "SIMPLE_CHEMICAL", 98, 101], ["HBoV2", "GENE_OR_GENE_PRODUCT", 113, 118], ["Further investigation", "TEST", 0, 21], ["oral or inhaled gastric viruses", "PROBLEM", 43, 74], ["NPA", "TEST", 98, 101], ["gastric", "ANATOMY", 59, 66], ["viruses", "OBSERVATION", 67, 74]]], ["Phylogenetic analysis showed a high degree of similarity between HBoV2 sequences found in China and those in other areas (Figure).", [["HBoV2", "GENE_OR_GENE_PRODUCT", 65, 70], ["HBoV2 sequences", "DNA", 65, 80], ["Phylogenetic analysis", "TEST", 0, 21], ["a high degree of similarity between HBoV2 sequences", "PROBLEM", 29, 80], ["high degree", "OBSERVATION_MODIFIER", 31, 42]]], ["Our results suggest that like HBoV, HBoV2 is distributed worldwide and may be associated with respiratory and enteric diseases.", [["respiratory", "ANATOMY", 94, 105], ["HBoV2", "CHEMICAL", 36, 41], ["respiratory and enteric diseases", "DISEASE", 94, 126], ["HBoV", "ORGANISM", 30, 34], ["HBoV2", "GENE_OR_GENE_PRODUCT", 36, 41], ["HBoV", "SPECIES", 30, 34], ["HBoV", "PROBLEM", 30, 34], ["respiratory and enteric diseases", "PROBLEM", 94, 126], ["HBoV", "OBSERVATION", 30, 34], ["may be associated with", "UNCERTAINTY", 71, 93], ["enteric diseases", "OBSERVATION", 110, 126]]], ["Additional studies are needed to confirm the association between human bocavirus species (HBoV2 and HBoV) and respiratory tract infections or other diseases.", [["respiratory tract", "ANATOMY", 110, 127], ["respiratory tract infections", "DISEASE", 110, 138], ["human", "ORGANISM", 65, 70], ["bocavirus species", "ORGANISM", 71, 88], ["HBoV", "ORGANISM", 100, 104], ["tract", "ORGANISM_SUBDIVISION", 122, 127], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["HBoV", "SPECIES", 100, 104], ["Additional studies", "TEST", 0, 18], ["human bocavirus species", "PROBLEM", 65, 88], ["HBoV2", "TEST", 90, 95], ["HBoV", "PROBLEM", 100, 104], ["respiratory tract infections", "PROBLEM", 110, 138], ["other diseases", "PROBLEM", 142, 156], ["bocavirus species", "OBSERVATION", 71, 88], ["respiratory tract", "ANATOMY", 110, 127]]]], "3471e36a7311e55758f42aecb5b2f74311602a94": [["INTRODUCTIONThe first reports of 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from China in December, but quickly spread as a pandemic.", [["coronavirus disease", "DISEASE", 44, 63], ["COVID-19", "CHEMICAL", 65, 73], ["acute respiratory syndrome coronavirus", "DISEASE", 92, 130], ["coronavirus", "ORGANISM", 44, 55], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 85, 132], ["SARS-CoV-2", "ORGANISM", 134, 144], ["severe acute respiratory syndrome coronavirus", "SPECIES", 85, 130], ["SARS-CoV-2", "SPECIES", 134, 144], ["novel coronavirus disease", "PROBLEM", 38, 63], ["COVID", "TEST", 65, 70], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 85, 130], ["SARS", "PROBLEM", 134, 138], ["coronavirus disease", "OBSERVATION", 44, 63], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory syndrome", "OBSERVATION", 98, 118]]], ["[1] [2] [3] Laboratory testing for SARS-CoV-2 plays an essential role in infection control and public health mitigation strategies; however, testing has been hampered by global supply chain shortage nasopharyngeal (NP) swabs and universal transport medium (UTM).", [["SARS", "DISEASE", 35, 39], ["infection", "DISEASE", 73, 82], ["nasopharyngeal", "CANCER", 199, 213], ["SARS-CoV", "SPECIES", 35, 43], ["Laboratory testing", "TEST", 12, 30], ["SARS", "TEST", 35, 39], ["CoV", "TEST", 40, 43], ["infection control", "TREATMENT", 73, 90], ["testing", "TEST", 141, 148], ["nasopharyngeal (NP)", "TREATMENT", 199, 218], ["infection", "OBSERVATION", 73, 82]]], ["As such, alternative collection methods were rapidly evaluated, including nasal swabs, oropharyngeal (OP) swabs, throat washings, and saliva.", [["nasal swabs", "ANATOMY", 74, 85], ["oropharyngeal", "ANATOMY", 87, 100], ["swabs", "ANATOMY", 106, 111], ["throat", "ANATOMY", 113, 119], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 74, 85], ["oropharyngeal", "ORGANISM_SUBDIVISION", 87, 100], ["saliva", "ORGANISM_SUBSTANCE", 134, 140], ["alternative collection methods", "TEST", 9, 39], ["nasal swabs", "TEST", 74, 85], ["oropharyngeal (OP) swabs", "TEST", 87, 111], ["throat washings", "TEST", 113, 128], ["oropharyngeal", "ANATOMY", 87, 100], ["throat", "ANATOMY", 113, 119]]], ["[4] [5] [6] [7] [8] While NP swabs in UTM are the specimen of choice for respiratory virus testing, a recent study demonstrated the feasibility of COVID-19 testing from nasal sample collected with a swab typically used for chlamydia and gonorrhea testing: the Aptima Multitest swab (Hologic, Inc.) and its accompanying specimen transport medium (STM).", [["nasal sample", "ANATOMY", 169, 181], ["specimen", "ANATOMY", 319, 327], ["gonorrhea", "DISEASE", 237, 246], ["[4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 19], ["UTM", "SIMPLE_CHEMICAL", 38, 41], ["NP swabs in UTM", "TEST", 26, 41], ["respiratory virus testing", "TEST", 73, 98], ["a recent study", "TEST", 100, 114], ["COVID", "TEST", 147, 152], ["nasal sample", "TEST", 169, 181], ["a swab", "TEST", 197, 203], ["chlamydia", "PROBLEM", 223, 232], ["gonorrhea testing", "TEST", 237, 254], ["the Aptima Multitest swab", "TEST", 256, 281]]], ["[9] This study sought to further validate the Aptima swab/STM collection kit for the detection of SARS-CoV-2 using a single swab approach to sample the oropharynx and anterior nares (OP/Na).J o u r n a l P r e -p r o o fIn community assessment centers prioritizing areas with suspected community spread of SARS-CoV-2, specimens were collected for COVID-19 testing from 190 individuals using two different collection devices: a flocked NP swab in 3 ml UTM (Copan Diagnostics Inc., Murrieta, CA) and combined OP/Na sampling using the Aptima Multitest swab in 2.9 ml of STM (Hologic, Inc., San Diego CA), according to an accompanying instructional video (https://vimeo.com/397169241).", [["oropharynx", "ANATOMY", 152, 162], ["anterior nares", "ANATOMY", 167, 181], ["specimens", "ANATOMY", 318, 327], ["SARS", "DISEASE", 98, 102], ["Na", "CHEMICAL", 186, 188], ["SARS", "DISEASE", 306, 310], ["OP", "CHEMICAL", 507, 509], ["Na", "CHEMICAL", 510, 512], ["Na", "CHEMICAL", 186, 188], ["Na", "CHEMICAL", 510, 512], ["oropharynx", "ORGAN", 152, 162], ["anterior nares", "MULTI-TISSUE_STRUCTURE", 167, 181], ["specimens", "CANCER", 318, 327], ["SARS-CoV", "SPECIES", 98, 106], ["SARS-CoV", "SPECIES", 306, 314], ["This study", "TEST", 4, 14], ["the Aptima swab", "TEST", 42, 57], ["STM collection kit", "TEST", 58, 76], ["the detection", "TEST", 81, 94], ["SARS", "PROBLEM", 98, 102], ["CoV", "TEST", 103, 106], ["a single swab approach", "TREATMENT", 115, 137], ["fIn community assessment", "TEST", 219, 243], ["SARS", "PROBLEM", 306, 310], ["CoV", "TEST", 311, 314], ["specimens", "TEST", 318, 327], ["COVID", "TEST", 347, 352], ["two different collection devices", "TREATMENT", 391, 423], ["a flocked NP swab", "TREATMENT", 425, 442], ["combined OP/Na sampling", "TREATMENT", 498, 521], ["the Aptima", "TEST", 528, 538], ["oropharynx", "ANATOMY", 152, 162], ["anterior", "ANATOMY_MODIFIER", 167, 175], ["nares", "ANATOMY", 176, 181]]], ["Each specimen was stored at 4\uf0b0C until testing, and an aliquot was stored at -80\uf0b0C. Both swabs were in parallel within 12h of collection using two molecular methods.", [["specimen", "ANATOMY", 5, 13], ["swabs", "ANATOMY", 88, 93], ["testing", "TEST", 38, 45], ["an aliquot", "TREATMENT", 51, 61], ["Both swabs", "TREATMENT", 83, 93], ["swabs", "OBSERVATION", 88, 93]]], ["First, the SARS-CoV-2 assay, was performed on a Cobas 6800 system Amplification was performed on an Applied BioSystems 7500 Fast system (Thermo Fisher Scientific), and threshold cycles (Ct) values were determined by the manufacturer software.", [["the SARS", "TEST", 7, 15], ["Ct) values", "TEST", 186, 196]]], ["Results for each instrument were classified as positive or negative, and specimens yielding discrepant results were subjected to testing using the Xpert Xpress SARS-CoV-2 assay (Cepheid).", [["specimens", "ANATOMY", 73, 82], ["each instrument", "TEST", 12, 27], ["specimens", "TEST", 73, 82], ["testing", "TEST", 129, 136], ["the Xpert Xpress SARS", "TEST", 143, 164], ["CoV", "TEST", 165, 168]]], ["Each test was compared to a modified reference standard defined as concordant results from at least two methods with different genetic targets.", [["Each test", "TEST", 0, 9]]], ["Sensitivity and specificity were calculated from 2 \u00d7 2 contingency tables with 95% confidence intervals (CI) for each collection (NP or OP/Na swabs) and instrument (LDT and commercial assay) using J o u r n a l P r e -p r o o f online software (https://www.medcalc.org/calc/diagnostic_test.php).", [["Na", "CHEMICAL", 139, 141], ["Na", "CHEMICAL", 139, 141], ["Sensitivity", "TEST", 0, 11], ["specificity", "TEST", 16, 27], ["CI", "TEST", 105, 107], ["each collection (NP or OP/Na swabs", "TEST", 113, 147], ["instrument", "TEST", 153, 163]]], ["A Fisher exact test was used to assess differences and P \u2264 0.05 was considered statistically significant.Results and DiscussionThe limited and unpredictable supply of NP swabs during the COVID-19 pandemic prompted the evaluation of swabs that were readily available and commonly used for sexually transmitted infections.", [["sexually transmitted infections", "DISEASE", 288, 319], ["A Fisher exact test", "TEST", 0, 19], ["NP swabs", "TREATMENT", 167, 175], ["the COVID", "TEST", 183, 192], ["the evaluation", "TEST", 214, 228], ["swabs", "TEST", 232, 237], ["sexually transmitted infections", "PROBLEM", 288, 319], ["infections", "OBSERVATION", 309, 319]]], ["OP/Na was lower than NP swabs using the LDT or commercial assays, no significant differences were observed (P = 0.679 and 0.115, respectively).Results and DiscussionPatients with discrepant NP and OP/Na results are summarized in (Table 1) .", [["OP", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 3, 5], ["OP", "CHEMICAL", 197, 199], ["Na", "CHEMICAL", 200, 202], ["Na", "CHEMICAL", 3, 5], ["Na", "CHEMICAL", 200, 202], ["OP", "SIMPLE_CHEMICAL", 0, 2], ["Na", "SIMPLE_CHEMICAL", 3, 5], ["OP/Na", "TEST", 0, 5], ["NP swabs", "TREATMENT", 21, 29], ["the LDT", "TEST", 36, 43], ["commercial assays", "TEST", 47, 64], ["P", "TEST", 108, 109]]], ["With the exception of patient 4, the other five patients with discrepant NP and OP/Na results had specimens with low viral loads (Table 1) .", [["specimens", "ANATOMY", 98, 107], ["Na", "CHEMICAL", 83, 85], ["Na", "CHEMICAL", 83, 85], ["patient", "ORGANISM", 22, 29], ["patients", "ORGANISM", 48, 56], ["patient", "SPECIES", 22, 29], ["patients", "SPECIES", 48, 56], ["discrepant NP and OP/Na results", "TEST", 62, 93], ["specimens", "TEST", 98, 107], ["low viral loads", "PROBLEM", 113, 128]]], ["Low viral loads are known to occur in the early and late stages of COVID-19 illness [4] [5] [6] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and false negative results can arise from differences in analytical sensitivity between methods (Table S1 ) [20, 21] , the variability in specimen collection, or factors influencing specimen stability or recovery of SARS-CoV-2 RNA during specimen transport, storage or processing.", [["specimen", "ANATOMY", 281, 289], ["specimen", "ANATOMY", 325, 333], ["specimen", "ANATOMY", 381, 389], ["illness", "DISEASE", 76, 83], ["SARS", "DISEASE", 359, 363], ["[4] [5] [6] [11] [12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 84, 140], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 359, 369], ["specimen", "MULTI-TISSUE_STRUCTURE", 381, 389], ["SARS-CoV-2 RNA", "RNA", 359, 373], ["Low viral loads", "PROBLEM", 0, 15], ["COVID", "TEST", 67, 72], ["analytical sensitivity", "TEST", 200, 222], ["the variability in specimen collection", "PROBLEM", 262, 300], ["specimen stability", "TEST", 325, 343], ["SARS", "PROBLEM", 359, 363], ["CoV", "TEST", 364, 367], ["viral loads", "OBSERVATION", 4, 15]]], ["[4, 13] For example, three different SARS-CoV-2 targets were detected between the various PCR methods used for testing of J o u r n a l P r e -p r o o f specimens from patient 1, yet high Ct values were observed for these targets (Table 1) .", [["SARS", "DISEASE", 37, 41], ["patient", "ORGANISM", 168, 175], ["SARS-CoV-2 targets", "DNA", 37, 55], ["patient", "SPECIES", 168, 175], ["three different SARS", "PROBLEM", 21, 41], ["a l P r e -p r o o f specimens", "TEST", 132, 162], ["high Ct values", "PROBLEM", 183, 197]]], ["High Ct values are suggestive of low viral loads, and it is known that detection of PCR targets near the limit of detection lacks reproducibility.", [["PCR targets", "DNA", 84, 95], ["High Ct values", "TEST", 0, 14], ["low viral loads", "PROBLEM", 33, 48], ["PCR targets", "PROBLEM", 84, 95], ["suggestive of", "UNCERTAINTY", 19, 32], ["low", "OBSERVATION_MODIFIER", 33, 36], ["viral loads", "OBSERVATION", 37, 48]]], ["[20, 21] Therefore, low viral loads and differences in analytical sensitivity of the various molecular methods could explain differences in SARS-CoV-2 detection between the NP and OP/Na collections (Table S1 ).", [["OP", "CHEMICAL", 180, 182], ["Na", "CHEMICAL", 183, 185], ["Na", "CHEMICAL", 183, 185], ["low viral loads", "PROBLEM", 20, 35], ["analytical sensitivity", "TEST", 55, 77], ["SARS", "PROBLEM", 140, 144], ["CoV", "TEST", 145, 148], ["the NP and OP/Na collections", "PROBLEM", 169, 197], ["low", "OBSERVATION_MODIFIER", 20, 23], ["viral loads", "OBSERVATION", 24, 35], ["NP", "ANATOMY", 173, 175]]], ["Similar arguments could be made for patients 2 to 4, who were either asymptomatic or in the pre-symptomatic stage of infection where low viral loads can occur.", [["infection", "DISEASE", 117, 126], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["asymptomatic", "PROBLEM", 69, 81], ["infection", "PROBLEM", 117, 126], ["low viral loads", "PROBLEM", 133, 148], ["infection", "OBSERVATION", 117, 126]]], ["[4] [5] [6] [11] [12] [13] [14] [15] [16] [17] [18] [19] Discrepant results for patients 5 and 6 were in the setting of known positive cases, with symptoms predating their sample collection by 14 and 18 days, respectively.", [["sample", "ANATOMY", 172, 178], ["[4] [5] [6] [11] [12] [13] [14", "CHEMICAL", 0, 30], ["[4] [5] [6] [11] [12] [13] [14] [15] [16] [17] [18] [19] Discrepant", "SIMPLE_CHEMICAL", 0, 67], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["Discrepant results", "TEST", 57, 75], ["known positive cases", "PROBLEM", 120, 140], ["symptoms", "PROBLEM", 147, 155], ["positive cases", "OBSERVATION", 126, 140]]], ["Waning viral loads over time in the upper respiratory tract are well documented for SARS-CoV-2; however, discrepant NP and OP/Na results from sampling in the later stages of illness may be of little clinical significance, as detection of SARS-CoV-2 RNA does not imply infectivity.", [["upper respiratory tract", "ANATOMY", 36, 59], ["OP", "CHEMICAL", 123, 125], ["Na", "CHEMICAL", 126, 128], ["illness", "DISEASE", 174, 181], ["SARS", "DISEASE", 238, 242], ["Na", "CHEMICAL", 126, 128], ["upper respiratory", "ORGANISM_SUBDIVISION", 36, 53], ["tract", "ORGANISM_SUBDIVISION", 54, 59], ["SARS-CoV-2", "ORGANISM", 84, 94], ["SARS-CoV-2", "ORGANISM", 238, 248], ["SARS-CoV-2 RNA", "RNA", 238, 252], ["SARS-CoV", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 238, 246], ["Waning viral loads", "PROBLEM", 0, 18], ["SARS", "PROBLEM", 84, 88], ["CoV", "TEST", 89, 92], ["discrepant NP and OP/Na results", "TEST", 105, 136], ["sampling", "TEST", 142, 150], ["illness", "PROBLEM", 174, 181], ["SARS", "PROBLEM", 238, 242], ["CoV", "TEST", 243, 246], ["viral loads", "OBSERVATION", 7, 18], ["upper", "ANATOMY_MODIFIER", 36, 41], ["respiratory tract", "ANATOMY", 42, 59], ["infectivity", "OBSERVATION", 268, 279]]], ["[4, 6, 11, 19] Further analyses are underway to correlate SARS-CoV-2 detection, and better understand viral shedding from various anatomical sites in patients stratified by disease onset, clinical presentation, and outcomes.", [["anatomical sites", "MULTI-TISSUE_STRUCTURE", 130, 146], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["SARS-CoV", "SPECIES", 58, 66], ["Further analyses", "TEST", 15, 31], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["viral shedding from various anatomical sites", "PROBLEM", 102, 146]]], ["Interestingly, patient 4 had a positive NP swab with low Ct values (i.e. high viral load) by three different methods, but the OP/Na on the same patient was negative.", [["OP", "CHEMICAL", 126, 128], ["Na", "CHEMICAL", 129, 131], ["Na", "CHEMICAL", 129, 131], ["patient", "ORGANISM", 15, 22], ["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 15, 22], ["patient", "SPECIES", 144, 151], ["a positive NP swab", "PROBLEM", 29, 47], ["low Ct values", "PROBLEM", 53, 66], ["high viral load", "PROBLEM", 73, 88], ["the OP/Na", "TEST", 122, 131], ["negative", "OBSERVATION", 156, 164]]], ["The exogenous internal control in the commercial assay was amplified from the OP/Na specimen (arguing against the presence of PCR inhibitors); however, the LDT endogenous control in the OP/Na reaction was near the cutoff (Ct value of 34.9).", [["OP", "CHEMICAL", 78, 80], ["Na", "CHEMICAL", 81, 83], ["OP", "CHEMICAL", 186, 188], ["Na", "CHEMICAL", 189, 191], ["Na", "CHEMICAL", 81, 83], ["Na", "CHEMICAL", 189, 191], ["the commercial assay", "TEST", 34, 54], ["the OP/Na specimen", "TEST", 74, 92], ["PCR inhibitors", "TREATMENT", 126, 140], ["the LDT endogenous control", "TREATMENT", 152, 178], ["the OP/Na reaction", "TEST", 182, 200], ["the cutoff", "TEST", 210, 220], ["Ct value", "TEST", 222, 230], ["exogenous", "OBSERVATION_MODIFIER", 4, 13], ["internal control", "OBSERVATION", 14, 30]]], ["While an unlikely alternative explanation could be a false-positive result for the NP swab, it is more likely that there were collection or transport deficiencies for the OP/Na specimen.Results and DiscussionThe data obtained from this study represents a relatively short time period in a community setting with a mixed population of asymptomatic and mildly-symptomatic patients.", [["OP", "CHEMICAL", 171, 173], ["Na", "CHEMICAL", 174, 176], ["Na", "CHEMICAL", 174, 176], ["patients", "ORGANISM", 370, 378], ["patients", "SPECIES", 370, 378], ["the NP swab", "TEST", 79, 90], ["collection", "PROBLEM", 126, 136], ["transport deficiencies", "PROBLEM", 140, 162], ["the OP/Na specimen", "TEST", 167, 185], ["this study", "TEST", 231, 241], ["mildly-symptomatic patients", "PROBLEM", 351, 378], ["more likely", "UNCERTAINTY", 98, 109], ["collection", "OBSERVATION", 126, 136], ["mildly", "OBSERVATION_MODIFIER", 351, 357], ["symptomatic", "OBSERVATION_MODIFIER", 358, 369]]], ["While OP/Na swabs collection showed excellent performance for the detection of SARS-CoV-2, as previously shown for nasal sampling [9] , one should exercise caution in applying these findings to other patient populations, collection *Discrepant analysis using Xpert testing was only performed on nasopharyngeal swabs in UTM, as the OP/Na showed reduced sensitivity for this assay (Table S1 ).", [["nasopharyngeal swabs", "ANATOMY", 295, 315], ["OP", "CHEMICAL", 6, 8], ["Na", "CHEMICAL", 9, 11], ["SARS", "DISEASE", 79, 83], ["OP", "CHEMICAL", 331, 333], ["Na", "CHEMICAL", 334, 336], ["Na", "CHEMICAL", 9, 11], ["Na", "CHEMICAL", 334, 336], ["patient", "ORGANISM", 200, 207], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 295, 315], ["patient", "SPECIES", 200, 207], ["SARS-CoV", "SPECIES", 79, 87], ["OP/Na swabs collection", "TEST", 6, 28], ["SARS", "PROBLEM", 79, 83], ["CoV", "TEST", 84, 87], ["nasal sampling", "TREATMENT", 115, 129], ["Discrepant analysis", "TEST", 233, 252], ["Xpert testing", "TEST", 259, 272], ["nasopharyngeal swabs", "TEST", 295, 315], ["the OP/Na", "TEST", 327, 336], ["reduced sensitivity", "PROBLEM", 344, 363], ["this assay", "TEST", 368, 378]]], ["Abbreviations: Threshold cycle (Ct), envelope (E); laboratory-developed test (LDT); nucleoprotein (N2); not available (N/A); J o u r n a l P r e -p r o o f", [["Ct", "TEST", 32, 34], ["test", "TEST", 72, 76]]]], "PMC2950129": [["What Happened?There is general consensus that the only predictable characteristic of influenza viruses and pandemics is their unpredictability [1].", [["influenza viruses", "DISEASE", 85, 102], ["influenza viruses", "PROBLEM", 85, 102], ["pandemics", "PROBLEM", 107, 116], ["influenza viruses", "OBSERVATION", 85, 102]]], ["Given such uncertainty, reasonable application of the precautionary principle should prevail in the responses.", [["the precautionary principle", "TREATMENT", 50, 77]]], ["Once isolated, the pandemic virus strain was shared immediately, specific diagnostic assays were produced and distributed worldwide, antivirals were available in many countries, vaccine development started promptly, and clinical trials demonstrating vaccine safety and immunogenicity were conducted rapidly.What Happened?There were many inherently favourable features of the pandemic itself, not all of which were immediately apparent (Table 1).", [["the pandemic virus strain", "PROBLEM", 15, 40], ["specific diagnostic assays", "TEST", 65, 91], ["antivirals", "TREATMENT", 133, 143], ["vaccine", "TREATMENT", 178, 185], ["vaccine safety", "TREATMENT", 250, 264], ["many", "OBSERVATION_MODIFIER", 332, 336], ["inherently", "OBSERVATION_MODIFIER", 337, 347], ["favourable", "OBSERVATION_MODIFIER", 348, 358], ["pandemic", "OBSERVATION", 375, 383]]], ["But that impact has been significant and heterogeneous, with pressure experienced by primary and hospital care (especially intensive care and paediatric services).", [["significant", "OBSERVATION_MODIFIER", 25, 36], ["heterogeneous", "OBSERVATION_MODIFIER", 41, 54], ["pressure", "OBSERVATION_MODIFIER", 61, 69]]], ["Distilling descriptions of the impact of a complex public health threat like a pandemic into a single term like \u201cmild,\u201d \u201cmoderate,\u201d or \u201csevere\u201d can potentially be misleading [2].", [["mild", "OBSERVATION_MODIFIER", 113, 117], ["moderate", "OBSERVATION_MODIFIER", 121, 129]]], ["Certainly the experience of hospital clinicians indicated that this pandemic, sometimes described as \u201cmild to moderate,\u201d was not limited to only mild or moderate illness.", [["this pandemic", "PROBLEM", 63, 76], ["\u201cmild to moderate,\u201d", "PROBLEM", 101, 120], ["mild or moderate illness", "PROBLEM", 145, 169], ["mild", "OBSERVATION_MODIFIER", 102, 106], ["moderate", "OBSERVATION_MODIFIER", 110, 118], ["mild", "OBSERVATION_MODIFIER", 145, 149], ["moderate", "OBSERVATION_MODIFIER", 153, 161], ["illness", "OBSERVATION", 162, 169]]], ["Many patients were severely ill and died, and undoubtedly, high-quality clinical management of patients with severe complications in intensive care units saved many lives of the critically ill, who often required prolonged hospitalisation [3].What Happened?The epidemiology of this pandemic is different than for seasonal influenza epidemics, but not unlike previous pandemics.", [["critically ill", "DISEASE", 178, 192], ["influenza", "DISEASE", 322, 331], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 95, 103], ["severely ill", "PROBLEM", 19, 31], ["severe complications", "PROBLEM", 109, 129], ["seasonal influenza epidemics", "PROBLEM", 313, 341], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["complications", "OBSERVATION", 116, 129]]], ["Young people have been disproportionately affected in terms of hospitalisation and deaths compared to seasonal influenza in which complications and mortality are predominantly borne by the elderly [4].", [["deaths", "DISEASE", 83, 89], ["influenza", "DISEASE", 111, 120], ["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["seasonal influenza", "PROBLEM", 102, 120]]], ["Similarly, the risk to pregnant women has been higher than for seasonal influenza [5],[6], which was also noted in previous pandemics.", [["influenza", "DISEASE", 72, 81], ["women", "ORGANISM", 32, 37], ["women", "SPECIES", 32, 37], ["seasonal influenza", "PROBLEM", 63, 81]]], ["The attributable premature mortality may remain unclear for some time.", [["The attributable premature mortality", "PROBLEM", 0, 36], ["premature", "OBSERVATION_MODIFIER", 17, 26], ["mortality", "OBSERVATION", 27, 36]]], ["Recent American analyses have estimated many more deaths than those officially reported with laboratory confirmation of infection and that years of life lost were equivalent to the 1968 pandemic.", [["deaths", "DISEASE", 50, 56], ["infection", "DISEASE", 120, 129], ["laboratory confirmation", "TEST", 93, 116], ["infection", "PROBLEM", 120, 129], ["infection", "OBSERVATION", 120, 129]]], ["The lower bound of such estimates is equivalent to the annual burden caused by a typical H3N2 seasonal epidemic in temperate climates [7],[8].", [["a typical H3N2 seasonal epidemic", "PROBLEM", 79, 111]]], ["The years-of-life-lost metric captures the impact of a different age-specific mortality pattern which death counts cannot.", [["death", "DISEASE", 102, 107]]], ["Deaths involving the young and healthy incur many more potential years of life lost compared to those of older adults and of chronically ill individuals.What Happened?There are also a number of \u201cfirsts\u201d for the 2009 pandemic after an interpandemic period of more than four decades (Box 1).", [["chronically ill", "DISEASE", 125, 140], ["chronically ill individuals", "PROBLEM", 125, 152], ["number", "OBSERVATION_MODIFIER", 184, 190]]], ["They were nominated by national authorities and are led by an elected chair who assessed the handling of the 1976 swine influenza event among US military personnel at Fort Dix [9].", [["influenza", "DISEASE", 120, 129]]], ["Here we offer some initial reflections on the first 12 months of the present pandemic.SurveillanceConsiderable effort in recent years had been dedicated to preparing for surveillance during a pandemic and to incorporating modelling in planning in some countries.", [["surveillance", "TEST", 170, 182]]], ["The pandemic virus was detected and isolated reasonably early, although too late for any attempt at containment.", [["pandemic virus", "SPECIES", 4, 18], ["The pandemic virus", "PROBLEM", 0, 18], ["pandemic", "OBSERVATION_MODIFIER", 4, 12], ["virus", "OBSERVATION", 13, 18]]], ["It remains unclear precisely when or where it first emerged, but the earliest human infections were detected in North America and the best estimates of the timing of emergence are variously mid-February from field epidemiology in southeast Mexico or mid-January from a molecular clock model [10].", [["infections", "DISEASE", 84, 94], ["human", "ORGANISM", 78, 83], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["the earliest human infections", "PROBLEM", 65, 94], ["infections", "OBSERVATION", 84, 94]]], ["Situational awareness during the early phase allowed quick assessment by countries, notably those affected first (Mexico, US, Canada, and Southern hemisphere temperate countries).", [["Situational awareness", "PROBLEM", 0, 21], ["quick assessment", "TEST", 53, 69]]], ["The integration of clinical, laboratory, and epidemiologic data proved essential and gave important insights into disease severity, transmission dynamics, and anticipated impact of interventions.", [["epidemiologic data", "TEST", 45, 63], ["interventions", "TREATMENT", 181, 194]]], ["Focused local or national studies with analyses shared through WHO or regional bodies proved more valuable than relying on collection of primary data for analysis in some regions [2].", [["national studies", "TEST", 17, 33], ["primary data", "TEST", 137, 149], ["analysis", "TEST", 154, 162]]], ["Although there were modelling efforts underway, only a few governments incorporated such data for policy decisions.SeroepidemiologyData from seroepidemiological studies have been limited, primarily due to the lack of routine influenza serosurveys, and technical challenges with the assays, interpretation, and validation of results.", [["SeroepidemiologyData", "TEST", 115, 135], ["seroepidemiological studies", "TEST", 141, 168], ["routine influenza serosurveys", "TREATMENT", 217, 246], ["the assays", "TEST", 278, 288]]], ["Available serological data on prevalence or seroincidence of humoral immunity yielded age-specific attack rates that indicated a substantial proportion of asymptomatic infections and mild illnesses, similar to or greater than past pandemics and seasonal outbreaks.", [["infections", "DISEASE", 168, 178], ["Available serological data", "TEST", 0, 26], ["asymptomatic infections", "PROBLEM", 155, 178], ["mild illnesses", "PROBLEM", 183, 197], ["seasonal outbreaks", "PROBLEM", 245, 263], ["substantial", "OBSERVATION_MODIFIER", 129, 140], ["asymptomatic", "OBSERVATION_MODIFIER", 155, 167], ["infections", "OBSERVATION", 168, 178], ["mild", "OBSERVATION_MODIFIER", 183, 187], ["illnesses", "OBSERVATION", 188, 197]]], ["This was confirmed by a recent Hong Kong study showing the proportion of asymptomatic infection, secondary attack rates, viral shedding, and course of illness among household members were largely similar between infections with seasonal and pandemic influenza virus strains circulating during 2009 [11].", [["infection", "DISEASE", 86, 95], ["infections", "DISEASE", 212, 222], ["influenza", "DISEASE", 250, 259], ["influenza virus", "ORGANISM", 250, 265], ["pandemic influenza virus", "SPECIES", 241, 265], ["pandemic influenza virus", "SPECIES", 241, 265], ["Kong study", "TEST", 36, 46], ["asymptomatic infection", "PROBLEM", 73, 95], ["secondary attack rates", "PROBLEM", 97, 119], ["viral shedding", "PROBLEM", 121, 135], ["infections", "PROBLEM", 212, 222], ["seasonal and pandemic influenza virus strains", "PROBLEM", 228, 273], ["asymptomatic", "OBSERVATION_MODIFIER", 73, 85], ["infection", "OBSERVATION", 86, 95]]], ["The few published serosurveys revealed heterogeneities in infection rates among different groups and between different places [12]\u2013[14].", [["infection", "DISEASE", 58, 67], ["heterogeneities in infection rates", "PROBLEM", 39, 73], ["heterogeneities", "OBSERVATION_MODIFIER", 39, 54], ["infection", "OBSERVATION", 58, 67]]], ["In particular there appears to be serological evidence of substantial preexisting humoral immunity among older adults, ranging from 23% (1\u223632 titre by haemagglutination inhibition in those 65 years or over) [14] to 34% (1\u223680 titre by microneutralisation assay in those 60 years or over) [15] in different studies.", [["substantial preexisting humoral immunity", "PROBLEM", 58, 98], ["titre", "TEST", 225, 230], ["appears to be", "UNCERTAINTY", 20, 33], ["substantial", "OBSERVATION_MODIFIER", 58, 69], ["humoral immunity", "OBSERVATION", 82, 98]]], ["Further data on population susceptibility by age or the availability of a rapid and accurate serological test could allow health services to further target vaccine efforts for subsequent waves, as has been done in a few countries [14].Nonpharmaceutical InterventionsEarly on, some airports installed thermal screening and others asked travellers to declare fever or respiratory symptoms at disembarkation.", [["respiratory", "ANATOMY", 366, 377], ["fever", "DISEASE", 357, 362], ["respiratory symptoms", "DISEASE", 366, 386], ["accurate serological test", "TEST", 84, 109], ["further target vaccine efforts", "TREATMENT", 141, 171], ["Nonpharmaceutical Interventions", "TREATMENT", 235, 266], ["thermal screening", "TEST", 300, 317], ["fever", "PROBLEM", 357, 362], ["respiratory symptoms at disembarkation", "PROBLEM", 366, 404]]], ["The utility of these interventions has been repeatedly challenged [16], although if executed well could delay the start of community transmission by a few weeks [15],[17] (Table 2).", [["these interventions", "TREATMENT", 15, 34]]], ["Similarly, during the early stages of global or local spread, quarantine, isolation, school closures, and other social distancing measures were variously implemented in some populations (e.g., Mexico [18], western Japan [19], UK), although most have not yet been formally evaluated and published [20].", [["global or local spread", "PROBLEM", 38, 60], ["school closures", "TREATMENT", 85, 100], ["global", "OBSERVATION_MODIFIER", 38, 44], ["local", "OBSERVATION_MODIFIER", 48, 53], ["spread", "OBSERVATION_MODIFIER", 54, 60]]], ["In settings like Hong Kong, with the infrastructure and resources to implement such measures and a populace sensitised by the 1997 H5N1 and 2003 SARS experiences, not carrying out border screening and social distancing would have been untenable.", [["SARS", "DISEASE", 145, 149], ["such measures", "TREATMENT", 79, 92], ["border screening", "TEST", 180, 196]]], ["It had been felt that containment of a pandemic would be ineffective except perhaps during Phase 4 (WHO definition) [22] but some countries attempted containment in Phases 5 and 6.", [["a pandemic", "PROBLEM", 37, 47]]], ["Some countries even instituted a \u201ccontainment phase\u201d using case-finding and various measures such as isolation and antiviral treatment of ill suspected and confirmed cases, and quarantine of exposed persons with or without antiviral chemoprophylaxis, while others never attempted or quickly moved from resource-intensive containment to mitigation [22].", [["persons", "ORGANISM", 199, 206], ["persons", "SPECIES", 199, 206], ["various measures", "TREATMENT", 76, 92], ["isolation", "TREATMENT", 101, 110], ["antiviral treatment", "TREATMENT", 115, 134], ["antiviral chemoprophylaxis", "TREATMENT", 223, 249]]], ["A preliminary evaluation of intensive containment undertaken in parts of the UK during its spring/summer wave of 2009 demonstrates how resource- and labour-intensive community containment could have been and also how even with a lot of resources the measures had to be abandoned [23].", [["A preliminary evaluation", "TEST", 0, 24], ["intensive containment", "TREATMENT", 28, 49]]], ["It is now recognised that the phrase \u201ccontainment\u201d was unfortunate and potentially misleading since at best the actions were only mitigating impact [24].Nonpharmaceutical InterventionsThis pandemic virus transmitted efficiently among children and at least one study has shown that school closures were associated with reduced population transmission when implemented early [21].", [["children", "ORGANISM", 234, 242], ["children", "SPECIES", 234, 242], ["Nonpharmaceutical Interventions", "TREATMENT", 153, 184]]], ["However, decisions on this intervention were contextually specific, dependent on feasibility and their potential downsides [26].", [["this intervention", "TREATMENT", 22, 39]]], ["In Europe and the US the judgement was generally that proactive school closures would not be justified as a community mitigation intervention in the context of a perceived mild-to-moderate pandemic among the general population, and reserve plans for widespread closure have not been activated in most jurisdictions.", [["proactive school closures", "TREATMENT", 54, 79], ["a community mitigation intervention", "TREATMENT", 106, 141], ["a perceived mild-to-moderate pandemic", "PROBLEM", 160, 197], ["widespread closure", "TREATMENT", 250, 268]]], ["However, local decisions were made to close schools in some areas as a response to prevent transmission and high attack rates among schoolchildren or simply where there was too much illness and absenteeism to sustain teaching [21],[27].Nonpharmaceutical InterventionsPersonal protective interventions such as face masks, hand hygiene, and early isolation may have been beneficial in reducing transmission at the individual level in the home [27],[28], although household secondary attack rates during the pandemic were similar to those with seasonal influenza [13],[29].", [["hand", "ANATOMY", 321, 325], ["influenza", "DISEASE", 550, 559], ["hand", "ORGANISM_SUBDIVISION", 321, 325], ["schoolchildren", "SPECIES", 132, 146], ["Nonpharmaceutical Interventions", "TREATMENT", 236, 267], ["Personal protective interventions", "TREATMENT", 267, 300], ["face masks", "TREATMENT", 309, 319], ["hand hygiene", "TREATMENT", 321, 333], ["secondary attack rates", "PROBLEM", 471, 493], ["seasonal influenza", "PROBLEM", 541, 559]]], ["There was much debate over whether to use conventional masks or respirators in health care settings.", [["conventional masks", "TREATMENT", 42, 60]]], ["One well-conducted Canadian trial on seasonal influenza virus transmission published during the pandemic suggested no additional advantage from N95 respirators [30].AntiviralsOseltamivir and zanamivir (and later peramivir in some countries) played a role in the mitigation effort, sometimes drawing on national stockpiles.", [["influenza virus transmission", "DISEASE", 46, 74], ["Oseltamivir", "CHEMICAL", 175, 186], ["zanamivir", "CHEMICAL", 191, 200], ["peramivir", "CHEMICAL", 212, 221], ["Oseltamivir", "CHEMICAL", 175, 186], ["zanamivir", "CHEMICAL", 191, 200], ["peramivir", "CHEMICAL", 212, 221], ["seasonal influenza virus", "ORGANISM", 37, 61], ["Oseltamivir", "SIMPLE_CHEMICAL", 175, 186], ["zanamivir", "SIMPLE_CHEMICAL", 191, 200], ["seasonal influenza virus", "SPECIES", 37, 61], ["seasonal influenza virus", "SPECIES", 37, 61], ["seasonal influenza virus transmission", "TREATMENT", 37, 74], ["AntiviralsOseltamivir", "TREATMENT", 165, 186], ["zanamivir", "TREATMENT", 191, 200], ["peramivir", "TREATMENT", 212, 221]]], ["Except for Japan, widespread use of antivirals had not been the norm previously.", [["antivirals", "TREATMENT", 36, 46]]], ["It became standard to recommend neuraminidase inhibitors for treatment of inpatients and high-risk outpatients, and in restricted circumstances for chemoprophylaxis.", [["outpatients", "ORGANISM", 99, 110], ["neuraminidase inhibitors", "TREATMENT", 32, 56], ["treatment", "TREATMENT", 61, 70], ["chemoprophylaxis", "TREATMENT", 148, 164]]], ["Innovative delivery schemes were sometimes developed.", [["Innovative delivery schemes", "TREATMENT", 0, 27]]], ["Those who fell sick in England could have a telephone assessment (taking pressure off primary care) and then if appropriate receive empiric oseltamivir treatment from a local pharmacist.", [["oseltamivir", "CHEMICAL", 140, 151], ["oseltamivir", "CHEMICAL", 140, 151], ["a telephone assessment", "TEST", 42, 64], ["pressure off primary care", "TREATMENT", 73, 98], ["empiric oseltamivir treatment", "TREATMENT", 132, 161]]], ["In Norway oseltamivir was made available \u201cover the counter.\u201d", [["oseltamivir", "CHEMICAL", 10, 21], ["oseltamivir", "CHEMICAL", 10, 21], ["Norway oseltamivir", "TREATMENT", 3, 21]]], ["Another controversy was whether to offer oseltamivir to all those with symptoms or target those at higher risk for complications.", [["oseltamivir", "CHEMICAL", 41, 52], ["oseltamivir", "CHEMICAL", 41, 52], ["oseltamivir", "SIMPLE_CHEMICAL", 41, 52], ["oseltamivir", "TREATMENT", 41, 52], ["symptoms", "PROBLEM", 71, 79], ["complications", "PROBLEM", 115, 128]]], ["The observational data so far suggest that early treatment with neuraminidase inhibitors have worked to reduce severe disease and have not been linked to significant adverse risks [31],[32].", [["neuraminidase", "GENE_OR_GENE_PRODUCT", 64, 77], ["The observational data", "TEST", 0, 22], ["neuraminidase inhibitors", "TREATMENT", 64, 88], ["severe disease", "PROBLEM", 111, 125], ["significant adverse risks", "PROBLEM", 154, 179]]], ["Late clinical presentation and delayed initiation of antiviral treatment have been implicated with more severe complications worldwide, indicating gaps in identifying and treating patients before disease severity increases.", [["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["Late clinical presentation", "PROBLEM", 0, 26], ["antiviral treatment", "TREATMENT", 53, 72], ["more severe complications", "PROBLEM", 99, 124], ["disease severity", "PROBLEM", 196, 212], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["complications", "OBSERVATION", 111, 124]]], ["While sporadic cases of oseltamivir resistance have been reported in association with a specific mutation (H275Y in neuraminidase), such oseltamivir-resistant viruses have rarely transmitted [3].", [["oseltamivir", "CHEMICAL", 24, 35], ["oseltamivir", "CHEMICAL", 137, 148], ["oseltamivir", "CHEMICAL", 24, 35], ["oseltamivir", "CHEMICAL", 137, 148], ["oseltamivir resistance", "TREATMENT", 24, 46], ["a specific mutation", "PROBLEM", 86, 105], ["neuraminidase", "TREATMENT", 116, 129], ["oseltamivir", "TREATMENT", 137, 148], ["resistant viruses", "PROBLEM", 149, 166], ["oseltamivir resistance", "OBSERVATION", 24, 46]]], ["Indeed, the pandemic virus has remained genetically and antigenically stable so far.VaccinesThe core pharmaceutical preventive intervention was vaccines and this has been a particular focus for critics citing the uneven and suboptimal uptake across countries.", [["the pandemic virus", "PROBLEM", 8, 26], ["Vaccines", "TREATMENT", 84, 92], ["The core pharmaceutical preventive intervention", "TREATMENT", 92, 139], ["vaccines", "TREATMENT", 144, 152], ["critics citing", "TREATMENT", 194, 208], ["pandemic", "OBSERVATION_MODIFIER", 12, 20], ["virus", "OBSERVATION", 21, 26], ["stable", "OBSERVATION_MODIFIER", 70, 76]]], ["Development of a pandemic vaccine was a scientific success, but limited availability until after the autumn/winter wave had nearly peaked in the Northern Hemisphere contributed to lower coverage than anticipated [33].", [["a pandemic vaccine", "TREATMENT", 15, 33]]], ["Vaccination coverage depended on many factors, including availability, preordering, licensing and bureaucratic hurdles, logistics, convenience, and, most crucially, public and professional perceptions.", [["Vaccination coverage", "TREATMENT", 0, 20]]], ["This pandemic presented a particular risk communication challenge, since while infection usually results in mild illness, occasionally it is lethal, even in the young and previously healthy despite optimal treatment [34]\u2013[36].", [["infection", "DISEASE", 79, 88], ["infection", "PROBLEM", 79, 88], ["mild illness", "PROBLEM", 108, 120], ["optimal treatment", "TREATMENT", 198, 215], ["mild", "OBSERVATION_MODIFIER", 108, 112], ["illness", "OBSERVATION", 113, 120]]], ["In the absence of any excess risk of serious side effects compared to annual seasonal vaccines [37] (despite the intensive effort to look for such) the benefits of immunisation far outweighed any potential downsides at the individual level, particularly for those at higher risk for complications.", [["serious side effects", "PROBLEM", 37, 57], ["annual seasonal vaccines", "TREATMENT", 70, 94], ["immunisation", "TREATMENT", 164, 176], ["complications", "PROBLEM", 283, 296]]], ["Notwithstanding such evidence, the cost of pandemic vaccines was considerable and a loss of public confidence has sometimes been triggered by unsubstantiated media reports of serious side effects with a \u201cnew vaccine\u201d that utilised the same manufacturing technology as for years of seasonal vaccines.", [["pandemic vaccines", "TREATMENT", 43, 60], ["serious side effects", "PROBLEM", 175, 195], ["a \u201cnew vaccine", "TREATMENT", 201, 215], ["seasonal vaccines", "TREATMENT", 281, 298]]], ["Uptake among health care providers as role models has been mixed, as has their expression of the need for vaccination at all.", [["vaccination", "TREATMENT", 106, 117]]], ["This sometimes cast doubt in the minds of the public.", [["cast", "OBSERVATION", 15, 19], ["public", "ANATOMY", 46, 52]]], ["Conversely, pandemic deaths in young healthy people abruptly changed public perception (such as in Canada, Romania, and Finland); supply and organisational issues then became crucial.VaccinesAnother more fundamental criticism challenges whether vaccines should have been procured at all given an eventual surplus in the developed North.", [["deaths", "DISEASE", 21, 27], ["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["Vaccines", "TREATMENT", 183, 191], ["vaccines", "TREATMENT", 245, 253], ["an eventual surplus", "TREATMENT", 293, 312]]], ["The unexpected finding that a single dose was immunogenic among all persons except for younger children, which reduced the required number of doses by half from the projected number needed in most countries, but this was not known in advance of countries placing vaccine orders.", [["persons", "ORGANISM", 68, 75], ["children", "ORGANISM", 95, 103], ["persons", "SPECIES", 68, 75], ["children", "SPECIES", 95, 103]]], ["The prior worry had been the reverse \u2013 would there be sufficient production capacity to meet needs [38]?", [["sufficient production capacity", "PROBLEM", 54, 84]]], ["Even in retrospect, and with the observed burden of the pandemic, a vaccine was clearly justified for countries where annual vaccines for seasonal influenza are routinely recommended.VaccinesField and pharmacovigilance data so far have shown that these vaccines were immunogenic, effective, and very safe [39].", [["influenza", "DISEASE", 147, 156], ["a vaccine", "TREATMENT", 66, 75], ["annual vaccines", "TREATMENT", 118, 133], ["seasonal influenza", "PROBLEM", 138, 156], ["pharmacovigilance data", "TEST", 201, 223], ["these vaccines", "TREATMENT", 247, 261]]], ["However, the frailty was timing and availability.", [["frailty", "DISEASE", 13, 20]]], ["Generally supplies came in later and in smaller amounts than forecasted, in part due to lower yield in growth of the vaccine virus strain than expected.", [["the vaccine virus strain", "PROBLEM", 113, 137]]], ["Most of the orders arrived after the peak of the autumn/winter wave in the geographic north (whose countries had received most vaccines).", [["most vaccines", "TREATMENT", 122, 135]]], ["Therefore, judgement on their impact in averting serious morbidity and deaths may come only after the second winter.", [["deaths", "DISEASE", 71, 77], ["averting serious morbidity", "PROBLEM", 40, 66]]], ["Perhaps then, differential use by countries will allow for comparisons where there is good surveillance for severe disease and deaths.VaccinesThere have been claims of extraneous influence on the independent and objective judgment of expert advice that in turn influenced decision-making [40].", [["deaths", "DISEASE", 127, 133], ["severe disease and deaths", "PROBLEM", 108, 133], ["Vaccines", "TREATMENT", 134, 142]]], ["As Harvey Fineberg, chair of WHO's external review, pointed out, when assessing any allegations of impropriety or bias, or the perception of such, it would be important to distinguish between financial or other conflicts with potential pecuniary gains versus predispositions arising from an individual's background and experience.", [["impropriety", "DISEASE", 99, 110]]], ["Rather than aiming for a complete purge of any and all experts who had worked with vaccine manufacturers and received sponsorship, as these are often the very same group who possess the most relevant and useful expertise precisely because they have been closely involved in the research and development process, the focus should be on making the declaration of such interest wholly transparent and comprehensive according to a set of robustly established procedures that can withstand the strictest scrutiny.", [["vaccine manufacturers", "TREATMENT", 83, 104]]], ["The people entrusted with undertaking the latter task should then judge the validity of the advice rendered by experts, having taken into account their interest declarations.", [["people", "ORGANISM", 4, 10], ["people", "SPECIES", 4, 10]]], ["The decision makers should also be prepared to justify their actions.Looking ForwardIt is important to learn from our experience through the first year and beyond as we move into the new seasonal influenza [42],[43].", [["influenza", "DISEASE", 196, 205], ["Forward", "DNA", 77, 84]]], ["It is theoretically possible, although unlikely, that the second winter of this pandemic will be worse than the first, as happened for the 1968 pandemic when transmissibility increased [44].", [["theoretically possible", "UNCERTAINTY", 6, 28]]], ["Equally, if the pandemic virus out-competed the A(H3N2) virus strains responsible for more intense seasonal epidemics, there may even be a diminution of disease burden in older people.", [["A(H3N2) virus", "ORGANISM", 48, 61], ["people", "ORGANISM", 177, 183], ["H3N2) virus", "SPECIES", 50, 61], ["people", "SPECIES", 177, 183], ["A(H3N2) virus", "SPECIES", 48, 61], ["the pandemic virus", "PROBLEM", 12, 30], ["the A(H3N2) virus strains", "PROBLEM", 44, 69], ["disease burden", "PROBLEM", 153, 167], ["may even be", "UNCERTAINTY", 125, 136], ["diminution", "OBSERVATION_MODIFIER", 139, 149], ["disease", "OBSERVATION", 153, 160]]], ["As of this writing, seasonal influenza A (H3N2) and B virus strains continue to cocirculate.", [["influenza A", "DISEASE", 29, 40], ["seasonal influenza A (H3N2) and B virus", "ORGANISM", 20, 59], ["B virus", "SPECIES", 52, 59], ["B virus", "SPECIES", 52, 59], ["seasonal influenza A (H3N2", "PROBLEM", 20, 46], ["B virus strains", "PROBLEM", 52, 67]]], ["Antigenic drift in the 2009 H1N1 virus is expected to occur in the future, especially under the pressure of so many people now being immune through infection or immunisation, although the timing is unpredictable.", [["infection", "DISEASE", 148, 157], ["2009 H1N1 virus", "ORGANISM", 23, 38], ["people", "ORGANISM", 116, 122], ["H1N1 virus", "SPECIES", 28, 38], ["people", "SPECIES", 116, 122], ["2009 H1N1 virus", "SPECIES", 23, 38], ["Antigenic drift", "PROBLEM", 0, 15], ["H1N1 virus", "PROBLEM", 28, 38], ["immune through infection", "PROBLEM", 133, 157], ["immunisation", "TREATMENT", 161, 173], ["drift", "OBSERVATION", 10, 15], ["infection", "OBSERVATION", 148, 157]]], ["The pandemic virus is included in the trivalent seasonal influenza vaccine composition for both hemispheres.", [["hemispheres", "ANATOMY", 96, 107], ["hemispheres", "CANCER", 96, 107], ["The pandemic virus", "PROBLEM", 0, 18], ["the trivalent seasonal influenza vaccine", "TREATMENT", 34, 74], ["pandemic", "OBSERVATION_MODIFIER", 4, 12], ["virus", "OBSERVATION", 13, 18]]], ["Broadening surveillance for a range of influenza A viruses among a wide range of animals (e.g., swine), not just in avian species, as well as strengthening the monitoring of seasonal influenza virus infections in humans will facilitate identification of novel influenza A viruses of pandemic potential, and earlier detection of the emergence of a pandemic virus.", [["influenza A viruses", "DISEASE", 39, 58], ["influenza virus infections", "DISEASE", 183, 209], ["pandemic", "DISEASE", 347, 355], ["influenza A viruses", "ORGANISM", 39, 58], ["seasonal influenza virus", "ORGANISM", 174, 198], ["humans", "ORGANISM", 213, 219], ["influenza A viruses", "ORGANISM", 260, 279], ["swine", "SPECIES", 96, 101], ["seasonal influenza virus", "SPECIES", 174, 198], ["humans", "SPECIES", 213, 219], ["influenza A viruses", "SPECIES", 39, 58], ["swine", "SPECIES", 96, 101], ["seasonal influenza virus", "SPECIES", 174, 198], ["humans", "SPECIES", 213, 219], ["Broadening surveillance", "TEST", 0, 23], ["influenza A viruses", "PROBLEM", 39, 58], ["seasonal influenza virus infections", "PROBLEM", 174, 209], ["novel influenza", "PROBLEM", 254, 269], ["a pandemic virus", "PROBLEM", 345, 361]]], ["More broadly we should look beyond influenza and draw up contingencies for the emergence or re-emergence of other novel and known pathogens [45].Looking ForwardOne challenge faced initially in this pandemic was for timely collection and sharing of clinical data to inform optimal management of critically ill patients worldwide.", [["influenza", "DISEASE", 35, 44], ["critically ill", "DISEASE", 294, 308], ["patients", "ORGANISM", 309, 317], ["Forward", "DNA", 153, 160], ["patients", "SPECIES", 309, 317], ["influenza", "PROBLEM", 35, 44], ["known pathogens", "PROBLEM", 124, 139], ["clinical data", "TEST", 248, 261]]], ["Establishing clinical research infrastructure prior to a pandemic and a central institutional review board will facilitate data collection and analyses [46], whether for the next influenza pandemic, SARS outbreak, or next novel respiratory pathogen of global importance.", [["influenza pandemic", "DISEASE", 179, 197], ["SARS", "DISEASE", 199, 203], ["data collection", "TEST", 123, 138], ["analyses", "TEST", 143, 151], ["the next influenza pandemic", "PROBLEM", 170, 197], ["SARS outbreak", "PROBLEM", 199, 212]]], ["Clinical management of severe influenza disease should not be limited to the current antiviral regimen, and include the development of other therapeutics (e.g., novel antivirals and immunotherapy).Looking ForwardOngoing improvements in the routine and timely monitoring of hospital admissions and deaths attributable to influenza, as well as representative serological surveys at regular intervals can provide epidemiological data with which to reduce uncertainty around the true burden of influenza and thus inform policy choices [47].Looking ForwardAssessment of the humoral and cellular immune response over time in a subset of vaccinated individuals could reveal how vaccine-induced immunity differs from natural infection, and whether cross-reactive responses to other influenza virus strains are modulated by the two types of immunological response [48].", [["cellular", "ANATOMY", 581, 589], ["influenza disease", "DISEASE", 30, 47], ["deaths", "DISEASE", 297, 303], ["influenza", "DISEASE", 320, 329], ["influenza", "DISEASE", 490, 499], ["infection", "DISEASE", 717, 726], ["cellular", "CELL", 581, 589], ["influenza virus strains", "ORGANISM", 774, 797], ["influenza virus", "SPECIES", 774, 789], ["Clinical management", "TREATMENT", 0, 19], ["severe influenza disease", "PROBLEM", 23, 47], ["the current antiviral regimen", "TREATMENT", 73, 102], ["novel antivirals", "TREATMENT", 161, 177], ["immunotherapy", "TREATMENT", 182, 195], ["deaths", "PROBLEM", 297, 303], ["influenza", "PROBLEM", 320, 329], ["epidemiological data", "TEST", 410, 430], ["influenza", "PROBLEM", 490, 499], ["vaccinated individuals", "PROBLEM", 631, 653], ["natural infection", "PROBLEM", 709, 726], ["cross-reactive responses", "PROBLEM", 740, 764], ["other influenza virus strains", "PROBLEM", 768, 797], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["influenza", "OBSERVATION", 30, 39], ["influenza", "OBSERVATION", 320, 329], ["humoral", "ANATOMY", 569, 576], ["cellular immune response", "OBSERVATION", 581, 605], ["infection", "OBSERVATION", 717, 726]]], ["The latter could become important as the pandemic strain has already been cocirculating with other interpandemic influenza A virus strains in some parts of the world.Looking ForwardGreater access to antivirals and influenza vaccines worldwide is an ongoing challenge.", [["interpandemic influenza A virus", "ORGANISM", 99, 130], ["influenza A virus", "SPECIES", 113, 130], ["influenza A virus", "SPECIES", 113, 130], ["the pandemic strain", "PROBLEM", 37, 56], ["other interpandemic influenza A virus strains", "PROBLEM", 93, 138], ["antivirals", "TREATMENT", 199, 209], ["influenza vaccines", "TREATMENT", 214, 232]]], ["Although WHO secured pledges of 200 million vaccine doses and monies for operations, and more than 80 less-resourced countries have signed agreements with WHO for supply of vaccines, this gap remains.", [["operations", "TREATMENT", 73, 83], ["supply of vaccines", "TREATMENT", 163, 181]]], ["It is an indefensible fact that these vaccines started to flow to the poorer countries well after they began going to the countries with advance purchase arrangements.", [["these vaccines", "TREATMENT", 32, 46]]], ["Delivering timely pandemic influenza vaccination in countries without existing seasonal vaccine programmes is proving difficult.", [["influenza", "DISEASE", 27, 36], ["timely pandemic influenza vaccination", "TREATMENT", 11, 48], ["seasonal vaccine programmes", "TREATMENT", 79, 106]]], ["The long-term solution has to be improved surveillance, expanded monitoring of disease burden, and better prevention and control of influenza, including the development of seasonal vaccine use and production in all regions of the world [49].", [["influenza", "DISEASE", 132, 141], ["The long-term solution", "TREATMENT", 0, 22], ["disease burden", "PROBLEM", 79, 93], ["influenza", "PROBLEM", 132, 141], ["seasonal vaccine use", "TREATMENT", 172, 192], ["long-term", "OBSERVATION_MODIFIER", 4, 13], ["influenza", "OBSERVATION", 132, 141], ["seasonal vaccine", "OBSERVATION", 172, 188]]], ["Increased coverage of available bacterial vaccines (Hib, pneumococcal) will help prevent secondary invasive bacterial coinfections with either seasonal or pandemic influenza.Looking ForwardFinally accusations of \u201coverreaction\u201d can be countered by the observation that investment in fire services or insurance is usually judged against their ability to respond to conflagrations.", [["bacterial coinfections", "DISEASE", 108, 130], ["influenza", "DISEASE", 164, 173], ["Hib", "ORGANISM", 52, 55], ["pneumococcal", "SPECIES", 57, 69], ["Increased coverage", "TREATMENT", 0, 18], ["available bacterial vaccines", "TREATMENT", 22, 50], ["Hib, pneumococcal)", "TREATMENT", 52, 70], ["secondary invasive bacterial coinfections", "PROBLEM", 89, 130], ["pandemic influenza", "PROBLEM", 155, 173], ["coverage", "OBSERVATION_MODIFIER", 10, 18], ["secondary", "OBSERVATION_MODIFIER", 89, 98], ["invasive", "OBSERVATION_MODIFIER", 99, 107], ["bacterial coinfections", "OBSERVATION", 108, 130]]]], "PMC7470800": [["IntroductionImmunotherapy has been recognized as a novel and attractive treatment for cancer patients by boosting host immune responses to kill tumor cells [1].", [["cancer", "ANATOMY", 86, 92], ["tumor cells", "ANATOMY", 144, 155], ["cancer", "DISEASE", 86, 92], ["tumor", "DISEASE", 144, 149], ["cancer", "CANCER", 86, 92], ["patients", "ORGANISM", 93, 101], ["tumor cells", "CELL", 144, 155], ["tumor cells", "CELL_TYPE", 144, 155], ["patients", "SPECIES", 93, 101], ["IntroductionImmunotherapy", "TREATMENT", 0, 25], ["a novel and attractive treatment", "TREATMENT", 49, 81], ["cancer", "PROBLEM", 86, 92]]], ["In particular, approved immune checkpoint inhibitors (ICIs) have shown considerable and long-lasting clinical benefit in several tumor types, targeting the suppression of T cells in cancer patients [2, 3].", [["tumor", "ANATOMY", 129, 134], ["T cells", "ANATOMY", 171, 178], ["cancer", "ANATOMY", 182, 188], ["tumor", "DISEASE", 129, 134], ["cancer", "DISEASE", 182, 188], ["tumor", "CANCER", 129, 134], ["T cells", "CELL", 171, 178], ["cancer", "CANCER", 182, 188], ["patients", "ORGANISM", 189, 197], ["T cells", "CELL_TYPE", 171, 178], ["patients", "SPECIES", 189, 197], ["immune checkpoint inhibitors", "TREATMENT", 24, 52], ["several tumor types", "PROBLEM", 121, 140], ["tumor", "OBSERVATION", 129, 134]]], ["Clinical data has indicated that the overall response rate (ORR) to nivolumab in unresectable or metastatic melanoma patients was 31.7%, compared to an ORR of 10.6% in those treated with chemotherapy [4].", [["unresectable", "ANATOMY", 81, 93], ["metastatic melanoma", "ANATOMY", 97, 116], ["nivolumab", "CHEMICAL", 68, 77], ["melanoma", "DISEASE", 108, 116], ["nivolumab", "CHEMICAL", 68, 77], ["nivolumab", "SIMPLE_CHEMICAL", 68, 77], ["melanoma", "CANCER", 108, 116], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["Clinical data", "TEST", 0, 13], ["nivolumab", "TREATMENT", 68, 77], ["metastatic melanoma", "PROBLEM", 97, 116], ["an ORR", "TEST", 149, 155], ["chemotherapy", "TREATMENT", 187, 199], ["unresectable", "OBSERVATION_MODIFIER", 81, 93], ["metastatic", "OBSERVATION_MODIFIER", 97, 107], ["melanoma", "OBSERVATION", 108, 116]]], ["However, a minority of patients (nearly 10%\u201330% response rates, depending on the type of cancer) respond to ICIs [2, 5].", [["cancer", "ANATOMY", 89, 95], ["cancer", "DISEASE", 89, 95], ["ICIs", "DISEASE", 108, 112], ["patients", "ORGANISM", 23, 31], ["cancer", "CANCER", 89, 95], ["patients", "SPECIES", 23, 31], ["cancer", "PROBLEM", 89, 95], ["cancer", "OBSERVATION", 89, 95]]], ["Insufficient systemic T cell responses in the majority of patients [6], failure of effector T cells to infiltrate into tumors or T cell exhaustion induced by the tumor microenvironment [7] limit antitumor immune responses.", [["T cell", "ANATOMY", 22, 28], ["effector T cells", "ANATOMY", 83, 99], ["tumors", "ANATOMY", 119, 125], ["T cell", "ANATOMY", 129, 135], ["tumor", "ANATOMY", 162, 167], ["antitumor", "ANATOMY", 195, 204], ["tumors", "DISEASE", 119, 125], ["tumor", "DISEASE", 162, 167], ["T cell", "CELL", 22, 28], ["patients", "ORGANISM", 58, 66], ["T cells", "CELL", 92, 99], ["tumors", "CANCER", 119, 125], ["T cell", "CELL", 129, 135], ["tumor", "CANCER", 162, 167], ["antitumor", "CANCER", 195, 204], ["effector T cells", "CELL_TYPE", 83, 99], ["patients", "SPECIES", 58, 66], ["Insufficient systemic T cell responses", "PROBLEM", 0, 38], ["failure of effector T cells", "PROBLEM", 72, 99], ["infiltrate into tumors", "PROBLEM", 103, 125], ["T cell exhaustion", "PROBLEM", 129, 146], ["the tumor microenvironment", "PROBLEM", 158, 184], ["cell", "OBSERVATION", 24, 28], ["tumors", "OBSERVATION", 119, 125], ["cell", "OBSERVATION", 131, 135]]], ["It is crucial to explore novel approaches to enhance tumor-specific T cell responses and augment tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment.IntroductionNanomedicine has been extensively employed as a therapeutic in healthcare [8].", [["tumor", "ANATOMY", 53, 58], ["T cell", "ANATOMY", 68, 74], ["tumor-infiltrating lymphocytes", "ANATOMY", 97, 127], ["TILs", "ANATOMY", 129, 133], ["tumor", "ANATOMY", 146, 151], ["tumor", "DISEASE", 53, 58], ["tumor", "DISEASE", 97, 102], ["tumor", "DISEASE", 146, 151], ["Nanomedicine", "CHEMICAL", 181, 193], ["tumor", "CANCER", 53, 58], ["T cell", "CELL", 68, 74], ["tumor-infiltrating lymphocytes", "CELL", 97, 127], ["TILs", "CELL", 129, 133], ["tumor", "CANCER", 146, 151], ["tumor-infiltrating lymphocytes", "CELL_TYPE", 97, 127], ["TILs", "CELL_TYPE", 129, 133], ["tumor", "TEST", 53, 58], ["augment tumor", "PROBLEM", 89, 102], ["infiltrating lymphocytes", "PROBLEM", 103, 127], ["IntroductionNanomedicine", "TREATMENT", 169, 193], ["tumor", "OBSERVATION", 53, 58], ["tumor", "OBSERVATION", 97, 102], ["infiltrating lymphocytes", "OBSERVATION", 103, 127], ["tumor microenvironment", "OBSERVATION", 146, 168]]], ["Nanoscale particles, such as liposomes, polymer nanoparticles (NPs) and micelles, show advantages for drugs delivery.", [["polymer nanoparticles", "CHEMICAL", 40, 61], ["NPs", "CHEMICAL", 63, 66], ["liposomes", "SIMPLE_CHEMICAL", 29, 38], ["polymer nanoparticles", "SIMPLE_CHEMICAL", 40, 61], ["NPs", "SIMPLE_CHEMICAL", 63, 66], ["Nanoscale particles", "TREATMENT", 0, 19], ["liposomes, polymer nanoparticles (NPs) and micelles", "TREATMENT", 29, 80], ["drugs delivery", "TREATMENT", 102, 116], ["particles", "OBSERVATION", 10, 19]]], ["Drugs encapsulated in polymer nanoparticles or chemical nanostructures can exhibit improved bioavailability and pharmacokinetic properties (e.g., Abranxane or Doxil) [9].", [["polymer nanoparticles", "CHEMICAL", 22, 43], ["Abranxane", "CHEMICAL", 146, 155], ["Doxil", "CHEMICAL", 159, 164], ["Abranxane", "CHEMICAL", 146, 155], ["Doxil", "CHEMICAL", 159, 164], ["polymer nanoparticles", "SIMPLE_CHEMICAL", 22, 43], ["Abranxane", "SIMPLE_CHEMICAL", 146, 155], ["Doxil", "SIMPLE_CHEMICAL", 159, 164], ["Drugs", "TREATMENT", 0, 5], ["polymer nanoparticles", "TREATMENT", 22, 43], ["chemical nanostructures", "PROBLEM", 47, 70], ["Abranxane or Doxil)", "TREATMENT", 146, 165]]], ["NPs also play an important role in the development of DNA- and RNA-based drugs.", [["NPs", "SIMPLE_CHEMICAL", 0, 3], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["NPs", "TREATMENT", 0, 3], ["DNA", "PROBLEM", 54, 57]]], ["They have been used in the manufacture of Onpattro (patisiran, siRNA-containing lipid NPs for the treatment of transthyretin-related hereditary amyloidosis) [10].", [["Onpattro", "CHEMICAL", 42, 50], ["patisiran", "CHEMICAL", 52, 61], ["hereditary amyloidosis", "DISEASE", 133, 155], ["Onpattro", "CHEMICAL", 42, 50], ["patisiran", "CHEMICAL", 52, 61], ["Onpattro", "SIMPLE_CHEMICAL", 42, 50], ["patisiran", "SIMPLE_CHEMICAL", 52, 61], ["lipid NPs", "SIMPLE_CHEMICAL", 80, 89], ["transthyretin", "GENE_OR_GENE_PRODUCT", 111, 124], ["transthyretin", "PROTEIN", 111, 124], ["Onpattro (patisiran, siRNA", "TREATMENT", 42, 68], ["lipid NPs", "TREATMENT", 80, 89], ["the treatment of transthyretin", "TREATMENT", 94, 124], ["hereditary amyloidosis", "PROBLEM", 133, 155], ["hereditary", "OBSERVATION_MODIFIER", 133, 143], ["amyloidosis", "OBSERVATION", 144, 155]]], ["Proteins are another type of drug that can benefit from nanomedicine, such as the immunostimulatory agent interleukin-2, which can be nanoparticlized for cancer immunotherapy, with decreased systemic toxicity [11].", [["cancer", "ANATOMY", 154, 160], ["cancer", "DISEASE", 154, 160], ["toxicity", "DISEASE", 200, 208], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 106, 119], ["cancer", "CANCER", 154, 160], ["nanomedicine", "TREATMENT", 56, 68], ["the immunostimulatory agent interleukin", "TREATMENT", 78, 117], ["cancer immunotherapy", "TREATMENT", 154, 174], ["decreased systemic toxicity", "PROBLEM", 181, 208]]], ["NP contrast agents can be used for MRI and ultrasound.", [["NP contrast agents", "TREATMENT", 0, 18], ["MRI", "TEST", 35, 38], ["ultrasound", "TEST", 43, 53]]], ["Superparamagnetic iron oxide nanoparticles are employed as MRI agents that improve contrast and favorable biodistribution [12].", [["iron oxide", "CHEMICAL", 18, 28], ["iron oxide", "CHEMICAL", 18, 28], ["iron oxide nanoparticles", "SIMPLE_CHEMICAL", 18, 42], ["Superparamagnetic iron oxide nanoparticles", "TREATMENT", 0, 42], ["MRI agents", "TREATMENT", 59, 69]]], ["Some types of NPs can improve the mechanical properties and biocompatibility of biomaterials for medical implants and tissue engineering, such as nanomaterials exploited as dental fillers [13].", [["tissue", "ANATOMY", 118, 124], ["NPs", "SIMPLE_CHEMICAL", 14, 17], ["tissue", "TISSUE", 118, 124], ["NPs", "TREATMENT", 14, 17], ["the mechanical properties", "TREATMENT", 30, 55], ["biocompatibility of biomaterials", "TREATMENT", 60, 92], ["medical implants", "TREATMENT", 97, 113], ["tissue engineering", "TREATMENT", 118, 136], ["NPs", "OBSERVATION", 14, 17], ["mechanical properties", "OBSERVATION_MODIFIER", 34, 55]]], ["Furthermore, the properties of coencapsulation and the enhanced permeability and retention (EPR) effect improve the function of nanomedicine in multiple therapies [12].IntroductionIn recent years, the application of nanomedicine in cancer immunotherapy has received much attention and holds tremendous promise.", [["cancer", "ANATOMY", 232, 238], ["cancer", "DISEASE", 232, 238], ["cancer", "CANCER", 232, 238], ["coencapsulation", "TREATMENT", 31, 46], ["the enhanced permeability", "PROBLEM", 51, 76], ["retention (EPR)", "TREATMENT", 81, 96], ["nanomedicine in multiple therapies", "TREATMENT", 128, 162], ["nanomedicine in cancer immunotherapy", "TREATMENT", 216, 252], ["enhanced", "OBSERVATION_MODIFIER", 55, 63], ["permeability", "OBSERVATION_MODIFIER", 64, 76], ["retention", "OBSERVATION_MODIFIER", 81, 90], ["cancer", "OBSERVATION", 232, 238]]], ["In particular, nanomaterial-based vaccines (nanovaccines) can target the lymph node system via subcutaneous injection, enhance antigen uptake and stimulate the tumor-specific T cell response.", [["lymph node system", "ANATOMY", 73, 90], ["subcutaneous", "ANATOMY", 95, 107], ["tumor", "ANATOMY", 160, 165], ["T cell", "ANATOMY", 175, 181], ["tumor", "DISEASE", 160, 165], ["nanovaccines", "SIMPLE_CHEMICAL", 44, 56], ["lymph node", "MULTI-TISSUE_STRUCTURE", 73, 83], ["subcutaneous", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 107], ["tumor", "CANCER", 160, 165], ["T cell", "CELL", 175, 181], ["nanomaterial-based vaccines (nanovaccines", "TREATMENT", 15, 56], ["the lymph node system", "TREATMENT", 69, 90], ["subcutaneous injection", "TREATMENT", 95, 117], ["the tumor", "PROBLEM", 156, 165], ["lymph node", "OBSERVATION", 73, 83], ["subcutaneous", "ANATOMY", 95, 107], ["tumor", "OBSERVATION", 160, 165]]], ["Moreover, based on the EPR effect, nanomedicine can enhance drug accumulation in tumors via intravenous injection and remodel the immunosuppressive tumor microenvironment to boost the antitumor immune response.", [["tumors", "ANATOMY", 81, 87], ["intravenous", "ANATOMY", 92, 103], ["tumor", "ANATOMY", 148, 153], ["antitumor", "ANATOMY", 184, 193], ["tumors", "DISEASE", 81, 87], ["tumor", "DISEASE", 148, 153], ["tumors", "CANCER", 81, 87], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 103], ["tumor", "CANCER", 148, 153], ["antitumor", "CANCER", 184, 193], ["the EPR effect", "TREATMENT", 19, 33], ["nanomedicine", "TREATMENT", 35, 47], ["drug accumulation in tumors", "PROBLEM", 60, 87], ["intravenous injection", "TREATMENT", 92, 113], ["remodel the immunosuppressive tumor microenvironment", "TREATMENT", 118, 170], ["immunosuppressive tumor", "OBSERVATION", 130, 153]]], ["In this review, we discuss mainly how nanoengineering technologies provide innovative approaches for cancer immunotherapy, especially focusing on lymph node-targeting nanovaccines, as well as tumor microenvironment-targeting drug delivery.Lymph node-targeting effect ::: Lymph node-targeting nanovaccinesThe physical size of the vaccine formulation was found to play an important role in lymph node delivery [14, 20].", [["cancer", "ANATOMY", 101, 107], ["lymph node", "ANATOMY", 146, 156], ["tumor", "ANATOMY", 192, 197], ["Lymph node", "ANATOMY", 239, 249], ["Lymph node", "ANATOMY", 271, 281], ["lymph node", "ANATOMY", 388, 398], ["cancer", "DISEASE", 101, 107], ["tumor", "DISEASE", 192, 197], ["cancer", "CANCER", 101, 107], ["lymph node", "MULTI-TISSUE_STRUCTURE", 146, 156], ["tumor", "CANCER", 192, 197], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 239, 249], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 271, 281], ["lymph node", "MULTI-TISSUE_STRUCTURE", 388, 398], ["innovative approaches", "TREATMENT", 75, 96], ["cancer immunotherapy", "TREATMENT", 101, 121], ["lymph node", "TREATMENT", 146, 156], ["targeting nanovaccines", "TREATMENT", 157, 179], ["tumor microenvironment", "PROBLEM", 192, 214], ["targeting drug delivery", "TREATMENT", 215, 238], ["Lymph node", "TEST", 271, 281], ["targeting nanovaccines", "TREATMENT", 282, 304], ["the vaccine formulation", "TREATMENT", 325, 348], ["lymph node delivery", "TREATMENT", 388, 407], ["lymph node", "OBSERVATION", 146, 156], ["tumor", "OBSERVATION", 192, 197], ["Lymph node", "OBSERVATION", 239, 249], ["Lymph node", "OBSERVATION", 271, 281], ["size", "OBSERVATION_MODIFIER", 317, 321], ["lymph node", "OBSERVATION", 388, 398]]], ["Molecules and particles injected in local tissues are cleared through the blood system if they are smaller than 5 nm.", [["tissues", "ANATOMY", 42, 49], ["blood", "ANATOMY", 74, 79], ["tissues", "TISSUE", 42, 49], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["the blood system", "TEST", 70, 86], ["particles", "OBSERVATION_MODIFIER", 14, 23], ["local tissues", "ANATOMY", 36, 49], ["smaller", "OBSERVATION_MODIFIER", 99, 106]]], ["However, particles with hydrodynamic diameters of 10\u2013100 nm can improve the efficiency of lymphatic uptake [21\u201323].", [["lymphatic", "ANATOMY", 90, 99], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 90, 99], ["hydrodynamic diameters", "TEST", 24, 46], ["lymphatic uptake", "TEST", 90, 106], ["particles", "OBSERVATION_MODIFIER", 9, 18], ["hydrodynamic diameters", "OBSERVATION_MODIFIER", 24, 46], ["lymphatic uptake", "OBSERVATION", 90, 106]]], ["Reddy et al. exploited poly-(ethylene glycol)-stabilized poly-(propylene sulfide) (PPS) NPs to target lymph nodes, and the results demonstrated that 20 nm particles drained to the lymphatic system following interstitial injection; NPs between 20 and 45 nm in size displayed significant accumulation in lymph nodes, showing strong retention at 24, 72, 96, and 120 h post-injection [24].", [["lymph nodes", "ANATOMY", 102, 113], ["lymphatic system", "ANATOMY", 180, 196], ["interstitial", "ANATOMY", 207, 219], ["lymph nodes", "ANATOMY", 302, 313], ["poly-(ethylene glycol", "CHEMICAL", 23, 44], ["poly-(propylene sulfide", "CHEMICAL", 57, 80], ["NPs", "CHEMICAL", 231, 234], ["poly-(ethylene glycol)", "CHEMICAL", 23, 45], ["poly-(propylene sulfide)", "CHEMICAL", 57, 81], ["PPS", "CHEMICAL", 83, 86], ["poly-(ethylene glycol)", "SIMPLE_CHEMICAL", 23, 45], ["poly-(propylene sulfide) (PPS) NPs", "SIMPLE_CHEMICAL", 57, 91], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 102, 113], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 180, 196], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 207, 219], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 302, 313], ["poly-(ethylene glycol)", "TREATMENT", 23, 45], ["stabilized poly-(propylene sulfide)", "TREATMENT", 46, 81], ["NPs", "TREATMENT", 88, 91], ["target lymph nodes", "TEST", 95, 113], ["20 nm particles", "PROBLEM", 149, 164], ["interstitial injection", "TREATMENT", 207, 229], ["NPs", "TEST", 231, 234], ["significant accumulation in lymph nodes", "PROBLEM", 274, 313], ["et al", "OBSERVATION", 6, 11], ["lymph nodes", "OBSERVATION", 102, 113], ["lymphatic system", "ANATOMY", 180, 196], ["interstitial", "ANATOMY_MODIFIER", 207, 219], ["size", "OBSERVATION_MODIFIER", 259, 263], ["significant", "OBSERVATION_MODIFIER", 274, 285], ["accumulation", "OBSERVATION_MODIFIER", 286, 298], ["lymph nodes", "OBSERVATION", 302, 313], ["strong", "OBSERVATION_MODIFIER", 323, 329], ["retention", "OBSERVATION_MODIFIER", 330, 339]]], ["Moreover, particles larger than 170 nm displayed poor lymphatic uptake and strong retention at the injection site [20].", [["lymphatic", "ANATOMY", 54, 63], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 54, 63], ["poor lymphatic uptake", "PROBLEM", 49, 70], ["strong retention at the injection site", "PROBLEM", 75, 113], ["particles", "OBSERVATION_MODIFIER", 10, 19], ["larger", "OBSERVATION_MODIFIER", 20, 26], ["poor", "OBSERVATION_MODIFIER", 49, 53], ["lymphatic uptake", "OBSERVATION", 54, 70], ["strong", "OBSERVATION_MODIFIER", 75, 81], ["retention", "OBSERVATION_MODIFIER", 82, 91]]], ["Therefore, nanovaccine development has focused mainly on NPs smaller than 200 nm.Antigen/adjuvant codelivery ::: Lymph node-targeting nanovaccinesCompared to traditional vaccines, nanovaccines with controlled size and codelivery of antigen and adjuvant have shown promising effects.", [["Lymph node", "ANATOMY", 113, 123], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 113, 123], ["nanovaccines", "SIMPLE_CHEMICAL", 180, 192], ["nanovaccine", "TREATMENT", 11, 22], ["Lymph node", "TEST", 113, 123], ["targeting nanovaccines", "TREATMENT", 124, 146], ["traditional vaccines", "TREATMENT", 158, 178], ["nanovaccines", "TREATMENT", 180, 192], ["codelivery of antigen", "TREATMENT", 218, 239], ["adjuvant", "TREATMENT", 244, 252], ["Lymph node", "OBSERVATION", 113, 123], ["size", "OBSERVATION_MODIFIER", 209, 213]]], ["Lipid vesicles have attracted much attention for antigen delivery due to their low toxicity and immunogenicity, facile preparation process and reliable manufacturability at commercial scales [25].", [["Lipid vesicles", "ANATOMY", 0, 14], ["toxicity", "DISEASE", 83, 91], ["Lipid vesicles", "CELLULAR_COMPONENT", 0, 14], ["Lipid vesicles", "PROBLEM", 0, 14], ["antigen delivery", "TREATMENT", 49, 65], ["their low toxicity", "PROBLEM", 73, 91], ["facile preparation process", "TREATMENT", 112, 138]]], ["James et al. reported a novel design of lipid drug carriers, interbilayer-crosslinked multilamellar vesicles (ICMVs).", [["multilamellar vesicles", "ANATOMY", 86, 108], ["ICMVs", "ANATOMY", 110, 115], ["lipid", "SIMPLE_CHEMICAL", 40, 45], ["interbilayer-crosslinked multilamellar vesicles", "SIMPLE_CHEMICAL", 61, 108], ["lipid drug carriers", "PROBLEM", 40, 59], ["crosslinked multilamellar vesicles", "PROBLEM", 74, 108], ["multilamellar vesicles", "OBSERVATION", 86, 108]]], ["The multilamellar vesicles stably encapsulate protein antigens in the core, and the immune stimulatory molecules are rapidly released from the vesicles under extracellular conditions.", [["multilamellar vesicles", "ANATOMY", 4, 26], ["vesicles", "ANATOMY", 143, 151], ["extracellular", "ANATOMY", 158, 171], ["vesicles", "CELLULAR_COMPONENT", 143, 151], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 158, 171], ["protein antigens", "PROTEIN", 46, 62], ["immune stimulatory molecules", "PROTEIN", 84, 112], ["multilamellar vesicles", "ANATOMY", 4, 26], ["stably encapsulate", "OBSERVATION", 27, 45], ["protein antigens", "OBSERVATION", 46, 62], ["immune", "OBSERVATION", 84, 90], ["stimulatory molecules", "OBSERVATION", 91, 112], ["vesicles", "ANATOMY_MODIFIER", 143, 151], ["extracellular conditions", "OBSERVATION", 158, 182]]], ["The results showed that these antigen/adjuvant codelivery vesicles could elicit antigen-specific T cells and antibody responses [26].", [["codelivery vesicles", "ANATOMY", 47, 66], ["T cells", "ANATOMY", 97, 104], ["antigen", "GENE_OR_GENE_PRODUCT", 30, 37], ["T cells", "CELL", 97, 104], ["T cells", "CELL_TYPE", 97, 104], ["these antigen/adjuvant codelivery vesicles", "TREATMENT", 24, 66], ["antigen", "TEST", 80, 87], ["antibody responses", "TEST", 109, 127]]], ["Liu et al. developed a vaccine comprising lipid-modified antigenic peptides or CpG-DNA, which exploited albumin to transport lipids in vivo and target lymph nodes.", [["lymph nodes", "ANATOMY", 151, 162], ["lipid", "SIMPLE_CHEMICAL", 42, 47], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["albumin", "GENE_OR_GENE_PRODUCT", 104, 111], ["lipids", "SIMPLE_CHEMICAL", 125, 131], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 151, 162], ["CpG-DNA", "DNA", 79, 86], ["albumin", "PROTEIN", 104, 111], ["a vaccine", "TREATMENT", 21, 30], ["lipid", "TREATMENT", 42, 47], ["modified antigenic peptides", "TREATMENT", 48, 75], ["CpG", "PROBLEM", 79, 82], ["DNA", "PROBLEM", 83, 86], ["albumin", "TREATMENT", 104, 111], ["transport lipids", "TEST", 115, 131], ["target lymph nodes", "PROBLEM", 144, 162], ["lymph nodes", "OBSERVATION", 151, 162]]], ["The results showed that this nanovaccine produced a 30-fold increase in T cell priming and improved antitumor efficacy while apparently reducing systemic toxicity [27].", [["T cell", "ANATOMY", 72, 78], ["antitumor", "ANATOMY", 100, 109], ["toxicity", "DISEASE", 154, 162], ["T cell", "CELL", 72, 78], ["antitumor", "CANCER", 100, 109], ["this nanovaccine", "TREATMENT", 24, 40], ["T cell priming", "TREATMENT", 72, 86], ["systemic toxicity", "PROBLEM", 145, 162], ["T cell", "OBSERVATION", 72, 78]]], ["Additionally, based on this design, Ma et al. designed amphiphile CAR-T ligands (amph ligands) that, once injected, trafficked to lymph nodes and modified the surfaces of APCs, thus priming CAR-Ts in the lymph node microenvironment.", [["lymph nodes", "ANATOMY", 130, 141], ["APCs", "ANATOMY", 171, 175], ["lymph node", "ANATOMY", 204, 214], ["CAR-T ligands", "GENE_OR_GENE_PRODUCT", 66, 79], ["amph ligands", "GENE_OR_GENE_PRODUCT", 81, 93], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 130, 141], ["APCs", "CELL", 171, 175], ["CAR-Ts", "GENE_OR_GENE_PRODUCT", 190, 196], ["lymph node", "MULTI-TISSUE_STRUCTURE", 204, 214], ["CAR", "PROTEIN", 66, 69], ["T ligands", "PROTEIN", 70, 79], ["APCs", "CELL_TYPE", 171, 175], ["CAR", "PROTEIN", 190, 193], ["amphiphile CAR-T ligands (amph ligands", "TREATMENT", 55, 93], ["APCs", "PROBLEM", 171, 175], ["lymph nodes", "OBSERVATION", 130, 141], ["lymph node microenvironment", "OBSERVATION", 204, 231]]], ["This design induced massive CAR-T expansion and subsequently enhanced antitumor efficacy in multiple mouse tumor models, with low side effects [28].Antigen/adjuvant codelivery ::: Lymph node-targeting nanovaccinesPolymer-derived nanovaccines allow effective encapsulation and integrated function and are interesting candidates for vaccination purposes.", [["antitumor", "ANATOMY", 70, 79], ["tumor", "ANATOMY", 107, 112], ["Lymph node", "ANATOMY", 180, 190], ["tumor", "DISEASE", 107, 112], ["CAR-T", "GENE_OR_GENE_PRODUCT", 28, 33], ["antitumor", "CANCER", 70, 79], ["mouse", "ORGANISM", 101, 106], ["tumor", "CANCER", 107, 112], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 180, 190], ["CAR", "PROTEIN", 28, 31], ["mouse", "SPECIES", 101, 106], ["mouse", "SPECIES", 101, 106], ["massive CAR-T expansion", "PROBLEM", 20, 43], ["subsequently enhanced antitumor efficacy in multiple mouse tumor models", "PROBLEM", 48, 119], ["low side effects", "PROBLEM", 126, 142], ["Lymph node", "TEST", 180, 190], ["targeting nanovaccines", "TREATMENT", 191, 213], ["Polymer", "TREATMENT", 213, 220], ["nanovaccines", "TREATMENT", 229, 241], ["effective encapsulation", "TREATMENT", 248, 271], ["vaccination purposes", "TREATMENT", 331, 351], ["massive", "OBSERVATION_MODIFIER", 20, 27], ["enhanced", "OBSERVATION_MODIFIER", 61, 69], ["antitumor", "OBSERVATION_MODIFIER", 70, 79], ["multiple", "OBSERVATION_MODIFIER", 92, 100], ["mouse", "OBSERVATION_MODIFIER", 101, 106], ["tumor", "OBSERVATION", 107, 112], ["low side", "OBSERVATION_MODIFIER", 126, 134], ["Lymph node", "OBSERVATION", 180, 190]]], ["Luo et al. reported that a minimalist nanovaccine, a simple physical mixture of antigens and synthetic polymeric NPs, PC7A NPs (20\u201350 nm), can efficiently deliver any tumor-related antigens to APCs in draining lymph nodes while simultaneously stimulating the type I interferon-STING innate immune pathway (Fig. 2).", [["tumor", "ANATOMY", 167, 172], ["APCs", "ANATOMY", 193, 197], ["lymph nodes", "ANATOMY", 210, 221], ["PC7A NPs", "CHEMICAL", 118, 126], ["tumor", "DISEASE", 167, 172], ["polymeric NPs", "SIMPLE_CHEMICAL", 103, 116], ["PC7A NPs", "SIMPLE_CHEMICAL", 118, 126], ["tumor", "CANCER", 167, 172], ["APCs", "CELL", 193, 197], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 210, 221], ["type I interferon", "GENE_OR_GENE_PRODUCT", 259, 276], ["STING", "GENE_OR_GENE_PRODUCT", 277, 282], ["antigens", "PROTEIN", 80, 88], ["APCs", "CELL_TYPE", 193, 197], ["type I interferon", "PROTEIN", 259, 276], ["STING", "PROTEIN", 277, 282], ["a minimalist nanovaccine", "TREATMENT", 25, 49], ["synthetic polymeric NPs", "TREATMENT", 93, 116], ["PC7A NPs", "TREATMENT", 118, 126], ["any tumor", "PROBLEM", 163, 172], ["draining lymph nodes", "PROBLEM", 201, 221], ["the type I interferon", "TREATMENT", 255, 276], ["STING innate immune pathway", "TREATMENT", 277, 304], ["et al", "OBSERVATION", 4, 9], ["tumor", "OBSERVATION", 167, 172], ["draining", "OBSERVATION_MODIFIER", 201, 209], ["lymph nodes", "OBSERVATION", 210, 221]]], ["This nanovaccine induced significant immune responses to retard tumor growth in melanoma, colon cancer and human papilloma virus E6/E7 mouse tumor models [29].", [["tumor", "ANATOMY", 64, 69], ["melanoma", "ANATOMY", 80, 88], ["colon cancer", "ANATOMY", 90, 102], ["tumor", "ANATOMY", 141, 146], ["tumor", "DISEASE", 64, 69], ["melanoma", "DISEASE", 80, 88], ["colon cancer", "DISEASE", 90, 102], ["tumor", "DISEASE", 141, 146], ["tumor", "CANCER", 64, 69], ["melanoma", "CANCER", 80, 88], ["colon cancer", "CANCER", 90, 102], ["human papilloma virus E6", "ORGANISM", 107, 131], ["E7", "ORGANISM", 132, 134], ["mouse", "ORGANISM", 135, 140], ["tumor", "CANCER", 141, 146], ["human", "SPECIES", 107, 112], ["papilloma virus", "SPECIES", 113, 128], ["mouse", "SPECIES", 135, 140], ["human papilloma virus", "SPECIES", 107, 128], ["mouse", "SPECIES", 135, 140], ["This nanovaccine", "TREATMENT", 0, 16], ["significant immune responses", "PROBLEM", 25, 53], ["tumor growth", "PROBLEM", 64, 76], ["melanoma", "PROBLEM", 80, 88], ["colon cancer", "PROBLEM", 90, 102], ["human papilloma virus", "PROBLEM", 107, 128], ["retard", "OBSERVATION_MODIFIER", 57, 63], ["tumor", "OBSERVATION_MODIFIER", 64, 69], ["growth", "OBSERVATION_MODIFIER", 70, 76], ["melanoma", "OBSERVATION", 80, 88], ["colon", "ANATOMY", 90, 95], ["cancer", "OBSERVATION", 96, 102], ["papilloma virus", "OBSERVATION", 113, 128]]], ["Mechanistically, the particle size and simple protein loading strategy facilitate antigen delivery to APCs in lymph nodes, the pH-specific proton sponge effect promotes antigen cross-presentation via membrane disruption, and STING pathway stimulation by this polymer leads to robust APC maturation and subsequent T cell activation.", [["APCs", "ANATOMY", 102, 106], ["lymph nodes", "ANATOMY", 110, 121], ["membrane", "ANATOMY", 200, 208], ["T cell", "ANATOMY", 313, 319], ["APCs", "CELL", 102, 106], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 110, 121], ["membrane", "CELLULAR_COMPONENT", 200, 208], ["STING", "GENE_OR_GENE_PRODUCT", 225, 230], ["APC", "GENE_OR_GENE_PRODUCT", 283, 286], ["T cell", "CELL", 313, 319], ["APCs", "CELL_TYPE", 102, 106], ["STING", "PROTEIN", 225, 230], ["APC", "CELL_TYPE", 283, 286], ["the particle size", "PROBLEM", 17, 34], ["simple protein loading strategy", "TREATMENT", 39, 70], ["antigen delivery", "TREATMENT", 82, 98], ["APCs in lymph nodes", "PROBLEM", 102, 121], ["the pH", "TEST", 123, 129], ["specific proton sponge effect", "TREATMENT", 130, 159], ["membrane disruption", "PROBLEM", 200, 219], ["STING pathway stimulation", "TREATMENT", 225, 250], ["this polymer leads", "TREATMENT", 254, 272], ["robust APC maturation", "TREATMENT", 276, 297], ["subsequent T cell activation", "PROBLEM", 302, 330], ["particle", "OBSERVATION_MODIFIER", 21, 29], ["size", "OBSERVATION_MODIFIER", 30, 34], ["protein loading", "OBSERVATION", 46, 61], ["lymph nodes", "OBSERVATION", 110, 121], ["membrane disruption", "OBSERVATION", 200, 219], ["cell activation", "OBSERVATION", 315, 330]]], ["Moreover, Luo et al. demonstrated that nanovaccines combined with radiotherapy could induce a synergistic therapeutic effect in both primary and distal tumors in a STING-dependent manner [30].", [["primary", "ANATOMY", 133, 140], ["distal tumors", "ANATOMY", 145, 158], ["nanovaccines", "CHEMICAL", 39, 51], ["primary and distal tumors", "DISEASE", 133, 158], ["nanovaccines", "SIMPLE_CHEMICAL", 39, 51], ["tumors", "CANCER", 152, 158], ["STING", "GENE_OR_GENE_PRODUCT", 164, 169], ["STING", "PROTEIN", 164, 169], ["nanovaccines", "TREATMENT", 39, 51], ["radiotherapy", "TREATMENT", 66, 78], ["a synergistic therapeutic effect in both primary and distal tumors", "PROBLEM", 92, 158], ["Luo et", "OBSERVATION", 10, 16], ["both", "OBSERVATION_MODIFIER", 128, 132], ["primary", "OBSERVATION_MODIFIER", 133, 140], ["distal", "OBSERVATION_MODIFIER", 145, 151], ["tumors", "OBSERVATION", 152, 158]]], ["Qiao et al. used the flash nanocomplexation (FNC) approach to prepare nanovaccines, and they complexed chitosan and heparin with antigens and adjuvants by electronic affinity.", [["chitosan", "CHEMICAL", 103, 111], ["heparin", "CHEMICAL", 116, 123], ["chitosan", "SIMPLE_CHEMICAL", 103, 111], ["heparin", "SIMPLE_CHEMICAL", 116, 123], ["antigens", "PROTEIN", 129, 137], ["the flash nanocomplexation (FNC) approach", "TREATMENT", 17, 58], ["nanovaccines", "TREATMENT", 70, 82], ["heparin", "TREATMENT", 116, 123], ["antigens", "TREATMENT", 129, 137], ["adjuvants", "TREATMENT", 142, 151]]], ["This nanovaccine elicited potent Th1-biased immune responses and showed effective protection against lethal virus challenge [31].Antigen/adjuvant codelivery ::: Lymph node-targeting nanovaccinesAntigens derived from apoptotic or cancerous cells undergo membrane dynamic curvature and lateral diffusion.", [["Lymph node", "ANATOMY", 161, 171], ["cancerous cells", "ANATOMY", 229, 244], ["membrane", "ANATOMY", 253, 261], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 161, 171], ["cancerous cells", "CELL", 229, 244], ["membrane", "CELLULAR_COMPONENT", 253, 261], ["apoptotic or cancerous cells", "CELL_TYPE", 216, 244], ["This nanovaccine", "TREATMENT", 0, 16], ["lethal virus challenge", "PROBLEM", 101, 123], ["Lymph node", "TEST", 161, 171], ["targeting nanovaccines", "TREATMENT", 172, 194], ["membrane dynamic curvature and lateral diffusion", "PROBLEM", 253, 301], ["Lymph node", "OBSERVATION", 161, 171], ["apoptotic", "OBSERVATION_MODIFIER", 216, 225], ["cancerous cells", "OBSERVATION", 229, 244], ["membrane", "OBSERVATION_MODIFIER", 253, 261], ["dynamic curvature", "OBSERVATION", 262, 279], ["lateral", "OBSERVATION_MODIFIER", 284, 291], ["diffusion", "OBSERVATION_MODIFIER", 292, 301]]], ["This process increases the contact area and multiple interactions of antigens with APCs, which could enhance antigen internalization and cross-presentation [32, 33].", [["APCs", "ANATOMY", 83, 87], ["APCs", "CELL", 83, 87], ["antigens", "PROTEIN", 69, 77], ["APCs", "CELL_TYPE", 83, 87], ["multiple", "OBSERVATION_MODIFIER", 44, 52]]], ["Here, Xia et al. developed a novel Pickering emulsion that is particle stabilized and retains properties of force-dependent deformability and lateral mobility of presented antigens.", [["a novel Pickering emulsion", "PROBLEM", 27, 53], ["dependent deformability", "PROBLEM", 114, 137], ["Pickering emulsion", "OBSERVATION", 35, 53], ["dependent", "OBSERVATION_MODIFIER", 114, 123], ["deformability", "OBSERVATION_MODIFIER", 124, 137], ["lateral", "OBSERVATION_MODIFIER", 142, 149]]], ["Hence, this emulsion could improve the recruitment of APCs and enhance antigen uptake and APC activation.", [["APCs", "ANATOMY", 54, 58], ["APCs", "CELL", 54, 58], ["antigen", "GENE_OR_GENE_PRODUCT", 71, 78], ["APC", "GENE_OR_GENE_PRODUCT", 90, 93], ["APCs", "CELL_TYPE", 54, 58], ["APC", "CELL_TYPE", 90, 93], ["this emulsion", "TREATMENT", 7, 20], ["APC activation", "PROBLEM", 90, 104]]], ["The results showed that this vaccine could effectively activate both humoral and cellular responses, further protecting mice from infections and diseases [34].Biomimetic mimicking delivery ::: Lymph node-targeting nanovaccinesBiomimetic particles represent a promising formulation for the development of safe nanomedicines.", [["cellular", "ANATOMY", 81, 89], ["Lymph node", "ANATOMY", 193, 203], ["infections", "DISEASE", 130, 140], ["cellular", "CELL", 81, 89], ["mice", "ORGANISM", 120, 124], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 193, 203], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 120, 124], ["this vaccine", "TREATMENT", 24, 36], ["infections", "PROBLEM", 130, 140], ["diseases", "PROBLEM", 145, 153], ["Lymph node", "TREATMENT", 193, 203], ["targeting nanovaccinesBiomimetic particles", "TREATMENT", 204, 246], ["a promising formulation", "TREATMENT", 257, 280], ["safe nanomedicines", "TREATMENT", 304, 322], ["cellular responses", "OBSERVATION", 81, 99], ["Lymph node", "OBSERVATION", 193, 203]]], ["Compared to synthetic particles, biomimetic NPs can target tumors or immune cells with prolonged circulating time and low toxicity [35\u201337].Biomimetic mimicking delivery ::: Lymph node-targeting nanovaccinesHigh-density lipoprotein nanodisks (~10 nm) are endogenous NPs that transport fats and cholesterol in blood, so they have been clinically tested for drug delivery and show high tolerance [38].", [["tumors", "ANATOMY", 59, 65], ["immune cells", "ANATOMY", 69, 81], ["Lymph node", "ANATOMY", 173, 183], ["blood", "ANATOMY", 308, 313], ["NPs", "CHEMICAL", 44, 47], ["tumors", "DISEASE", 59, 65], ["toxicity", "DISEASE", 122, 130], ["cholesterol", "CHEMICAL", 293, 304], ["cholesterol", "CHEMICAL", 293, 304], ["biomimetic NPs", "SIMPLE_CHEMICAL", 33, 47], ["tumors", "CANCER", 59, 65], ["immune cells", "CELL", 69, 81], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 173, 183], ["High-density lipoprotein nanodisks", "SIMPLE_CHEMICAL", 206, 240], ["fats", "SIMPLE_CHEMICAL", 284, 288], ["cholesterol", "SIMPLE_CHEMICAL", 293, 304], ["blood", "ORGANISM_SUBSTANCE", 308, 313], ["immune cells", "CELL_TYPE", 69, 81], ["biomimetic NPs", "TREATMENT", 33, 47], ["target tumors", "PROBLEM", 52, 65], ["immune cells", "PROBLEM", 69, 81], ["prolonged circulating time", "PROBLEM", 87, 113], ["low toxicity", "PROBLEM", 118, 130], ["Lymph node", "TEST", 173, 183], ["targeting nanovaccines", "TREATMENT", 184, 206], ["High-density lipoprotein nanodisks", "TREATMENT", 206, 240], ["endogenous NPs", "PROBLEM", 254, 268], ["cholesterol in blood", "PROBLEM", 293, 313], ["drug delivery", "TREATMENT", 355, 368], ["tumors", "OBSERVATION", 59, 65], ["immune cells", "OBSERVATION", 69, 81], ["Lymph node", "OBSERVATION", 173, 183], ["-density", "OBSERVATION_MODIFIER", 210, 218], ["lipoprotein nanodisks", "OBSERVATION", 219, 240], ["transport fats", "OBSERVATION", 274, 288]]], ["Rui et al. conjugated antigens/adjuvant (Cho-CpG) on these nanodisks, which markedly enhanced the antigen-specific T cell response.", [["T cell", "ANATOMY", 115, 121], ["Cho-CpG", "CHEMICAL", 41, 48], ["Cho-CpG", "SIMPLE_CHEMICAL", 41, 48], ["T cell", "CELL", 115, 121], ["conjugated antigens", "PROTEIN", 11, 30], ["conjugated antigens/adjuvant (Cho-CpG)", "TREATMENT", 11, 49], ["these nanodisks", "TREATMENT", 53, 68], ["the antigen", "TEST", 94, 105], ["cell response", "OBSERVATION", 117, 130]]], ["The nanovaccine could eliminate MC-38 and B16F10 tumors when synergized with anti-PD-1 and anti-CTLA-4 therapy [39].Biomimetic mimicking delivery ::: Lymph node-targeting nanovaccinesCell-membrane coating technology is an emerging platform for drug delivery [36].", [["MC-38", "ANATOMY", 32, 37], ["B16F10 tumors", "ANATOMY", 42, 55], ["Lymph node", "ANATOMY", 150, 160], ["Cell", "ANATOMY", 183, 187], ["membrane", "ANATOMY", 188, 196], ["tumors", "DISEASE", 49, 55], ["anti-CTLA-4", "CHEMICAL", 91, 102], ["nanovaccine", "SIMPLE_CHEMICAL", 4, 15], ["MC-38", "CELL", 32, 37], ["B16F10 tumors", "CANCER", 42, 55], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 77, 86], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 91, 102], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 150, 160], ["Cell", "CELL", 183, 187], ["membrane", "CELLULAR_COMPONENT", 188, 196], ["The nanovaccine", "TREATMENT", 0, 15], ["MC", "TEST", 32, 34], ["B16F10 tumors", "PROBLEM", 42, 55], ["anti-PD", "TREATMENT", 77, 84], ["anti-CTLA", "TREATMENT", 91, 100], ["Lymph node", "TEST", 150, 160], ["targeting nanovaccines", "TREATMENT", 161, 183], ["Cell-membrane coating technology", "TREATMENT", 183, 215], ["drug delivery", "TREATMENT", 244, 257], ["Lymph node", "OBSERVATION", 150, 160], ["membrane coating", "OBSERVATION", 188, 204]]], ["Cell membrane-coated NPs possess intrinsic properties of source cells, such as a remarkable capacity to contact their surrounding environment due to their biomimetic interface.", [["Cell membrane", "ANATOMY", 0, 13], ["cells", "ANATOMY", 64, 69], ["Cell", "CELL", 0, 4], ["cells", "CELL", 64, 69], ["source cells", "CELL_TYPE", 57, 69], ["Cell membrane-coated NPs", "TREATMENT", 0, 24], ["source cells", "PROBLEM", 57, 69], ["coated NPs", "OBSERVATION_MODIFIER", 14, 24], ["source cells", "OBSERVATION", 57, 69], ["biomimetic interface", "OBSERVATION", 155, 175]]], ["Compared to traditional nanoparticles, they displayed outstanding characteristics of long circulation and disease-relevant targeting.", [["traditional nanoparticles", "TEST", 12, 37], ["long circulation and disease", "PROBLEM", 85, 113]]], ["Since many tumor-related antigens exist on the tumor cell membrane [17, 40], Ashley et al. developed tumor cell membrane-coated NPs containing a highly immunostimulatory adjuvant.", [["tumor", "ANATOMY", 11, 16], ["tumor cell membrane", "ANATOMY", 47, 66], ["tumor cell membrane", "ANATOMY", 101, 120], ["tumor", "DISEASE", 11, 16], ["tumor", "DISEASE", 47, 52], ["tumor", "DISEASE", 101, 106], ["tumor", "CANCER", 11, 16], ["tumor cell membrane", "CELLULAR_COMPONENT", 47, 66], ["tumor cell", "CELL", 101, 111], ["tumor-related antigens", "PROTEIN", 11, 33], ["many tumor-related antigens", "PROBLEM", 6, 33], ["the tumor cell membrane", "TEST", 43, 66], ["tumor cell membrane", "TREATMENT", 101, 120], ["coated NPs", "TREATMENT", 121, 131], ["a highly immunostimulatory adjuvant", "TREATMENT", 143, 178], ["many", "OBSERVATION_MODIFIER", 6, 10], ["tumor", "OBSERVATION", 11, 16], ["tumor cell membrane", "OBSERVATION", 47, 66], ["tumor cell membrane", "OBSERVATION", 101, 120], ["coated NPs", "OBSERVATION", 121, 131], ["highly", "OBSERVATION_MODIFIER", 145, 151], ["immunostimulatory adjuvant", "OBSERVATION", 152, 178]]], ["The results showed that this nanovaccine could generate a durable anticancer response in vivo and have synergistic effects with checkpoint blockade inhibitors to retard cancer growth [41].mRNA vaccine ::: Lymph node-targeting nanovaccinesIn recent years, messenger RNA (mRNA)-based vaccines have been developed as an alternative prophylactic or therapeutic vaccine technology against infectious diseases or cancers [42].", [["anticancer", "ANATOMY", 66, 76], ["cancer", "ANATOMY", 169, 175], ["Lymph node", "ANATOMY", 205, 215], ["cancers", "ANATOMY", 407, 414], ["cancer", "DISEASE", 169, 175], ["infectious diseases", "DISEASE", 384, 403], ["cancers", "DISEASE", 407, 414], ["nanovaccine", "SIMPLE_CHEMICAL", 29, 40], ["anticancer", "CANCER", 66, 76], ["cancer", "CANCER", 169, 175], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 205, 215], ["cancers", "CANCER", 407, 414], ["messenger RNA", "RNA", 255, 268], ["mRNA", "RNA", 270, 274], ["this nanovaccine", "TREATMENT", 24, 40], ["synergistic effects", "TREATMENT", 103, 122], ["checkpoint blockade inhibitors", "TREATMENT", 128, 158], ["cancer growth", "PROBLEM", 169, 182], ["Lymph node", "TEST", 205, 215], ["targeting nanovaccines", "TREATMENT", 216, 238], ["messenger RNA (mRNA)", "PROBLEM", 255, 275], ["based vaccines", "TREATMENT", 276, 290], ["an alternative prophylactic", "TREATMENT", 314, 341], ["therapeutic vaccine technology", "TREATMENT", 345, 375], ["infectious diseases", "PROBLEM", 384, 403], ["cancers", "PROBLEM", 407, 414], ["Lymph node", "OBSERVATION", 205, 215]]], ["Compared to traditional DNA vaccines, mRNA vaccines have a safety advantage, as they have very little interaction with the genome.", [["DNA", "CELLULAR_COMPONENT", 24, 27], ["genome", "CELLULAR_COMPONENT", 123, 129], ["traditional DNA vaccines", "TREATMENT", 12, 36], ["mRNA vaccines", "TREATMENT", 38, 51]]], ["Compared to subunit protein or peptide vaccines, mRNA vaccines are able to deliver multiple antigens in one protein-encoding open reading frame, offering great flexibility and convenience for application and production [43].", [["subunit protein", "PROTEIN", 12, 27], ["open reading frame", "DNA", 125, 143], ["subunit protein", "TREATMENT", 12, 27], ["peptide vaccines", "TREATMENT", 31, 47], ["mRNA vaccines", "TREATMENT", 49, 62]]], ["Two challenges limit the clinical translation of mRNA vaccines: (1) insufficient cytosolic delivery and (2) rapid degradation with low expression levels.", [["cytosolic", "ANATOMY", 81, 90], ["cytosolic", "ORGANISM_SUBSTANCE", 81, 90], ["mRNA vaccines", "TREATMENT", 49, 62], ["insufficient cytosolic delivery", "TREATMENT", 68, 99], ["rapid degradation with low expression levels", "PROBLEM", 108, 152], ["low expression", "OBSERVATION_MODIFIER", 131, 145]]], ["Nanotechnology provides a unique strategy for mRNA delivery [44, 45].mRNA vaccine ::: Lymph node-targeting nanovaccinesMiao et al. designed a library of ionizable lipid-like materials to screen for mRNA delivery vehicles.", [["Lymph node", "ANATOMY", 86, 96], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 86, 96], ["mRNA delivery", "TREATMENT", 46, 59], ["Lymph node", "TEST", 86, 96], ["targeting nanovaccines", "TREATMENT", 97, 119], ["ionizable lipid", "TREATMENT", 153, 168], ["mRNA delivery vehicles", "TREATMENT", 198, 220], ["Lymph node", "OBSERVATION", 86, 96]]], ["They identified a lipid vesicle that not only showed high delivery and expression levels but also stimulated the STING innate immune pathway.", [["lipid vesicle", "ANATOMY", 18, 31], ["lipid vesicle", "CELLULAR_COMPONENT", 18, 31], ["STING", "GENE_OR_GENE_PRODUCT", 113, 118], ["STING", "PROTEIN", 113, 118], ["a lipid vesicle", "TEST", 16, 31], ["high delivery and expression levels", "PROBLEM", 53, 88], ["lipid vesicle", "OBSERVATION", 18, 31], ["high", "OBSERVATION", 53, 57]]], ["This formulation could elicit a robust immune response, resulting in inhibition of tumor growth and prolonged survival in melanoma and human papillomavirus E7 tumor models [46].mRNA vaccine ::: Lymph node-targeting nanovaccinesThe cytotoxic T cell response plays an important role in antitumor immune responses.", [["tumor", "ANATOMY", 83, 88], ["melanoma", "ANATOMY", 122, 130], ["tumor", "ANATOMY", 159, 164], ["Lymph node", "ANATOMY", 194, 204], ["T cell", "ANATOMY", 241, 247], ["antitumor", "ANATOMY", 284, 293], ["tumor", "DISEASE", 83, 88], ["melanoma", "DISEASE", 122, 130], ["papillomavirus E7 tumor", "DISEASE", 141, 164], ["tumor", "CANCER", 83, 88], ["melanoma", "CANCER", 122, 130], ["human", "ORGANISM", 135, 140], ["papillomavirus", "ORGANISM", 141, 155], ["E7", "ORGANISM", 156, 158], ["tumor", "CANCER", 159, 164], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 194, 204], ["cytotoxic T cell", "CELL", 231, 247], ["antitumor", "CANCER", 284, 293], ["human", "SPECIES", 135, 140], ["human papillomavirus", "SPECIES", 135, 155], ["This formulation", "TREATMENT", 0, 16], ["tumor growth", "PROBLEM", 83, 95], ["prolonged survival in melanoma", "PROBLEM", 100, 130], ["human papillomavirus E7 tumor models", "PROBLEM", 135, 171], ["Lymph node", "TEST", 194, 204], ["targeting nanovaccines", "TREATMENT", 205, 227], ["tumor", "OBSERVATION", 83, 88], ["melanoma", "OBSERVATION", 122, 130], ["Lymph node", "OBSERVATION", 194, 204], ["cytotoxic T cell response", "OBSERVATION", 231, 256]]], ["Oberli et al. developed lipid-based NPs for the delivery of mRNA vaccines to elicit strong cytotoxic CD8+ T cell responses.", [["T cell", "ANATOMY", 106, 112], ["lipid-based NPs", "SIMPLE_CHEMICAL", 24, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 101, 104], ["T cell", "CELL", 106, 112], ["CD8", "PROTEIN", 101, 104], ["lipid-based NPs", "TREATMENT", 24, 39], ["the delivery of mRNA vaccines", "TREATMENT", 44, 73]]], ["The vaccine consisted of ionizable lipids, which are positively charged at low pH and form complexes with negatively charged mRNA.", [["lipids", "SIMPLE_CHEMICAL", 35, 41], ["negatively charged mRNA", "RNA", 106, 129], ["The vaccine", "TREATMENT", 0, 11], ["ionizable lipids", "TREATMENT", 25, 41], ["low pH", "OBSERVATION_MODIFIER", 75, 81], ["charged mRNA", "OBSERVATION", 117, 129]]], ["This formulation helps with cellular uptake and cross-presentation of expressed antigens.", [["cellular", "ANATOMY", 28, 36], ["cellular", "CELL", 28, 36], ["This formulation", "TREATMENT", 0, 16], ["cellular uptake", "PROBLEM", 28, 43], ["cellular uptake", "OBSERVATION", 28, 43]]], ["The results showed that mRNA vaccines led to tumor shrinkage and prolonged the survival of mice (Fig. 3) [47].Personalized vaccine design ::: Lymph node-targeting nanovaccinesTAAs are unmutated self-antigens that are highly expressed in tumor tissues but are also expressed in some normal tissues [16].", [["tumor", "ANATOMY", 45, 50], ["Lymph node", "ANATOMY", 142, 152], ["tumor tissues", "ANATOMY", 237, 250], ["tissues", "ANATOMY", 289, 296], ["tumor", "DISEASE", 45, 50], ["tumor", "DISEASE", 237, 242], ["tumor", "CANCER", 45, 50], ["mice", "ORGANISM", 91, 95], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 142, 152], ["nanovaccinesTAAs", "SIMPLE_CHEMICAL", 163, 179], ["tumor tissues", "TISSUE", 237, 250], ["tissues", "TISSUE", 289, 296], ["nanovaccinesTAAs", "PROTEIN", 163, 179], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["mRNA vaccines", "TREATMENT", 24, 37], ["tumor shrinkage", "PROBLEM", 45, 60], ["Lymph node", "TEST", 142, 152], ["tumor shrinkage", "OBSERVATION", 45, 60], ["Lymph node", "OBSERVATION", 142, 152], ["tumor tissues", "OBSERVATION", 237, 250], ["normal tissues", "OBSERVATION", 282, 296]]], ["Two obstacles, central tolerance (low immunogenicity) and aberrant autoimmunity, limit their efficacy and application in cancer therapeutic vaccines [48, 49].", [["cancer", "ANATOMY", 121, 127], ["autoimmunity", "DISEASE", 67, 79], ["cancer", "DISEASE", 121, 127], ["cancer", "CANCER", 121, 127], ["central tolerance (low immunogenicity)", "PROBLEM", 15, 53], ["aberrant autoimmunity", "PROBLEM", 58, 79], ["cancer therapeutic vaccines", "TREATMENT", 121, 148], ["central tolerance", "OBSERVATION", 15, 32], ["low immunogenicity", "OBSERVATION_MODIFIER", 34, 52], ["aberrant", "OBSERVATION_MODIFIER", 58, 66], ["autoimmunity", "OBSERVATION", 67, 79]]], ["Recently, the emergence of next-generation sequencing and innovative bioinformatics tools has enabled the discovery of tumor neoantigens.", [["tumor", "ANATOMY", 119, 124], ["tumor", "DISEASE", 119, 124], ["tumor", "CANCER", 119, 124], ["neoantigens", "CANCER", 125, 136], ["next-generation sequencing", "TREATMENT", 27, 53], ["innovative bioinformatics tools", "TEST", 58, 89], ["tumor neoantigens", "PROBLEM", 119, 136], ["tumor", "OBSERVATION", 119, 124]]], ["Tumor neoantigens are immunogenic tumor-specific mutations that do not exist in normal tissues [16, 50].", [["Tumor", "ANATOMY", 0, 5], ["tumor", "ANATOMY", 34, 39], ["tissues", "ANATOMY", 87, 94], ["tumor", "DISEASE", 34, 39], ["Tumor neoantigens", "CANCER", 0, 17], ["tumor", "CANCER", 34, 39], ["tissues", "TISSUE", 87, 94], ["Tumor neoantigens", "PROBLEM", 0, 17], ["immunogenic tumor", "PROBLEM", 22, 39], ["specific mutations", "PROBLEM", 40, 58], ["immunogenic", "OBSERVATION_MODIFIER", 22, 33], ["tumor", "OBSERVATION", 34, 39], ["normal tissues", "OBSERVATION", 80, 94]]], ["Personalized vaccines are generated based on neoantigens for the wide variety of tumor mutations in different cancers and persons, which have shown great potential in the clinic.Personalized vaccine design ::: Lymph node-targeting nanovaccinesPatrick et al. incorporated 20 predicted cancer neoantigens present in every person into one formulated vaccine; in a clinical trial, vaccine-induced polyfunctional CD4+ and CD8+ T cells targeted 58 (60%) and 15 (16%) of the 97 neoantigens utilized across patients [51].Personalized vaccine design ::: Lymph node-targeting nanovaccinesGlioblastoma (GBM) is the most common and aggressive primary brain tumor [52], which is not sensitive to cancer immunotherapy, especially checkpoint inhibitors.", [["tumor", "ANATOMY", 81, 86], ["cancers", "ANATOMY", 110, 117], ["Lymph node", "ANATOMY", 210, 220], ["cancer", "ANATOMY", 284, 290], ["CD4+ and CD8+ T cells", "ANATOMY", 408, 429], ["Lymph node", "ANATOMY", 545, 555], ["Glioblastoma", "ANATOMY", 578, 590], ["GBM", "ANATOMY", 592, 595], ["primary brain tumor", "ANATOMY", 631, 650], ["cancer", "ANATOMY", 683, 689], ["tumor", "DISEASE", 81, 86], ["cancers", "DISEASE", 110, 117], ["cancer neoantigens", "DISEASE", 284, 302], ["Glioblastoma", "DISEASE", 578, 590], ["GBM", "DISEASE", 592, 595], ["primary brain tumor", "DISEASE", 631, 650], ["cancer", "DISEASE", 683, 689], ["neoantigens", "CANCER", 45, 56], ["tumor", "CANCER", 81, 86], ["cancers", "CANCER", 110, 117], ["persons", "ORGANISM", 122, 129], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 210, 220], ["cancer", "CANCER", 284, 290], ["CD4", "GENE_OR_GENE_PRODUCT", 408, 411], ["CD8", "GENE_OR_GENE_PRODUCT", 417, 420], ["neoantigens", "CANCER", 471, 482], ["patients", "ORGANISM", 499, 507], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 545, 555], ["Glioblastoma", "CANCER", 578, 590], ["GBM", "CANCER", 592, 595], ["brain tumor", "CANCER", 639, 650], ["cancer", "CANCER", 683, 689], ["polyfunctional CD4+ and CD8+ T cells", "CELL_TYPE", 393, 429], ["persons", "SPECIES", 122, 129], ["person", "SPECIES", 320, 326], ["patients", "SPECIES", 499, 507], ["Personalized vaccines", "TREATMENT", 0, 21], ["tumor mutations", "PROBLEM", 81, 96], ["different cancers", "PROBLEM", 100, 117], ["Lymph node", "TEST", 210, 220], ["targeting nanovaccines", "TREATMENT", 221, 243], ["20 predicted cancer neoantigens", "PROBLEM", 271, 302], ["vaccine", "TREATMENT", 377, 384], ["polyfunctional CD4", "TEST", 393, 411], ["CD8", "TEST", 417, 420], ["T cells", "TEST", 422, 429], ["Lymph node", "TEST", 545, 555], ["targeting nanovaccines", "TREATMENT", 556, 578], ["Glioblastoma (GBM", "PROBLEM", 578, 595], ["aggressive primary brain tumor", "PROBLEM", 620, 650], ["cancer immunotherapy", "TREATMENT", 683, 703], ["checkpoint inhibitors", "TREATMENT", 716, 737], ["tumor", "OBSERVATION", 81, 86], ["cancers", "OBSERVATION", 110, 117], ["Lymph node", "OBSERVATION", 210, 220], ["20 predicted", "OBSERVATION_MODIFIER", 271, 283], ["cancer", "OBSERVATION", 284, 290], ["Lymph node", "OBSERVATION", 545, 555], ["GBM", "OBSERVATION", 592, 595], ["most common", "OBSERVATION_MODIFIER", 604, 615], ["aggressive", "OBSERVATION_MODIFIER", 620, 630], ["primary", "OBSERVATION_MODIFIER", 631, 638], ["brain", "ANATOMY", 639, 644], ["tumor", "OBSERVATION", 645, 650], ["not sensitive", "UNCERTAINTY", 666, 679]]], ["The limited intratumoral infiltration of immune cells and low mutation load (low immunogenicity) lead to a dilemma [53\u201355].", [["intratumoral", "ANATOMY", 12, 24], ["immune cells", "ANATOMY", 41, 53], ["immune cells", "CELL", 41, 53], ["immune cells", "CELL_TYPE", 41, 53], ["The limited intratumoral infiltration of immune cells", "PROBLEM", 0, 53], ["low mutation load (low immunogenicity)", "PROBLEM", 58, 96], ["intratumoral", "OBSERVATION_MODIFIER", 12, 24], ["infiltration", "OBSERVATION", 25, 37], ["immune cells", "OBSERVATION", 41, 53], ["low mutation", "OBSERVATION", 58, 70]]], ["Norbert et al. reported a clinical program named the Glioma Actively Personalized Vaccine Consortium (GAPVAC) that tested a personalized vaccine in a phase I trial [56].", [["the Glioma", "PROBLEM", 49, 59], ["Personalized Vaccine Consortium (GAPVAC)", "TREATMENT", 69, 109], ["a personalized vaccine", "TREATMENT", 122, 144], ["Glioma", "ANATOMY", 53, 59]]], ["This vaccine included both unmutated TAAs and neoantigens.", [["TAAs", "GENE_OR_GENE_PRODUCT", 37, 41], ["neoantigens", "CANCER", 46, 57], ["unmutated TAAs", "PROTEIN", 27, 41], ["This vaccine", "TREATMENT", 0, 12], ["both unmutated TAAs", "TREATMENT", 22, 41]]], ["The results showed that unmutated APVAC1 antigens activated a sustained central memory CD8+ T cell response and that APVAC2 elicited predominantly CD4+ T helper 1-type T cell responses against the predicted neoepitopes [56].Personalized vaccine design ::: Lymph node-targeting nanovaccinesLena et al. reported a vaccine design based on an RNA-lipoplex (RNA-LPX)-based delivery system.", [["memory CD8+ T cell", "ANATOMY", 80, 98], ["CD4+ T helper 1-type T cell", "ANATOMY", 147, 174], ["Lymph node", "ANATOMY", 256, 266], ["APVAC1 antigens", "GENE_OR_GENE_PRODUCT", 34, 49], ["CD8", "GENE_OR_GENE_PRODUCT", 87, 90], ["APVAC2", "SIMPLE_CHEMICAL", 117, 123], ["CD4", "GENE_OR_GENE_PRODUCT", 147, 150], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 256, 266], ["unmutated APVAC1 antigens", "PROTEIN", 24, 49], ["CD8", "PROTEIN", 87, 90], ["APVAC2", "PROTEIN", 117, 123], ["CD4", "PROTEIN", 147, 150], ["unmutated APVAC1 antigens", "PROBLEM", 24, 49], ["APVAC2", "TEST", 117, 123], ["CD4", "TEST", 147, 150], ["Lymph node", "TEST", 256, 266], ["targeting nanovaccines", "TREATMENT", 267, 289], ["a vaccine design", "TREATMENT", 310, 326], ["an RNA", "TEST", 336, 342], ["based delivery system", "TREATMENT", 362, 383], ["Lymph node", "OBSERVATION", 256, 266]]], ["By systemically adjusting the net charge of lipid carriers, this vaccine could precisely and efficiently target DCs in vivo via intravenous administration.", [["DCs", "ANATOMY", 112, 115], ["intravenous", "ANATOMY", 128, 139], ["lipid", "SIMPLE_CHEMICAL", 44, 49], ["DCs", "CELL", 112, 115], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 128, 139], ["DCs", "CELL_TYPE", 112, 115], ["the net charge of lipid carriers", "TREATMENT", 26, 58], ["this vaccine", "TREATMENT", 60, 72], ["vivo via intravenous administration", "TREATMENT", 119, 154]]], ["The results indicated that RNA-LPX-encoded tumor neoantigens or that TAA could elicit potent effector and memory T cell responses as well as retard the progression of tumors in an IFN-alpha-dependent manner [57].Personalized vaccine design ::: Lymph node-targeting nanovaccinesMin et al. designed a novel antigen-capturing nanoparticle (AC-NP) based on PLAG.", [["tumor", "ANATOMY", 43, 48], ["memory T cell", "ANATOMY", 106, 119], ["tumors", "ANATOMY", 167, 173], ["Lymph node", "ANATOMY", 244, 254], ["tumor", "DISEASE", 43, 48], ["TAA", "CHEMICAL", 69, 72], ["tumors", "DISEASE", 167, 173], ["AC-NP", "CHEMICAL", 337, 342], ["PLAG", "CHEMICAL", 353, 357], ["LPX", "GENE_OR_GENE_PRODUCT", 31, 34], ["tumor", "CANCER", 43, 48], ["TAA", "SIMPLE_CHEMICAL", 69, 72], ["memory T cell", "CELL", 106, 119], ["tumors", "CANCER", 167, 173], ["IFN-alpha", "GENE_OR_GENE_PRODUCT", 180, 189], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 244, 254], ["PLAG", "SIMPLE_CHEMICAL", 353, 357], ["LPX", "PROTEIN", 31, 34], ["IFN", "PROTEIN", 180, 183], ["RNA", "TEST", 27, 30], ["LPX", "TEST", 31, 34], ["encoded tumor neoantigens", "PROBLEM", 35, 60], ["TAA", "PROBLEM", 69, 72], ["tumors", "PROBLEM", 167, 173], ["Lymph node", "TEST", 244, 254], ["targeting nanovaccines", "TREATMENT", 255, 277], ["a novel antigen", "TREATMENT", 297, 312], ["nanoparticle (AC-NP)", "TREATMENT", 323, 343], ["tumor", "OBSERVATION", 43, 48], ["progression", "OBSERVATION_MODIFIER", 152, 163], ["tumors", "OBSERVATION", 167, 173], ["Lymph node", "OBSERVATION", 244, 254]]], ["This NP could capture tumor antigens, especially neoantigens, via surface properties after intratumor injection.", [["tumor", "ANATOMY", 22, 27], ["neoantigens", "ANATOMY", 49, 60], ["surface", "ANATOMY", 66, 73], ["intratumor", "ANATOMY", 91, 101], ["tumor", "DISEASE", 22, 27], ["tumor", "CANCER", 22, 27], ["tumor antigens", "PROTEIN", 22, 36], ["tumor antigens", "PROBLEM", 22, 36], ["neoantigens", "PROBLEM", 49, 60], ["intratumor injection", "TREATMENT", 91, 111], ["tumor", "OBSERVATION", 22, 27]]], ["It could enhance the uptake of tumor-specific antigens by APCs and promote an antitumor immune response in both injected tumors and distal tumors in melanoma and breast tumor models [58].Personalized vaccine design ::: Lymph node-targeting nanovaccinesIn conclusion, nanovaccines are a promising avenue to elicit the T cell response and inhibit tumor progression.", [["tumor", "ANATOMY", 31, 36], ["APCs", "ANATOMY", 58, 62], ["antitumor", "ANATOMY", 78, 87], ["tumors", "ANATOMY", 121, 127], ["distal tumors", "ANATOMY", 132, 145], ["melanoma", "ANATOMY", 149, 157], ["breast tumor", "ANATOMY", 162, 174], ["Lymph node", "ANATOMY", 219, 229], ["T cell", "ANATOMY", 317, 323], ["tumor", "ANATOMY", 345, 350], ["tumor", "DISEASE", 31, 36], ["tumors", "DISEASE", 121, 127], ["tumors", "DISEASE", 139, 145], ["melanoma", "DISEASE", 149, 157], ["breast tumor", "DISEASE", 162, 174], ["tumor", "DISEASE", 345, 350], ["tumor", "CANCER", 31, 36], ["APCs", "CELL", 58, 62], ["antitumor", "CANCER", 78, 87], ["tumors", "CANCER", 121, 127], ["distal tumors", "CANCER", 132, 145], ["melanoma", "CANCER", 149, 157], ["breast tumor", "CANCER", 162, 174], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 219, 229], ["nanovaccines", "SIMPLE_CHEMICAL", 267, 279], ["T cell", "CELL", 317, 323], ["tumor", "CANCER", 345, 350], ["tumor-specific antigens", "PROTEIN", 31, 54], ["APCs", "CELL_TYPE", 58, 62], ["the uptake of tumor", "PROBLEM", 17, 36], ["an antitumor immune response", "TREATMENT", 75, 103], ["both injected tumors", "PROBLEM", 107, 127], ["distal tumors in melanoma and breast tumor models", "PROBLEM", 132, 181], ["Lymph node", "TEST", 219, 229], ["targeting nanovaccines", "TREATMENT", 230, 252], ["nanovaccines", "TREATMENT", 267, 279], ["the T cell response", "PROBLEM", 313, 332], ["tumor progression", "PROBLEM", 345, 362], ["uptake", "OBSERVATION_MODIFIER", 21, 27], ["tumor", "OBSERVATION", 31, 36], ["injected tumors", "OBSERVATION", 112, 127], ["distal", "OBSERVATION_MODIFIER", 132, 138], ["tumors", "OBSERVATION", 139, 145], ["melanoma", "OBSERVATION", 149, 157], ["breast", "ANATOMY", 162, 168], ["tumor", "OBSERVATION", 169, 174], ["Lymph node", "OBSERVATION", 219, 229], ["tumor", "OBSERVATION", 345, 350]]], ["Although great progress has been achieved in nanovaccine design, enormous challenges remain.", [["enormous", "OBSERVATION_MODIFIER", 65, 73], ["challenges", "OBSERVATION", 74, 84]]], ["Facile and stable manufacturing processes, as well as effective clinical translation, are desired.EPR effect ::: Tumor microenvironment-targeting nanomedicineNP drugs can accumulate in tumors for EPR effects, which was first described by Matsumura and Maeda in 1986 [72].", [["Tumor", "ANATOMY", 113, 118], ["tumors", "ANATOMY", 185, 191], ["tumors", "DISEASE", 185, 191], ["Tumor", "CANCER", 113, 118], ["nanomedicineNP", "SIMPLE_CHEMICAL", 146, 160], ["tumors", "CANCER", 185, 191], ["Tumor microenvironment", "PROBLEM", 113, 135], ["nanomedicineNP drugs", "TREATMENT", 146, 166], ["tumors", "PROBLEM", 185, 191], ["EPR effects", "PROBLEM", 196, 207], ["stable", "OBSERVATION_MODIFIER", 11, 17], ["manufacturing", "OBSERVATION", 18, 31], ["tumors", "OBSERVATION", 185, 191]]], ["EPR depends on specific pathophysiological traits of tumors.", [["tumors", "ANATOMY", 53, 59], ["tumors", "DISEASE", 53, 59], ["tumors", "CANCER", 53, 59], ["tumors", "PROBLEM", 53, 59], ["tumors", "OBSERVATION", 53, 59]]], ["In healthy tissues, small molecules easily leak from the blood vessels, yet NPs cannot due to their size difference.", [["tissues", "ANATOMY", 11, 18], ["blood vessels", "ANATOMY", 57, 70], ["tissues", "TISSUE", 11, 18], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 57, 70], ["NPs", "SIMPLE_CHEMICAL", 76, 79], ["small molecules easily leak from the blood vessels", "PROBLEM", 20, 70], ["NPs", "TREATMENT", 76, 79], ["healthy tissues", "OBSERVATION_MODIFIER", 3, 18], ["small", "OBSERVATION_MODIFIER", 20, 25], ["molecules", "OBSERVATION_MODIFIER", 26, 35], ["easily", "OBSERVATION_MODIFIER", 36, 42], ["leak", "OBSERVATION", 43, 47], ["blood vessels", "ANATOMY", 57, 70], ["size", "OBSERVATION_MODIFIER", 100, 104]]], ["In tumor sites, abnormally broad fenestrations in blood vessels permit extravasation of particles with sizes up to several hundred nanometers [73].", [["tumor sites", "ANATOMY", 3, 14], ["fenestrations", "ANATOMY", 33, 46], ["blood vessels", "ANATOMY", 50, 63], ["tumor", "DISEASE", 3, 8], ["tumor", "CANCER", 3, 8], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 50, 63], ["tumor sites", "PROBLEM", 3, 14], ["abnormally broad fenestrations in blood vessels", "PROBLEM", 16, 63], ["extravasation of particles", "PROBLEM", 71, 97], ["tumor", "OBSERVATION", 3, 8], ["abnormally", "OBSERVATION_MODIFIER", 16, 26], ["broad", "OBSERVATION_MODIFIER", 27, 32], ["fenestrations", "OBSERVATION", 33, 46], ["blood vessels", "ANATOMY", 50, 63], ["extravasation", "OBSERVATION", 71, 84], ["particles", "OBSERVATION_MODIFIER", 88, 97], ["sizes", "OBSERVATION_MODIFIER", 103, 108]]], ["With the absence of lymphatic drainage, NPs show a relatively effective and selective accumulation in tumor tissue, which is 10\u2013200 times higher than that in normal tissues or organs [74].", [["lymphatic", "ANATOMY", 20, 29], ["tumor tissue", "ANATOMY", 102, 114], ["tissues", "ANATOMY", 165, 172], ["organs", "ANATOMY", 176, 182], ["tumor", "DISEASE", 102, 107], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 20, 29], ["NPs", "SIMPLE_CHEMICAL", 40, 43], ["tumor tissue", "TISSUE", 102, 114], ["normal tissues", "TISSUE", 158, 172], ["organs", "ORGAN", 176, 182], ["lymphatic drainage", "TREATMENT", 20, 38], ["NPs", "TREATMENT", 40, 43], ["selective accumulation in tumor tissue", "PROBLEM", 76, 114], ["lymphatic", "ANATOMY", 20, 29], ["drainage", "OBSERVATION", 30, 38], ["relatively", "OBSERVATION_MODIFIER", 51, 61], ["effective", "OBSERVATION_MODIFIER", 62, 71], ["selective", "OBSERVATION_MODIFIER", 76, 85], ["accumulation", "OBSERVATION_MODIFIER", 86, 98], ["tumor tissue", "OBSERVATION", 102, 114], ["normal tissues", "OBSERVATION", 158, 172]]], ["For example, compared with free doxorubicin, doxorubicin with a liposomal formulation achieves at least a 60-fold increase in tumors under a concentration-time curve (AUC) [75].", [["tumors", "ANATOMY", 126, 132], ["doxorubicin", "CHEMICAL", 32, 43], ["doxorubicin", "CHEMICAL", 45, 56], ["tumors", "DISEASE", 126, 132], ["doxorubicin", "CHEMICAL", 32, 43], ["doxorubicin", "CHEMICAL", 45, 56], ["doxorubicin", "SIMPLE_CHEMICAL", 32, 43], ["doxorubicin", "SIMPLE_CHEMICAL", 45, 56], ["tumors", "CANCER", 126, 132], ["free doxorubicin", "TREATMENT", 27, 43], ["doxorubicin", "TREATMENT", 45, 56], ["a liposomal formulation", "TREATMENT", 62, 85], ["a 60-fold increase in tumors", "PROBLEM", 104, 132], ["60-fold", "OBSERVATION_MODIFIER", 106, 113], ["increase", "OBSERVATION_MODIFIER", 114, 122], ["tumors", "OBSERVATION", 126, 132]]], ["Therefore, nanotechnology shows potential in cancer therapy via EPR-based tumor targeting [76].Targeting immunosuppressive cells ::: Tumor microenvironment-targeting nanomedicineTAMs displaying an antiinflammatory M2-like phenotype as well as a proinflammatory M1-like phenotype play a key role in tumor progression, influencing proliferation, metastasis and recurrence [77].", [["cancer", "ANATOMY", 45, 51], ["tumor", "ANATOMY", 74, 79], ["cells", "ANATOMY", 123, 128], ["Tumor", "ANATOMY", 133, 138], ["tumor", "ANATOMY", 298, 303], ["cancer", "DISEASE", 45, 51], ["tumor", "DISEASE", 74, 79], ["tumor", "DISEASE", 298, 303], ["cancer", "CANCER", 45, 51], ["EPR", "SIMPLE_CHEMICAL", 64, 67], ["tumor", "CANCER", 74, 79], ["immunosuppressive cells", "CELL", 105, 128], ["Tumor", "CANCER", 133, 138], ["tumor", "CANCER", 298, 303], ["immunosuppressive cells", "CELL_TYPE", 105, 128], ["M2", "PROTEIN", 214, 216], ["cancer therapy", "TREATMENT", 45, 59], ["EPR", "TEST", 64, 67], ["Tumor microenvironment", "PROBLEM", 133, 155], ["targeting nanomedicineTAMs", "PROBLEM", 156, 182], ["an antiinflammatory M2-like phenotype", "PROBLEM", 194, 231], ["a proinflammatory M1", "PROBLEM", 243, 263], ["tumor progression", "PROBLEM", 298, 315], ["influencing proliferation", "PROBLEM", 317, 342], ["metastasis", "PROBLEM", 344, 354], ["recurrence", "PROBLEM", 359, 369], ["cancer", "OBSERVATION", 45, 51], ["tumor", "OBSERVATION", 74, 79], ["immunosuppressive cells", "OBSERVATION", 105, 128], ["antiinflammatory M2", "OBSERVATION", 197, 216], ["tumor", "OBSERVATION", 298, 303], ["proliferation", "OBSERVATION_MODIFIER", 329, 342], ["metastasis", "OBSERVATION", 344, 354]]], ["Chen et al. designed an in situ-formed bioresponsive immunotherapeutic nanogel that was preloaded with an anti-CD47 antibody in fibrin gel calcium carbonate (CaCO3) NPs.", [["nanogel", "ANATOMY", 71, 78], ["calcium carbonate", "CHEMICAL", 139, 156], ["CaCO3", "CHEMICAL", 158, 163], ["calcium carbonate", "CHEMICAL", 139, 156], ["CaCO3", "CHEMICAL", 158, 163], ["nanogel", "SIMPLE_CHEMICAL", 71, 78], ["anti-CD47", "GENE_OR_GENE_PRODUCT", 106, 115], ["fibrin gel calcium carbonate", "SIMPLE_CHEMICAL", 128, 156], ["CaCO3) NPs", "SIMPLE_CHEMICAL", 158, 168], ["anti-CD47 antibody", "PROTEIN", 106, 124], ["bioresponsive immunotherapeutic nanogel", "TREATMENT", 39, 78], ["an anti-CD47 antibody", "TREATMENT", 103, 124], ["fibrin gel calcium carbonate (CaCO3) NPs", "TREATMENT", 128, 168]]], ["The fibrin gel NPs could release anti-CD47 antibodies in acidic tumor surgical wounds, resulting in TAMs polarized to the M1-like proinflammatory phenotype.", [["tumor surgical wounds", "ANATOMY", 64, 85], ["TAMs", "ANATOMY", 100, 104], ["tumor", "DISEASE", 64, 69], ["fibrin", "GENE_OR_GENE_PRODUCT", 4, 10], ["anti-CD47 antibodies", "GENE_OR_GENE_PRODUCT", 33, 53], ["tumor", "CANCER", 64, 69], ["wounds", "PATHOLOGICAL_FORMATION", 79, 85], ["TAMs", "CELL", 100, 104], ["anti-CD47 antibodies", "PROTEIN", 33, 53], ["TAMs", "CELL_TYPE", 100, 104], ["The fibrin gel NPs", "TREATMENT", 0, 18], ["acidic tumor surgical wounds", "PROBLEM", 57, 85], ["TAMs", "PROBLEM", 100, 104], ["proinflammatory phenotype", "PROBLEM", 130, 155], ["fibrin", "OBSERVATION", 4, 10], ["acidic", "OBSERVATION_MODIFIER", 57, 63], ["tumor", "OBSERVATION_MODIFIER", 64, 69], ["surgical wounds", "OBSERVATION", 70, 85], ["M1", "ANATOMY", 122, 124], ["proinflammatory phenotype", "OBSERVATION", 130, 155]]], ["Activated phagocytes can present antigens and induce a T cell response against tumor recurrence and metastasis [78].Targeting immunosuppressive cells ::: Tumor microenvironment-targeting nanomedicineWang et al. developed mannose-decorated lactoferrin nanoparticles (Man-LF NPs) and codelivery with the drugs Shikonin and JQ1.", [["phagocytes", "ANATOMY", 10, 20], ["T cell", "ANATOMY", 55, 61], ["tumor", "ANATOMY", 79, 84], ["cells", "ANATOMY", 144, 149], ["Tumor", "ANATOMY", 154, 159], ["tumor", "DISEASE", 79, 84], ["mannose", "CHEMICAL", 221, 228], ["Man-LF NPs", "CHEMICAL", 266, 276], ["Shikonin", "CHEMICAL", 308, 316], ["JQ1", "CHEMICAL", 321, 324], ["mannose", "CHEMICAL", 221, 228], ["Shikonin", "CHEMICAL", 308, 316], ["JQ1", "CHEMICAL", 321, 324], ["phagocytes", "CELL", 10, 20], ["T cell", "CELL", 55, 61], ["tumor", "CANCER", 79, 84], ["immunosuppressive cells", "CELL", 126, 149], ["Tumor", "CANCER", 154, 159], ["mannose-decorated lactoferrin nanoparticles", "SIMPLE_CHEMICAL", 221, 264], ["Man-LF NPs", "SIMPLE_CHEMICAL", 266, 276], ["Shikonin", "SIMPLE_CHEMICAL", 308, 316], ["JQ1", "SIMPLE_CHEMICAL", 321, 324], ["Activated phagocytes", "CELL_TYPE", 0, 20], ["antigens", "PROTEIN", 33, 41], ["immunosuppressive cells", "CELL_TYPE", 126, 149], ["Activated phagocytes", "PROBLEM", 0, 20], ["a T cell response", "PROBLEM", 53, 70], ["tumor recurrence", "PROBLEM", 79, 95], ["metastasis", "PROBLEM", 100, 110], ["Tumor microenvironment", "PROBLEM", 154, 176], ["mannose-decorated lactoferrin nanoparticles (Man-LF NPs", "TREATMENT", 221, 276], ["codelivery", "TREATMENT", 282, 292], ["the drugs Shikonin", "TREATMENT", 298, 316], ["metastasis", "OBSERVATION", 100, 110], ["immunosuppressive cells", "OBSERVATION", 126, 149]]], ["Shikonin is isolated from Chinese herbs and shows potential anticancer activity.", [["anticancer", "ANATOMY", 60, 70], ["Shikonin", "CHEMICAL", 0, 8], ["Shikonin", "CHEMICAL", 0, 8], ["Shikonin", "SIMPLE_CHEMICAL", 0, 8], ["anticancer", "CANCER", 60, 70], ["Shikonin", "PROBLEM", 0, 8], ["Chinese herbs", "TREATMENT", 26, 39], ["potential anticancer activity", "PROBLEM", 50, 79], ["anticancer activity", "OBSERVATION", 60, 79]]], ["JQ1 can reduce PD-L1 expression on tumor cells.", [["tumor cells", "ANATOMY", 35, 46], ["JQ1", "CHEMICAL", 0, 3], ["tumor", "DISEASE", 35, 40], ["JQ1", "SIMPLE_CHEMICAL", 0, 3], ["PD-L1", "GENE_OR_GENE_PRODUCT", 15, 20], ["tumor cells", "CELL", 35, 46], ["L1", "DNA", 18, 20], ["tumor cells", "CELL_TYPE", 35, 46], ["JQ1", "PROBLEM", 0, 3], ["PD-L1 expression on tumor cells", "PROBLEM", 15, 46], ["L1 expression", "OBSERVATION_MODIFIER", 18, 31], ["tumor cells", "OBSERVATION", 35, 46]]], ["This formulation managed to target mannose receptor-expressing tumor cells and repolarize TAMs, resulting in remodeling of the TME [79].Targeting immunosuppressive cells ::: Tumor microenvironment-targeting nanomedicineRegulatory T cells (Tregs) also contribute to the TME and induce tumor escape [80].", [["tumor cells", "ANATOMY", 63, 74], ["TAMs", "ANATOMY", 90, 94], ["cells", "ANATOMY", 164, 169], ["Tumor", "ANATOMY", 174, 179], ["Regulatory T cells", "ANATOMY", 219, 237], ["Tregs", "ANATOMY", 239, 244], ["tumor", "ANATOMY", 284, 289], ["tumor", "DISEASE", 63, 68], ["tumor", "DISEASE", 284, 289], ["mannose", "CHEMICAL", 35, 42], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 35, 51], ["tumor cells", "CELL", 63, 74], ["TAMs", "CELL", 90, 94], ["immunosuppressive cells", "CELL", 146, 169], ["Tumor", "CANCER", 174, 179], ["Regulatory T cells", "CELL", 219, 237], ["Tregs", "CELL", 239, 244], ["tumor", "CANCER", 284, 289], ["mannose receptor", "PROTEIN", 35, 51], ["expressing tumor cells", "CELL_TYPE", 52, 74], ["TAMs", "CELL_TYPE", 90, 94], ["immunosuppressive cells", "CELL_TYPE", 146, 169], ["Regulatory T cells", "CELL_TYPE", 219, 237], ["Tregs", "CELL_TYPE", 239, 244], ["This formulation", "TREATMENT", 0, 16], ["target mannose receptor", "TREATMENT", 28, 51], ["expressing tumor cells", "PROBLEM", 52, 74], ["repolarize TAMs", "TREATMENT", 79, 94], ["Tumor microenvironment", "PROBLEM", 174, 196], ["the TME", "PROBLEM", 265, 272], ["tumor escape", "PROBLEM", 284, 296], ["tumor cells", "OBSERVATION", 63, 74], ["immunosuppressive cells", "OBSERVATION", 146, 169], ["tumor", "OBSERVATION", 284, 289]]], ["Ou et al. reported tLyp 1 peptide-modified hybrid NPs to deliver a drug, IMT, into Tregs in tumors.", [["Tregs", "ANATOMY", 83, 88], ["tumors", "ANATOMY", 92, 98], ["tumors", "DISEASE", 92, 98], ["tLyp 1 peptide", "SIMPLE_CHEMICAL", 19, 33], ["hybrid NPs", "SIMPLE_CHEMICAL", 43, 53], ["IMT", "SIMPLE_CHEMICAL", 73, 76], ["Tregs", "CELL", 83, 88], ["tumors", "CANCER", 92, 98], ["Tregs", "CELL_TYPE", 83, 88], ["modified hybrid NPs", "TREATMENT", 34, 53], ["tumors", "PROBLEM", 92, 98], ["tumors", "OBSERVATION", 92, 98]]], ["The peptide tLyp 1 could specifically recognize Neuropilin-1 (Nrp1) proteins on Tregs.", [["Tregs", "ANATOMY", 80, 85], ["peptide tLyp 1", "GENE_OR_GENE_PRODUCT", 4, 18], ["Neuropilin-1", "GENE_OR_GENE_PRODUCT", 48, 60], ["Nrp1", "GENE_OR_GENE_PRODUCT", 62, 66], ["Tregs", "CELL", 80, 85], ["Neuropilin-1 (Nrp1) proteins", "PROTEIN", 48, 76], ["Tregs", "CELL_TYPE", 80, 85], ["The peptide tLyp", "TEST", 0, 16], ["Neuropilin", "TEST", 48, 58]]], ["Combination with anti-CTLA-4 antibodies could modulate the immunosuppressive environment and boost antitumor T cell responses [81].Targeting immunosuppressive cells ::: Tumor microenvironment-targeting nanomedicineMDSCs are heterogeneous cells from the myeloid cell lineage that are strongly expanded in cancer and chronic inflammation sites [82].", [["antitumor T cell", "ANATOMY", 99, 115], ["cells", "ANATOMY", 159, 164], ["Tumor", "ANATOMY", 169, 174], ["nanomedicineMDSCs", "ANATOMY", 202, 219], ["cells", "ANATOMY", 238, 243], ["myeloid cell lineage", "ANATOMY", 253, 273], ["cancer", "ANATOMY", 304, 310], ["cancer", "DISEASE", 304, 310], ["inflammation", "DISEASE", 323, 335], ["anti-CTLA-4 antibodies", "GENE_OR_GENE_PRODUCT", 17, 39], ["antitumor T cell", "CELL", 99, 115], ["immunosuppressive cells", "CELL", 141, 164], ["Tumor", "CANCER", 169, 174], ["nanomedicineMDSCs", "CELL", 202, 219], ["cells", "CELL", 238, 243], ["myeloid cell lineage", "CELL", 253, 273], ["cancer", "CANCER", 304, 310], ["anti-CTLA-4 antibodies", "PROTEIN", 17, 39], ["immunosuppressive cells", "CELL_TYPE", 141, 164], ["nanomedicineMDSCs", "CELL_TYPE", 202, 219], ["myeloid cell lineage", "CELL_TYPE", 253, 273], ["anti-CTLA-4 antibodies", "TREATMENT", 17, 39], ["the immunosuppressive environment", "TREATMENT", 55, 88], ["Tumor microenvironment", "PROBLEM", 169, 191], ["heterogeneous cells", "PROBLEM", 224, 243], ["the myeloid cell lineage", "PROBLEM", 249, 273], ["chronic inflammation sites", "PROBLEM", 315, 341], ["immunosuppressive cells", "OBSERVATION", 141, 164], ["heterogeneous cells", "OBSERVATION", 224, 243], ["myeloid cell lineage", "OBSERVATION", 253, 273], ["expanded", "OBSERVATION_MODIFIER", 292, 300], ["cancer", "OBSERVATION", 304, 310], ["chronic", "OBSERVATION_MODIFIER", 315, 322], ["inflammation", "OBSERVATION", 323, 335]]], ["Yu et al. developed a MDSC membrane-coated iron oxide nanoparticle (MNP@MDSC) to achieve active tumor targeting.", [["MDSC membrane", "ANATOMY", 22, 35], ["tumor", "ANATOMY", 96, 101], ["iron oxide", "CHEMICAL", 43, 53], ["MNP@MDSC", "CHEMICAL", 68, 76], ["tumor", "DISEASE", 96, 101], ["iron oxide", "CHEMICAL", 43, 53], ["MDSC", "CELL", 22, 26], ["iron oxide nanoparticle", "SIMPLE_CHEMICAL", 43, 66], ["MNP@MDSC", "SIMPLE_CHEMICAL", 68, 76], ["tumor", "CANCER", 96, 101], ["a MDSC membrane-coated iron oxide nanoparticle (MNP@MDSC)", "TREATMENT", 20, 77], ["active tumor targeting", "PROBLEM", 89, 111], ["MDSC membrane", "OBSERVATION", 22, 35], ["active", "OBSERVATION_MODIFIER", 89, 95], ["tumor", "OBSERVATION", 96, 101]]], ["The results showed that the formulation could induce PTT-induced immunogenic cell death, reverse macrophage polarization, and reduce tumor metabolic activity.Targeting the metabolism of the TME ::: Tumor microenvironment-targeting nanomedicineHypoxia and acidity of the tumor microenvironment are associated with tumor metabolism and can strongly inhibit the antitumor immune response by reducing the cytotoxic activity of CTLs and NK cells [83, 84].Targeting the metabolism of the TME ::: Tumor microenvironment-targeting nanomedicineYang et al. reported a pH-responsive nanoplatform that could control the release of the photodynamic agent chlorine e6 (Ce6) and doxorubicin (DOX).", [["cell", "ANATOMY", 77, 81], ["macrophage", "ANATOMY", 97, 107], ["tumor", "ANATOMY", 133, 138], ["Tumor", "ANATOMY", 198, 203], ["tumor", "ANATOMY", 270, 275], ["tumor", "ANATOMY", 313, 318], ["antitumor", "ANATOMY", 359, 368], ["CTLs", "ANATOMY", 423, 427], ["NK cells", "ANATOMY", 432, 440], ["Tumor", "ANATOMY", 490, 495], ["death", "DISEASE", 82, 87], ["tumor", "DISEASE", 133, 138], ["Hypoxia", "DISEASE", 243, 250], ["tumor", "DISEASE", 270, 275], ["tumor", "DISEASE", 313, 318], ["chlorine e6", "CHEMICAL", 642, 653], ["Ce6", "CHEMICAL", 655, 658], ["doxorubicin", "CHEMICAL", 664, 675], ["DOX", "CHEMICAL", 677, 680], ["chlorine e6", "CHEMICAL", 642, 653], ["Ce6", "CHEMICAL", 655, 658], ["doxorubicin", "CHEMICAL", 664, 675], ["DOX", "CHEMICAL", 677, 680], ["PTT", "SIMPLE_CHEMICAL", 53, 56], ["cell", "CELL", 77, 81], ["macrophage", "CELL", 97, 107], ["tumor", "CANCER", 133, 138], ["Tumor", "CANCER", 198, 203], ["tumor", "CANCER", 270, 275], ["tumor", "CANCER", 313, 318], ["antitumor", "CANCER", 359, 368], ["CTLs", "CELL", 423, 427], ["NK cells", "CELL", 432, 440], ["Tumor", "CANCER", 490, 495], ["chlorine e6", "SIMPLE_CHEMICAL", 642, 653], ["Ce6", "SIMPLE_CHEMICAL", 655, 658], ["doxorubicin", "SIMPLE_CHEMICAL", 664, 675], ["DOX", "SIMPLE_CHEMICAL", 677, 680], ["CTLs", "CELL_TYPE", 423, 427], ["NK cells", "CELL_TYPE", 432, 440], ["the formulation", "TREATMENT", 24, 39], ["PTT", "TEST", 53, 56], ["immunogenic cell death", "PROBLEM", 65, 87], ["reverse macrophage polarization", "TREATMENT", 89, 120], ["tumor metabolic activity", "PROBLEM", 133, 157], ["Tumor microenvironment", "PROBLEM", 198, 220], ["Hypoxia", "PROBLEM", 243, 250], ["acidity of the tumor microenvironment", "PROBLEM", 255, 292], ["tumor metabolism", "PROBLEM", 313, 329], ["NK cells", "TEST", 432, 440], ["Tumor microenvironment", "PROBLEM", 490, 512], ["a pH-responsive nanoplatform", "TREATMENT", 556, 584], ["the photodynamic agent chlorine e6 (Ce6", "TREATMENT", 619, 658], ["doxorubicin (DOX)", "TREATMENT", 664, 681], ["immunogenic cell death", "OBSERVATION", 65, 87], ["macrophage polarization", "OBSERVATION", 97, 120], ["tumor", "OBSERVATION", 133, 138], ["metabolic activity", "OBSERVATION", 139, 157], ["acidity", "OBSERVATION_MODIFIER", 255, 262], ["tumor", "OBSERVATION", 270, 275], ["associated with", "UNCERTAINTY", 297, 312], ["tumor", "OBSERVATION", 313, 318]]], ["This drug formulation could relieve the hypoxic TME by inducing the decomposition of endogenous H2O2 inside the tumor and remarkably enhance a series of antitumor immune responses.Targeting the metabolism of the TME ::: Tumor microenvironment-targeting nanomedicineTumor cells overexpressing LDHA convert glucose into lactate, display accelerated glycolysis, and cause tumor acidity [85].", [["tumor", "ANATOMY", 112, 117], ["antitumor", "ANATOMY", 153, 162], ["Tumor", "ANATOMY", 220, 225], ["nanomedicineTumor cells", "ANATOMY", 253, 276], ["tumor", "ANATOMY", 369, 374], ["H2O2", "CHEMICAL", 96, 100], ["tumor", "DISEASE", 112, 117], ["glucose", "CHEMICAL", 305, 312], ["lactate", "CHEMICAL", 318, 325], ["tumor", "DISEASE", 369, 374], ["H2O2", "CHEMICAL", 96, 100], ["glucose", "CHEMICAL", 305, 312], ["lactate", "CHEMICAL", 318, 325], ["H2O2", "SIMPLE_CHEMICAL", 96, 100], ["tumor", "CANCER", 112, 117], ["antitumor", "CANCER", 153, 162], ["Tumor", "CANCER", 220, 225], ["nanomedicineTumor cells", "CELL", 253, 276], ["LDHA", "SIMPLE_CHEMICAL", 292, 296], ["glucose", "SIMPLE_CHEMICAL", 305, 312], ["lactate", "SIMPLE_CHEMICAL", 318, 325], ["tumor", "CANCER", 369, 374], ["nanomedicineTumor cells", "CELL_LINE", 253, 276], ["LDHA", "PROTEIN", 292, 296], ["This drug formulation", "TREATMENT", 0, 21], ["the hypoxic TME", "PROBLEM", 36, 51], ["endogenous H2O2 inside the tumor", "PROBLEM", 85, 117], ["Tumor microenvironment", "PROBLEM", 220, 242], ["nanomedicineTumor cells", "PROBLEM", 253, 276], ["glucose into lactate", "TEST", 305, 325], ["accelerated glycolysis", "PROBLEM", 335, 357], ["tumor acidity", "PROBLEM", 369, 382], ["hypoxic TME", "OBSERVATION", 40, 51], ["tumor", "OBSERVATION", 112, 117], ["tumor", "OBSERVATION", 369, 374]]], ["Zhang et al. exploited a cationic lipid-assisted NP loaded with LDHA siRNA to knockdown the LDHA gene.", [["LDHA", "CHEMICAL", 64, 68], ["lipid", "SIMPLE_CHEMICAL", 34, 39], ["LDHA", "SIMPLE_CHEMICAL", 64, 68], ["LDHA", "GENE_OR_GENE_PRODUCT", 92, 96], ["LDHA gene", "DNA", 92, 101], ["a cationic lipid-assisted NP", "TREATMENT", 23, 51], ["LDHA siRNA", "TREATMENT", 64, 74]]], ["By interfering with tumor acidification, this NP decreased the number of immunosuppressive cells, increased the infiltration of CD8+ T cells, and restored antitumor functions [86].Combination with photothermal therapy to the remodel TME ::: Tumor microenvironment-targeting nanomedicineDeep penetration of nanomedicine into tumors remains challenging due to the pathophysiological barrier of solid tumors, so physical intervention may help to overcome this barrier [87].", [["tumor", "ANATOMY", 20, 25], ["cells", "ANATOMY", 91, 96], ["CD8+ T cells", "ANATOMY", 128, 140], ["antitumor", "ANATOMY", 155, 164], ["Tumor", "ANATOMY", 241, 246], ["tumors", "ANATOMY", 324, 330], ["solid tumors", "ANATOMY", 392, 404], ["tumor", "DISEASE", 20, 25], ["tumors", "DISEASE", 324, 330], ["tumors", "DISEASE", 398, 404], ["tumor", "CANCER", 20, 25], ["cells", "CELL", 91, 96], ["CD8", "GENE_OR_GENE_PRODUCT", 128, 131], ["antitumor", "CANCER", 155, 164], ["Tumor", "CANCER", 241, 246], ["tumors", "CANCER", 324, 330], ["solid tumors", "CANCER", 392, 404], ["immunosuppressive cells", "CELL_TYPE", 73, 96], ["CD8", "PROTEIN", 128, 131], ["T cells", "CELL_TYPE", 133, 140], ["tumor acidification", "PROBLEM", 20, 39], ["this NP", "TREATMENT", 41, 48], ["immunosuppressive cells", "TREATMENT", 73, 96], ["the infiltration of CD8+ T cells", "TREATMENT", 108, 140], ["photothermal therapy", "TREATMENT", 197, 217], ["Tumor microenvironment", "PROBLEM", 241, 263], ["Deep penetration of nanomedicine into tumors", "PROBLEM", 286, 330], ["solid tumors", "PROBLEM", 392, 404], ["physical intervention", "TREATMENT", 409, 430], ["tumor", "OBSERVATION", 20, 25], ["immunosuppressive cells", "OBSERVATION", 73, 96], ["infiltration", "OBSERVATION_MODIFIER", 112, 124], ["tumors", "OBSERVATION", 324, 330], ["tumors", "OBSERVATION", 398, 404]]], ["Feng et al. developed a light-inducible nanocargo (LINC) combined with chemotherapy for immunotherapy.", [["LINC", "CHEMICAL", 51, 55], ["nanocargo", "SIMPLE_CHEMICAL", 40, 49], ["LINC", "SIMPLE_CHEMICAL", 51, 55], ["a light-inducible nanocargo (LINC", "PROBLEM", 22, 55], ["chemotherapy", "TREATMENT", 71, 83], ["immunotherapy", "TREATMENT", 88, 101]]], ["Upon fluorescence activation, the first wave of NIR laser irradiation generated reactive oxygen species (ROS), induced the cleavage of the polyethylene glycol (PEG) coating, and further enhanced tumor retention and deep penetration of the LINC.", [["tumor", "ANATOMY", 195, 200], ["oxygen", "CHEMICAL", 89, 95], ["ROS", "CHEMICAL", 105, 108], ["polyethylene glycol", "CHEMICAL", 139, 158], ["PEG", "CHEMICAL", 160, 163], ["tumor", "DISEASE", 195, 200], ["oxygen", "CHEMICAL", 89, 95], ["polyethylene glycol", "CHEMICAL", 139, 158], ["PEG", "CHEMICAL", 160, 163], ["reactive oxygen species", "SIMPLE_CHEMICAL", 80, 103], ["ROS", "SIMPLE_CHEMICAL", 105, 108], ["polyethylene glycol", "SIMPLE_CHEMICAL", 139, 158], ["PEG", "SIMPLE_CHEMICAL", 160, 163], ["tumor", "CANCER", 195, 200], ["NIR laser irradiation", "TREATMENT", 48, 69], ["reactive oxygen species", "PROBLEM", 80, 103], ["the polyethylene glycol (PEG) coating", "TREATMENT", 135, 172], ["further enhanced tumor retention", "TREATMENT", 178, 210], ["deep penetration of the LINC", "TREATMENT", 215, 243], ["reactive", "OBSERVATION_MODIFIER", 80, 88], ["oxygen species", "OBSERVATION", 89, 103], ["polyethylene glycol", "OBSERVATION", 139, 158], ["tumor retention", "OBSERVATION", 195, 210], ["deep penetration", "OBSERVATION", 215, 231], ["LINC", "ANATOMY", 239, 243]]], ["After exposure to NIR wave laser eradication, the LINC successfully elicited an immune response against tumors (Fig. 5) [88].Combination with photothermal therapy to the remodel TME ::: Tumor microenvironment-targeting nanomedicineInsufficient infiltration of cytotoxic T lymphocytes (CTLs) in the tumor microenvironment is critical for cancer immunological tolerance [89].", [["tumors", "ANATOMY", 104, 110], ["Tumor", "ANATOMY", 186, 191], ["cytotoxic T lymphocytes", "ANATOMY", 260, 283], ["CTLs", "ANATOMY", 285, 289], ["tumor", "ANATOMY", 298, 303], ["cancer", "ANATOMY", 337, 343], ["LINC", "CHEMICAL", 50, 54], ["tumors", "DISEASE", 104, 110], ["tumor", "DISEASE", 298, 303], ["cancer", "DISEASE", 337, 343], ["LINC", "SIMPLE_CHEMICAL", 50, 54], ["tumors", "CANCER", 104, 110], ["Tumor", "CANCER", 186, 191], ["cytotoxic T lymphocytes", "CELL", 260, 283], ["CTLs", "CELL", 285, 289], ["tumor", "CANCER", 298, 303], ["cancer", "CANCER", 337, 343], ["cytotoxic T lymphocytes", "CELL_TYPE", 260, 283], ["CTLs", "CELL_TYPE", 285, 289], ["NIR wave laser eradication", "TREATMENT", 18, 44], ["the LINC", "TREATMENT", 46, 54], ["tumors", "PROBLEM", 104, 110], ["photothermal therapy", "TREATMENT", 142, 162], ["Tumor microenvironment", "PROBLEM", 186, 208], ["Insufficient infiltration", "PROBLEM", 231, 256], ["cytotoxic T lymphocytes", "PROBLEM", 260, 283], ["cancer immunological tolerance", "PROBLEM", 337, 367], ["infiltration", "OBSERVATION", 244, 256], ["cytotoxic T lymphocytes", "OBSERVATION", 260, 283], ["tumor", "OBSERVATION", 298, 303]]], ["Wang et al. reported an engineered MMP-2-sensitive nanocomplex loaded with anti-PD-L1 antibodies and the photosensitizer indocyanine green.", [["indocyanine green", "CHEMICAL", 121, 138], ["indocyanine green", "CHEMICAL", 121, 138], ["MMP-2", "GENE_OR_GENE_PRODUCT", 35, 40], ["anti-PD-L1", "GENE_OR_GENE_PRODUCT", 75, 85], ["indocyanine green", "SIMPLE_CHEMICAL", 121, 138], ["MMP-2-sensitive nanocomplex", "PROTEIN", 35, 62], ["anti-PD-L1 antibodies", "PROTEIN", 75, 96], ["an engineered MMP", "TEST", 21, 38], ["anti-PD-L1 antibodies", "TREATMENT", 75, 96], ["the photosensitizer indocyanine green", "TREATMENT", 101, 138], ["L1", "ANATOMY", 83, 85]]], ["The NPs could precisely target the tumor site, and near-infrared (NIR) laser irradiation triggered the activation of the photosensitizer and released the anti-PD-L1 antibodies.", [["tumor site", "ANATOMY", 35, 45], ["tumor", "DISEASE", 35, 40], ["NPs", "SIMPLE_CHEMICAL", 4, 7], ["tumor", "CANCER", 35, 40], ["anti-PD-L1 antibodies", "GENE_OR_GENE_PRODUCT", 154, 175], ["anti-PD-L1 antibodies", "PROTEIN", 154, 175], ["The NPs", "TREATMENT", 0, 7], ["laser irradiation", "TREATMENT", 71, 88], ["the photosensitizer", "TREATMENT", 117, 136], ["tumor", "OBSERVATION", 35, 40], ["L1", "ANATOMY", 162, 164]]], ["The results showed that the NPs could increase the frequency of tumor-infiltrating CTLs and promote the effectiveness of PD-L1 blockade therapy [90].Combination with photodynamic therapy (PDT) to remodel the TME ::: Tumor microenvironment-targeting nanomedicineNanomaterial-based PDT also shows some advantages in antitumor immunotherapy [91].", [["tumor-infiltrating CTLs", "ANATOMY", 64, 87], ["Tumor", "ANATOMY", 216, 221], ["antitumor", "ANATOMY", 314, 323], ["NPs", "CHEMICAL", 28, 31], ["tumor", "DISEASE", 64, 69], ["NPs", "SIMPLE_CHEMICAL", 28, 31], ["tumor", "CANCER", 64, 69], ["CTLs", "CELL", 83, 87], ["PD-L1", "GENE_OR_GENE_PRODUCT", 121, 126], ["Tumor", "CANCER", 216, 221], ["antitumor", "CANCER", 314, 323], ["tumor-infiltrating CTLs", "CELL_TYPE", 64, 87], ["the NPs", "PROBLEM", 24, 31], ["tumor", "PROBLEM", 64, 69], ["infiltrating CTLs", "TREATMENT", 70, 87], ["PD-L1 blockade therapy", "TREATMENT", 121, 143], ["photodynamic therapy (PDT", "TREATMENT", 166, 191], ["Tumor microenvironment", "PROBLEM", 216, 238], ["Nanomaterial-based PDT", "TREATMENT", 261, 283], ["antitumor immunotherapy", "TREATMENT", 314, 337], ["tumor", "OBSERVATION", 64, 69]]], ["Meng et al. developed a light-triggered in situ gelation system composed of photosensitizer-modified catalase and poly-(ethylene glycol) double acrylate (PEGDA).", [["photosensitizer", "CHEMICAL", 76, 91], ["poly-(ethylene glycol) double acrylate", "CHEMICAL", 114, 152], ["PEGDA", "CHEMICAL", 154, 159], ["poly-(ethylene glycol)", "CHEMICAL", 114, 136], ["acrylate", "CHEMICAL", 144, 152], ["PEGDA", "CHEMICAL", 154, 159], ["photosensitizer", "SIMPLE_CHEMICAL", 76, 91], ["catalase", "SIMPLE_CHEMICAL", 101, 109], ["poly-(ethylene glycol) double acrylate", "SIMPLE_CHEMICAL", 114, 152], ["PEGDA", "SIMPLE_CHEMICAL", 154, 159], ["catalase", "PROTEIN", 101, 109], ["a light-triggered in situ gelation system", "TREATMENT", 22, 63], ["photosensitizer", "TREATMENT", 76, 91], ["modified catalase and poly-(ethylene glycol) double acrylate (PEGDA", "TREATMENT", 92, 159]]], ["Furthermore, adjuvant NPs were introduced into the gelation system.", [["NPs", "CHEMICAL", 22, 25], ["NPs", "SIMPLE_CHEMICAL", 22, 25], ["adjuvant NPs", "TREATMENT", 13, 25]]], ["The results showed that local injection of the mixed precursor solution into tumors and subsequent light exposure could trigger robust antitumor immune responses.", [["tumors", "ANATOMY", 77, 83], ["antitumor", "ANATOMY", 135, 144], ["tumors", "DISEASE", 77, 83], ["tumors", "CANCER", 77, 83], ["antitumor", "CANCER", 135, 144], ["local injection", "TREATMENT", 24, 39], ["the mixed precursor solution", "TREATMENT", 43, 71], ["tumors", "PROBLEM", 77, 83], ["tumors", "OBSERVATION", 77, 83]]], ["Accordingly, such a local light-elicited gelation system could effectively trigger antitumor responses via synergistic photoimmunotherapy [92].Combination with radiation to remodel the TME ::: Tumor microenvironment-targeting nanomedicineRadiotherapy has been broadly applied in clinical cancer treatment; however, the therapeutic effect is limited by tumor hypoxia-associated radiation resistance [91].", [["antitumor", "ANATOMY", 83, 92], ["Tumor", "ANATOMY", 193, 198], ["cancer", "ANATOMY", 288, 294], ["tumor", "ANATOMY", 352, 357], ["cancer", "DISEASE", 288, 294], ["tumor", "DISEASE", 352, 357], ["antitumor", "CANCER", 83, 92], ["Tumor", "CANCER", 193, 198], ["cancer", "CANCER", 288, 294], ["tumor", "CANCER", 352, 357], ["a local light-elicited gelation system", "TREATMENT", 18, 56], ["synergistic photoimmunotherapy", "TREATMENT", 107, 137], ["Tumor microenvironment", "PROBLEM", 193, 215], ["Radiotherapy", "TREATMENT", 238, 250], ["clinical cancer treatment", "TREATMENT", 279, 304], ["tumor hypoxia-associated radiation resistance", "PROBLEM", 352, 397], ["cancer", "OBSERVATION", 288, 294], ["tumor", "OBSERVATION", 352, 357], ["radiation resistance", "OBSERVATION", 377, 397]]], ["Nanomedicine can improve radiotherapy and promote antitumor immune responses.", [["antitumor", "ANATOMY", 50, 59], ["Nanomedicine", "CHEMICAL", 0, 12], ["antitumor", "CANCER", 50, 59], ["Nanomedicine", "TREATMENT", 0, 12], ["radiotherapy", "TREATMENT", 25, 37]]], ["Chen et al. utilized a PLGA-based core-shell nanomaterial to coencapsulate water-soluble catalase (Cat), an enzyme that transforms H2O2 into O2, and a hydrophobic TLR-7 agonist (R837).", [["PLGA", "CHEMICAL", 23, 27], ["H2O2", "CHEMICAL", 131, 135], ["O2", "CHEMICAL", 141, 143], ["PLGA", "CHEMICAL", 23, 27], ["H2O2", "CHEMICAL", 131, 135], ["O2", "CHEMICAL", 141, 143], ["PLGA", "SIMPLE_CHEMICAL", 23, 27], ["catalase", "SIMPLE_CHEMICAL", 89, 97], ["Cat", "SIMPLE_CHEMICAL", 99, 102], ["H2O2", "SIMPLE_CHEMICAL", 131, 135], ["O2", "SIMPLE_CHEMICAL", 141, 143], ["TLR-7", "GENE_OR_GENE_PRODUCT", 163, 168], ["R837", "SIMPLE_CHEMICAL", 178, 182], ["catalase", "PROTEIN", 89, 97], ["Cat", "PROTEIN", 99, 102], ["a PLGA-based core-shell nanomaterial", "TREATMENT", 21, 57], ["water-soluble catalase", "TREATMENT", 75, 97], ["an enzyme", "TEST", 105, 114], ["H2O2 into O2", "TREATMENT", 131, 143], ["a hydrophobic TLR", "TREATMENT", 149, 166]]], ["The PLGA-R837@Cat NPs could increase radiotherapy efficacy by relieving tumor hypoxia and remodeling the immunosuppressive tumor microenvironment by the Toll-like receptor.", [["tumor", "ANATOMY", 72, 77], ["tumor", "ANATOMY", 123, 128], ["PLGA-R837@Cat NPs", "CHEMICAL", 4, 21], ["tumor", "DISEASE", 72, 77], ["hypoxia", "DISEASE", 78, 85], ["tumor", "DISEASE", 123, 128], ["PLGA", "CHEMICAL", 4, 8], ["PLGA-R837@Cat NPs", "SIMPLE_CHEMICAL", 4, 21], ["tumor", "CANCER", 72, 77], ["tumor", "CANCER", 123, 128], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 153, 171], ["Toll-like receptor", "PROTEIN", 153, 171], ["The PLGA-R837@Cat NPs", "TREATMENT", 0, 21], ["radiotherapy efficacy", "TREATMENT", 37, 58], ["tumor hypoxia", "PROBLEM", 72, 85], ["remodeling the immunosuppressive tumor microenvironment", "TREATMENT", 90, 145], ["tumor", "OBSERVATION", 72, 77], ["immunosuppressive tumor", "OBSERVATION", 105, 128]]], ["Furthermore, the formulation showed a great abscopal effect and long-term immune memory combined with CTLA-4 checkpoint blockade [93].Combination with chemotherapy ::: Tumor microenvironment-targeting nanomedicineChemotherapy is extensively used in the clinic.", [["Tumor", "ANATOMY", 168, 173], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 102, 108], ["Tumor", "CANCER", 168, 173], ["the formulation", "TEST", 13, 28], ["a great abscopal effect", "PROBLEM", 36, 59], ["long-term immune memory", "PROBLEM", 64, 87], ["CTLA-4 checkpoint blockade", "TREATMENT", 102, 128], ["chemotherapy", "TREATMENT", 151, 163], ["Tumor microenvironment", "PROBLEM", 168, 190], ["Chemotherapy", "TREATMENT", 213, 225], ["great", "OBSERVATION_MODIFIER", 38, 43], ["abscopal effect", "OBSERVATION", 44, 59]]], ["Some chemotherapeutics (e.g., oxaliplatin, OXA) can induce an antitumor immune response via immunogenic cell death (ICD), but the subsequent immune response is suppressed by immunosuppressive mechanisms (e.g., IDO upregulation for OXA) [94].", [["antitumor", "ANATOMY", 62, 71], ["cell", "ANATOMY", 104, 108], ["oxaliplatin", "CHEMICAL", 30, 41], ["OXA", "CHEMICAL", 43, 46], ["immunogenic cell death", "DISEASE", 92, 114], ["OXA", "CHEMICAL", 231, 234], ["oxaliplatin", "CHEMICAL", 30, 41], ["OXA", "CHEMICAL", 43, 46], ["OXA", "CHEMICAL", 231, 234], ["oxaliplatin", "SIMPLE_CHEMICAL", 30, 41], ["OXA", "SIMPLE_CHEMICAL", 43, 46], ["antitumor", "CANCER", 62, 71], ["cell", "CELL", 104, 108], ["IDO", "GENE_OR_GENE_PRODUCT", 210, 213], ["OXA", "GENE_OR_GENE_PRODUCT", 231, 234], ["IDO", "PROTEIN", 210, 213], ["Some chemotherapeutics", "TREATMENT", 0, 22], ["oxaliplatin", "TREATMENT", 30, 41], ["OXA", "TREATMENT", 43, 46], ["immunogenic cell death", "PROBLEM", 92, 114], ["ICD", "TREATMENT", 116, 119], ["immunosuppressive mechanisms", "TREATMENT", 174, 202], ["IDO upregulation", "TREATMENT", 210, 226], ["chemotherapeutics", "OBSERVATION", 5, 22]]], ["Huang et al. reported cationic lipid-assisted nanoparticles (CLANs) loaded with IDO1 siRNA.", [["cationic lipid-assisted nanoparticles", "SIMPLE_CHEMICAL", 22, 59], ["CLANs", "SIMPLE_CHEMICAL", 61, 66], ["IDO1", "GENE_OR_GENE_PRODUCT", 80, 84], ["IDO1", "PROTEIN", 80, 84], ["cationic lipid-assisted nanoparticles (CLANs)", "TREATMENT", 22, 67], ["IDO1 siRNA", "TREATMENT", 80, 90], ["IDO1 siRNA", "OBSERVATION", 80, 90]]], ["Coadministration of OXA and CLANsiIDO1 to tumor-bearing mice systemically activated the immune response, improved the frequency of tumor-infiltrating T lymphocytes and decreased the frequency of Tregs in a colorectal tumor model [95].Combination with chemotherapy ::: Tumor microenvironment-targeting nanomedicineIn summary, the unique characteristics of the tumor microenvironment have been recognized as a considerable target for precise and effective nanomedicine design.", [["tumor", "ANATOMY", 42, 47], ["tumor-infiltrating T lymphocytes", "ANATOMY", 131, 163], ["Tregs", "ANATOMY", 195, 200], ["colorectal tumor", "ANATOMY", 206, 222], ["Tumor", "ANATOMY", 268, 273], ["tumor", "ANATOMY", 359, 364], ["OXA", "CHEMICAL", 20, 23], ["CLANsiIDO1", "CHEMICAL", 28, 38], ["tumor", "DISEASE", 42, 47], ["tumor", "DISEASE", 131, 136], ["colorectal tumor", "DISEASE", 206, 222], ["tumor", "DISEASE", 359, 364], ["OXA", "CHEMICAL", 20, 23], ["CLANsiIDO1", "CHEMICAL", 28, 38], ["OXA", "SIMPLE_CHEMICAL", 20, 23], ["CLANsiIDO1", "SIMPLE_CHEMICAL", 28, 38], ["tumor", "CANCER", 42, 47], ["mice", "ORGANISM", 56, 60], ["tumor-infiltrating T lymphocytes", "CELL", 131, 163], ["Tregs", "CELL", 195, 200], ["colorectal tumor", "CANCER", 206, 222], ["Tumor", "CANCER", 268, 273], ["tumor", "CANCER", 359, 364], ["tumor-infiltrating T lymphocytes", "CELL_TYPE", 131, 163], ["Tregs", "CELL_TYPE", 195, 200], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["Coadministration of OXA", "TREATMENT", 0, 23], ["CLANsiIDO1", "TREATMENT", 28, 38], ["tumor", "PROBLEM", 131, 136], ["infiltrating T lymphocytes", "PROBLEM", 137, 163], ["a colorectal tumor model", "TREATMENT", 204, 228], ["chemotherapy", "TREATMENT", 251, 263], ["Tumor microenvironment", "PROBLEM", 268, 290], ["the tumor microenvironment", "PROBLEM", 355, 381], ["tumor", "OBSERVATION", 131, 136], ["infiltrating T lymphocytes", "OBSERVATION", 137, 163], ["decreased", "OBSERVATION_MODIFIER", 168, 177], ["colorectal", "ANATOMY", 206, 216], ["tumor", "OBSERVATION", 217, 222], ["tumor", "OBSERVATION", 359, 364]]], ["Moreover, depending on the regulation of tumor-associated immune cells, the tumor metabolism microenvironment and combination with conventional therapies (especially localized therapeutics), nanomedicine offers a promising platform to remodel the tumor microenvironment, relieving the immunosuppression and evoking antitumor immune responses to destroy cancer cells (Fig. 6) [91].PerspectiveHigh-efficiency cancer immunotherapy is still challenging due to low response rates, immune evasion or immune resistance.", [["tumor", "ANATOMY", 41, 46], ["immune cells", "ANATOMY", 58, 70], ["tumor", "ANATOMY", 76, 81], ["tumor", "ANATOMY", 247, 252], ["antitumor", "ANATOMY", 315, 324], ["cancer cells", "ANATOMY", 353, 365], ["cancer", "ANATOMY", 407, 413], ["tumor", "DISEASE", 41, 46], ["tumor", "DISEASE", 76, 81], ["tumor", "DISEASE", 247, 252], ["cancer", "DISEASE", 353, 359], ["cancer", "DISEASE", 407, 413], ["tumor", "CANCER", 41, 46], ["immune cells", "CELL", 58, 70], ["tumor", "CANCER", 76, 81], ["tumor", "CANCER", 247, 252], ["antitumor", "CANCER", 315, 324], ["cancer cells", "CELL", 353, 365], ["cancer", "CANCER", 407, 413], ["tumor-associated immune cells", "CELL_TYPE", 41, 70], ["cancer cells", "CELL_TYPE", 353, 365], ["tumor", "PROBLEM", 41, 46], ["immune cells", "PROBLEM", 58, 70], ["the tumor metabolism microenvironment", "PROBLEM", 72, 109], ["conventional therapies", "TREATMENT", 131, 153], ["nanomedicine", "TREATMENT", 191, 203], ["remodel the tumor microenvironment", "TREATMENT", 235, 269], ["the immunosuppression", "TREATMENT", 281, 302], ["evoking antitumor immune responses", "TREATMENT", 307, 341], ["destroy cancer cells", "PROBLEM", 345, 365], ["PerspectiveHigh-efficiency cancer immunotherapy", "TREATMENT", 380, 427], ["low response rates", "PROBLEM", 456, 474], ["immune evasion", "TREATMENT", 476, 490], ["immune resistance", "PROBLEM", 494, 511], ["tumor", "OBSERVATION", 41, 46], ["immune cells", "OBSERVATION", 58, 70], ["tumor", "OBSERVATION", 247, 252], ["efficiency", "OBSERVATION_MODIFIER", 396, 406], ["cancer", "OBSERVATION", 407, 413], ["immune resistance", "OBSERVATION", 494, 511]]], ["Nanoengineered technology plays a crucial role in overcoming these challenges.PerspectiveCancer vaccines have shown feasible therapeutic effects in some preliminary clinical trials.", [["PerspectiveCancer vaccines", "TREATMENT", 78, 104]]], ["GAPVAC-101, a formulation with lipids, poly(I:C) and antigens, displayed safety and immunogenicity in a phase I trial [96].", [["GAPVAC-101", "CHEMICAL", 0, 10], ["poly(I:C", "CHEMICAL", 39, 47], ["GAPVAC-101", "CHEMICAL", 0, 10], ["GAPVAC-101", "SIMPLE_CHEMICAL", 0, 10], ["lipids", "SIMPLE_CHEMICAL", 31, 37], ["poly(I:C", "SIMPLE_CHEMICAL", 39, 47], ["poly(I:C) and antigens", "PROTEIN", 39, 61], ["GAPVAC", "TEST", 0, 6], ["a formulation with lipids", "TREATMENT", 12, 37]]], ["Polymer-based nanomedicines also show potential in cancer immunotherapy, such as PLGA copolymers, which can encapsulate antigens and extend circulation half-life [97, 98], as well as improve T cell responses.", [["cancer", "ANATOMY", 51, 57], ["T cell", "ANATOMY", 191, 197], ["cancer", "DISEASE", 51, 57], ["PLGA copolymers", "CHEMICAL", 81, 96], ["PLGA", "CHEMICAL", 81, 85], ["cancer", "CANCER", 51, 57], ["PLGA copolymers", "SIMPLE_CHEMICAL", 81, 96], ["T cell", "CELL", 191, 197], ["antigens", "PROTEIN", 120, 128], ["Polymer-based nanomedicines", "TREATMENT", 0, 27], ["cancer immunotherapy", "TREATMENT", 51, 71], ["PLGA copolymers", "TREATMENT", 81, 96], ["cancer", "OBSERVATION", 51, 57]]], ["However, many synthetic or modified materials need be approved through new drug certification; complicated chemistry and multiple components in one formulation may be challenging for clinical translation and CMC (chemistry, manufacturing, and controls).", [["many synthetic or modified materials", "PROBLEM", 9, 45], ["complicated chemistry", "TEST", 95, 116], ["multiple components in one formulation", "TREATMENT", 121, 159]]], ["There is a growing demand for researchers to engineer simple nanomedicines and improve the rate of clinical translation.PerspectiveSmall molecules (e.g., inhibitors or agonists), monoclonal antibodies and nanomedicine have shown remarkable potential in cancer immunotherapy [99].", [["cancer", "ANATOMY", 253, 259], ["cancer", "DISEASE", 253, 259], ["cancer", "CANCER", 253, 259], ["monoclonal antibodies", "PROTEIN", 179, 200], ["engineer simple nanomedicines", "TREATMENT", 45, 74], ["PerspectiveSmall molecules", "PROBLEM", 120, 146], ["inhibitors", "TREATMENT", 154, 164], ["agonists", "TREATMENT", 168, 176], ["monoclonal antibodies", "TREATMENT", 179, 200], ["nanomedicine", "TREATMENT", 205, 217], ["cancer immunotherapy", "TREATMENT", 253, 273], ["cancer", "OBSERVATION", 253, 259]]], ["Compared to small molecules, nanomedicine displays potential advantages, such as (1) prolonged circulation half-life [98]; (2) enhanced tumor accumulation; and (3) controlled release and multiple function orchestration by unique design.", [["tumor", "ANATOMY", 136, 141], ["tumor", "DISEASE", 136, 141], ["tumor", "CANCER", 136, 141], ["enhanced tumor accumulation", "PROBLEM", 127, 154], ["small molecules", "OBSERVATION_MODIFIER", 12, 27], ["tumor", "OBSERVATION", 136, 141]]], ["EPR-based NP delivery also showed potential auxiliary therapeutic effects with surgery, chemotherapy and radiotherapy [98].", [["EPR", "SIMPLE_CHEMICAL", 0, 3], ["EPR", "TEST", 0, 3], ["surgery", "TREATMENT", 79, 86], ["chemotherapy", "TREATMENT", 88, 100], ["radiotherapy", "TREATMENT", 105, 117]]], ["However, it has been reported that only 0.7% (median) of the administered NPs were delivered to solid tumors in patients [100].", [["solid tumors", "ANATOMY", 96, 108], ["NPs", "CHEMICAL", 74, 77], ["tumors", "DISEASE", 102, 108], ["NPs", "SIMPLE_CHEMICAL", 74, 77], ["solid tumors", "CANCER", 96, 108], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["the administered NPs", "TREATMENT", 57, 77], ["solid tumors", "PROBLEM", 96, 108], ["tumors", "OBSERVATION", 102, 108]]], ["Inefficient targeting of NPs in the clinic limits the wide application of nanomedicine.", [["NPs", "CHEMICAL", 25, 28], ["NPs", "TREATMENT", 25, 28], ["nanomedicine", "TREATMENT", 74, 86], ["NPs", "OBSERVATION_MODIFIER", 25, 28]]], ["Nanomaterials could also be applied to tumor diagnosis and other types of disease treatment to increase their application field.", [["tumor", "ANATOMY", 39, 44], ["tumor", "DISEASE", 39, 44], ["tumor", "CANCER", 39, 44], ["Nanomaterials", "TREATMENT", 0, 13], ["tumor diagnosis", "TEST", 39, 54], ["disease treatment", "TREATMENT", 74, 91], ["tumor", "OBSERVATION", 39, 44]]], ["Additional research will be needed to simplify nanomedicine and improve targeting efficiency, which would lead to more exciting medical breakthroughs.", [["nanomedicine", "TREATMENT", 47, 59], ["targeting efficiency", "PROBLEM", 72, 92]]]], "372d732c40c958bf2b2c7b0712d27e57f092d6d8": [["IntroductionThe epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing COVID-19, has rapidly spread worldwide.", [["acute respiratory syndrome coronavirus", "DISEASE", 35, 73], ["COVID-19", "CHEMICAL", 98, 106], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 28, 75], ["SARS-CoV-2", "ORGANISM", 77, 87], ["severe acute respiratory syndrome coronavirus", "SPECIES", 28, 73], ["SARS-CoV-2", "SPECIES", 77, 87], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 28, 73], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85], ["COVID", "TEST", 98, 103], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory syndrome", "OBSERVATION", 41, 61], ["rapidly", "OBSERVATION_MODIFIER", 112, 119], ["spread", "OBSERVATION_MODIFIER", 120, 126]]], ["Currently, Italy has reported 132 547 COVID-19-positive cases, 51 534 of which are in Lombardy.", [["COVID", "TEST", 38, 43]]], ["1 It is estimated that at least 10% of the Italian population-ie, approximately 1 million people-have been exposed to the virus.", [["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96], ["the virus", "PROBLEM", 118, 127]]], ["2 The city of Bergamo has the highest rate of infections and deaths in Italy, which makes the province of Bergamo a natural epidemiological setting where SARS-CoV-2 infections appeared earlier and were more evident.IntroductionIn adults, COVID-19 is typically characterised by severe interstitial pneumonia and hyperactivation of the inflammatory cascade.", [["interstitial", "ANATOMY", 284, 296], ["infections", "DISEASE", 46, 56], ["deaths", "DISEASE", 61, 67], ["SARS", "DISEASE", 154, 158], ["infections", "DISEASE", 165, 175], ["interstitial pneumonia", "DISEASE", 284, 306], ["SARS-CoV-2", "ORGANISM", 154, 164], ["SARS-CoV", "SPECIES", 154, 162], ["infections", "PROBLEM", 46, 56], ["SARS", "PROBLEM", 154, 158], ["CoV-2 infections", "PROBLEM", 159, 175], ["COVID", "TEST", 238, 243], ["severe interstitial pneumonia", "PROBLEM", 277, 306], ["hyperactivation of the inflammatory cascade", "PROBLEM", 311, 354], ["infections", "OBSERVATION", 46, 56], ["severe", "OBSERVATION_MODIFIER", 277, 283], ["interstitial", "ANATOMY_MODIFIER", 284, 296], ["pneumonia", "OBSERVATION", 297, 306], ["hyperactivation", "OBSERVATION", 311, 326], ["inflammatory cascade", "OBSERVATION", 334, 354]]], ["3, 4 In children, the respiratory involvement appears to have a more benign course, with almost no fatalities reported in this age group.", [["respiratory", "ANATOMY", 22, 33], ["children", "ORGANISM", 8, 16], ["children", "SPECIES", 8, 16], ["the respiratory involvement", "PROBLEM", 18, 45], ["respiratory", "ANATOMY", 22, 33]]], ["[5] [6] [7] Nonetheless, the respiratory tract seems not to be the only system susceptible to SARS-CoV-2 infection.", [["respiratory tract", "ANATOMY", 29, 46], ["SARS", "DISEASE", 94, 98], ["infection", "DISEASE", 105, 114], ["respiratory tract", "ORGANISM_SUBDIVISION", 29, 46], ["SARS-CoV-2", "ORGANISM", 94, 104], ["SARS-CoV", "SPECIES", 94, 102], ["the respiratory tract", "PROBLEM", 25, 46], ["SARS", "PROBLEM", 94, 98], ["CoV-2 infection", "PROBLEM", 99, 114], ["respiratory tract", "ANATOMY", 29, 46], ["SARS", "OBSERVATION", 94, 98], ["infection", "OBSERVATION", 105, 114]]], ["8 Increasing evidence suggests that tissue damage in COVID-19 is mostly mediated by the host innate immunity.", [["tissue", "ANATOMY", 36, 42], ["tissue damage", "DISEASE", 36, 49], ["COVID-19", "CHEMICAL", 53, 61], ["tissue", "TISSUE", 36, 42], ["COVID-19", "GENE_OR_GENE_PRODUCT", 53, 61], ["tissue damage", "PROBLEM", 36, 49], ["COVID", "TEST", 53, 58], ["evidence suggests", "UNCERTAINTY", 13, 30], ["tissue", "OBSERVATION_MODIFIER", 36, 42], ["damage", "OBSERVATION", 43, 49]]], ["9, 10 This disease is characterised by a cytokine storm resembling that of macrophage activation seen in viral-induced haemophagocytic lymphohistiocytosis.", [["macrophage", "ANATOMY", 75, 85], ["haemophagocytic lymphohistiocytosis", "DISEASE", 119, 154], ["macrophage", "CELL", 75, 85], ["cytokine", "PROTEIN", 41, 49], ["This disease", "PROBLEM", 6, 18], ["a cytokine storm", "PROBLEM", 39, 55], ["macrophage activation", "PROBLEM", 75, 96], ["haemophagocytic lymphohistiocytosis", "PROBLEM", 119, 154], ["disease", "OBSERVATION", 11, 18], ["cytokine storm", "OBSERVATION", 41, 55], ["macrophage activation", "OBSERVATION", 75, 96], ["viral", "OBSERVATION", 105, 110], ["haemophagocytic lymphohistiocytosis", "OBSERVATION", 119, 154]]], ["11 Kawasaki disease is an acute and usually self-limiting vasculitis of the medium calibre vessels, which almost exclusively affects children.", [["medium calibre vessels", "ANATOMY", 76, 98], ["Kawasaki disease", "DISEASE", 3, 19], ["vasculitis", "DISEASE", 58, 68], ["calibre vessels", "MULTI-TISSUE_STRUCTURE", 83, 98], ["children", "ORGANISM", 133, 141], ["children", "SPECIES", 133, 141], ["Kawasaki disease", "PROBLEM", 3, 19], ["an acute", "PROBLEM", 23, 31], ["self-limiting vasculitis of the medium calibre vessels", "PROBLEM", 44, 98], ["Kawasaki disease", "OBSERVATION", 3, 19], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["self-limiting", "OBSERVATION_MODIFIER", 44, 57], ["vasculitis", "OBSERVATION", 58, 68], ["medium calibre", "OBSERVATION_MODIFIER", 76, 90], ["vessels", "ANATOMY", 91, 98]]], ["12, 13 In the acute phase of the disease, patients with Kawasaki disease might have haemo dynamic instability, a condition known as Kawasaki disease shock syndrome (KDSS).", [["Kawasaki disease", "DISEASE", 56, 72], ["haemo dynamic instability", "DISEASE", 84, 109], ["Kawasaki disease shock syndrome", "DISEASE", 132, 163], ["KDSS", "DISEASE", 165, 169], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["the disease", "PROBLEM", 29, 40], ["Kawasaki disease", "PROBLEM", 56, 72], ["haemo dynamic instability", "PROBLEM", 84, 109], ["Kawasaki disease shock syndrome", "PROBLEM", 132, 163], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["phase", "OBSERVATION_MODIFIER", 20, 25], ["disease", "OBSERVATION", 33, 40]]], ["14 Other patients with Kawasaki disease might fulfil the criteria of macrophage activation syndrome (MAS), resembling secondary haemophagocytic lymphohistiocytosis.", [["macrophage", "ANATOMY", 69, 79], ["Kawasaki disease", "DISEASE", 23, 39], ["MAS", "DISEASE", 101, 104], ["haemophagocytic lymphohistiocytosis", "DISEASE", 128, 163], ["patients", "ORGANISM", 9, 17], ["macrophage", "CELL", 69, 79], ["patients", "SPECIES", 9, 17], ["Kawasaki disease", "PROBLEM", 23, 39], ["macrophage activation syndrome", "PROBLEM", 69, 99], ["MAS)", "PROBLEM", 101, 105], ["secondary haemophagocytic lymphohistiocytosis", "PROBLEM", 118, 163], ["macrophage activation syndrome", "OBSERVATION", 69, 99], ["secondary", "OBSERVATION_MODIFIER", 118, 127], ["haemophagocytic lymphohistiocytosis", "OBSERVATION", 128, 163]]], ["15 The cause of Kawasaki disease remains unknown; however, earlier evidence 16 suggests that an infectious agent triggers a cascade that causes the illness.IntroductionThe aim of this study was to describe the incidence and features of new cases of Kawasaki-like presentations admitted to our unit during the SARS-CoV-2 epidemic.PatientsWe retrospectively reviewed the notes of patients diagnosed with Kawasaki disease admitted to the General Paediatric Unit of Hospital Papa Giovanni XXIII (Bergamo, Italy), between Jan 1, 2015, and April 20, 2020.", [["Kawasaki disease", "DISEASE", 16, 32], ["Kawasaki-like presentations", "DISEASE", 249, 276], ["SARS", "DISEASE", 309, 313], ["Kawasaki disease", "DISEASE", 402, 418], ["Patients", "ORGANISM", 329, 337], ["patients", "ORGANISM", 378, 386], ["Patients", "SPECIES", 329, 337], ["patients", "SPECIES", 378, 386], ["Kawasaki disease", "PROBLEM", 16, 32], ["an infectious agent", "PROBLEM", 93, 112], ["the illness", "PROBLEM", 144, 155], ["this study", "TEST", 179, 189], ["the SARS", "TEST", 305, 313], ["CoV", "TEST", 314, 317], ["Kawasaki disease", "PROBLEM", 402, 418], ["Kawasaki disease", "OBSERVATION", 16, 32], ["infectious", "OBSERVATION", 96, 106], ["new", "OBSERVATION_MODIFIER", 236, 239]]], ["Our unit is a tertiary paediatric referral centre with approximately 1300 paediatric admissions per year, serving a province of approximately 1 million people, and hosting the largest Italian paediatric liver transplant programme and the largest paediatric intensive care unit of northern Italy (16 beds).", [["liver", "ANATOMY", 203, 208], ["people", "ORGANISM", 152, 158], ["liver", "ORGAN", 203, 208], ["people", "SPECIES", 152, 158], ["liver", "ANATOMY", 203, 208], ["transplant", "OBSERVATION", 209, 219], ["largest", "OBSERVATION_MODIFIER", 238, 245]]], ["In the general paediatric unit, there are paediatric consultants fully trained in all paediatric subspecialties.PatientsPatients with Kawasaki-like presentations were defined according to the 2017 criteria of the American Heart Association, including both the classic type (fever for \u22655 days plus four or more clinical criteria, including bilateral bulbar non-exudative conjunctivitis, changes of the lips or oral cavity, non-suppurative laterocervical lymphadenopathy, polymorphic rash, erythema of the palms and soles, firm induration of the hands or feet, or both) and incomplete types.", [["bulbar", "ANATOMY", 349, 355], ["lips", "ANATOMY", 401, 405], ["oral cavity", "ANATOMY", 409, 420], ["laterocervical", "ANATOMY", 438, 452], ["palms", "ANATOMY", 504, 509], ["soles", "ANATOMY", 514, 519], ["hands", "ANATOMY", 544, 549], ["feet", "ANATOMY", 553, 557], ["Kawasaki-like presentations", "DISEASE", 134, 161], ["fever", "DISEASE", 274, 279], ["conjunctivitis", "DISEASE", 370, 384], ["lymphadenopathy", "DISEASE", 453, 468], ["rash", "DISEASE", 482, 486], ["erythema", "DISEASE", 488, 496], ["Patients", "ORGANISM", 112, 120], ["Patients", "ORGANISM", 120, 128], ["lips", "ORGANISM_SUBDIVISION", 401, 405], ["oral cavity", "ORGANISM_SUBDIVISION", 409, 420], ["palms", "ORGANISM_SUBDIVISION", 504, 509], ["soles", "ORGANISM_SUBDIVISION", 514, 519], ["Patients", "SPECIES", 112, 120], ["Patients", "SPECIES", 120, 128], ["fever", "PROBLEM", 274, 279], ["bilateral bulbar non-exudative conjunctivitis", "PROBLEM", 339, 384], ["changes of the lips or oral cavity", "PROBLEM", 386, 420], ["non-suppurative laterocervical lymphadenopathy", "PROBLEM", 422, 468], ["polymorphic rash", "PROBLEM", 470, 486], ["erythema of the palms and soles", "PROBLEM", 488, 519], ["firm induration of the hands or feet", "PROBLEM", 521, 557], ["Heart", "ANATOMY", 222, 227], ["bilateral", "ANATOMY_MODIFIER", 339, 348], ["bulbar", "ANATOMY", 349, 355], ["conjunctivitis", "OBSERVATION", 370, 384], ["lips", "ANATOMY", 401, 405], ["oral cavity", "ANATOMY", 409, 420], ["non-suppurative", "OBSERVATION_MODIFIER", 422, 437], ["lymphadenopathy", "OBSERVATION", 453, 468], ["polymorphic", "OBSERVATION_MODIFIER", 470, 481], ["rash", "OBSERVATION", 482, 486], ["erythema", "OBSERVATION", 488, 496], ["palms", "ANATOMY", 504, 509], ["soles", "ANATOMY", 514, 519], ["firm", "OBSERVATION_MODIFIER", 521, 525], ["induration", "OBSERVATION", 526, 536], ["hands", "ANATOMY", 544, 549], ["feet", "ANATOMY", 553, 557]]], ["In incomplete types (fever for \u22655 days plus two or three of the aforementioned clinical criteria), the values of erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), or both, were taken as an additional diagnostic criterion in association with the presence of anaemia, thrombocytosis after 7 days of fever, hypoalbuminaemia, hypertrans aminasaemia, leucocytosis, sterile pyuria, or an echo cardiogram showing coronary aneurysms or cardiac dysfunction (ie, left ventricular function depression, mitral valve regurgitation, or pericardial effusion).", [["erythrocyte", "ANATOMY", 113, 124], ["coronary", "ANATOMY", 422, 430], ["cardiac", "ANATOMY", 444, 451], ["left ventricular", "ANATOMY", 469, 485], ["mitral valve", "ANATOMY", 507, 519], ["pericardial", "ANATOMY", 538, 549], ["fever", "DISEASE", 21, 26], ["anaemia", "DISEASE", 273, 280], ["thrombocytosis", "DISEASE", 282, 296], ["fever", "DISEASE", 313, 318], ["hypoalbuminaemia", "DISEASE", 320, 336], ["aminasaemia", "DISEASE", 349, 360], ["leucocytosis", "DISEASE", 362, 374], ["pyuria", "DISEASE", 384, 390], ["coronary aneurysms", "DISEASE", 422, 440], ["cardiac dysfunction", "DISEASE", 444, 463], ["left ventricular function depression", "DISEASE", 469, 505], ["mitral valve regurgitation", "DISEASE", 507, 533], ["pericardial effusion", "DISEASE", 538, 558], ["erythrocyte", "CELL", 113, 124], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 153, 171], ["CRP", "GENE_OR_GENE_PRODUCT", 173, 176], ["coronary", "MULTI-TISSUE_STRUCTURE", 422, 430], ["cardiac", "ORGAN", 444, 451], ["ventricular", "MULTI-TISSUE_STRUCTURE", 474, 485], ["C-reactive protein", "PROTEIN", 153, 171], ["CRP", "PROTEIN", 173, 176], ["fever", "PROBLEM", 21, 26], ["erythrocyte sedimentation rate", "TEST", 113, 143], ["ESR", "TEST", 145, 148], ["C-reactive protein", "TEST", 153, 171], ["CRP", "TEST", 173, 176], ["anaemia", "PROBLEM", 273, 280], ["thrombocytosis", "PROBLEM", 282, 296], ["fever", "PROBLEM", 313, 318], ["hypoalbuminaemia", "PROBLEM", 320, 336], ["hypertrans aminasaemia", "PROBLEM", 338, 360], ["leucocytosis", "PROBLEM", 362, 374], ["sterile pyuria", "PROBLEM", 376, 390], ["an echo cardiogram", "TEST", 395, 413], ["coronary aneurysms", "PROBLEM", 422, 440], ["cardiac dysfunction", "PROBLEM", 444, 463], ["left ventricular function depression", "PROBLEM", 469, 505], ["mitral valve regurgitation", "PROBLEM", 507, 533], ["pericardial effusion", "PROBLEM", 538, 558], ["incomplete types", "OBSERVATION_MODIFIER", 3, 19], ["anaemia", "OBSERVATION", 273, 280], ["thrombocytosis", "OBSERVATION", 282, 296], ["hypoalbuminaemia", "OBSERVATION", 320, 336], ["leucocytosis", "OBSERVATION_MODIFIER", 362, 374], ["pyuria", "OBSERVATION", 384, 390], ["coronary", "ANATOMY", 422, 430], ["aneurysms", "OBSERVATION", 431, 440], ["cardiac", "ANATOMY", 444, 451], ["dysfunction", "OBSERVATION", 452, 463], ["left ventricular", "ANATOMY", 469, 485], ["depression", "OBSERVATION", 495, 505], ["mitral valve", "ANATOMY", 507, 519], ["regurgitation", "OBSERVATION", 520, 533], ["pericardial", "ANATOMY", 538, 549], ["effusion", "OBSERVATION", 550, 558]]], ["17 All patients were diagnosed and managed by LV, who has been in charge of paediatric rheumatology in the Paediatric Department since 2010.PatientsKDSS was defined as Kawasaki disease accompanied by systolic arterial hypotension, a decrease from basal systolic blood pressure of at least 20%, or the appearance of signs of peripheral hypoperfusion.", [["LV", "ANATOMY", 46, 48], ["arterial", "ANATOMY", 209, 217], ["blood", "ANATOMY", 262, 267], ["Kawasaki disease", "DISEASE", 168, 184], ["systolic arterial hypotension", "DISEASE", 200, 229], ["peripheral hypoperfusion", "DISEASE", 324, 348], ["patients", "ORGANISM", 7, 15], ["LV", "MULTI-TISSUE_STRUCTURE", 46, 48], ["arterial", "MULTI-TISSUE_STRUCTURE", 209, 217], ["blood", "ORGANISM_SUBSTANCE", 262, 267], ["patients", "SPECIES", 7, 15], ["Kawasaki disease", "PROBLEM", 168, 184], ["systolic arterial hypotension", "PROBLEM", 200, 229], ["basal systolic blood pressure", "TEST", 247, 276], ["peripheral hypoperfusion", "PROBLEM", 324, 348], ["LV", "ANATOMY", 46, 48], ["arterial", "ANATOMY", 209, 217], ["hypotension", "OBSERVATION", 218, 229], ["decrease", "OBSERVATION_MODIFIER", 233, 241], ["peripheral", "ANATOMY_MODIFIER", 324, 334], ["hypoperfusion", "OBSERVATION", 335, 348]]], ["14 Ejection fraction, and concentrations of troponin I and pro-B-type natriuretic peptide (proBNP) were measured and used as indirect signs of myocarditis and heart failure.PatientsMAS was defined using the Paediatric Rheumatology International Trials Organisation criteria 18 for the classification of MAS in systemic juvenile idiopathic arthritis.", [["heart", "ANATOMY", 159, 164], ["myocarditis", "DISEASE", 143, 154], ["heart failure", "DISEASE", 159, 172], ["MAS", "DISEASE", 303, 306], ["juvenile idiopathic arthritis", "DISEASE", 319, 348], ["troponin I", "GENE_OR_GENE_PRODUCT", 44, 54], ["pro-B-type natriuretic peptide", "GENE_OR_GENE_PRODUCT", 59, 89], ["proBNP", "GENE_OR_GENE_PRODUCT", 91, 97], ["heart", "ORGAN", 159, 164], ["troponin I", "PROTEIN", 44, 54], ["pro-B", "PROTEIN", 59, 64], ["Ejection fraction", "TEST", 3, 20], ["troponin I", "TEST", 44, 54], ["pro-B-type natriuretic peptide", "TEST", 59, 89], ["proBNP", "TEST", 91, 97], ["myocarditis", "PROBLEM", 143, 154], ["heart failure", "PROBLEM", 159, 172], ["MAS", "PROBLEM", 303, 306], ["systemic juvenile idiopathic arthritis", "PROBLEM", 310, 348], ["Ejection fraction", "OBSERVATION", 3, 20], ["myocarditis", "OBSERVATION", 143, 154], ["heart", "ANATOMY", 159, 164], ["failure", "OBSERVATION", 165, 172], ["systemic", "OBSERVATION_MODIFIER", 310, 318], ["juvenile", "OBSERVATION_MODIFIER", 319, 327], ["idiopathic", "OBSERVATION_MODIFIER", 328, 338], ["arthritis", "OBSERVATION", 339, 348]]], ["The MAS criteria are validated for systemic juvenile idiopathic arthritis, but they are commonly used for other systemic autoinflammatory diseases such as Kawasaki disease and paediatric systemic lupus erythematosus.", [["juvenile idiopathic arthritis", "DISEASE", 44, 73], ["autoinflammatory diseases", "DISEASE", 121, 146], ["Kawasaki disease", "DISEASE", 155, 171], ["systemic lupus erythematosus", "DISEASE", 187, 215], ["systemic juvenile idiopathic arthritis", "PROBLEM", 35, 73], ["other systemic autoinflammatory diseases", "PROBLEM", 106, 146], ["Kawasaki disease", "PROBLEM", 155, 171], ["paediatric systemic lupus erythematosus", "PROBLEM", 176, 215], ["systemic", "OBSERVATION_MODIFIER", 35, 43], ["juvenile", "OBSERVATION_MODIFIER", 44, 52], ["idiopathic", "OBSERVATION_MODIFIER", 53, 63], ["arthritis", "OBSERVATION", 64, 73], ["systemic", "OBSERVATION_MODIFIER", 112, 120], ["autoinflammatory", "OBSERVATION", 121, 137], ["systemic lupus erythematosus", "OBSERVATION", 187, 215]]], ["19 We divided the patients in two groups according to the date of presentation: group 1, presenting during the 5 years preceding the local SARS-CoV-2 epidemic (ie, Jan 1, 2015, to Feb 17, 2020); and group 2, presenting thereafter (ie, Feb 18 to April 20, 2020).Clinical and laboratory evaluationData were obtained from hospital medical records, and included demographic data, presenting symptoms and history of previous treatments, contact with confirmed or suspected cases of COVID-19, vital signs, and laboratory data, including white blood cell count, lymphocyte count, ESR, CRP, procalcitonin, ferritin, fibrinogen, proBNP,Research in contextEvidence before this study Kawasaki disease is an acute self-limiting vasculitis with specific predilection for the coronary arteries that affects previously healthy young infants and children.", [["white blood cell", "ANATOMY", 531, 547], ["lymphocyte", "ANATOMY", 555, 565], ["coronary arteries", "ANATOMY", 762, 779], ["SARS", "DISEASE", 139, 143], ["Kawasaki disease", "DISEASE", 673, 689], ["vasculitis", "DISEASE", 716, 726], ["patients", "ORGANISM", 18, 26], ["white blood cell", "CELL", 531, 547], ["lymphocyte", "CELL", 555, 565], ["CRP", "GENE_OR_GENE_PRODUCT", 578, 581], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 583, 596], ["ferritin", "GENE_OR_GENE_PRODUCT", 598, 606], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 608, 618], ["proBNP", "SIMPLE_CHEMICAL", 620, 626], ["coronary arteries", "MULTI-TISSUE_STRUCTURE", 762, 779], ["infants", "ORGANISM", 818, 825], ["children", "ORGANISM", 830, 838], ["ESR", "PROTEIN", 573, 576], ["CRP", "PROTEIN", 578, 581], ["procalcitonin", "PROTEIN", 583, 596], ["ferritin", "PROTEIN", 598, 606], ["fibrinogen", "PROTEIN", 608, 618], ["proBNP", "PROTEIN", 620, 626], ["patients", "SPECIES", 18, 26], ["infants", "SPECIES", 818, 825], ["children", "SPECIES", 830, 838], ["laboratory evaluation", "TEST", 274, 295], ["demographic data", "TEST", 358, 374], ["presenting symptoms", "PROBLEM", 376, 395], ["previous treatments", "TREATMENT", 411, 430], ["COVID", "TEST", 477, 482], ["vital signs", "TEST", 487, 498], ["laboratory data", "TEST", 504, 519], ["white blood cell count", "TEST", 531, 553], ["lymphocyte count", "TEST", 555, 571], ["ESR", "TEST", 573, 576], ["CRP", "TEST", 578, 581], ["procalcitonin", "TEST", 583, 596], ["ferritin", "TEST", 598, 606], ["fibrinogen", "TEST", 608, 618], ["proBNP", "TEST", 620, 626], ["this study", "TEST", 662, 672], ["Kawasaki disease", "PROBLEM", 673, 689], ["an acute self-limiting vasculitis", "PROBLEM", 693, 726], ["acute", "OBSERVATION_MODIFIER", 696, 701], ["self-limiting", "OBSERVATION_MODIFIER", 702, 715], ["vasculitis", "OBSERVATION", 716, 726], ["coronary arteries", "ANATOMY", 762, 779]]], ["Despite half a century having passed since Kawasaki disease was first reported in Japan, the cause of this condition remains unknown.", [["Kawasaki disease", "DISEASE", 43, 59], ["Kawasaki disease", "PROBLEM", 43, 59], ["this condition", "PROBLEM", 102, 116]]], ["We did a PubMed database search to identify studies investigating the cause and pathogenesis of Kawasaki disease using the terms \"Kawasaki disease\", \"etiology\", \"pathogenesis\", \"intravenous immunoglobulin\", \"corticosteroids\", \"macrophage activation syndrome (MAS)\", and \"KD shock syndrome\".", [["intravenous", "ANATOMY", 178, 189], ["macrophage", "ANATOMY", 227, 237], ["Kawasaki disease", "DISEASE", 96, 112], ["Kawasaki disease", "DISEASE", 130, 146], ["MAS", "DISEASE", 259, 262], ["KD shock", "DISEASE", 271, 279], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 178, 189], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 190, 204], ["macrophage", "CELL", 227, 237], ["Kawasaki disease", "PROBLEM", 96, 112], ["Kawasaki disease\"", "PROBLEM", 130, 147], ["intravenous immunoglobulin\"", "TREATMENT", 178, 205], ["\"corticosteroids", "TREATMENT", 207, 223], ["macrophage activation syndrome", "PROBLEM", 227, 257], ["\"KD shock syndrome", "PROBLEM", 270, 288], ["Kawasaki disease", "OBSERVATION", 96, 112], ["macrophage activation syndrome", "OBSERVATION", 227, 257], ["shock syndrome", "OBSERVATION", 274, 288]]], ["The most accepted pathogenetic hypothesis supports an aberrant response of the immune system to one or more unidentified pathogens in genetically predisposed subjects.", [["immune system", "ANATOMY", 79, 92], ["pathogenetic hypothesis", "PROBLEM", 18, 41], ["an aberrant response of the immune system", "PROBLEM", 51, 92], ["aberrant", "OBSERVATION_MODIFIER", 54, 62], ["response", "OBSERVATION_MODIFIER", 63, 71], ["pathogens", "OBSERVATION", 121, 130]]], ["An infectious trigger, however, has not been identified.Added value of this studyShortly after the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to our region (Bergamo, Italy), we found a 30-fold increased incidence of Kawasaki disease.", [["acute respiratory syndrome coronavirus", "DISEASE", 116, 154], ["Kawasaki disease", "DISEASE", 244, 260], ["severe acute respiratory syndrome coronavirus", "SPECIES", 109, 154], ["SARS-CoV-2", "SPECIES", 158, 168], ["An infectious trigger", "PROBLEM", 0, 21], ["this study", "TEST", 71, 81], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 109, 154], ["SARS", "TEST", 158, 162], ["CoV", "TEST", 163, 166], ["Kawasaki disease", "PROBLEM", 244, 260], ["infectious", "OBSERVATION", 3, 13], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["respiratory syndrome", "OBSERVATION", 122, 142], ["Kawasaki disease", "OBSERVATION", 244, 260]]], ["Children diagnosed after the SARS-CoV-2 epidemic began showed evidence of immune response to the virus, were older, had a higher rate of cardiac involvement, and features of MAS.", [["cardiac", "ANATOMY", 137, 144], ["MAS", "DISEASE", 174, 177], ["Children", "ORGANISM", 0, 8], ["cardiac", "ORGAN", 137, 144], ["Children", "SPECIES", 0, 8], ["the SARS", "TEST", 25, 33], ["CoV", "TEST", 34, 37], ["epidemic", "PROBLEM", 40, 48], ["immune response", "PROBLEM", 74, 89], ["the virus", "PROBLEM", 93, 102], ["cardiac involvement", "PROBLEM", 137, 156], ["MAS", "PROBLEM", 174, 177], ["evidence of", "UNCERTAINTY", 62, 73], ["immune response", "OBSERVATION", 74, 89], ["cardiac", "ANATOMY", 137, 144], ["involvement", "OBSERVATION", 145, 156]]], ["We therefore showed that SARS-CoV-2 might cause a severe form of Kawasaki-like disease.Implications of all the available evidenceOutbreaks of Kawasaki-like disease might occur in countries affected by the SARS-CoV-2 pandemic, and might present outside the classic Kawasaki disease phenotype.", [["Kawasaki-like disease", "DISEASE", 65, 86], ["Kawasaki-like disease", "DISEASE", 142, 163], ["SARS-CoV-2 pandemic", "DISEASE", 205, 224], ["Kawasaki disease", "DISEASE", 264, 280], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["SARS-CoV-2", "ORGANISM", 205, 215], ["SARS-CoV", "SPECIES", 25, 33], ["SARS-CoV", "SPECIES", 205, 213], ["SARS", "PROBLEM", 25, 29], ["CoV", "TEST", 30, 33], ["Kawasaki-like disease", "PROBLEM", 65, 86], ["Kawasaki-like disease", "PROBLEM", 142, 163], ["pandemic", "PROBLEM", 216, 224], ["the classic Kawasaki disease phenotype", "PROBLEM", 252, 290], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["Kawasaki", "OBSERVATION", 65, 73], ["Kawasaki disease", "OBSERVATION", 264, 280]]], ["This condition might be serious and requires prompt and more aggressive management.", [["aggressive management", "TREATMENT", 61, 82]]], ["Future research on the cause of Kawasaki disease and similar syndromes should focus on immune responses to viral triggers. troponin I, natural killer (NK) activity, and concentrations of interleukin 6 (IL-6).", [["NK", "ANATOMY", 151, 153], ["Kawasaki disease", "DISEASE", 32, 48], ["troponin I", "GENE_OR_GENE_PRODUCT", 123, 133], ["natural killer", "CELL", 135, 149], ["NK", "CELL", 151, 153], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 187, 200], ["IL-6", "GENE_OR_GENE_PRODUCT", 202, 206], ["troponin I", "PROTEIN", 123, 133], ["interleukin 6", "PROTEIN", 187, 200], ["IL-6", "PROTEIN", 202, 206], ["Kawasaki disease", "PROBLEM", 32, 48], ["similar syndromes", "PROBLEM", 53, 70], ["viral triggers", "PROBLEM", 107, 121], ["troponin I", "TEST", 123, 133], ["interleukin", "TEST", 187, 198], ["Kawasaki", "OBSERVATION", 32, 40]]], ["Electrocardiogram and echocardiogram were done in all children.Confirmation of SARS-CoV-2 infectionPatients and caregivers had nasopharyngeal and oropharyngeal swab sampling, testing SARS-CoV-2 nucleic acid using reverse-transcriptase quantitative PCR assay; patients with a positive nasopharyngeal and oropharyngeal swab sampling test were considered confirmed cases of SARS-CoV-2 infection.Confirmation of SARS-CoV-2 infectionThe patients diagnosed more recently had a test for the qualitative detection of SARS-CoV-2 antibodies (IgM and IgG) through a lateral flow chromatographic immunoassay (NADAL COVID-19 IgG/IgM Test, Nal Von Minden, Moers, Germany).", [["nasopharyngeal", "ANATOMY", 127, 141], ["oropharyngeal swab", "ANATOMY", 146, 164], ["nasopharyngeal", "ANATOMY", 284, 298], ["oropharyngeal swab", "ANATOMY", 303, 321], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 183, 206], ["SARS-CoV-2 infection", "DISEASE", 371, 391], ["SARS-CoV-2 infection", "DISEASE", 408, 428], ["SARS", "DISEASE", 509, 513], ["children", "ORGANISM", 54, 62], ["SARS-CoV-2", "ORGANISM", 79, 89], ["nasopharyngeal", "CANCER", 127, 141], ["oropharyngeal swab", "MULTI-TISSUE_STRUCTURE", 146, 164], ["patients", "ORGANISM", 259, 267], ["nasopharyngeal", "CANCER", 284, 298], ["SARS-CoV-2", "ORGANISM", 371, 381], ["SARS-CoV-2", "ORGANISM", 408, 418], ["patients", "ORGANISM", 432, 440], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 509, 530], ["IgM", "GENE_OR_GENE_PRODUCT", 532, 535], ["IgG", "GENE_OR_GENE_PRODUCT", 540, 543], ["reverse-transcriptase", "PROTEIN", 213, 234], ["SARS-CoV-2 antibodies", "PROTEIN", 509, 530], ["IgM", "PROTEIN", 532, 535], ["IgG", "PROTEIN", 540, 543], ["IgG", "PROTEIN", 612, 615], ["IgM", "PROTEIN", 616, 619], ["children", "SPECIES", 54, 62], ["patients", "SPECIES", 259, 267], ["patients", "SPECIES", 432, 440], ["SARS-CoV", "SPECIES", 79, 87], ["SARS-CoV", "SPECIES", 183, 191], ["SARS-CoV-2", "SPECIES", 371, 381], ["SARS-CoV-2", "SPECIES", 408, 418], ["SARS-CoV", "SPECIES", 509, 517], ["Electrocardiogram", "TEST", 0, 17], ["echocardiogram", "TEST", 22, 36], ["SARS", "PROBLEM", 79, 83], ["CoV-2 infectionPatients", "PROBLEM", 84, 107], ["nasopharyngeal and oropharyngeal swab sampling", "TEST", 127, 173], ["testing SARS", "TEST", 175, 187], ["CoV", "TEST", 188, 191], ["nucleic acid", "TEST", 194, 206], ["a positive nasopharyngeal", "PROBLEM", 273, 298], ["oropharyngeal swab sampling test", "TEST", 303, 335], ["SARS", "PROBLEM", 371, 375], ["CoV", "PROBLEM", 376, 379], ["2 infection", "PROBLEM", 380, 391], ["SARS", "PROBLEM", 408, 412], ["CoV-2 infection", "PROBLEM", 413, 428], ["a test", "TEST", 469, 475], ["the qualitative detection", "TEST", 480, 505], ["SARS", "TEST", 509, 513], ["CoV", "TEST", 514, 517], ["antibodies", "TEST", 520, 530], ["IgM", "TEST", 532, 535], ["IgG", "TEST", 540, 543], ["a lateral flow chromatographic immunoassay", "TEST", 553, 595], ["NADAL", "TEST", 597, 602], ["COVID", "TEST", 603, 608], ["IgG", "TEST", 612, 615], ["IgM Test", "TEST", 616, 624], ["SARS", "OBSERVATION", 79, 83], ["nasopharyngeal", "ANATOMY", 127, 141], ["oropharyngeal", "ANATOMY", 146, 159], ["nasopharyngeal", "ANATOMY", 284, 298], ["oropharyngeal", "ANATOMY", 303, 316], ["infection", "OBSERVATION", 382, 391], ["SARS", "OBSERVATION", 408, 412], ["CoV", "OBSERVATION_MODIFIER", 413, 416], ["infection", "OBSERVATION", 419, 428]]], ["Positivity for IgM or IgG, or both, was considered consistent with an earlier infection with SARS-CoV-2.TreatmentRisk of resistance to intravenous immunoglobulin treatment was ascertained according to the Kobayashi score.", [["intravenous", "ANATOMY", 135, 146], ["infection", "DISEASE", 78, 87], ["SARS", "DISEASE", 93, 97], ["IgM", "GENE_OR_GENE_PRODUCT", 15, 18], ["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["SARS-CoV-2", "ORGANISM", 93, 103], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 135, 146], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 147, 161], ["IgM", "PROTEIN", 15, 18], ["IgG", "PROTEIN", 22, 25], ["immunoglobulin", "PROTEIN", 147, 161], ["SARS-CoV", "SPECIES", 93, 101], ["IgM", "PROBLEM", 15, 18], ["IgG", "PROBLEM", 22, 25], ["an earlier infection", "PROBLEM", 67, 87], ["CoV", "TEST", 98, 101], ["intravenous immunoglobulin treatment", "TREATMENT", 135, 171], ["consistent with", "UNCERTAINTY", 51, 66], ["infection", "OBSERVATION", 78, 87], ["resistance", "OBSERVATION_MODIFIER", 121, 131]]], ["20 All patients were administered intravenous immuno globulin at 2 g/kg.", [["intravenous", "ANATOMY", 34, 45], ["immuno globulin", "CHEMICAL", 46, 61], ["patients", "ORGANISM", 7, 15], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 45], ["patients", "SPECIES", 7, 15], ["intravenous immuno globulin", "TREATMENT", 34, 61]]], ["According to the RAISE study, 20 based on risk stratification, patients were also treated with aspirin at 50-80 mg/kg per day (Kobayashi score <5) for 5 days or aspirin at 30 mg/kg per day plus methylprednisolone at 2 mg/kg per day for 5 days (Kobayashi score \u22655), followed by a tapering of methylprednisolone over 2 weeks.", [["aspirin", "CHEMICAL", 95, 102], ["aspirin", "CHEMICAL", 161, 168], ["methylprednisolone", "CHEMICAL", 194, 212], ["methylprednisolone", "CHEMICAL", 291, 309], ["aspirin", "CHEMICAL", 95, 102], ["aspirin", "CHEMICAL", 161, 168], ["methylprednisolone", "CHEMICAL", 194, 212], ["methylprednisolone", "CHEMICAL", 291, 309], ["patients", "ORGANISM", 63, 71], ["aspirin", "SIMPLE_CHEMICAL", 95, 102], ["aspirin", "SIMPLE_CHEMICAL", 161, 168], ["methylprednisolone", "SIMPLE_CHEMICAL", 194, 212], ["methylprednisolone", "SIMPLE_CHEMICAL", 291, 309], ["patients", "SPECIES", 63, 71], ["the RAISE study", "TEST", 13, 28], ["aspirin", "TREATMENT", 95, 102], ["aspirin", "TREATMENT", 161, 168], ["methylprednisolone", "TREATMENT", 194, 212], ["methylprednisolone", "TREATMENT", 291, 309]]], ["Aspirin was maintained until 48 h after defervescence, and then continued at an antiplatelet dose of 3-5 mg/kg per day for 8 weeks.", [["antiplatelet", "ANATOMY", 80, 92], ["Aspirin", "CHEMICAL", 0, 7], ["Aspirin", "CHEMICAL", 0, 7], ["Aspirin", "SIMPLE_CHEMICAL", 0, 7], ["Aspirin", "TREATMENT", 0, 7], ["defervescence", "PROBLEM", 40, 53], ["an antiplatelet dose", "TREATMENT", 77, 97]]], ["20 The schedule for patients at risk of intravenous immunglobulin resistance was adopted also in patients with KDSS or MAS.", [["intravenous", "ANATOMY", 40, 51], ["immunglobulin", "CHEMICAL", 52, 65], ["MAS", "DISEASE", 119, 122], ["patients", "ORGANISM", 20, 28], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 51], ["immunglobulin", "SIMPLE_CHEMICAL", 52, 65], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 97, 105], ["intravenous immunglobulin resistance", "TREATMENT", 40, 76], ["MAS", "PROBLEM", 119, 122]]], ["Response to treatment was defined as the normalisation of vital signs, CRP, and blood tests, and the resolution of symptoms and signs.Statistical analysisThe Student's t test, the \u03c7\u00b2 method, and Fisher's exact test were done when appropriate for statistical analysis to compare continuous and categorical variables.", [["blood", "ANATOMY", 80, 85], ["CRP", "GENE_OR_GENE_PRODUCT", 71, 74], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["CRP", "PROTEIN", 71, 74], ["treatment", "TREATMENT", 12, 21], ["vital signs", "TEST", 58, 69], ["CRP", "TEST", 71, 74], ["blood tests", "TEST", 80, 91], ["symptoms", "PROBLEM", 115, 123], ["signs", "PROBLEM", 128, 133], ["Statistical analysis", "TEST", 134, 154], ["The Student's t test", "TEST", 154, 174], ["Fisher's exact test", "TEST", 195, 214], ["statistical analysis", "TEST", 246, 266]]], ["A p value of <0\u00b705 was chosen as cutoff for significance.", [["A p value", "TEST", 0, 9]]], ["Data were analysed with SPSS (version 20.0) and GraphPad Prism (version 5.00 for Mac).", [["SPSS", "TEST", 24, 28], ["version", "TEST", 30, 37]]], ["The study was approved by the Bergamo Ethics Committee (registration number 37/20, 25/03/2020).Role of the funding sourceThere was no funding source for this study.", [["The study", "TEST", 0, 9], ["this study", "TEST", 153, 163], ["no", "UNCERTAINTY", 131, 133], ["funding", "OBSERVATION", 134, 141]]], ["The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.ResultsBetween Feb 18 and April 20, 2020, ten patients (aged 7\u00b75 years [SD 3\u00b75]; seven boys, three girls), were diagnosed with Kawasaki disease (incidence ten per month), and comprised group 2.", [["Kawasaki disease", "DISEASE", 269, 285], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["boys", "SPECIES", 229, 233], ["girls", "SPECIES", 241, 246], ["the study", "TEST", 60, 69], ["Kawasaki disease", "PROBLEM", 269, 285], ["Kawasaki disease", "OBSERVATION", 269, 285]]], ["Admission to hospital occurred, on average, on day 6 of fever (range 4-8).", [["fever", "DISEASE", 56, 61], ["fever", "PROBLEM", 56, 61]]], ["Five (50%) patients presented with a classic form of the disease, and five (50%) presented with an incomplete form.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["the disease", "PROBLEM", 53, 64], ["disease", "OBSERVATION", 57, 64]]], ["Patients presenting with the classic form had non-exudative conjunctivitis, hand and feet anomalies (ie, erythema or firm induration, or both), and polymorphic rash.", [["hand", "ANATOMY", 76, 80], ["feet", "ANATOMY", 85, 89], ["conjunctivitis", "DISEASE", 60, 74], ["hand and feet anomalies", "DISEASE", 76, 99], ["erythema", "DISEASE", 105, 113], ["rash", "DISEASE", 160, 164], ["Patients", "ORGANISM", 0, 8], ["hand", "ORGANISM_SUBDIVISION", 76, 80], ["feet", "ORGANISM_SUBDIVISION", 85, 89], ["rash", "PATHOLOGICAL_FORMATION", 160, 164], ["Patients", "SPECIES", 0, 8], ["non-exudative conjunctivitis", "PROBLEM", 46, 74], ["hand and feet anomalies", "PROBLEM", 76, 99], ["erythema", "PROBLEM", 105, 113], ["firm induration", "PROBLEM", 117, 132], ["polymorphic rash", "PROBLEM", 148, 164], ["conjunctivitis", "OBSERVATION", 60, 74], ["hand", "ANATOMY", 76, 80], ["feet", "ANATOMY", 85, 89], ["anomalies", "OBSERVATION", 90, 99], ["erythema", "OBSERVATION", 105, 113], ["firm", "OBSERVATION_MODIFIER", 117, 121], ["induration", "OBSERVATION", 122, 132], ["polymorphic", "OBSERVATION_MODIFIER", 148, 159], ["rash", "OBSERVATION", 160, 164]]], ["Four (80%) of five patients had associated changes of the lips or oral cavity, or both; patient 7 also had laterocervical lymphadenopathy (table 1) .ResultsIn group 2, five (50%) of ten patients were diagnosed with incomplete Kawasaki disease, presenting with three or fewer clinical criteria associated with additional laboratory criteria (n=1) or an abnormal echocardiography (n=4).", [["lips", "ANATOMY", 58, 62], ["oral cavity", "ANATOMY", 66, 77], ["laterocervical", "ANATOMY", 107, 121], ["lymphadenopathy", "DISEASE", 122, 137], ["Kawasaki disease", "DISEASE", 226, 242], ["patients", "ORGANISM", 19, 27], ["lips", "ORGANISM_SUBDIVISION", 58, 62], ["oral cavity", "ORGAN", 66, 77], ["patient", "ORGANISM", 88, 95], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 19, 27], ["patient", "SPECIES", 88, 95], ["patients", "SPECIES", 186, 194], ["associated changes of the lips or oral cavity", "PROBLEM", 32, 77], ["laterocervical lymphadenopathy", "PROBLEM", 107, 137], ["incomplete Kawasaki disease", "PROBLEM", 215, 242], ["an abnormal echocardiography", "PROBLEM", 349, 377], ["lips", "ANATOMY", 58, 62], ["oral cavity", "ANATOMY", 66, 77], ["lymphadenopathy", "OBSERVATION", 122, 137], ["Kawasaki disease", "OBSERVATION", 226, 242]]], ["Two (20%) patients had bulbar non-exudative conjunctivitis; changes of the lips or oral cavity, or both; and polymorphic rash.", [["bulbar", "ANATOMY", 23, 29], ["lips", "ANATOMY", 75, 79], ["oral cavity", "ANATOMY", 83, 94], ["conjunctivitis", "DISEASE", 44, 58], ["rash", "DISEASE", 121, 125], ["patients", "ORGANISM", 10, 18], ["lips", "ORGANISM_SUBDIVISION", 75, 79], ["oral cavity", "ORGANISM_SUBDIVISION", 83, 94], ["rash", "PATHOLOGICAL_FORMATION", 121, 125], ["patients", "SPECIES", 10, 18], ["bulbar non-exudative conjunctivitis", "PROBLEM", 23, 58], ["changes of the lips or oral cavity", "PROBLEM", 60, 94], ["polymorphic rash", "PROBLEM", 109, 125], ["conjunctivitis", "OBSERVATION", 44, 58], ["lips", "ANATOMY", 75, 79], ["oral cavity", "ANATOMY", 83, 94], ["polymorphic", "OBSERVATION_MODIFIER", 109, 120], ["rash", "OBSERVATION", 121, 125]]], ["One (10%) patient had only bulbar non-exudative conjunctivitis and polymorphic rash.", [["bulbar", "ANATOMY", 27, 33], ["conjunctivitis", "DISEASE", 48, 62], ["rash", "DISEASE", 79, 83], ["patient", "ORGANISM", 10, 17], ["rash", "PATHOLOGICAL_FORMATION", 79, 83], ["patient", "SPECIES", 10, 17], ["bulbar non-exudative conjunctivitis", "PROBLEM", 27, 62], ["polymorphic rash", "PROBLEM", 67, 83], ["bulbar", "ANATOMY", 27, 33], ["conjunctivitis", "OBSERVATION", 48, 62], ["polymorphic", "OBSERVATION_MODIFIER", 67, 78], ["rash", "OBSERVATION", 79, 83]]], ["In two (20%) patients, the echocardiography detected a left coronary aneurysm (>4 mm), reduced ejection fraction (48% and 40%), and mitral valve regurgitation; patient 1 also had pericardial effusion.", [["left coronary aneurysm", "ANATOMY", 55, 77], ["mitral valve", "ANATOMY", 132, 144], ["pericardial", "ANATOMY", 179, 190], ["left coronary aneurysm", "DISEASE", 55, 77], ["mitral valve regurgitation", "DISEASE", 132, 158], ["pericardial effusion", "DISEASE", 179, 199], ["patients", "ORGANISM", 13, 21], ["coronary aneurysm", "PATHOLOGICAL_FORMATION", 60, 77], ["patient", "ORGANISM", 160, 167], ["patients", "SPECIES", 13, 21], ["patient", "SPECIES", 160, 167], ["the echocardiography", "TEST", 23, 43], ["a left coronary aneurysm", "PROBLEM", 53, 77], ["reduced ejection fraction", "PROBLEM", 87, 112], ["mitral valve regurgitation", "PROBLEM", 132, 158], ["pericardial effusion", "PROBLEM", 179, 199], ["left coronary", "ANATOMY", 55, 68], ["aneurysm", "OBSERVATION", 69, 77], ["ejection fraction", "OBSERVATION", 95, 112], ["mitral valve", "ANATOMY", 132, 144], ["regurgitation", "OBSERVATION", 145, 158], ["pericardial", "ANATOMY", 179, 190], ["effusion", "OBSERVATION", 191, 199]]], ["Patient 2 met the diagnosis with four additional laboratory criteria (ie, hypoalbuminaemia, hypertrans aminasaemia, leucocytosis, and sterile pyuria).ResultsPatients 4 and 5 diagnosed with incomplete Kawasaki disease, presented with non-exudative conjunctivitis associated with changes in the lips and oral cavity (patient 4), or polymorphic rash (patient 5).", [["lips", "ANATOMY", 293, 297], ["oral cavity", "ANATOMY", 302, 313], ["hypoalbuminaemia", "DISEASE", 74, 90], ["aminasaemia", "DISEASE", 103, 114], ["leucocytosis", "DISEASE", 116, 128], ["pyuria", "DISEASE", 142, 148], ["Kawasaki disease", "DISEASE", 200, 216], ["conjunctivitis", "DISEASE", 247, 261], ["rash", "DISEASE", 342, 346], ["lips", "ORGANISM_SUBDIVISION", 293, 297], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 302, 313], ["patient", "ORGANISM", 315, 322], ["patient", "ORGANISM", 348, 355], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 315, 322], ["patient", "SPECIES", 348, 355], ["hypoalbuminaemia", "PROBLEM", 74, 90], ["hypertrans aminasaemia", "PROBLEM", 92, 114], ["leucocytosis", "PROBLEM", 116, 128], ["sterile pyuria", "PROBLEM", 134, 148], ["incomplete Kawasaki disease", "PROBLEM", 189, 216], ["non-exudative conjunctivitis", "PROBLEM", 233, 261], ["changes in the lips and oral cavity", "PROBLEM", 278, 313], ["polymorphic rash", "PROBLEM", 330, 346], ["hypoalbuminaemia", "OBSERVATION", 74, 90], ["leucocytosis", "OBSERVATION", 116, 128], ["pyuria", "OBSERVATION", 142, 148], ["Kawasaki disease", "OBSERVATION", 200, 216], ["conjunctivitis", "OBSERVATION", 247, 261], ["lips", "ANATOMY", 293, 297], ["oral cavity", "ANATOMY", 302, 313]]], ["In these patients, echocardiography revealed left ventricular function depression, mitral valve regurgitation, and pericardial effusion; they also required inotropic support.", [["left ventricular", "ANATOMY", 45, 61], ["mitral valve", "ANATOMY", 83, 95], ["pericardial", "ANATOMY", 115, 126], ["left ventricular function depression", "DISEASE", 45, 81], ["mitral valve regurgitation", "DISEASE", 83, 109], ["pericardial effusion", "DISEASE", 115, 135], ["patients", "ORGANISM", 9, 17], ["ventricular", "MULTI-TISSUE_STRUCTURE", 50, 61], ["mitral valve", "PATHOLOGICAL_FORMATION", 83, 95], ["patients", "SPECIES", 9, 17], ["echocardiography", "TEST", 19, 35], ["left ventricular function depression", "PROBLEM", 45, 81], ["mitral valve regurgitation", "PROBLEM", 83, 109], ["pericardial effusion", "PROBLEM", 115, 135], ["inotropic support", "TREATMENT", 156, 173], ["left ventricular", "ANATOMY", 45, 61], ["function depression", "OBSERVATION", 62, 81], ["mitral valve", "ANATOMY", 83, 95], ["regurgitation", "OBSERVATION", 96, 109], ["pericardial", "ANATOMY", 115, 126], ["effusion", "OBSERVATION", 127, 135], ["inotropic support", "OBSERVATION", 156, 173]]], ["Patient 4 had an underlying diagnosis of congenital adrenal hyperplasia.ResultsChest x-ray, done in all patients in group 2, was positive in five (50%) patients for minimal mono or bilateral infiltrates.", [["adrenal hyperplasia", "ANATOMY", 52, 71], ["congenital adrenal hyperplasia", "DISEASE", 41, 71], ["adrenal", "ORGAN", 52, 59], ["hyperplasia", "PATHOLOGICAL_FORMATION", 60, 71], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 152, 160], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 152, 160], ["congenital adrenal hyperplasia", "PROBLEM", 41, 71], ["Chest x-ray", "TEST", 79, 90], ["minimal mono", "PROBLEM", 165, 177], ["bilateral infiltrates", "PROBLEM", 181, 202], ["congenital", "OBSERVATION_MODIFIER", 41, 51], ["adrenal", "ANATOMY", 52, 59], ["hyperplasia", "OBSERVATION", 60, 71], ["Chest", "ANATOMY", 79, 84], ["minimal", "OBSERVATION_MODIFIER", 165, 172], ["mono", "OBSERVATION_MODIFIER", 173, 177], ["bilateral", "ANATOMY_MODIFIER", 181, 190], ["infiltrates", "OBSERVATION", 191, 202]]], ["Patients 1 and 10 had a chest CT and a confirmed bibasilar pulmonary thickening.", [["chest", "ANATOMY", 24, 29], ["pulmonary", "ANATOMY", 59, 68], ["Patients", "ORGANISM", 0, 8], ["pulmonary", "ORGAN", 59, 68], ["Patients", "SPECIES", 0, 8], ["a chest CT", "TEST", 22, 32], ["bibasilar pulmonary thickening", "PROBLEM", 49, 79], ["chest", "ANATOMY", 24, 29], ["bibasilar", "ANATOMY_MODIFIER", 49, 58], ["pulmonary", "ANATOMY", 59, 68], ["thickening", "OBSERVATION", 69, 79]]], ["Patients 2 and 7, who had meningeal signs, had an electroencephalogram that showed a slow wave pattern; patient 7 had a lumbar puncture revealing normal cerebrospinal fluid and the absence of SARS-CoV-2 in the cerebrospinal fluid.ResultsFive (50%) of ten patients in group 2 met the criteria for KDSS because of hypotension and clinical signs of hypoperfusion.", [["meningeal", "ANATOMY", 26, 35], ["lumbar", "ANATOMY", 120, 126], ["cerebrospinal fluid", "ANATOMY", 153, 172], ["cerebrospinal fluid", "ANATOMY", 210, 229], ["SARS", "DISEASE", 192, 196], ["KDSS", "DISEASE", 296, 300], ["hypotension", "DISEASE", 312, 323], ["hypoperfusion", "DISEASE", 346, 359], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 104, 111], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 153, 172], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 192, 202], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 210, 229], ["patients", "ORGANISM", 255, 263], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 104, 111], ["patients", "SPECIES", 255, 263], ["meningeal signs", "PROBLEM", 26, 41], ["an electroencephalogram", "TEST", 47, 70], ["a slow wave pattern", "PROBLEM", 83, 102], ["a lumbar puncture", "TEST", 118, 135], ["normal cerebrospinal fluid", "PROBLEM", 146, 172], ["SARS", "PROBLEM", 192, 196], ["CoV", "TEST", 197, 200], ["the cerebrospinal fluid", "TEST", 206, 229], ["KDSS", "TREATMENT", 296, 300], ["hypotension", "PROBLEM", 312, 323], ["hypoperfusion", "PROBLEM", 346, 359], ["meningeal", "ANATOMY", 26, 35], ["lumbar", "ANATOMY", 120, 126], ["normal", "OBSERVATION", 146, 152], ["cerebrospinal fluid", "OBSERVATION", 153, 172], ["cerebrospinal", "ANATOMY", 210, 223], ["fluid", "OBSERVATION", 224, 229], ["hypotension", "OBSERVATION", 312, 323], ["hypoperfusion", "OBSERVATION", 346, 359]]], ["Two (20%) patients had diarrhoea and meningeal signs, four (40%) had only diarrhoea, and two (20%) had only meningeal signs ( (6) Yes (6) No (4) Yes (6) Yes (6) No (3) No (2) Yes (6) Yes (6) Yes (6) <12 Nasopharyngeal and oropharyngeal swab sampling for SARS-CoV-2, available from Feb 24, 2020, was positive in two (20%) of ten patients in group 2 (table 1).", [["meningeal", "ANATOMY", 37, 46], ["meningeal", "ANATOMY", 108, 117], ["Nasopharyngeal", "ANATOMY", 203, 217], ["oropharyngeal swab", "ANATOMY", 222, 240], ["diarrhoea", "DISEASE", 23, 32], ["meningeal signs", "DISEASE", 37, 52], ["diarrhoea", "DISEASE", 74, 83], ["SARS", "DISEASE", 254, 258], ["patients", "ORGANISM", 10, 18], ["Nasopharyngeal", "CANCER", 203, 217], ["patients", "ORGANISM", 328, 336], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 328, 336], ["SARS-CoV", "SPECIES", 254, 262], ["diarrhoea", "PROBLEM", 23, 32], ["meningeal signs", "PROBLEM", 37, 52], ["diarrhoea", "PROBLEM", 74, 83], ["meningeal signs", "PROBLEM", 108, 123], ["Nasopharyngeal and oropharyngeal swab sampling", "TEST", 203, 249], ["SARS", "TEST", 254, 258], ["CoV", "TEST", 259, 262], ["diarrhoea", "OBSERVATION", 23, 32], ["meningeal", "ANATOMY", 37, 46], ["diarrhoea", "OBSERVATION", 74, 83], ["meningeal", "ANATOMY", 108, 117], ["Nasopharyngeal", "ANATOMY", 203, 217], ["oropharyngeal", "ANATOMY", 222, 235]]], ["All patients were tested at least twice.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Serology for SARS-CoV-2 antibodies, available from April 13, 2020, was investigated in all patients in group 2; eight (80%) of ten patients were IgG positive, and three were also IgM positive.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["patients", "ORGANISM", 91, 99], ["patients", "ORGANISM", 131, 139], ["IgG", "GENE_OR_GENE_PRODUCT", 145, 148], ["SARS-CoV-2 antibodies", "PROTEIN", 13, 34], ["IgM", "PROTEIN", 179, 182], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 13, 21], ["Serology", "TEST", 0, 8], ["SARS", "TEST", 13, 17], ["CoV", "TEST", 18, 21], ["IgG", "TEST", 145, 148], ["IgM", "TEST", 179, 182]]], ["Patient 6, who had a negative serology, was tested shortly after the infusion of high-dose intravenous immunoglobulin (table 1) .ResultsOn April 14, 2020, 31 health-care personnel from the Paediatric Department, Hospital Papa Giovanni XXIII (Bergamo, Italy) had serology testing.", [["intravenous", "ANATOMY", 91, 102], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 103, 117], ["intravenous immunoglobulin", "PROTEIN", 91, 117], ["Patient", "SPECIES", 0, 7], ["high-dose intravenous immunoglobulin", "TREATMENT", 81, 117], ["serology testing", "TEST", 262, 278]]], ["Nine (29%) of 31 were IgG positive, and three (10%) were also IgM positive, corresponding to the expected rate of exposure of our local heath-care personnel to SARS-CoV-2 infection.", [["SARS", "DISEASE", 160, 164], ["infection", "DISEASE", 171, 180], ["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["SARS-CoV-2", "ORGANISM", 160, 170], ["IgG", "PROTEIN", 22, 25], ["IgM", "PROTEIN", 62, 65], ["SARS-CoV-2", "SPECIES", 160, 170], ["IgG", "TEST", 22, 25], ["IgM", "TEST", 62, 65], ["SARS", "PROBLEM", 160, 164], ["CoV-2 infection", "PROBLEM", 165, 180], ["infection", "OBSERVATION", 171, 180]]], ["In addition, two patients from group 1 diagnosed before the start of the epidemic were contacted and tested for SARS-CoV-2 antibodies, and both were negative.", [["patients", "ORGANISM", 17, 25], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 112, 122], ["SARS-CoV-2 antibodies", "PROTEIN", 112, 133], ["patients", "SPECIES", 17, 25], ["SARS-CoV", "SPECIES", 112, 120], ["the epidemic", "PROBLEM", 69, 81], ["SARS-CoV-2 antibodies", "TEST", 112, 133], ["negative", "OBSERVATION", 149, 157]]], ["To date, all patients in group 2 have been discharged, treatment with aspirin at an antiplatelet dose is ongoing, and a follow-up echocardiogram is scheduled at 8 weeks.ResultsFrom Jan 1, 2015, to the start of the epidemic on Feb 17, 2020, 19 children were diagnosed with Kawasaki disease (incidence 0\u00b73 per month; mean age 3 years [SD 2\u00b75]; seven boys, 12 girls); these patients comprised group 1.", [["aspirin", "CHEMICAL", 70, 77], ["Kawasaki disease", "DISEASE", 272, 288], ["aspirin", "CHEMICAL", 70, 77], ["patients", "ORGANISM", 13, 21], ["aspirin", "SIMPLE_CHEMICAL", 70, 77], ["children", "ORGANISM", 243, 251], ["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 13, 21], ["children", "SPECIES", 243, 251], ["boys", "SPECIES", 348, 352], ["girls", "SPECIES", 357, 362], ["patients", "SPECIES", 371, 379], ["treatment", "TREATMENT", 55, 64], ["aspirin", "TREATMENT", 70, 77], ["an antiplatelet dose", "TREATMENT", 81, 101], ["a follow-up echocardiogram", "TEST", 118, 144], ["Kawasaki disease", "PROBLEM", 272, 288], ["Kawasaki disease", "OBSERVATION", 272, 288]]], ["Admission to hospital occurred, on average, on day 6 of fever (range 4-11 days).", [["fever", "DISEASE", 56, 61], ["fever", "PROBLEM", 56, 61]]], ["13 (68%) of 19 patients presented with a classic form of the disease, and six (31%) of 19 with an incomplete form.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["the disease", "PROBLEM", 57, 68], ["disease", "OBSERVATION", 61, 68]]], ["None of the patients had hypotension, clinical signs of hypoperfusion, or other atypical symptoms.", [["hypotension", "DISEASE", 25, 36], ["hypoperfusion", "DISEASE", 56, 69], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["hypotension", "PROBLEM", 25, 36], ["hypoperfusion", "PROBLEM", 56, 69], ["other atypical symptoms", "PROBLEM", 74, 97], ["hypoperfusion", "OBSERVATION", 56, 69], ["atypical", "OBSERVATION_MODIFIER", 80, 88]]], ["Laboratory criteria predicted intravenous immunoglobulin resistance in two (10%) of 19 patients.", [["intravenous", "ANATOMY", 30, 41], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 41], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 42, 56], ["patients", "ORGANISM", 87, 95], ["immunoglobulin", "PROTEIN", 42, 56], ["patients", "SPECIES", 87, 95], ["Laboratory criteria", "TEST", 0, 19], ["intravenous immunoglobulin resistance", "TEST", 30, 67], ["immunoglobulin resistance", "OBSERVATION", 42, 67]]], ["MAS was not diagnosed in any of the patients.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44]]], ["All patients included had a favourable outcome.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Patients in group 1 had concluded their treatment and follow-up period, and recovered completely with no residual coronary artery aneurisms.ResultsGroup 1 comprised 19 patients diagnosed over 5 years, whereas group 2 included ten patients diagnosed over 1 month (incidence 0\u00b73 per month vs ten per month; figure) .", [["coronary artery", "ANATOMY", 114, 129], ["coronary artery aneurisms", "DISEASE", 114, 139], ["Patients", "ORGANISM", 0, 8], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 114, 129], ["patients", "ORGANISM", 168, 176], ["patients", "ORGANISM", 230, 238], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 168, 176], ["patients", "SPECIES", 230, 238], ["their treatment", "TREATMENT", 34, 49], ["residual coronary artery aneurisms", "PROBLEM", 105, 139], ["coronary artery", "ANATOMY", 114, 129], ["aneurisms", "OBSERVATION", 130, 139]]], ["To rule out the possible effect of number of referrals to the emergency department in different periods, we calculated incidence corrected for number of patients seen at the emergency department.", [["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161]]], ["We found that in the past 5 years, from January, 2015, to December, 2019, 98 572 patients had been evaluated, with a mean of 1642 (SD 280) per month, compared with 283 patients per month during the study periodapproximately six-fold lower.", [["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 168, 176], ["the study", "TEST", 194, 203], ["lower", "ANATOMY_MODIFIER", 233, 238]]], ["With these figures, the incidence of Kawasaki disease in group 1 was 0\u00b7019% (95% CI -0\u00b7002 to 0\u00b70019), compared with 3\u00b75% (-3\u00b75 to 3\u00b76) in group 2 (odds ratio 184; p<0\u00b70001; figure).", [["Kawasaki disease", "DISEASE", 37, 53], ["Kawasaki disease", "PROBLEM", 37, 53], ["CI", "TEST", 81, 83], ["odds ratio", "TEST", 148, 158], ["p", "TEST", 164, 165], ["Kawasaki disease", "OBSERVATION", 37, 53]]], ["To rule out the possible effect of a change in the geographical catchment area in the prepandemic (group 1) versus the pandemic (group 2) period, we reviewed the place of residence of all our patients with Kawasaki disease and drew a referral map, showing that all but one came from the Bergamo province (appendix p 1).", [["Kawasaki disease", "DISEASE", 206, 222], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["a change", "PROBLEM", 35, 43], ["Kawasaki disease", "PROBLEM", 206, 222], ["a referral map", "TEST", 232, 246], ["change", "OBSERVATION_MODIFIER", 37, 43], ["geographical", "OBSERVATION_MODIFIER", 51, 63], ["catchment", "OBSERVATION_MODIFIER", 64, 73], ["area", "OBSERVATION_MODIFIER", 74, 78], ["appendix", "ANATOMY", 305, 313]]], ["In group 1, 14 of 19 patients were white, versus eight of ten patients in group 2.", [["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 62, 70]]], ["The mean body-mass index of patients in group 1 was 15\u00b793 kg/m\u00b2 (SD 1\u00b772) versus 19\u00b711 kg/m\u00b2 (SD 3\u00b721) in group 2 (p=0\u00b70016).", [["body", "ANATOMY", 9, 13], ["body", "ORGANISM_SUBDIVISION", 9, 13], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["The mean body-mass index", "TEST", 0, 24], ["SD", "TEST", 65, 67], ["SD", "TEST", 94, 96], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["mass index", "OBSERVATION", 14, 24]]], ["Two patients tested in group 1 had a negative serology for SARS-CoV-2 versus eight of ten positive patients in group 2 (one of the two negative patients was tested after high-dose intravenous immunoglobulin); five (50%) of ten patients had been in contact with confirmed COVID-19 cases.", [["SARS", "DISEASE", 59, 63], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 99, 107], ["patients", "ORGANISM", 144, 152], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 192, 206], ["patients", "ORGANISM", 227, 235], ["immunoglobulin", "PROTEIN", 192, 206], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 227, 235], ["SARS-CoV", "SPECIES", 59, 67], ["SARS", "PROBLEM", 59, 63], ["CoV", "TEST", 64, 67], ["high-dose intravenous immunoglobulin", "TREATMENT", 170, 206], ["COVID", "TEST", 271, 276]]], ["Group 2 had a significantly lower white cell count, lymphocyte count, and platelet count when compared with group 1 (table 2).", [["white cell", "ANATOMY", 34, 44], ["lymphocyte", "ANATOMY", 52, 62], ["platelet", "ANATOMY", 74, 82], ["cell", "CELL", 40, 44], ["lymphocyte", "CELL", 52, 62], ["platelet", "CELL", 74, 82], ["platelet", "CELL_TYPE", 74, 82], ["a significantly lower white cell count", "PROBLEM", 12, 50], ["lymphocyte count", "TEST", 52, 68], ["platelet count", "TEST", 74, 88], ["cell count", "OBSERVATION", 40, 50], ["lymphocyte count", "OBSERVATION", 52, 68], ["platelet count", "OBSERVATION", 74, 88]]], ["Group 2 also differed significantly from group 1 for increased rate of markers of severity.", [["increased rate of markers of severity", "PROBLEM", 53, 90]]], ["An abnormal echocardiogram was recorded in six (60%) of ten patients of group 2 versus two (10%) of 19 patients in group 1 (p=0\u00b70089); fulfilment of criteria for KDSS and MAS was found in five (50%) of ten patients in group 2, and in none of the patients in group 1 (p=0\u00b7021).", [["KDSS", "DISEASE", 162, 166], ["MAS", "DISEASE", 171, 174], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 206, 214], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 246, 254], ["An abnormal echocardiogram", "TEST", 0, 26], ["KDSS", "PROBLEM", 162, 166], ["MAS", "PROBLEM", 171, 174], ["abnormal", "OBSERVATION_MODIFIER", 3, 11]]], ["Seven (70%) patients in group 2 met the criteria for a Kobayashi score of 5 or more, compared with two (10%) of 19 patients in group 1 (p=0\u00b70021).", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 115, 123], ["a Kobayashi score", "TEST", 53, 70]]], ["Adjunctive steroid treatment was required in four (16%) of 19 patients in group 1 versus eight (80%) of ten patients in group 2 (p=0\u00b70045; table 2).DiscussionDespite half a century having passed since Tomisaku Kawasaki first reported his 50 cases in Japan, 12 the cause of Kawasaki disease remains unknown.", [["steroid", "CHEMICAL", 11, 18], ["Kawasaki", "DISEASE", 210, 218], ["Kawasaki disease", "DISEASE", 273, 289], ["steroid", "CHEMICAL", 11, 18], ["steroid", "SIMPLE_CHEMICAL", 11, 18], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 108, 116], ["Adjunctive steroid treatment", "TREATMENT", 0, 28], ["Kawasaki disease", "PROBLEM", 273, 289], ["Kawasaki disease", "OBSERVATION", 273, 289]]], ["The most accepted hypothesis supports an aberrant response of the immune system to one or more unidentified pathogens in genetically predisposed patients; 21-23 however, the search for the infectious triggers has been disappointing.", [["immune system", "ANATOMY", 66, 79], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["an aberrant response of the immune system", "PROBLEM", 38, 79], ["the infectious triggers", "PROBLEM", 185, 208], ["aberrant", "OBSERVATION_MODIFIER", 41, 49], ["response", "OBSERVATION_MODIFIER", 50, 58], ["pathogens", "OBSERVATION", 108, 117], ["infectious", "OBSERVATION", 189, 199]]], ["24 In Japan, during three epidemics recorded in 1979, 1982, and 1986 , the highest Kawasaki disease incidence was seen in January, potentially suggesting that factors during winter months may trigger Kawasaki disease.", [["Kawasaki disease", "DISEASE", 83, 99], ["Kawasaki disease", "DISEASE", 200, 216], ["the highest Kawasaki disease incidence", "PROBLEM", 71, 109], ["Kawasaki disease", "PROBLEM", 200, 216]]], ["25, 26 In 2010, the incidence of Kawasaki disease in Japan was 239\u00b76 per 100 000 children younger than 5 years, compared with 20\u00b78 per 100 000 in the USA.", [["Kawasaki disease", "DISEASE", 33, 49], ["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89], ["Kawasaki disease", "PROBLEM", 33, 49], ["Kawasaki disease", "OBSERVATION", 33, 49]]], ["27 A 2-year retrospective survey done in northeastern Italy calculated an incidence of 14\u00b77 cases per 100 000 children younger than 5 years.", [["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118]]], ["28 We report a high number of Kawasaki-like disease cases in the Bergamo province following the SARS-CoV-2 epidemic, with a monthly incidence that is at least 30 times greater than the monthly incidence of the previous 5 years, and has a clear starting point after the first case of COVID-19 was diagnosed in our area.", [["Kawasaki-like disease", "DISEASE", 30, 51], ["SARS", "DISEASE", 96, 100], ["Kawasaki-like disease cases", "PROBLEM", 30, 57], ["COVID", "TEST", 283, 288]]], ["Group 2, diagnosed after SARS-CoV-2 appeared, showed evidence of seroconversion to the virus in the majority of patients.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "PROBLEM", 25, 29], ["CoV", "TEST", 30, 33], ["seroconversion", "PROBLEM", 65, 79], ["the virus", "PROBLEM", 83, 92], ["seroconversion", "OBSERVATION", 65, 79], ["virus", "OBSERVATION", 87, 92]]], ["A serological test was not done.", [["A serological test", "TEST", 0, 18]]], ["This report was followed by commentaries expressing a mixed sense of interest and scepticism.", [["scepticism", "PROBLEM", 82, 92]]], ["30 The arguments against this association were expressed by a group from Japan, who did a retrospective study [31] [32] [33] on nasopharyngeal swab samples from 19 children with Kawasaki disease and 208 controls with respiratory tract infections, and found RNA sequences of HCoV-NH in five (2%) of 208 controls versus zero of 19 children with Kawasaki disease.DiscussionAnother group from Japan explored the association between two different coronaviruses (HCoV-NL63 and HCoV-229E) and Kawasaki disease by serological tests.", [["nasopharyngeal swab samples", "ANATOMY", 128, 155], ["respiratory tract", "ANATOMY", 217, 234], ["Kawasaki disease", "DISEASE", 178, 194], ["respiratory tract infections", "DISEASE", 217, 245], ["Kawasaki disease", "DISEASE", 343, 359], ["Kawasaki disease", "DISEASE", 486, 502], ["nasopharyngeal swab samples", "CANCER", 128, 155], ["children", "ORGANISM", 164, 172], ["tract", "ORGANISM_SUBDIVISION", 229, 234], ["HCoV-NH", "GENE_OR_GENE_PRODUCT", 274, 281], ["children", "ORGANISM", 329, 337], ["coronaviruses", "ORGANISM", 442, 455], ["HCoV-NL63", "ORGANISM", 457, 466], ["HCoV-229E", "CELL", 471, 480], ["children", "SPECIES", 164, 172], ["children", "SPECIES", 329, 337], ["HCoV-229E", "SPECIES", 471, 480], ["a retrospective study", "TEST", 88, 109], ["nasopharyngeal swab samples", "TEST", 128, 155], ["Kawasaki disease", "PROBLEM", 178, 194], ["respiratory tract infections", "PROBLEM", 217, 245], ["RNA sequences", "TEST", 257, 270], ["HCoV", "TEST", 274, 278], ["Kawasaki disease", "PROBLEM", 343, 359], ["two different coronaviruses", "PROBLEM", 428, 455], ["HCoV", "TEST", 457, 461], ["HCoV", "TEST", 471, 475], ["Kawasaki disease", "PROBLEM", 486, 502], ["serological tests", "TEST", 506, 523], ["respiratory tract", "ANATOMY", 217, 234]]], ["The immunofluorescence assay detected no difference in HCoV-NL63 antibody positivity between patients and controls, whereas HCoV-229E antibody positivity was higher in patients with Kawasaki disease.", [["Kawasaki disease", "DISEASE", 182, 198], ["HCoV", "GENE_OR_GENE_PRODUCT", 55, 59], ["NL63", "GENE_OR_GENE_PRODUCT", 60, 64], ["patients", "ORGANISM", 93, 101], ["HCoV-229E antibody", "GENE_OR_GENE_PRODUCT", 124, 142], ["patients", "ORGANISM", 168, 176], ["NL63 antibody", "PROTEIN", 60, 73], ["HCoV", "PROTEIN", 124, 128], ["229E antibody", "PROTEIN", 129, 142], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 168, 176], ["HCoV", "SPECIES", 55, 59], ["HCoV", "SPECIES", 124, 128], ["The immunofluorescence assay", "TEST", 0, 28], ["HCoV", "TEST", 55, 59], ["antibody positivity", "TEST", 65, 84], ["HCoV", "TEST", 124, 128], ["229E antibody positivity", "TEST", 129, 153], ["Kawasaki disease", "PROBLEM", 182, 198], ["Kawasaki disease", "OBSERVATION", 182, 198]]], ["34 Given the pathogenesis of the disease, serology testing seems a more reliable tool than RT-PCR in detecting the cause of infection.", [["infection", "DISEASE", 124, 133], ["the disease", "PROBLEM", 29, 40], ["serology testing", "TEST", 42, 58], ["RT-PCR", "TEST", 91, 97], ["infection", "PROBLEM", 124, 133], ["disease", "OBSERVATION", 33, 40], ["infection", "OBSERVATION", 124, 133]]], ["This suggests that the coronavirus family might represent one of the triggers of Kawasaki disease, SARS-CoV-2 being a particularly virulent strain able to elicit a powerful immune response in the host.DiscussionIn this study, the clinical and biochemical features of patients with Kawasaki disease diagnosed during the COVID-19 pandemic appeared to differ from our historical cohort of patients; therefore, we have classified these patients as Kawasaki-like disease.", [["Kawasaki disease", "DISEASE", 81, 97], ["SARS", "DISEASE", 99, 103], ["Kawasaki disease", "DISEASE", 281, 297], ["Kawasaki-like disease", "DISEASE", 444, 465], ["coronavirus", "ORGANISM", 23, 34], ["SARS-CoV-2", "ORGANISM", 99, 109], ["patients", "ORGANISM", 267, 275], ["patients", "ORGANISM", 386, 394], ["patients", "ORGANISM", 432, 440], ["Kawasaki-like disease", "CANCER", 444, 465], ["patients", "SPECIES", 267, 275], ["patients", "SPECIES", 386, 394], ["patients", "SPECIES", 432, 440], ["SARS-CoV", "SPECIES", 99, 107], ["Kawasaki disease", "PROBLEM", 81, 97], ["SARS", "PROBLEM", 99, 103], ["a particularly virulent strain", "PROBLEM", 116, 146], ["this study", "TEST", 214, 224], ["Kawasaki disease", "PROBLEM", 281, 297], ["the COVID", "TEST", 315, 324], ["Kawasaki-like disease", "PROBLEM", 444, 465], ["coronavirus", "OBSERVATION", 23, 34]]], ["From a clinical perspective, they were older, had respiratory and gastrointestinal involvement, meningeal signs, and signs of cardiovascular involvement.", [["respiratory", "ANATOMY", 50, 61], ["gastrointestinal", "ANATOMY", 66, 82], ["meningeal", "ANATOMY", 96, 105], ["cardiovascular", "ANATOMY", 126, 140], ["respiratory and gastrointestinal involvement", "DISEASE", 50, 94], ["gastrointestinal", "ORGAN", 66, 82], ["cardiovascular", "ANATOMICAL_SYSTEM", 126, 140], ["respiratory and gastrointestinal involvement", "PROBLEM", 50, 94], ["meningeal signs", "PROBLEM", 96, 111], ["cardiovascular involvement", "PROBLEM", 126, 152], ["gastrointestinal", "ANATOMY", 66, 82], ["meningeal", "ANATOMY", 96, 105], ["cardiovascular", "ANATOMY", 126, 140], ["involvement", "OBSERVATION", 141, 152]]], ["From a biochemical perspective, they had leucopenia with marked lymphopenia, thrombocytopenia, and increased ferritin, as well as markers of myocarditis.", [["leucopenia", "DISEASE", 41, 51], ["lymphopenia", "DISEASE", 64, 75], ["thrombocytopenia", "DISEASE", 77, 93], ["myocarditis", "DISEASE", 141, 152], ["ferritin", "GENE_OR_GENE_PRODUCT", 109, 117], ["ferritin", "PROTEIN", 109, 117], ["leucopenia", "PROBLEM", 41, 51], ["marked lymphopenia", "PROBLEM", 57, 75], ["thrombocytopenia", "PROBLEM", 77, 93], ["increased ferritin", "PROBLEM", 99, 117], ["myocarditis", "PROBLEM", 141, 152], ["marked", "OBSERVATION_MODIFIER", 57, 63], ["lymphopenia", "OBSERVATION", 64, 75], ["thrombocytopenia", "OBSERVATION", 77, 93], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["ferritin", "OBSERVATION", 109, 117], ["myocarditis", "OBSERVATION", 141, 152]]], ["Similar clinical features are shared by patients with COVID-19.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["COVID", "TEST", 54, 59]]], ["4 Additionally, these patients had a more severe disease course, with resistance to intravenous immunoglobulin and need of adjunctive steroids, biochemical evidence of MAS, and clinical signs in keeping with KDSS.DiscussionThe proinflammatory effect of SARS-CoV-2 has been reported in adults with the most severe respiratory complications of COVID-19.", [["intravenous", "ANATOMY", 84, 95], ["respiratory", "ANATOMY", 313, 324], ["steroids", "CHEMICAL", 134, 142], ["MAS", "DISEASE", 168, 171], ["KDSS", "DISEASE", 208, 212], ["SARS", "DISEASE", 253, 257], ["respiratory complications", "DISEASE", 313, 338], ["steroids", "CHEMICAL", 134, 142], ["COVID-19", "CHEMICAL", 342, 350], ["patients", "ORGANISM", 22, 30], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 96, 110], ["SARS-CoV-2", "ORGANISM", 253, 263], ["intravenous immunoglobulin", "PROTEIN", 84, 110], ["patients", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 253, 261], ["a more severe disease course", "PROBLEM", 35, 63], ["intravenous immunoglobulin", "TREATMENT", 84, 110], ["adjunctive steroids", "TREATMENT", 123, 142], ["MAS", "PROBLEM", 168, 171], ["clinical signs", "TEST", 177, 191], ["KDSS", "PROBLEM", 208, 212], ["SARS", "PROBLEM", 253, 257], ["COVID", "TEST", 342, 347], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["disease", "OBSERVATION", 49, 56]]], ["35, 36 Many of these patients have a constellation of features classified under the term cytokine storm, such as fever, lymphopenia, elevated transaminases, lactate dehydrogenase, D-dimer, and ferritin, in keeping with MAS.", [["fever", "DISEASE", 113, 118], ["lymphopenia", "DISEASE", 120, 131], ["lactate", "CHEMICAL", 157, 164], ["lactate", "CHEMICAL", 157, 164], ["patients", "ORGANISM", 21, 29], ["transaminases", "SIMPLE_CHEMICAL", 142, 155], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 157, 178], ["D-dimer", "SIMPLE_CHEMICAL", 180, 187], ["ferritin", "GENE_OR_GENE_PRODUCT", 193, 201], ["cytokine", "PROTEIN", 89, 97], ["lactate dehydrogenase", "PROTEIN", 157, 178], ["D-dimer", "PROTEIN", 180, 187], ["ferritin", "PROTEIN", 193, 201], ["patients", "SPECIES", 21, 29], ["the term cytokine storm", "PROBLEM", 80, 103], ["fever", "PROBLEM", 113, 118], ["lymphopenia", "PROBLEM", 120, 131], ["elevated transaminases", "PROBLEM", 133, 155], ["lactate dehydrogenase", "TEST", 157, 178], ["D-dimer", "TEST", 180, 187], ["ferritin", "TEST", 193, 201], ["MAS", "PROBLEM", 219, 222], ["cytokine storm", "OBSERVATION", 89, 103], ["lymphopenia", "OBSERVATION", 120, 131], ["elevated", "OBSERVATION_MODIFIER", 133, 141], ["transaminases", "OBSERVATION_MODIFIER", 142, 155], ["ferritin", "OBSERVATION", 193, 201], ["MAS", "OBSERVATION", 219, 222]]], ["11, 35, 37 Likewise, MAS is a form of cytokine storm, and might affect patients with Kawasaki disease.", [["Kawasaki disease", "DISEASE", 85, 101], ["patients", "ORGANISM", 71, 79], ["cytokine", "PROTEIN", 38, 46], ["patients", "SPECIES", 71, 79], ["cytokine storm", "PROBLEM", 38, 52], ["Kawasaki disease", "PROBLEM", 85, 101], ["cytokine storm", "OBSERVATION", 38, 52]]], ["9, 15 All these elements supported the need to start adjunctive steroids.", [["steroids", "CHEMICAL", 64, 72], ["9, 15", "CHEMICAL", 0, 5], ["steroids", "CHEMICAL", 64, 72], ["adjunctive steroids", "TREATMENT", 53, 72]]], ["In our experience, this treatment is effective and safe, and should be considered by physicians treating patients with Kawasaki-like presentations in the context of the COVID-19 pandemic.DiscussionEvidence of contact with the virus was confirmed by the presence of antibodies against SARS-CoV-2 in eight of ten patients in group 2.", [["Kawasaki-like presentations", "DISEASE", 119, 146], ["patients", "ORGANISM", 105, 113], ["SARS-CoV-2", "ORGANISM", 284, 294], ["patients", "ORGANISM", 311, 319], ["antibodies", "PROTEIN", 265, 275], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 311, 319], ["SARS-CoV", "SPECIES", 284, 292], ["this treatment", "TREATMENT", 19, 33], ["the COVID", "TEST", 165, 174], ["pandemic", "PROBLEM", 178, 186], ["the virus", "PROBLEM", 222, 231], ["antibodies", "TEST", 265, 275], ["SARS", "PROBLEM", 284, 288], ["CoV", "TEST", 289, 292]]], ["It is possible that in the remaining two patients, who both had a negative serology, con founding factors played a role.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49]]], ["One patient was tested just after an infusion of high-dose immunoglobulins.", [["patient", "ORGANISM", 4, 11], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 59, 74], ["high-dose immunoglobulins", "PROTEIN", 49, 74], ["patient", "SPECIES", 4, 11], ["high-dose immunoglobulins", "TREATMENT", 49, 74]]], ["Additionally, qualitative antibody testing is reported to have a sensitivity of 95% and a specificity of 85-90% when compared with PCR test by nasal swab.", [["nasal swab", "ANATOMY", 143, 153], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 143, 153], ["qualitative antibody testing", "TEST", 14, 42], ["PCR test", "TEST", 131, 139], ["nasal swab", "TEST", 143, 153], ["nasal", "ANATOMY", 143, 148]]], ["It is also possible that this patient represents an usual presentation of Kawasaki disease outside of SARS-CoV-2 epidemic, as seen in previous years.", [["Kawasaki disease", "DISEASE", 74, 90], ["SARS-CoV-2 epidemic", "DISEASE", 102, 121], ["patient", "ORGANISM", 30, 37], ["SARS-CoV-2", "ORGANISM", 102, 112], ["patient", "SPECIES", 30, 37], ["Kawasaki disease", "PROBLEM", 74, 90], ["SARS", "PROBLEM", 102, 106], ["also possible", "UNCERTAINTY", 6, 19]]], ["Only two patients in group 2 presented a positive nasopharyngeal and oropharyngeal swab sampling for SARS-CoV-2.", [["nasopharyngeal", "ANATOMY", 50, 64], ["oropharyngeal swab", "ANATOMY", 69, 87], ["SARS", "DISEASE", 101, 105], ["patients", "ORGANISM", 9, 17], ["nasopharyngeal", "CANCER", 50, 64], ["patients", "SPECIES", 9, 17], ["SARS-CoV", "SPECIES", 101, 109], ["oropharyngeal swab sampling", "TEST", 69, 96], ["SARS", "PROBLEM", 101, 105], ["nasopharyngeal", "ANATOMY", 50, 64], ["oropharyngeal", "ANATOMY", 69, 82]]], ["This finding and the positivity of IgG antibodies suggest a late onset of the disease compared with the primary infection, due to the host immune response.", [["primary infection", "DISEASE", 104, 121], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 35, 49], ["IgG antibodies", "PROTEIN", 35, 49], ["IgG antibodies", "TEST", 35, 49], ["the disease", "PROBLEM", 74, 85], ["the primary infection", "PROBLEM", 100, 121], ["late onset", "OBSERVATION_MODIFIER", 60, 70], ["disease", "OBSERVATION", 78, 85], ["infection", "OBSERVATION", 112, 121]]], ["This might be the reason why, in the past, no active viral infection could be shown in this disease.", [["viral infection", "DISEASE", 53, 68], ["active viral infection", "PROBLEM", 46, 68], ["this disease", "PROBLEM", 87, 99], ["no", "UNCERTAINTY", 43, 45], ["active", "OBSERVATION_MODIFIER", 46, 52], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infection", "OBSERVATION", 59, 68]]], ["All these results and considerations support the hypothesis that the immune response to SARS-CoV-2 is responsible for a Kawasaki-like disease in susceptible patients.DiscussionWe believe these findings have important implications for public health.", [["SARS", "DISEASE", 88, 92], ["Kawasaki-like disease", "DISEASE", 120, 141], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["SARS-CoV", "SPECIES", 88, 96], ["the hypothesis", "PROBLEM", 45, 59], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["a Kawasaki-like disease", "PROBLEM", 118, 141]]], ["The association between SARS-CoV-2 and Kawasaki-like disease should be taken into account when it comes to considering social reintegration policies for the paediatric population.", [["Kawasaki-like disease", "DISEASE", 39, 60], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["Kawasaki-like disease", "PROBLEM", 39, 60], ["social reintegration policies", "TREATMENT", 119, 148], ["the paediatric population", "TREATMENT", 153, 178]]], ["However, the Kawasaki-like disease described here remains a rare condition, probably affecting no more than one in 1000 children exposed to SARS-CoV-2.", [["Kawasaki-like disease", "DISEASE", 13, 34], ["SARS", "DISEASE", 140, 144], ["children", "ORGANISM", 120, 128], ["SARS-CoV-2", "ORGANISM", 140, 150], ["children", "SPECIES", 120, 128], ["SARS-CoV", "SPECIES", 140, 148], ["the Kawasaki-like disease", "PROBLEM", 9, 34]]], ["This estimate is based on the limited data from the case series in this region.DiscussionThis study has the limitations of a relatively small case series, requiring confirmation in larger groups.", [["This study", "TEST", 89, 99], ["a relatively small case series", "PROBLEM", 123, 153]]], ["Genetic studies investigating the susceptibility of patients developing this disease to the triggering effect of SARS-CoV-2 should be done.", [["SARS", "DISEASE", 113, 117], ["patients", "ORGANISM", 52, 60], ["SARS-CoV-2", "ORGANISM", 113, 123], ["patients", "SPECIES", 52, 60], ["SARS-CoV", "SPECIES", 113, 121], ["Genetic studies", "TEST", 0, 15], ["this disease", "PROBLEM", 72, 84], ["SARS", "PROBLEM", 113, 117], ["CoV", "TEST", 118, 121]]], ["Nonetheless, we reported a strong association between an outbreak of Kawasaki-like disease and the SARS-CoV-2 epidemic in the Bergamo province of Italy.", [["Kawasaki-like disease", "DISEASE", 69, 90], ["SARS-CoV-2 epidemic", "DISEASE", 99, 118], ["CoV-2", "ORGANISM", 104, 109], ["SARS-CoV", "SPECIES", 99, 107], ["Kawasaki-like disease", "PROBLEM", 69, 90], ["the SARS", "TEST", 95, 103], ["CoV", "TEST", 104, 107]]], ["Patients diagnosed with Kawasaki-like disease after the viral spreading revealed a severe course, including KDSS and MAS, and required adjunctive steroid treatment.", [["Kawasaki-like disease", "DISEASE", 24, 45], ["KDSS", "DISEASE", 108, 112], ["MAS", "DISEASE", 117, 120], ["steroid", "CHEMICAL", 146, 153], ["steroid", "CHEMICAL", 146, 153], ["Patients", "ORGANISM", 0, 8], ["steroid", "SIMPLE_CHEMICAL", 146, 153], ["Patients", "SPECIES", 0, 8], ["Kawasaki-like disease", "PROBLEM", 24, 45], ["the viral spreading", "PROBLEM", 52, 71], ["KDSS", "PROBLEM", 108, 112], ["MAS", "PROBLEM", 117, 120], ["adjunctive steroid treatment", "TREATMENT", 135, 163], ["severe", "OBSERVATION_MODIFIER", 83, 89]]], ["A similar outbreak of Kawasaki-like disease is expected in countries affected by the SARS-CoV-2 pandemic.ContributorsLV and LD'A made substantial contributions to the conception or design of the work.", [["Kawasaki-like disease", "DISEASE", 22, 43], ["SARS-CoV-2 pandemic", "DISEASE", 85, 104], ["SARS-CoV-2", "ORGANISM", 85, 95], ["Kawasaki-like disease", "PROBLEM", 22, 43], ["the SARS", "TEST", 81, 89], ["pandemic", "PROBLEM", 96, 104], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["outbreak", "OBSERVATION_MODIFIER", 10, 18], ["Kawasaki", "OBSERVATION", 22, 30]]], ["LV and AM drafted the work.", [["LV", "ANATOMY", 0, 2], ["LV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["LV", "TEST", 0, 2]]], ["LV, AM, AG, LM, MR, MC, EB, and LD'A gave final approval for the Article to be published.", [["LV", "ANATOMY", 0, 2], ["LV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["MR", "PROTEIN", 16, 18], ["LV", "TEST", 0, 2], ["MR", "TEST", 16, 18], ["LM", "ANATOMY", 12, 14], ["EB", "ANATOMY", 24, 26]]], ["LV, AM, AG, LM, MR, MC, EB, and LD'A agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.", [["LV", "ANATOMY", 0, 2], ["LV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["MR", "PROTEIN", 16, 18], ["LV", "TEST", 0, 2], ["MR", "TEST", 16, 18], ["LM", "ANATOMY", 12, 14], ["EB", "ANATOMY", 24, 26]]], ["AM, AG, LM, MR, MC, and EB acquired, analysed, or interpreted data for the Article.", [["MR", "PROTEIN", 12, 14], ["AG", "TEST", 4, 6], ["MR", "TEST", 12, 14], ["MC", "TEST", 16, 18], ["LM", "ANATOMY", 8, 10]]], ["AG, LM, MR, MC, and EB revised the Article critically for important intellectual content.", [["MR", "PROTEIN", 8, 10], ["MR", "TEST", 8, 10], ["LM", "ANATOMY", 4, 6]]], ["LD'A prepared the final draft and critically revised the Article for important intellectual content.Declaration of interestsWe declare no competing interests and no financial support for this study.", [["financial support", "TREATMENT", 165, 182], ["this study", "TEST", 187, 197]]]], "2103b43595a5f0c240b1f1c52c3701572b57d844": [["Introduction: 152The Eurolung is a model developed from the ESTS database to stratify the risk of immediate 153 postoperative mortality based on patient and surgical related characteristics (1) .", [["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["the ESTS database", "TEST", 56, 73]]], ["Recent 154 evidence has shown that different physiologic and patient related factors may influence not 155 only perioperative outcomes but also long-term survival after curative treatment for cancer 156Introduction: 152(2-6).", [["cancer", "ANATOMY", 192, 198], ["cancer", "DISEASE", 192, 198], ["patient", "ORGANISM", 61, 68], ["cancer", "CANCER", 192, 198], ["patient", "SPECIES", 61, 68], ["curative treatment", "TREATMENT", 169, 187], ["cancer", "PROBLEM", 192, 198]]], ["As the Eurolung model includes non oncologic factors potentially associated with 157 prognosis it may represent a valuable tool to estimate not only the immediate risk of death 158 following surgery but also the long-term mortality after curative resection.", [["death", "DISEASE", 171, 176], ["death", "PROBLEM", 171, 176], ["surgery", "TREATMENT", 191, 198], ["curative resection", "TREATMENT", 238, 256], ["resection", "OBSERVATION", 247, 256]]], ["159Introduction: 152The objective of this study was therefore to verify whether the Eurolung aggregate score was 160 associated with overall and disease-specific survival after lung cancer resection.", [["lung cancer", "ANATOMY", 177, 188], ["lung cancer", "DISEASE", 177, 188], ["lung cancer", "CANCER", 177, 188], ["this study", "TEST", 37, 47], ["the Eurolung aggregate score", "TEST", 80, 108], ["lung cancer resection", "TREATMENT", 177, 198], ["lung", "ANATOMY", 177, 181], ["cancer", "OBSERVATION", 182, 188]]], ["161Patients and Methods: 162This is a retrospective single center analysis performed on prospectively collected data.", [["prospectively collected data", "TEST", 88, 116]]], ["1359 163 consecutive patients undergoing anatomic lung resection for non-small cell lung cancer (1136 164 lobectomies, 103 pneumonectomies, 120 segmentectomies) from April 2014 through 165Patients and Methods: 162December 2018 were analysed.", [["lung", "ANATOMY", 50, 54], ["non-small cell lung cancer", "ANATOMY", 69, 95], ["pneumonectomies", "ANATOMY", 123, 138], ["non-small cell lung cancer", "DISEASE", 69, 95], ["patients", "ORGANISM", 21, 29], ["lung", "ORGAN", 50, 54], ["non-small cell lung cancer", "CANCER", 69, 95], ["patients", "SPECIES", 21, 29], ["anatomic lung resection", "TREATMENT", 41, 64], ["non-small cell lung cancer", "PROBLEM", 69, 95], ["lobectomies", "TREATMENT", 106, 117], ["pneumonectomies", "TREATMENT", 123, 138], ["lung", "ANATOMY", 50, 54], ["resection", "OBSERVATION", 55, 64], ["non-small cell", "OBSERVATION", 69, 83], ["lung", "ANATOMY", 84, 88], ["cancer", "OBSERVATION", 89, 95], ["pneumonectomies", "OBSERVATION", 123, 138]]], ["166Patients and Methods: 162The study was reviewed by the Research and Innovation Department of the hospital and 167 classified as service evaluation not requiring review by an NHS Research Ethics Committee.", [["The study", "TEST", 28, 37], ["service evaluation", "TEST", 131, 149]]], ["168Patients and Methods: 162All patients were selected for operation following discussion in a multidisciplinary tumour 169 board.", [["tumour", "ANATOMY", 113, 119], ["tumour", "DISEASE", 113, 119], ["patients", "ORGANISM", 32, 40], ["tumour", "CANCER", 113, 119], ["patients", "SPECIES", 32, 40], ["operation", "TREATMENT", 59, 68]]], ["A patient was deemed unfit for surgery in case of a ppoFEV1 and ppoDLCO<30% of 170 predicted associated with VO2max<10 ml/kg/min, according to published guidelines (7). dedicated thoracic surgery unit following surgery.", [["thoracic", "ANATOMY", 179, 187], ["patient", "ORGANISM", 2, 9], ["thoracic", "ORGAN", 179, 187], ["patient", "SPECIES", 2, 9], ["surgery", "TREATMENT", 31, 38], ["ppoDLCO", "TEST", 64, 71], ["dedicated thoracic surgery", "TREATMENT", 169, 195], ["surgery", "TREATMENT", 211, 218], ["thoracic", "ANATOMY", 179, 187]]], ["Only patients with pathologically staged 176 R0 resections were included in the analysis.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["pathologically staged 176 R0 resections", "TREATMENT", 19, 58], ["the analysis", "TEST", 76, 88], ["R0 resections", "OBSERVATION", 45, 58]]], ["A systematic lymph node dissection was 177 performed in all patients.", [["lymph node", "ANATOMY", 13, 23], ["lymph node", "MULTI-TISSUE_STRUCTURE", 13, 23], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["A systematic lymph node dissection", "TREATMENT", 0, 34], ["systematic", "OBSERVATION_MODIFIER", 2, 12], ["lymph node dissection", "OBSERVATION", 13, 34]]], ["Patients were staged according to the 8 th edition of the TNM 178 staging system.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["staging system", "TEST", 66, 80]]], ["449 patients were alive at more than 3 years following surgery.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["surgery", "TREATMENT", 55, 62]]], ["229Patients and Methods: 162The median Eurolung score was 2.5 (IQR 1-4.5) and ranged from 0 to 11.5 points.", [["The median Eurolung score", "TEST", 28, 53], ["IQR", "TEST", 63, 66], ["median", "OBSERVATION_MODIFIER", 32, 38]]], ["230Patients and Methods: 162Most patients were in class A (52%) and B (33%), 8% were in class C and 7% were in class 231D.", [["patients", "ORGANISM", 33, 41], ["class A", "CANCER", 50, 57], ["B", "CANCER", 68, 69], ["patients", "SPECIES", 33, 41], ["class A", "SPECIES", 50, 57]]], ["232There was an incremental 30 day mortality rate across the Eurolung categories (A: 0.9%, B: 233 5.4%, C: 9.7%, and D: 14%, p<0.0001).", [["mortality rate", "TEST", 35, 49], ["C", "TEST", 104, 105], ["D", "TEST", 117, 118], ["p", "TEST", 125, 126]]], ["The score stratified well the 3-year OS in patients with either pT1 (p<0.0001) or pT greater 247 than 1 (p<0.0001) (Figure 2a and 2b ).", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["pT1", "TEST", 64, 67], ["pT", "TEST", 82, 84]]], ["In addition, the different classes were associated with 248 incremental risk of long-term mortality in patients with negative nodal disease (p<0.0001) 249 and in those with positive nodes (p=0.0007).", [["nodal", "ANATOMY", 126, 131], ["nodes", "ANATOMY", 182, 187], ["patients", "ORGANISM", 103, 111], ["nodal", "MULTI-TISSUE_STRUCTURE", 126, 131], ["patients", "SPECIES", 103, 111], ["long-term mortality", "PROBLEM", 80, 99], ["negative nodal disease", "PROBLEM", 117, 139], ["positive nodes", "PROBLEM", 173, 187], ["long-term", "OBSERVATION_MODIFIER", 80, 89], ["nodal disease", "OBSERVATION", 126, 139], ["positive", "OBSERVATION_MODIFIER", 173, 181], ["nodes", "OBSERVATION", 182, 187]]], ["(Figure 3a and The Eurolung score was developed to stratify the risk of postoperative 30 day morbidity and 280 mortality (1).", [["The Eurolung score", "TEST", 15, 33]]], ["The model includes several patient-related and surgical-related variables such 281 as age, gender, ppoFEV1, BMI, extent of resection and surgical access.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["resection", "TREATMENT", 123, 132], ["surgical access", "TREATMENT", 137, 152], ["resection", "OBSERVATION", 123, 132], ["surgical access", "OBSERVATION", 137, 152]]], ["Some of these factors 282 are clearly associated with patient frailty and co-morbidities and others reflect the complexity 283 of the operation often dictated by the locally advanced stage of disease.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["patient frailty and co-morbidities", "PROBLEM", 54, 88], ["the operation", "TREATMENT", 130, 143], ["disease", "PROBLEM", 192, 199], ["disease", "OBSERVATION", 192, 199]]], ["In addition, the extent 284 of surgery may lead to further disabilities leading in turn to increased long term morbidity 285 and mortality.", [["surgery", "TREATMENT", 31, 38], ["further disabilities", "PROBLEM", 51, 71], ["increased long term morbidity", "PROBLEM", 91, 120], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["long term", "OBSERVATION_MODIFIER", 101, 110]]], ["For this reason, we hypothesized that a cumulative score such as Eurolung 286 may be associated not only with short term outcome but also with long term survival 287 following curative surgery.", [["a cumulative score", "PROBLEM", 38, 56], ["short term outcome", "PROBLEM", 110, 128], ["long term survival", "TREATMENT", 143, 161], ["curative surgery", "TREATMENT", 176, 192]]], ["The rationale is to develop an additional tool which can be used 288 in combination with the most traditional oncologic prognostic factors (such as stage of 289 disease) to enhance the prediction of long-term mortality to more specifically tailor curative 290 treatment to individual patients.", [["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 284, 292]]], ["291Main Finding 292The main finding of this study was that the Eurolung aggregate score was associated with an 293 incremental risk of long-term overall and lung cancer specific mortality.", [["lung cancer", "ANATOMY", 157, 168], ["lung cancer", "DISEASE", 157, 168], ["lung cancer", "CANCER", 157, 168], ["this study", "TEST", 39, 49], ["the Eurolung aggregate score", "PROBLEM", 59, 87], ["long-term overall and lung cancer specific mortality", "PROBLEM", 135, 187], ["main", "OBSERVATION_MODIFIER", 23, 27], ["long-term", "OBSERVATION_MODIFIER", 135, 144], ["lung", "ANATOMY", 157, 161], ["cancer", "OBSERVATION", 162, 168]]], ["Patients in class D 294 had 64% and 73% 3-and 5-year overall mortality rate, which was 3-fold higher than the one 295 observed in class A (with the lowest risk).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["mortality rate", "TEST", 61, 75]]], ["296Main Finding 292The incremental risk of long-term death is in line with the incremental risk of perioperative 297 mortality shown in the original study (1) and also found in this set of patients.", [["death", "DISEASE", 53, 58], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["long-term death", "PROBLEM", 43, 58], ["the original study", "TEST", 136, 154], ["long-term", "OBSERVATION_MODIFIER", 43, 52]]], ["This is in part 298 frailty of patients which may have an impact not only on the short-term outcomes but also on 300 the long-term survival.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["the long-term survival", "TREATMENT", 117, 139]]], ["Older age, reduced pulmonary function and lower BMI encapsulating 301 the risk of sarcopenia as well as being a potential marker of more advanced disease, are well 302 known adverse prognostic factors in lung cancer patients.", [["pulmonary", "ANATOMY", 19, 28], ["lung cancer", "ANATOMY", 204, 215], ["sarcopenia", "DISEASE", 82, 92], ["lung cancer", "DISEASE", 204, 215], ["pulmonary", "ORGAN", 19, 28], ["lung cancer", "CANCER", 204, 215], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["reduced pulmonary function", "PROBLEM", 11, 37], ["lower BMI encapsulating", "PROBLEM", 42, 65], ["sarcopenia", "PROBLEM", 82, 92], ["more advanced disease", "PROBLEM", 132, 153], ["lung cancer", "PROBLEM", 204, 215], ["reduced", "OBSERVATION_MODIFIER", 11, 18], ["pulmonary", "ANATOMY", 19, 28], ["sarcopenia", "OBSERVATION", 82, 92], ["advanced", "OBSERVATION_MODIFIER", 137, 145], ["disease", "OBSERVATION", 146, 153], ["lung", "ANATOMY", 204, 208], ["cancer", "OBSERVATION", 209, 215]]], ["Even more interesting is the 303 finding that Eurolung is associated with lung cancer specific mortality.", [["lung cancer", "ANATOMY", 74, 85], ["lung cancer", "DISEASE", 74, 85], ["Eurolung", "SIMPLE_CHEMICAL", 46, 54], ["lung cancer", "CANCER", 74, 85], ["lung cancer specific mortality", "PROBLEM", 74, 104], ["associated with", "UNCERTAINTY", 58, 73], ["lung", "ANATOMY", 74, 78], ["cancer", "OBSERVATION", 79, 85]]], ["This may be 304 The concept of using risk models including patient and treatment related variables in order to 335 stratify the prognosis following lung cancer resection has been tested in previous studies (24-336 28).", [["lung cancer", "ANATOMY", 148, 159], ["lung cancer", "DISEASE", 148, 159], ["patient", "ORGANISM", 59, 66], ["lung cancer", "CANCER", 148, 159], ["patient", "SPECIES", 59, 66], ["treatment", "TREATMENT", 71, 80], ["lung cancer resection", "TREATMENT", 148, 169], ["previous studies", "TEST", 189, 205], ["lung", "ANATOMY", 148, 152], ["cancer", "OBSERVATION", 153, 159]]], ["In general, these studies showed that these \"mixed models\" were able to stratify both the 337 risk of all cause death and lung cancer specific death, in line with our findings.", [["lung cancer", "ANATOMY", 122, 133], ["death", "DISEASE", 112, 117], ["lung cancer", "DISEASE", 122, 133], ["death", "DISEASE", 143, 148], ["lung cancer", "CANCER", 122, 133], ["these studies", "TEST", 12, 25], ["all cause death", "PROBLEM", 102, 117], ["lung cancer specific death", "PROBLEM", 122, 148], ["lung", "ANATOMY", 122, 126], ["cancer", "OBSERVATION", 127, 133]]], ["338Limitations 339The study may have potential limitations.", [["338Limitations 339", "CHEMICAL", 0, 18], ["The study", "TEST", 18, 27]]], ["Unfortunately, the ESTS database does not collect long term 343 follow up preventing to develop a more specific score for survival.", [["the ESTS database", "TEST", 15, 32]]], ["344Limitations 339Although the use of a score to stratify prognosis is appealing, it must be interpreted with 345 caution as it likely represents a surrogate measure of patient frailty and extent of disease.", [["344Limitations 339", "CHEMICAL", 0, 18], ["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["disease", "PROBLEM", 199, 206], ["disease", "OBSERVATION", 199, 206]]], ["It 346 would be desirable that more precise parameters or measures will be developed and used in the future to improve prognostic stratification following curative treatment of lung cancer.", [["lung cancer", "ANATOMY", 177, 188], ["lung cancer", "DISEASE", 177, 188], ["lung cancer", "CANCER", 177, 188], ["curative treatment", "TREATMENT", 155, 173], ["lung cancer", "PROBLEM", 177, 188], ["lung", "ANATOMY", 177, 181], ["cancer", "OBSERVATION", 182, 188]]], ["348Limitations 339The IASLC has recently recognized this need and expanded their staging committee to 349 include a prognostic sub-committee with the aim to identify methods and instruments to 350 develop specific prognostic models incorporating patient, tumor, environment and treatment-351 specific factors (https://www.iaslc.org/About-IASLC/IASLC-Committees).", [["tumor", "ANATOMY", 255, 260], ["tumor", "DISEASE", 255, 260], ["patient", "ORGANISM", 246, 253], ["tumor", "CANCER", 255, 260], ["patient", "SPECIES", 246, 253], ["tumor", "PROBLEM", 255, 260], ["treatment", "TREATMENT", 278, 287], ["tumor", "OBSERVATION", 255, 260]]], ["Although 352Limitations 339Eurolung has proven to be associated with OS and DSS, in order to be reliably used in the 353 context of multifactorial prognostic instruments it needs to be re-calibrated to that specific Shaded areas represent 95% confidence intervals.", [["352Limitations 339", "CHEMICAL", 9, 27], ["Eurolung", "CHEMICAL", 27, 35], ["DSS", "DISEASE", 76, 79], ["DSS", "TREATMENT", 76, 79], ["multifactorial prognostic instruments", "PROBLEM", 132, 169]]]], "715b61d7c69b838218e55a9e96bd6c44f0d06bde": [["Furthermore, embedded location sensors (e.g., GPS) fail at locating the end user once indoor, which seriously prevents the deployment of location-based services at a small scale (e.g., offering locationbased services in a mall).IntroductionTo address these two challenges, we propose a new data structure to accurately capture the indoor location of end users without disclosing their physical location.", [["embedded location sensors (e.g., GPS)", "PROBLEM", 13, 50]]], ["More specifically, our contribution consists in the definition of a new similarity hash function (also known as simhash), named IndoorHash, which encodes the indoor location of an end user in a privacypreserving way.", [["IndoorHash", "PROTEIN", 128, 138], ["new", "OBSERVATION_MODIFIER", 68, 71]]], ["In this paper, we report on the robustness and accuracy of IndoorHash built from WiFi scan data, which is a lightweight contextual information to collect.", [["WiFi scan data", "TEST", 81, 95]]], ["As a matter of evaluation, we embedded IndoorHash in a mobile app that has been deployed during one month to capture the daily routine of 31 users.", [["evaluation", "TEST", 15, 25]]], ["Our results show that IndoorHash succeeds to accurately capture the location of end users by inferring stable logical places, while preserving their privacy.IntroductionThe remainder of this paper is organized as follows.", [["stable", "OBSERVATION_MODIFIER", 103, 109]]], ["Section 4 evaluates IndoorHash along an empirical deployment we conducted.", [["an empirical deployment", "TREATMENT", 37, 60]]], ["6 concludes on this work.Related WorkMobile devices are equipped with a wide panel of embedded sensors that mobile apps can use to acquire key insights about the surrounding environment and the user activities.", [["WorkMobile devices", "TREATMENT", 33, 51]]], ["Among these systems, WiFi-based systems, which take advantage of the legacy WiFi Access Points (APs) to estimate the location of a mobile device down to 1.5 meters precision using the WiFi signal strength [14] .", [["WiFi", "PROTEIN", 184, 188], ["a mobile device", "TREATMENT", 129, 144]]], ["While some research works require a prior training phase (online mode) to map the location of the antennas [26, 36] , other proposals have been proposing an automatic way to build a radio map without any prior knowledge about the antennas [16, 18, 32] .", [["a prior training phase", "TREATMENT", 34, 56], ["a radio map", "TREATMENT", 180, 191]]], ["In particular, Liu et al. [17] propose a peer-assisted localization method to improve localization accuracy.", [["a peer-assisted localization method", "TREATMENT", 39, 74], ["localization accuracy", "TEST", 86, 107]]], ["Li et al. [15] introduce a privacy-preserving WiFi indoor localization system.", [["Li", "CHEMICAL", 0, 2], ["a privacy", "TREATMENT", 25, 34]]], ["Jin et al. [13] propose a real-time WiFi positioning algorithm with the assistance of inertial measurement unit to overcome the Received Signal Strength (RSS) variation problem.", [["a real-time WiFi positioning algorithm", "TREATMENT", 24, 62], ["inertial measurement unit", "TREATMENT", 86, 111], ["variation problem", "PROBLEM", 159, 176]]], ["Pulkkinen et al. [26] present an automatic fingerprinting solution using theoretical properties of radio signals, they rely on the locations of WiFi APs and collecting training measurements.", [["an automatic fingerprinting solution", "TREATMENT", 30, 66], ["collecting training measurements", "TEST", 157, 189]]], ["Salamah et al. [29] use the Principle Component Analysis (PCA) to reduce the computation cost of the WiFi indoor localization systems based on machine learning approach.", [["the Principle Component Analysis (PCA)", "TREATMENT", 24, 62], ["machine learning approach", "TREATMENT", 143, 168]]], ["Yiu et al. [37] apply training measurements and a combined likelihood function from multiple APs to measure the indoor and the outdoor user position.", [["training measurements", "TEST", 22, 43]]], ["Then, they examined the different aspects of localization performance like the density of WiFi APs and the impact of an outdated radiomap.", [["localization performance", "TEST", 45, 69], ["an outdated radiomap", "TEST", 117, 137]]], ["Ahmed et al. [1] provide a new optimized algorithm for fast indoor localization using WiFi channel state information.", [["a new optimized algorithm", "TREATMENT", 25, 50]]], ["Caso et al. [5] introduce an indoor positioning system that relies on the RSS to generate a discrete RSS radiomap.", [["RSS", "DNA", 74, 77], ["an indoor positioning system", "TREATMENT", 26, 54]]], ["Indoor location systems leveraging WiFi scans are proven to be very useful and accurate.", [["WiFi scans", "TEST", 35, 45]]], ["Most approaches propose to learn the position of these WiFi antennas for every building.", [["these WiFi antennas", "TREATMENT", 49, 68]]], ["Then, we consider the related work that uses WiFi fingerprinting to capture the user context.WiFi Fingerprinting SystemsGiven the attractive cost of considering WiFi signals instead of GPS [38] , the state of the art has been extensively considering WiFi signals to capture both indoor and outdoor user contexts.", [["WiFi fingerprinting", "TREATMENT", 45, 64]]], ["Surrounding WiFi APs can be exposed to mobile apps and act as a place fingerprint-different WiFi AP signals received thus result in different places.", [["a place fingerprint", "TEST", 62, 81], ["different WiFi AP signals", "TEST", 82, 107]]], ["As such, using WiFi scans, one can track end users for several hours and obtain valuable information about activities [24] , personality traits [23] and routines [27] .", [["WiFi scans", "TEST", 15, 25]]], ["However, these WiFi scans can also be used to establish a unique user fingerprint [8, 39] , extract social networks [33] or track users offline [31, 35] .", [["these WiFi scans", "TEST", 9, 25]]], ["Zhang et al. [40] introduce Polaris, a location system using cluster-based solution for WiFi fingerprints.", [["Polaris", "TREATMENT", 28, 35], ["a location system", "TREATMENT", 37, 54], ["cluster-based solution", "TREATMENT", 61, 83], ["WiFi fingerprints", "TREATMENT", 88, 105]]], ["Sakib et al. [28] present a method to contextualize the mobile user using the WiFi APs fingerprints, with a clustering algorithm that creates a place for each group of WiFi APs.", [["the WiFi APs fingerprints", "TREATMENT", 74, 99]]], ["They validate their results with cellular cell ids datasets.", [["cellular cell", "ANATOMY", 33, 46], ["cellular cell", "CELL", 33, 46], ["cellular cell", "OBSERVATION", 33, 46]]], ["Sapiezynski et al. [30] use WiFi to enhance GPS traces composed of one GPS location per day, they can locate 80% of mobility across the population.", [["WiFi", "TREATMENT", 28, 32], ["GPS traces", "TEST", 44, 54]]], ["Wind et al. [34] use WiFi scans to infer stop locations for users, their algorithm can tell if a user is moving or in a stationary state using just WiFi fingerprints.", [["WiFi scans", "TEST", 21, 31]]], ["Finally, Choi et al. [7] propose a method for an energy efficient WiFi scanning for user contextualization, they try to minimize the number of scans depending on the scanned WiFi APs.WiFi Fingerprinting SystemsSynthesis.", [["scans", "TEST", 143, 148]]], ["While a lot of work have been done to localize the user using WiFi indoor location techniques, most of them require either a training phase or user input to locate the user using the WiFi antennas.", [["a training phase", "TREATMENT", 123, 139], ["the WiFi antennas", "TREATMENT", 179, 196]]], ["Furthermore, they do not provide any library or framework in order for their methods to be adopted, evaluated and further improved.Introducing IndoorHashThis section introduces our current design of IndoorHash and the properties we build on to control the number of relevant hashes.Computing an IndoorHashTo design our IndoorHash, we implement a modified version of the SimHash algorithm [6] .", [["Introducing IndoorHashThis section", "TREATMENT", 131, 165], ["IndoorHash", "TREATMENT", 199, 209], ["improved", "OBSERVATION_MODIFIER", 122, 130]]], ["SimHash is a technique for quickly estimating how similar two sets are.", [["a technique", "TREATMENT", 11, 22]]], ["This algorithm was reported to be used by the Google Crawler to find near duplicate pages.Computing an IndoorHashIn the context of IndoorHash, we tokenize the words from the SimHash algorithm as pairs of digits in the hexadecimal MAC address format-e.g., we convert the MAC address 00:FF:AB:0F:C2:C7 into the set of words { 00 : 1 , FF : 1 , AB : 1 , 0F : 1 , C2 : 1 , C7 : 1 }.", [["C2:C7", "PROTEIN", 294, 299], ["FF", "TEST", 333, 335], ["AB", "TEST", 342, 344], ["C2", "TEST", 360, 362], ["C7", "TEST", 369, 371], ["digits", "ANATOMY", 204, 210], ["C2", "ANATOMY", 360, 362], ["C7", "ANATOMY", 369, 371]]], ["Then, the input text we use is the list of all WiFi APs MAC addresses that is returned when triggering a WiFi scan.", [["a WiFi scan", "TEST", 103, 114]]], ["For example, a list of 3 MAC addresses can result in the following input set { 00 : 3 , FF : 2 , AB : 2 , 0F : 3 , C2 : 2 , C7 : 1 , C7 : 1 , D0 : 1 , 02 : 1 , DD : 1 , BE : 1 }.", [["FF", "TEST", 88, 90], ["AB", "TEST", 97, 99], ["C2", "TEST", 115, 117], ["C7", "TEST", 124, 126], ["C7", "TEST", 133, 135], ["D0", "TEST", 142, 144], ["02", "TEST", 151, 153], ["DD", "TEST", 160, 162], ["C2", "ANATOMY", 115, 117], ["C7", "ANATOMY_MODIFIER", 124, 126], ["C7", "ANATOMY", 133, 135]]], ["From this input set, we compute a SimHash whose size can be defined according to the targeted precision (cf. Algorithm 1).Comparing an IndoorHashUnlike standard hashing algorithms, hashes computed by the SimHash algorithm can be compared to estimate the similarity of their respective input sets.", [["SimHash", "PROTEIN", 34, 41]]], ["To compute this similarity, IndoorHash computes the Hamming distance between the two input hashes to report on the ratio of similar bits (cf. Algorithm 2).Comparing an IndoorHashHowever, applying standard SimHash similarity on IndoorHash tends to report a ratio above 0.50, due to the high probability of sharing words between dissimilar MAC addresses.", [["IndoorHash", "DNA", 28, 38], ["a ratio", "TEST", 254, 261]]], ["This approach improves the sensibility of the IndoorHash when comparing their values.Comparing an IndoorHashExpand the similarity score end functionIndexing an IndoorHashWe store an IndoorHash in a K-Nearest Neighbors (KNN) graph that organizes all the computed IndoorHash according to their pairwise similarity (cf. Algorithm 3).", [["IndoorHashWe", "DNA", 160, 172], ["IndoorHash", "DNA", 262, 272]]], ["The IndoorHash storage procedure searches and binds to the closest neighbors in the KNN graph.", [["The IndoorHash storage procedure", "TREATMENT", 0, 32]]], ["This indexing structure allows to quickly search for a similar IndoorHash in the KNN graph by starting from any random node in this graph and converging through the closest neighbors-i.e., most similar IndoorHash in our case.", [["node", "ANATOMY", 119, 123], ["IndoorHash", "DNA", 63, 73], ["a similar IndoorHash in the KNN graph", "PROBLEM", 53, 90], ["any random node", "PROBLEM", 108, 123], ["this graph", "TEST", 127, 137], ["node", "OBSERVATION", 119, 123]]], ["The similarity search (SimSearch) returns a node if the similarity of the closest neighbor with the input IndoorHash is above an expected similarity threshold (cf. Algorithm 4).Classifying an IndoorHashIndoorHash leverages the SimHash algorithm [6] to generate a robust hash from a list of visible WiFi APs.", [["node", "ANATOMY", 44, 48], ["SimSearch", "DNA", 23, 32], ["IndoorHash", "DNA", 106, 116], ["a node", "PROBLEM", 42, 48], ["Algorithm", "TEST", 164, 173], ["node", "OBSERVATION", 44, 48]]], ["Depending on situations, we can consider that:Classifying an IndoorHash1.", [["IndoorHash1", "GENE_OR_GENE_PRODUCT", 61, 72], ["IndoorHash1", "PROTEIN", 61, 72]]], ["IndoorHash refers to a new hash-i.e., whenever a hash is stable for more than 5mn, a new IndoorHash is stored locally, 2.", [["stable", "OBSERVATION_MODIFIER", 57, 63]]], ["IndoorHash refers to a commuting hash when no hash can be computed or the hash keeps changing after every scan.Classifying an IndoorHashAlgorithm 5 describes how we classify an IndoorHash along the above situations.", [["every scan", "TEST", 100, 110]]], ["This context classification algorithm allows not only the device to adjust its behavior accordingly, but also avoid an explosion of the number of collected IndoorHash.", [["the device", "TREATMENT", 54, 64]]], ["Indeed, by setting an appropriate DELAY and SIMILARITY threshold, one can filter out any candidate IndoorHash that is considered as irrelevant (e.g., spending less than 5mn in a place does not require to be remembered).", [["DELAY", "DNA", 34, 39]]], ["By adjusting the reference storage, the algorithm can leverage a graph of shared location hashes to quickly classify it as a known location, without waiting for the classification delay to be elapsed.Sharing an IndoorHashIndoorHash does not make any strong assumption on the mobile device that is used to capture the current indoor location.", [["the mobile device", "TREATMENT", 271, 288]]], ["For example, whenever an IndoorHash is computed, a device can query a cloud service to obtain some information associated to this location.", [["IndoorHash", "DNA", 25, 35]]], ["Furthermore, at scale, the remote storage of known IndoorHash can leverage the indexing structure introduced in Sect.", [["IndoorHash", "PROTEIN", 51, 61]]], ["3.3 to quickly find the most similar IndoorHash among the graph of known hashes shared online.Empirical EvaluationThis section reports on the empirical evaluation we conducted to assess IndoorHash as a robust indoor location hash that can be used to capture the current indoor location of a user, while preserving her privacy.", [["Empirical Evaluation", "TEST", 94, 114], ["the empirical evaluation", "TEST", 138, 162]]], ["Existing WiFi fingerprinting methods exploit raw MAC addresses to recover a GPS location from crowdsourced datasets that share key-value pairs of MAC addresses and the associated GPS location [30] .", [["Existing WiFi fingerprinting methods", "TREATMENT", 0, 36]]], ["In our solution, we therefore hash all detected MAC addresses of WiFi APs, which adds a huge entropy to the generated hash and therefore reduces the risk to infer the physical location captured by a given IndoorHash.", [["WiFi APs", "TREATMENT", 65, 73], ["a huge entropy", "TREATMENT", 86, 100]]], ["Yet, the adoption of IndoorHash does not prevent developers from carefully anonymizing any payload that could be attached to such a hash (e.g., IP address, device model, user identifier) to avoid indirect privacy breach.DayKeeper Android AppTo demonstrate and assess IndoorHash in the wild, we developed an Android app that embeds our IndoorHash as a software library.", [["IndoorHash", "DNA", 335, 345]]], ["4.3) are also periodically synchronized on a remote server, using the APISENSE platform [10] , for postmortem analysis purpose.", [["postmortem analysis purpose", "TEST", 99, 126]]], ["Furthermore, as DayKeeper leverages the WiFi APs, it provides a lightweight activity logger that does not drain the device battery by continuously requesting the GPS sensor.", [["a lightweight activity logger", "TREATMENT", 62, 91], ["the device battery", "TREATMENT", 112, 130]]], ["The IndoorHash is continuously updated by DayKeeper using a background service that periodically scans the surrounding WiFi APs, computes the associated IndoorHash (cf. Sect.", [["IndoorHash", "PROTEIN", 153, 163], ["periodically scans", "TEST", 84, 102]]], ["3.1) and classifies it with regards to known hashes (cf. Sect.", [["known hashes (cf", "PROBLEM", 39, 55]]], ["Figure 2a therefore depicts the number of WiFi scans triggered per user as a more representative indicator of the activity of registered users.Deployment StatisticsThen, Fig. 2b reports on the number of unique WiFi AP per user, this number reflects the diversity of locations that have been visited by a user: the more the user moves, the more WiFi APs.", [["WiFi scans", "TEST", 42, 52]]], ["Figure 2c shares some indications on the number of WiFi APs that can be captured along a scan.", [["a scan", "TEST", 87, 93]]], ["This number depends on the density of WiFi APs exposed to a user, but it clearly shows that users are often exposed to more than 5 MAC addresses, thus strengthening the resilience of IndoorHash against rainbow table attacks (cf. Sect.", [["IndoorHash", "CHEMICAL", 183, 193]]], ["Finally, Fig. 2d reports the average number of WiFi APs per hour for each user, thus giving a clear signal about the continuous WiFi coverage of users.", [["the continuous WiFi coverage", "TREATMENT", 113, 141]]], ["For example, we can observe that the user with the identifier 20 was mostly stationary, as her device contributed a lot of hours (cf. Fig. 2a) , but with only 57 unique WiFi APs (cf. Fig. 2b ) and an average of 0.10 WiFi APs per hour (cf. Fig. 2d ).", [["her device", "TREATMENT", 91, 101]]], ["The rest of our evaluation considers all the users who have been sharing their IndoorHash with our remote storage server, no matter their profile.IndoorHash EvaluationThis section focuses on a quantitative evaluation of the IndoorHash.", [["our evaluation", "TEST", 12, 26], ["IndoorHash Evaluation", "TEST", 146, 167], ["a quantitative evaluation", "TEST", 191, 216]]], ["To assess our contribution, we compare it to alternative hashing and similarity algorithms adopted by the state of the art, as described below.IndoorHash EvaluationEvaluation Metrics.", [["IndoorHash Evaluation", "TEST", 143, 164], ["Evaluation", "TEST", 164, 174]]], ["In the context of this evaluation, we focus on assessing the robustness of the location hash to accurately capture the context of a user.", [["this evaluation", "TEST", 18, 33]]], ["We therefore consider the following metrics:IndoorHash Evaluation-Total period represents the total number of hours of activities recognized by the algorithms for all of the users (the higher the better).", [["IndoorHash Evaluation", "TEST", 44, 65]]], ["This metrics highlights the capability of each algorithm to detect known locations; -Max occurrences represents the maximum number of occurrences that can be observed for one location hash (the higher the better).", [["each algorithm", "TEST", 42, 56], ["maximum", "OBSERVATION_MODIFIER", 116, 123]]], ["This metrics demonstrate the capability of the algorithms to infer similar location hashes for recurrent locations; -Hashes with 1+ hour represents the number of location hashes that last for more than one hour (the higher the better).", [["recurrent locations", "PROBLEM", 95, 114]]], ["This metrics highlights the capability of the location hash to capture stationary conditions; -Max detected hashes represents the maximum number of distinct location hashes for a given location (the lower the better).", [["maximum", "OBSERVATION_MODIFIER", 130, 137], ["number", "OBSERVATION_MODIFIER", 138, 144], ["distinct", "OBSERVATION_MODIFIER", 148, 156]]], ["We start by comparing IndoorHash with the most-related similarity algorithms:IndoorHash Evaluation-The Jaccard index is the baseline algorithm that we apply to compare raw scans including plain MAC addresses of detected WiFi APs, -The SimHash correspond to the standard SimHash algorithm [6] applied to plain MAC addresses, -The IndoorHash refers to the approach described in this paper.IndoorHash EvaluationFor all the algorithms, we consider a similarity threshold of 0.60f as a conservative policy to classify the inferred location hashes.", [["SimHash", "PROTEIN", 235, 242], ["IndoorHash Evaluation", "TEST", 77, 98], ["The Jaccard index", "TEST", 99, 116], ["raw scans", "TEST", 168, 177], ["the standard SimHash algorithm", "TREATMENT", 257, 287], ["IndoorHash Evaluation", "TEST", 387, 408], ["all the algorithms", "TEST", 412, 430], ["a conservative policy", "TREATMENT", 479, 500]]], ["The missing 55 h that are not recognized by IndoorHash refers to short periods of time (<5 min) where the recognition algorithm of IndoorHash considers the location as a new hash (cf. Algorithm 5).Impact of MAC addresses.To further evaluate IndoorHash, we consider 3 variants of IndoorHash to evaluate the impact of the number of MAC addresses on the stability of the computed hashes.", [["IndoorHash", "TREATMENT", 279, 289], ["MAC", "OBSERVATION", 207, 210], ["MAC", "OBSERVATION", 330, 333]]], ["Table 2 shows the metrics for the following variants:Impact of MAC addresses.-No limit refers to the baseline IndoorHash that does not limit the number of MAC addresses to be included in the computation of the hash; -10 MAC is a variant that limits the computation of the IndoorHash to the first 10 MAC addresses return by the scan; -5 MAC is a variant that limits the IndoorHash computation to the first 5 MAC addresses. -1 MAC is the extreme variant that only consider the first MAC address to compute an IndoorHash.", [["IndoorHash", "PROTEIN", 272, 282], ["the scan", "TEST", 323, 331]]], ["At the same time, one can see that most important places (Hashes with 1+ hour ) keep being recognized with the same accuracy as the baseline, thus indicating that limiting MAC addresses tends to reduce the capability to capture places visited for shorter periods.Towards Privacy-Preserving Location-Based ServicesIn this paper, we believe that Location-Based Services (LBS) require to guarantee the user privacy by design, in order to avoid any potential risk of data leaks that might contribute to learn sensitive knowledge from visited locations (e.g., home, office, leisure).", [["data leaks", "PROBLEM", 463, 473], ["leaks", "OBSERVATION", 468, 473]]], ["This section therefore lists candidate LBS features that could benefit from IndoorHash in the future.Towards Privacy-Preserving Location-Based ServicesPoints of Interest (POIs) refer to known physical locations that may reveal sensitive information about the habits and tastes of end users (e.g., shopping mall, restaurants) and can be used by third parties to feed recommendation algorithms.", [["LBS", "CANCER", 39, 42]]], ["IndoorHash can therefore support the definition of proximity datasets that are commonly used for various purposes, such as mobile testing [22] , by reporting on the colocation of end users and potential connections in a crowd that can support the evaluation of dissemination protocols [19, 21] .Towards Privacy-Preserving Location-Based ServicesContext prediction can also leverage the history of IndoorHash to understand the mobility of end users and possibly predict the next location (e.g., using markov chains or n-grams) of a given user in order to anticipate some actions, like fetching some content or buffering a video before loosing an Internet connection [25] .", [["mobile testing", "TEST", 123, 137], ["the evaluation", "TEST", 243, 257], ["dissemination protocols", "TEST", 261, 284], ["IndoorHash", "PROBLEM", 397, 407], ["markov chains", "TREATMENT", 500, 513]]], ["Such a mechanism can help the user to focus on her tasks (e.g., by enabling a do not disturb mode) or trigger specific assistance when she is not in a routine.Towards Privacy-Preserving Location-Based ServicesMobile crowdsourcing consists in gathering field measurements from a crowd of participants.", [["participants", "SPECIES", 287, 299]]], ["In such cases, beyond raw GPS locations, Geohash and Pluscode 4 provide a compact encoding of any physical location on earth.", [["Pluscode", "TREATMENT", 53, 61]]], ["In these situation, we believe that IndoorHash can provide a privacy-preserving spatial keys that can be used to process geolocated measurements.", [["a privacy-preserving spatial keys", "TREATMENT", 59, 92]]], ["For example, one can imagine a user getting the history of indoor air pollution using her current hash to query a remote measurement service built on top of IndoorHash [11] .ConclusionLocation-Based Services (LBS) are increasingly getting adopted by end users who expect to be delivered personalized user experiences depending on their current context.", [["indoor air pollution", "PROBLEM", 59, 79]]], ["More specifically, IndoorHash captures a logical user location without disclosing the physical place visited by this user.", [["IndoorHash", "PROTEIN", 19, 29]]], ["Our contribution consists in applying the SimHash algorithm to the processing of MAC addresses exposed by WiFi APs.", [["the SimHash algorithm", "TREATMENT", 38, 59]]], ["We show that the IndoorHash computed from such input data offers a robust location hash that accurately capture any user location.", [["IndoorHash", "DNA", 17, 27]]], ["We also implement a distributed system that allows to store and index IndoorHash in order to ease the detection of known locations and share geolocated data with privacy guarantees.ConclusionAs a matter of perspectives, we are interested in extending the IndoorHash to a more general location hash scheme that can leverage additional signals surrounding a user, like the GSM antennas or BLE beacons in order to increase the coverage of inferred locations.", [["privacy guarantees", "TREATMENT", 162, 180], ["the GSM antennas", "TREATMENT", 367, 383], ["BLE beacons", "PROBLEM", 387, 398]]], ["We are also interested in exploring new operations on location hashes to support privacy-preserving data clustering algorithms.", [["new operations", "TREATMENT", 36, 50]]]], "601a2a29ef252c46e3a3b19f35d1d6fb591b0af6": [["He was the eighth son out of ten, of which only four, Moritz, Hugo, Bertha and Clementine reached adulthood [1] .", [["Clementine", "CHEMICAL", 79, 89]]], ["He studied chemistry and physics in Frankfurt with Professors B\u00f6etteger and L\u00f6we, and continued his studies in G\u00f6ttingen, where he got his degree in 1857 under the supervision of professor W\u00f6lher.", [["his studies", "TEST", 96, 107]]], ["Professor W\u00f6lher was, in turn, student of Berzelius in Stockolm and was the first chemist to synthesize urea, an organic molecule, starting from inorganic compounds: the birth of modern organic chemistry is taught to start from this experiment, which, once and for all, excluded the presence of \"vis-vitalis\" (vital strength residing in the organic matter) demonstrating that there is no metaphysical difference between organic and inorganic substances.", [["Berzelius", "CHEMICAL", 42, 51], ["urea", "CHEMICAL", 104, 108], ["urea", "CHEMICAL", 104, 108], ["urea", "SIMPLE_CHEMICAL", 104, 108], ["inorganic compounds", "SIMPLE_CHEMICAL", 145, 164], ["inorganic substances", "SIMPLE_CHEMICAL", 432, 452], ["an organic molecule", "PROBLEM", 110, 129], ["modern organic chemistry", "TREATMENT", 179, 203], ["metaphysical difference between organic and inorganic substances", "PROBLEM", 388, 452], ["organic molecule", "OBSERVATION", 113, 129], ["no", "UNCERTAINTY", 385, 387], ["inorganic substances", "OBSERVATION", 432, 452]]], ["This was the origin of organic chemistry and the beginning of a new type of scientific research.", [["organic chemistry", "TEST", 23, 40], ["organic chemistry", "OBSERVATION", 23, 40]]], ["Schiff retained his liberal views and was a cofounder of the socialist Italian newspaper L'Avanti in 1894 ( Figure 2 ).", [["Schiff", "CHEMICAL", 0, 6]]], ["Between 1864 and 1915, Ugo Schiff spent his entire career in Florence and continued teaching until 1915, the year of his death (Figure 3) .", [["death", "DISEASE", 121, 126]]], ["He devoted his interest to organic and inorganic chemistry, physical and analytical chemistry, mineralogy, and natural substances.", [["inorganic chemistry", "TEST", 39, 58]]], ["His studies on Schiff bases, target of this Review, are very popular.", [["Schiff bases", "CHEMICAL", 15, 27], ["His studies", "TEST", 0, 11], ["Schiff bases", "TEST", 15, 27]]], ["The designation of these compounds as bases, although they are not used as bases in the conventional sense, has persisted up to the present time [4] .", [["compounds", "OBSERVATION", 25, 34], ["bases", "ANATOMY_MODIFIER", 38, 43]]], ["In the meantime, boric ethers, glucosides, arbutin, tannin and gallic acid, aromatic carboxylic acids and asparagine, urea and its derivatives were also studied by Schiff.", [["boric ethers, glucosides, arbutin, tannin and gallic acid", "CHEMICAL", 17, 74], ["aromatic carboxylic acids", "CHEMICAL", 76, 101], ["asparagine", "CHEMICAL", 106, 116], ["urea", "CHEMICAL", 118, 122], ["boric ethers", "CHEMICAL", 17, 29], ["glucosides", "CHEMICAL", 31, 41], ["arbutin", "CHEMICAL", 43, 50], ["tannin", "CHEMICAL", 52, 58], ["gallic acid", "CHEMICAL", 63, 74], ["aromatic carboxylic acids", "CHEMICAL", 76, 101], ["asparagine", "CHEMICAL", 106, 116], ["urea", "CHEMICAL", 118, 122], ["Schiff", "CHEMICAL", 164, 170], ["boric ethers", "SIMPLE_CHEMICAL", 17, 29], ["glucosides", "SIMPLE_CHEMICAL", 31, 41], ["arbutin", "SIMPLE_CHEMICAL", 43, 50], ["tannin", "SIMPLE_CHEMICAL", 52, 58], ["gallic acid", "SIMPLE_CHEMICAL", 63, 74], ["aromatic carboxylic acids", "SIMPLE_CHEMICAL", 76, 101], ["asparagine", "SIMPLE_CHEMICAL", 106, 116], ["urea", "SIMPLE_CHEMICAL", 118, 122], ["boric ethers", "TREATMENT", 17, 29], ["glucosides", "TREATMENT", 31, 41], ["arbutin", "TREATMENT", 43, 50], ["tannin", "TREATMENT", 52, 58], ["gallic acid", "TREATMENT", 63, 74], ["aromatic carboxylic acids", "TREATMENT", 76, 101], ["asparagine", "TREATMENT", 106, 116], ["urea", "TREATMENT", 118, 122], ["its derivatives", "TREATMENT", 127, 142]]], ["He developed the analytical methodology, later used by S\u00f6rensen, to determine amino acids in urine, and he devised the Schiff fuchsin aldehyde test [5] , still in use nowadays [6] .", [["urine", "ANATOMY", 93, 98], ["amino acids", "CHEMICAL", 78, 89], ["Schiff fuchsin aldehyde", "CHEMICAL", 119, 142], ["amino acids", "CHEMICAL", 78, 89], ["Schiff fuchsin aldehyde", "CHEMICAL", 119, 142], ["amino acids", "AMINO_ACID", 78, 89], ["urine", "ORGANISM_SUBSTANCE", 93, 98], ["Schiff fuchsin aldehyde", "SIMPLE_CHEMICAL", 119, 142], ["amino acids in urine", "TEST", 78, 98]]], ["Thionyl chloride must also be cited as one of his important discoveries [7] .Schiff Bases: Physical-Chemical PropertiesImines, known even as azomethines or Schiff bases [3, [8] [9] [10] [11] [12] [13] [14] are compounds that are represented by the general formula R 3 R 2 C=NR 1 .", [["Thionyl chloride", "CHEMICAL", 0, 16], ["azomethines", "CHEMICAL", 141, 152], ["3, [8] [9", "CHEMICAL", 170, 179], ["Thionyl chloride", "CHEMICAL", 0, 16], ["azomethines", "CHEMICAL", 141, 152], ["Schiff bases", "CHEMICAL", 156, 168], ["Thionyl chloride", "SIMPLE_CHEMICAL", 0, 16], ["azomethines", "SIMPLE_CHEMICAL", 141, 152], ["Schiff", "SIMPLE_CHEMICAL", 156, 162], ["[3, [8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 169, 205], ["Thionyl chloride", "TREATMENT", 0, 16], ["Chemical PropertiesImines", "TREATMENT", 100, 125], ["Schiff bases", "TEST", 156, 168]]], ["The substituents R 2 and R 3 may be alkyl, aryl, heteroaryl, hydrogen.", [["alkyl", "CHEMICAL", 36, 41], ["aryl", "CHEMICAL", 43, 47], ["heteroaryl", "CHEMICAL", 49, 59], ["hydrogen", "CHEMICAL", 61, 69], ["alkyl", "CHEMICAL", 36, 41], ["aryl", "CHEMICAL", 43, 47], ["heteroaryl", "CHEMICAL", 49, 59], ["hydrogen", "CHEMICAL", 61, 69], ["R 2", "SIMPLE_CHEMICAL", 17, 20], ["R 3", "SIMPLE_CHEMICAL", 25, 28], ["alkyl", "SIMPLE_CHEMICAL", 36, 41], ["aryl", "SIMPLE_CHEMICAL", 43, 47], ["heteroaryl", "SIMPLE_CHEMICAL", 49, 59], ["hydrogen", "SIMPLE_CHEMICAL", 61, 69], ["The substituents R", "TEST", 0, 18]]], ["The substituent at the N-imino (C=N) may be alkyl, aryl, heteroaryl, hydrogen or metallo (usually Si, Al, B, Sn).", [["N-imino", "CHEMICAL", 23, 30], ["alkyl", "CHEMICAL", 44, 49], ["aryl", "CHEMICAL", 51, 55], ["heteroaryl", "CHEMICAL", 57, 67], ["hydrogen", "CHEMICAL", 69, 77], ["metallo", "CHEMICAL", 81, 88], ["Si, Al, B, Sn", "CHEMICAL", 98, 111], ["N-imino (C=N", "CHEMICAL", 23, 35], ["alkyl", "CHEMICAL", 44, 49], ["aryl", "CHEMICAL", 51, 55], ["heteroaryl", "CHEMICAL", 57, 67], ["hydrogen", "CHEMICAL", 69, 77], ["metallo", "CHEMICAL", 81, 88], ["Si", "CHEMICAL", 98, 100], ["Al", "CHEMICAL", 102, 104], ["B", "CHEMICAL", 106, 107], ["Sn", "CHEMICAL", 109, 111], ["N-imino (C=N)", "SIMPLE_CHEMICAL", 23, 36], ["alkyl", "SIMPLE_CHEMICAL", 44, 49], ["aryl", "SIMPLE_CHEMICAL", 51, 55], ["heteroaryl", "SIMPLE_CHEMICAL", 57, 67], ["hydrogen", "SIMPLE_CHEMICAL", 69, 77], ["metallo", "SIMPLE_CHEMICAL", 81, 88], ["Si, Al, B, Sn", "SIMPLE_CHEMICAL", 98, 111], ["substituent", "OBSERVATION_MODIFIER", 4, 15]]], ["The physical properties and reactivity of imines are and continue to be studied by more than a hundred years [15] .", [["imines", "CHEMICAL", 42, 48]]], ["Physical-chemical properties (IR, Raman, 1 H-NMR, 13 C-NMR) of a large variety of Schiff bases are easily found in any current dedicated textbook.Reaction of Aldehydes and Ketones with AminesThe most common method for preparing imines is the original reaction discovered by Schiff [3, 5, 11, 16, 17] .", [["Aldehydes", "CHEMICAL", 158, 167], ["Ketones", "CHEMICAL", 172, 179], ["Amines", "CHEMICAL", 185, 191], ["H", "CHEMICAL", 43, 44], ["C", "CHEMICAL", 53, 54], ["Schiff bases", "CHEMICAL", 82, 94], ["Aldehydes", "CHEMICAL", 158, 167], ["Ketones", "CHEMICAL", 172, 179], ["Amines", "CHEMICAL", 185, 191], ["imines", "CHEMICAL", 228, 234], ["Schiff", "CHEMICAL", 274, 280], ["Aldehydes", "SIMPLE_CHEMICAL", 158, 167], ["Ketones", "SIMPLE_CHEMICAL", 172, 179], ["Amines", "SIMPLE_CHEMICAL", 185, 191], ["NMR", "TEST", 45, 48], ["a large variety of Schiff bases", "PROBLEM", 63, 94], ["Reaction of Aldehydes", "PROBLEM", 146, 167], ["Ketones", "TEST", 172, 179], ["Amines", "TREATMENT", 185, 191], ["preparing imines", "TREATMENT", 218, 234], ["large", "OBSERVATION_MODIFIER", 65, 70], ["variety", "OBSERVATION_MODIFIER", 71, 78], ["Schiff bases", "OBSERVATION", 82, 94]]], ["Basically it consists in the reaction of an aldehyde (respectively a ketone) with a primary amine and elimination of one water molecule (Scheme 1).", [["aldehyde", "CHEMICAL", 44, 52], ["ketone", "CHEMICAL", 69, 75], ["amine", "CHEMICAL", 92, 97], ["aldehyde", "CHEMICAL", 44, 52], ["ketone", "CHEMICAL", 69, 75], ["primary amine", "CHEMICAL", 84, 97], ["aldehyde", "SIMPLE_CHEMICAL", 44, 52], ["ketone", "SIMPLE_CHEMICAL", 69, 75], ["amine", "SIMPLE_CHEMICAL", 92, 97], ["a primary amine", "TREATMENT", 82, 97]]], ["This reaction can be accelerated by acid catalysis and is generally carried out by refluxing a mixture of a carbonyl compound 1 and an amine 2, in a Dean Stark apparatus in order to remove the water.", [["carbonyl", "CHEMICAL", 108, 116], ["amine", "CHEMICAL", 135, 140], ["amine 2", "SIMPLE_CHEMICAL", 135, 142], ["This reaction", "PROBLEM", 0, 13], ["acid catalysis", "PROBLEM", 36, 50], ["a carbonyl compound", "TREATMENT", 106, 125], ["acid catalysis", "OBSERVATION", 36, 50], ["refluxing", "OBSERVATION", 83, 92]]], ["This removal is important as the conversion of aminal 3 into the imine 4 is reversible (Scheme 1).", [["aminal 3 into the imine", "CHEMICAL", 47, 70], ["aminal 3", "CHEMICAL", 47, 55], ["imine", "CHEMICAL", 65, 70], ["aminal 3", "SIMPLE_CHEMICAL", 47, 55], ["imine 4", "SIMPLE_CHEMICAL", 65, 72], ["This removal", "TREATMENT", 0, 12], ["reversible", "OBSERVATION_MODIFIER", 76, 86]]], ["From this point several dehydrating agents have been successfully used including sodium sulphate and molecular sieves [18] .", [["sodium sulphate", "CHEMICAL", 81, 96], ["sodium sulphate", "CHEMICAL", 81, 96], ["sodium sulphate", "SIMPLE_CHEMICAL", 81, 96], ["several dehydrating agents", "TREATMENT", 16, 42], ["sodium sulphate", "TREATMENT", 81, 96]]], ["Alternatively, some in situ methods, involving dehydrating solvents such as tetramethyl orthosilicate or trimethyl orthoformate, have been reported as well [19, 20] .", [["tetramethyl orthosilicate", "CHEMICAL", 76, 101], ["trimethyl orthoformate", "CHEMICAL", 105, 127], ["tetramethyl orthosilicate", "CHEMICAL", 76, 101], ["trimethyl orthoformate", "CHEMICAL", 105, 127], ["tetramethyl orthosilicate", "SIMPLE_CHEMICAL", 76, 101], ["trimethyl orthoformate", "SIMPLE_CHEMICAL", 105, 127], ["dehydrating solvents", "TREATMENT", 47, 67], ["tetramethyl orthosilicate", "TREATMENT", 76, 101], ["trimethyl orthoformate", "TREATMENT", 105, 127]]], ["As far as the use of acid catalyst is required [21] [22] [23] [24] [25] [26] [27] , mineral acids, like H 2 SO 4 or HCl, organic acids such as p-toluene sulphonic acids or pyridinium p-toluenesulphonate, acid resin, montmorillonite or even Lewis acids like ZnCl 2 , TiCl 4 , SnCl 4 , BF 3 Et 2 O, MgSO 4 , Mg(ClO 4 ) 2 , etc., have been reported.", [["[21] [22] [23] [24] [25] [26] [27", "CHEMICAL", 47, 80], ["mineral acids", "CHEMICAL", 84, 97], ["H 2 SO 4 or HCl", "CHEMICAL", 104, 119], ["organic acids", "CHEMICAL", 121, 134], ["p-toluene sulphonic acids", "CHEMICAL", 143, 168], ["pyridinium p-toluenesulphonate", "CHEMICAL", 172, 202], ["montmorillonite", "CHEMICAL", 216, 231], ["ZnCl 2 , TiCl 4 , SnCl 4 , BF 3 Et 2 O", "CHEMICAL", 257, 295], ["MgSO 4 , Mg(ClO 4 ) 2", "CHEMICAL", 297, 318], ["[21] [22] [23] [24] [25] [26]", "CHEMICAL", 47, 76], ["H 2 SO 4", "CHEMICAL", 104, 112], ["HCl", "CHEMICAL", 116, 119], ["p-toluene sulphonic acids", "CHEMICAL", 143, 168], ["pyridinium p-toluenesulphonate", "CHEMICAL", 172, 202], ["montmorillonite", "CHEMICAL", 216, 231], ["Lewis acids", "CHEMICAL", 240, 251], ["ZnCl 2", "CHEMICAL", 257, 263], ["TiCl 4", "CHEMICAL", 266, 272], ["SnCl 4", "CHEMICAL", 275, 281], ["BF 3 Et 2 O", "CHEMICAL", 284, 295], ["MgSO 4", "CHEMICAL", 297, 303], ["Mg(ClO 4 ) 2", "CHEMICAL", 306, 318], ["[21] [22] [23] [24] [25] [26] [27]", "SIMPLE_CHEMICAL", 47, 81], ["mineral acids", "SIMPLE_CHEMICAL", 84, 97], ["H 2 SO 4", "SIMPLE_CHEMICAL", 104, 112], ["HCl", "SIMPLE_CHEMICAL", 116, 119], ["organic acids", "SIMPLE_CHEMICAL", 121, 134], ["p-toluene sulphonic acids", "SIMPLE_CHEMICAL", 143, 168], ["pyridinium p-toluenesulphonate", "SIMPLE_CHEMICAL", 172, 202], ["acid resin", "SIMPLE_CHEMICAL", 204, 214], ["montmorillonite", "SIMPLE_CHEMICAL", 216, 231], ["Lewis acids", "SIMPLE_CHEMICAL", 240, 251], ["ZnCl 2", "SIMPLE_CHEMICAL", 257, 263], ["TiCl 4", "SIMPLE_CHEMICAL", 266, 272], ["SnCl 4", "SIMPLE_CHEMICAL", 275, 281], ["BF 3 Et 2 O", "SIMPLE_CHEMICAL", 284, 295], ["MgSO 4", "SIMPLE_CHEMICAL", 297, 303], ["Mg(ClO 4 ) 2", "SIMPLE_CHEMICAL", 306, 318], ["acid catalyst", "TREATMENT", 21, 34], ["mineral acids", "TEST", 84, 97], ["HCl", "TREATMENT", 116, 119], ["organic acids", "TREATMENT", 121, 134], ["p-toluene sulphonic acids", "TREATMENT", 143, 168], ["pyridinium", "TREATMENT", 172, 182], ["-toluenesulphonate", "TREATMENT", 184, 202], ["acid resin", "TREATMENT", 204, 214], ["montmorillonite", "TREATMENT", 216, 231], ["Lewis acids like ZnCl", "TREATMENT", 240, 261], ["TiCl", "TREATMENT", 266, 270], ["MgSO", "TREATMENT", 297, 301]]], ["Schiff reaction for the preparation of imines.Reaction of Aldehydes and Ketones with AminesIn the course of the preparation of imines, if aliphatic aldehydes are used, a known competitive reaction, due to the formation of a condensation product arising from an aldol type reaction, can occur as well (Scheme 2).Scheme 2.", [["Aldehydes", "CHEMICAL", 58, 67], ["Ketones", "CHEMICAL", 72, 79], ["Amines", "CHEMICAL", 85, 91], ["aliphatic aldehydes", "CHEMICAL", 138, 157], ["imines", "CHEMICAL", 39, 45], ["Aldehydes", "CHEMICAL", 58, 67], ["Ketones", "CHEMICAL", 72, 79], ["Amines", "CHEMICAL", 85, 91], ["imines", "CHEMICAL", 127, 133], ["aliphatic aldehydes", "CHEMICAL", 138, 157], ["Aldehydes", "SIMPLE_CHEMICAL", 58, 67], ["Ketones", "SIMPLE_CHEMICAL", 72, 79], ["Amines", "SIMPLE_CHEMICAL", 85, 91], ["aliphatic aldehydes", "SIMPLE_CHEMICAL", 138, 157], ["Schiff reaction", "PROBLEM", 0, 15], ["the preparation of imines", "TREATMENT", 20, 45], ["Aldehydes", "TEST", 58, 67], ["Ketones", "TEST", 72, 79], ["Amines", "TREATMENT", 85, 91], ["the preparation of imines", "TREATMENT", 108, 133], ["aliphatic aldehydes", "PROBLEM", 138, 157], ["a known competitive reaction", "PROBLEM", 168, 196], ["a condensation product", "PROBLEM", 222, 244], ["an aldol type reaction", "PROBLEM", 258, 280], ["Aldehydes", "OBSERVATION_MODIFIER", 58, 67], ["condensation product", "OBSERVATION", 224, 244], ["aldol type", "OBSERVATION", 261, 271]]], ["Aldol like condensation of aliphatic aldehydes.Aliphatic ketones react with amines to form imines more slowly than aldehydes, therefore, higher reaction temperatures and longer reaction time are required.", [["Aldol", "CHEMICAL", 0, 5], ["aliphatic aldehydes", "CHEMICAL", 27, 46], ["Aliphatic ketones", "CHEMICAL", 47, 64], ["amines", "CHEMICAL", 76, 82], ["aldehydes", "CHEMICAL", 115, 124], ["Aldol", "CHEMICAL", 0, 5], ["aliphatic aldehydes", "CHEMICAL", 27, 46], ["Aliphatic ketones", "CHEMICAL", 47, 64], ["amines", "CHEMICAL", 76, 82], ["imines", "CHEMICAL", 91, 97], ["aldehydes", "CHEMICAL", 115, 124], ["Aldol", "SIMPLE_CHEMICAL", 0, 5], ["aliphatic aldehydes", "SIMPLE_CHEMICAL", 27, 46], ["Aliphatic ketones", "SIMPLE_CHEMICAL", 47, 64], ["amines", "SIMPLE_CHEMICAL", 76, 82], ["aldehydes", "SIMPLE_CHEMICAL", 115, 124], ["Aldol", "TREATMENT", 0, 5], ["aliphatic aldehydes", "PROBLEM", 27, 46], ["Aliphatic ketones", "TEST", 47, 64], ["higher reaction temperatures", "PROBLEM", 137, 165], ["aliphatic aldehydes", "OBSERVATION", 27, 46]]], ["Acid catalysts and water removal from the reaction mixture can significantly increase the reaction yields, which can reach 80%-95% values.", [["Acid", "SIMPLE_CHEMICAL", 0, 4], ["water", "SIMPLE_CHEMICAL", 19, 24], ["Acid catalysts", "TREATMENT", 0, 14], ["water removal", "TREATMENT", 19, 32], ["the reaction mixture", "PROBLEM", 38, 58], ["water removal", "OBSERVATION", 19, 32]]], ["Aromatic ketones are less reactive than aliphatic ones and require harsh conditions to be converted into imines [28] .", [["Aromatic ketones", "CHEMICAL", 0, 16], ["Aromatic ketones", "CHEMICAL", 0, 16], ["imines", "CHEMICAL", 105, 111], ["Aromatic ketones", "SIMPLE_CHEMICAL", 0, 16], ["Aromatic ketones", "TEST", 0, 16], ["harsh conditions", "PROBLEM", 67, 83], ["ketones", "OBSERVATION", 9, 16], ["less", "OBSERVATION_MODIFIER", 21, 25], ["reactive", "OBSERVATION_MODIFIER", 26, 34]]], ["Recently, several new techniques to produce imines have been published, including solvent-free, clay, microwave irradiation, water suspension medium, liquid crystals, molecular sieves, infrared and ultrasound irradiation [29] [30] [31] [32] [33] [34] [35] [36] .Aerobic Oxidative Synthesis in the Preparation of Schiff's BasesSince aldehydes and ketones are mostly obtained from the corresponding alcohols via oxidative process, a straightforward preparation of imines from amines and alcohols, through tandem oxidative processes, have recently been developed (Schemes 3 and 4) [37] [38] [39] [40] [41] [42] [43] [44] .Scheme 3.", [["BasesSince aldehydes", "CHEMICAL", 321, 341], ["ketones", "CHEMICAL", 346, 353], ["amines", "CHEMICAL", 474, 480], ["alcohols", "CHEMICAL", 485, 493], ["imines", "CHEMICAL", 44, 50], ["[29] [30] [31] [32] [33] [34] [35] [36]", "CHEMICAL", 221, 260], ["Schiff", "CHEMICAL", 312, 318], ["aldehydes", "CHEMICAL", 332, 341], ["ketones", "CHEMICAL", 346, 353], ["alcohols", "CHEMICAL", 397, 405], ["imines", "CHEMICAL", 462, 468], ["amines", "CHEMICAL", 474, 480], ["alcohols", "CHEMICAL", 485, 493], ["[30] [31] [32] [33] [34] [35] [36]", "SIMPLE_CHEMICAL", 226, 260], ["Schiff's BasesSince aldehydes", "SIMPLE_CHEMICAL", 312, 341], ["ketones", "SIMPLE_CHEMICAL", 346, 353], ["alcohols", "SIMPLE_CHEMICAL", 397, 405], ["amines", "SIMPLE_CHEMICAL", 474, 480], ["alcohols", "SIMPLE_CHEMICAL", 485, 493], ["4) [37] [38] [39] [40] [41] [42] [43] [44]", "SIMPLE_CHEMICAL", 575, 617], ["microwave irradiation", "TREATMENT", 102, 123], ["infrared and ultrasound irradiation", "TEST", 185, 220], ["Aerobic Oxidative Synthesis", "TREATMENT", 262, 289], ["Schiff's BasesSince aldehydes", "TEST", 312, 341], ["ketones", "TEST", 346, 353], ["alcohols", "TREATMENT", 485, 493], ["tandem oxidative processes", "PROBLEM", 503, 529], ["Oxidative Synthesis", "OBSERVATION", 270, 289]]], ["Oxidative synthesis of imines from alcohols and amines.Following this general approach a mild and efficient method of amine oxidation has been reported by Huang and Largeron (Scheme 4) [39, 45] .Scheme 4.Oxidative synthesis of imines from amines.Addition of Organometallic Reagents to CyanidesAddition of Grignard or organolithium reagents to aryl cyanides can lead to unsubstituted ketimines which, in turn, can be elaborated to the corresponding ketones depending on the hydrolysis conditions used to decompose the metallo imine intermediate 16 (Scheme 5) .", [["alcohols", "CHEMICAL", 35, 43], ["amines", "CHEMICAL", 48, 54], ["amine", "CHEMICAL", 118, 123], ["amines", "CHEMICAL", 239, 245], ["CyanidesAddition of Grignard", "CHEMICAL", 285, 313], ["organolithium", "CHEMICAL", 317, 330], ["aryl cyanides", "CHEMICAL", 343, 356], ["ketimines", "CHEMICAL", 383, 392], ["metallo imine", "CHEMICAL", 517, 530], ["imines", "CHEMICAL", 23, 29], ["alcohols", "CHEMICAL", 35, 43], ["amines", "CHEMICAL", 48, 54], ["amine", "CHEMICAL", 118, 123], ["imines", "CHEMICAL", 227, 233], ["amines", "CHEMICAL", 239, 245], ["Grignard", "CHEMICAL", 305, 313], ["organolithium", "CHEMICAL", 317, 330], ["aryl cyanides", "CHEMICAL", 343, 356], ["ketimines", "CHEMICAL", 383, 392], ["ketones", "CHEMICAL", 448, 455], ["metallo imine", "CHEMICAL", 517, 530], ["alcohols", "SIMPLE_CHEMICAL", 35, 43], ["amines", "SIMPLE_CHEMICAL", 48, 54], ["amine", "SIMPLE_CHEMICAL", 118, 123], ["amines", "SIMPLE_CHEMICAL", 239, 245], ["Grignard", "SIMPLE_CHEMICAL", 305, 313], ["organolithium reagents", "SIMPLE_CHEMICAL", 317, 339], ["aryl cyanides", "SIMPLE_CHEMICAL", 343, 356], ["ketimines", "SIMPLE_CHEMICAL", 383, 392], ["ketones", "SIMPLE_CHEMICAL", 448, 455], ["metallo imine", "SIMPLE_CHEMICAL", 517, 530], ["Oxidative synthesis of imines from alcohols", "TREATMENT", 0, 43], ["amines", "TREATMENT", 48, 54], ["a mild and efficient method of amine oxidation", "TREATMENT", 87, 133], ["Oxidative synthesis of imines from amines", "TREATMENT", 204, 245], ["Organometallic Reagents", "TREATMENT", 258, 281], ["Grignard", "TREATMENT", 305, 313], ["organolithium reagents", "TREATMENT", 317, 339], ["aryl cyanides", "TREATMENT", 343, 356], ["unsubstituted ketimines", "TREATMENT", 369, 392], ["the corresponding ketones", "PROBLEM", 430, 455], ["the hydrolysis conditions", "PROBLEM", 469, 494], ["the metallo imine intermediate", "TREATMENT", 513, 543], ["mild", "OBSERVATION_MODIFIER", 89, 93]]], ["The reaction has also been extended to aliphatic cyanides [46] , producing very high yields of ketimines, provided that the Mg-imine intermediate is treated with anhydrous methanol [47] .", [["aliphatic cyanides", "CHEMICAL", 39, 57], ["ketimines", "CHEMICAL", 95, 104], ["Mg-imine", "CHEMICAL", 124, 132], ["anhydrous methanol", "CHEMICAL", 162, 180], ["aliphatic cyanides", "CHEMICAL", 39, 57], ["ketimines", "CHEMICAL", 95, 104], ["Mg-imine", "CHEMICAL", 124, 132], ["anhydrous methanol", "CHEMICAL", 162, 180], ["aliphatic cyanides [46]", "SIMPLE_CHEMICAL", 39, 62], ["ketimines", "SIMPLE_CHEMICAL", 95, 104], ["Mg-imine", "SIMPLE_CHEMICAL", 124, 132], ["The reaction", "PROBLEM", 0, 12], ["aliphatic cyanides", "TEST", 39, 57], ["ketimines", "TREATMENT", 95, 104], ["anhydrous methanol", "TREATMENT", 162, 180]]], ["The use of heteroaryl lithium reagents affording the corresponding ketimines has also been reported [48] .Reaction of Phenols and Phenol-Ethers with NitrilesAlkyl and aryl cyanides react smoothly with phenols and their ethers producing ketimines in very good yields in the presence of an acid catalyst (Scheme 6) [49] [50] [51] .", [["heteroaryl lithium", "CHEMICAL", 11, 29], ["ketimines", "CHEMICAL", 67, 76], ["Phenols", "CHEMICAL", 118, 125], ["Phenol-Ethers", "CHEMICAL", 130, 143], ["NitrilesAlkyl and aryl cyanides", "CHEMICAL", 149, 180], ["phenols", "CHEMICAL", 201, 208], ["ketimines", "CHEMICAL", 236, 245], ["heteroaryl lithium", "CHEMICAL", 11, 29], ["ketimines", "CHEMICAL", 67, 76], ["Phenols", "CHEMICAL", 118, 125], ["Phenol-Ethers", "CHEMICAL", 130, 143], ["NitrilesAlkyl and aryl cyanides", "CHEMICAL", 149, 180], ["phenols", "CHEMICAL", 201, 208], ["ethers", "CHEMICAL", 219, 225], ["ketimines", "CHEMICAL", 236, 245], ["heteroaryl lithium reagents", "SIMPLE_CHEMICAL", 11, 38], ["ketimines", "SIMPLE_CHEMICAL", 67, 76], ["Phenols", "SIMPLE_CHEMICAL", 118, 125], ["Phenol-Ethers", "SIMPLE_CHEMICAL", 130, 143], ["NitrilesAlkyl", "SIMPLE_CHEMICAL", 149, 162], ["aryl cyanides", "SIMPLE_CHEMICAL", 167, 180], ["phenols", "SIMPLE_CHEMICAL", 201, 208], ["ethers", "SIMPLE_CHEMICAL", 219, 225], ["ketimines", "SIMPLE_CHEMICAL", 236, 245], ["Scheme 6) [49] [50] [51]", "SIMPLE_CHEMICAL", 303, 327], ["heteroaryl lithium reagents", "TREATMENT", 11, 38], ["the corresponding ketimines", "TREATMENT", 49, 76], ["Phenols", "TREATMENT", 118, 125], ["Phenol", "TREATMENT", 130, 136], ["NitrilesAlkyl and aryl cyanides", "TREATMENT", 149, 180], ["phenols", "TREATMENT", 201, 208], ["ketimines", "TREATMENT", 236, 245], ["an acid catalyst", "TREATMENT", 285, 301]]], ["The reaction is performed by mixing the nitrile and phenol in ether and saturating the solution with gaseous HCl, whereas, for less reactive phenols, ZnCl 2 must be used.Scheme 5.Addition of organometallic reagents to cyanides.", [["nitrile", "CHEMICAL", 40, 47], ["phenol", "CHEMICAL", 52, 58], ["gaseous HCl", "CHEMICAL", 101, 112], ["phenols", "CHEMICAL", 141, 148], ["ZnCl", "CHEMICAL", 150, 154], ["cyanides", "CHEMICAL", 218, 226], ["nitrile", "CHEMICAL", 40, 47], ["phenol", "CHEMICAL", 52, 58], ["ether", "CHEMICAL", 62, 67], ["HCl", "CHEMICAL", 109, 112], ["phenols", "CHEMICAL", 141, 148], ["ZnCl 2", "CHEMICAL", 150, 156], ["cyanides", "CHEMICAL", 218, 226], ["nitrile", "SIMPLE_CHEMICAL", 40, 47], ["phenol", "SIMPLE_CHEMICAL", 52, 58], ["ether", "SIMPLE_CHEMICAL", 62, 67], ["HCl", "SIMPLE_CHEMICAL", 109, 112], ["phenols", "SIMPLE_CHEMICAL", 141, 148], ["ZnCl 2", "SIMPLE_CHEMICAL", 150, 156], ["cyanides", "SIMPLE_CHEMICAL", 218, 226], ["The reaction", "PROBLEM", 0, 12], ["the nitrile", "TREATMENT", 36, 47], ["phenol in ether", "TREATMENT", 52, 67], ["gaseous HCl", "TREATMENT", 101, 112], ["less reactive phenols", "TREATMENT", 127, 148], ["ZnCl", "TREATMENT", 150, 154], ["organometallic reagents", "TREATMENT", 191, 214], ["organometallic reagents", "OBSERVATION", 191, 214]]], ["Synthesis of ketimines from phenols and nitriles.Reaction of Metal AmidesKetimine has been produced by the addition reactions of alkali metal (or calcium amine salts) to aromatic ketones [Equation (1)].", [["ketimines", "CHEMICAL", 13, 22], ["phenols", "CHEMICAL", 28, 35], ["nitriles", "CHEMICAL", 40, 48], ["Metal AmidesKetimine", "CHEMICAL", 61, 81], ["alkali", "CHEMICAL", 129, 135], ["calcium amine salts", "CHEMICAL", 146, 165], ["aromatic ketones", "CHEMICAL", 170, 186], ["ketimines", "CHEMICAL", 13, 22], ["phenols", "CHEMICAL", 28, 35], ["nitriles", "CHEMICAL", 40, 48], ["Metal AmidesKetimine", "CHEMICAL", 61, 81], ["calcium amine", "CHEMICAL", 146, 159], ["aromatic ketones", "CHEMICAL", 170, 186], ["ketimines", "SIMPLE_CHEMICAL", 13, 22], ["phenols", "SIMPLE_CHEMICAL", 28, 35], ["nitriles", "SIMPLE_CHEMICAL", 40, 48], ["Metal AmidesKetimine", "SIMPLE_CHEMICAL", 61, 81], ["alkali metal", "SIMPLE_CHEMICAL", 129, 141], ["calcium amine salts", "SIMPLE_CHEMICAL", 146, 165], ["aromatic ketones", "SIMPLE_CHEMICAL", 170, 186], ["Synthesis of ketimines", "TREATMENT", 0, 22], ["phenols", "TREATMENT", 28, 35], ["nitriles", "TREATMENT", 40, 48], ["Metal AmidesKetimine", "TREATMENT", 61, 81], ["alkali metal", "PROBLEM", 129, 141], ["calcium amine salts", "TEST", 146, 165], ["aromatic ketones", "TEST", 170, 186], ["Metal AmidesKetimine", "OBSERVATION", 61, 81]]], ["The scope of this reaction has been widely extended [52] :Reaction of Metal AmidesAn interesting reaction is the oxidation of metalloamines bearing an \u03b1-hydrogen by 2-bromoanisole [53] to yield imines (Scheme 7).Scheme 7.Oxidation of metal amines to imines by 2-bromoanisole.Other MethodologiesKetimine can be prepared in high yield using aryl ketone diethyl ketals and arylamines, while alkylamines give only low yields (Scheme 8) [54] .", [["Metal", "CHEMICAL", 70, 75], ["metalloamines", "CHEMICAL", 126, 139], ["\u03b1-hydrogen", "CHEMICAL", 151, 161], ["2-bromoanisole", "CHEMICAL", 165, 179], ["metal amines", "CHEMICAL", 234, 246], ["2-bromoanisole", "CHEMICAL", 260, 274], ["Ketimine", "CHEMICAL", 294, 302], ["aryl ketone diethyl ketals", "CHEMICAL", 339, 365], ["arylamines", "CHEMICAL", 370, 380], ["alkylamines", "CHEMICAL", 388, 399], ["Metal AmidesAn", "CHEMICAL", 70, 84], ["metalloamines", "CHEMICAL", 126, 139], ["\u03b1-hydrogen", "CHEMICAL", 151, 161], ["2-bromoanisole", "CHEMICAL", 165, 179], ["imines", "CHEMICAL", 194, 200], ["metal amines", "CHEMICAL", 234, 246], ["imines", "CHEMICAL", 250, 256], ["2-bromoanisole", "CHEMICAL", 260, 274], ["Ketimine", "CHEMICAL", 294, 302], ["aryl ketone diethyl ketals", "CHEMICAL", 339, 365], ["arylamines", "CHEMICAL", 370, 380], ["alkylamines", "CHEMICAL", 388, 399], ["[52]", "SIMPLE_CHEMICAL", 52, 56], ["Metal AmidesAn", "SIMPLE_CHEMICAL", 70, 84], ["metalloamines", "SIMPLE_CHEMICAL", 126, 139], ["\u03b1-hydrogen", "SIMPLE_CHEMICAL", 151, 161], ["2-bromoanisole [53]", "SIMPLE_CHEMICAL", 165, 184], ["metal amines", "SIMPLE_CHEMICAL", 234, 246], ["imines", "SIMPLE_CHEMICAL", 250, 256], ["2-bromoanisole", "SIMPLE_CHEMICAL", 260, 274], ["Ketimine", "SIMPLE_CHEMICAL", 294, 302], ["aryl ketone diethyl ketals", "SIMPLE_CHEMICAL", 339, 365], ["arylamines", "SIMPLE_CHEMICAL", 370, 380], ["alkylamines", "SIMPLE_CHEMICAL", 388, 399], ["this reaction", "PROBLEM", 13, 26], ["Metal AmidesAn interesting reaction", "TREATMENT", 70, 105], ["the oxidation of metalloamines", "TREATMENT", 109, 139], ["Oxidation of metal amines to imines", "TREATMENT", 221, 256], ["Other MethodologiesKetimine", "TREATMENT", 275, 302], ["aryl ketone diethyl ketals", "TREATMENT", 339, 365], ["arylamines", "TREATMENT", 370, 380], ["alkylamines", "TREATMENT", 388, 399]]], ["Similarly, imines can react with higher boiling point amines to give the exchange products.", [["amines", "CHEMICAL", 54, 60], ["imines", "CHEMICAL", 11, 17], ["amines", "CHEMICAL", 54, 60], ["imines", "SIMPLE_CHEMICAL", 11, 17], ["higher boiling point amines", "TREATMENT", 33, 60], ["the exchange products", "TREATMENT", 69, 90]]], ["Synthesis of ketimines from ketals.Olefins and tertiary alcohols can be converted into ketimines [56] by reaction of hydrazoic acid in sulfuric acid (Scheme 9).", [["ketimines", "CHEMICAL", 13, 22], ["Olefins", "CHEMICAL", 35, 42], ["ketimines", "CHEMICAL", 87, 96], ["hydrazoic acid", "CHEMICAL", 117, 131], ["sulfuric acid", "CHEMICAL", 135, 148], ["ketimines", "CHEMICAL", 13, 22], ["Olefins", "CHEMICAL", 35, 42], ["tertiary alcohols", "CHEMICAL", 47, 64], ["ketimines", "CHEMICAL", 87, 96], ["hydrazoic acid", "CHEMICAL", 117, 131], ["sulfuric acid", "CHEMICAL", 135, 148], ["ketimines", "SIMPLE_CHEMICAL", 13, 22], ["ketals", "SIMPLE_CHEMICAL", 28, 34], ["Olefins", "SIMPLE_CHEMICAL", 35, 42], ["tertiary alcohols", "SIMPLE_CHEMICAL", 47, 64], ["ketimines [56]", "SIMPLE_CHEMICAL", 87, 101], ["hydrazoic acid", "SIMPLE_CHEMICAL", 117, 131], ["sulfuric acid", "SIMPLE_CHEMICAL", 135, 148], ["Synthesis of ketimines", "TREATMENT", 0, 22], ["hydrazoic acid in sulfuric acid", "TREATMENT", 117, 148]]], ["Reaction of olefins and tertiary alcohols with hydrazoic acid.Scheme 8.", [["hydrazoic acid", "CHEMICAL", 47, 61], ["olefins", "CHEMICAL", 12, 19], ["tertiary alcohols", "CHEMICAL", 24, 41], ["hydrazoic acid", "CHEMICAL", 47, 61], ["olefins", "SIMPLE_CHEMICAL", 12, 19], ["tertiary alcohols", "SIMPLE_CHEMICAL", 24, 41], ["hydrazoic acid", "SIMPLE_CHEMICAL", 47, 61], ["tertiary alcohols", "TREATMENT", 24, 41], ["hydrazoic acid", "TREATMENT", 47, 61]]], ["Synthesis of ketimines from ketals.Imines can also be formed by reaction of amino acids with sodium hypochlorite (Scheme 10).", [["ketimines", "CHEMICAL", 13, 22], ["Imines", "CHEMICAL", 35, 41], ["amino acids", "CHEMICAL", 76, 87], ["sodium hypochlorite", "CHEMICAL", 93, 112], ["ketimines", "CHEMICAL", 13, 22], ["Imines", "CHEMICAL", 35, 41], ["amino acids", "CHEMICAL", 76, 87], ["sodium hypochlorite", "CHEMICAL", 93, 112], ["ketimines", "SIMPLE_CHEMICAL", 13, 22], ["ketals", "SIMPLE_CHEMICAL", 28, 34], ["Imines", "SIMPLE_CHEMICAL", 35, 41], ["amino acids", "AMINO_ACID", 76, 87], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 93, 112], ["Synthesis of ketimines", "TREATMENT", 0, 22], ["amino acids", "TREATMENT", 76, 87], ["sodium hypochlorite", "TREATMENT", 93, 112]]], ["The first step of this reaction is the formation of a chloramine intermediate that gives rise to the imine via elimination of carbon dioxide and sodium chloride [57] .Scheme 10.Conversion of \u03b1-amino acids into imines.Preparation of N-Metallo-Imines as Stable Synthetic Equivalents of N-Unsubstituted Schiff Bases [58]N-metallo-imines constitute a young family of organometallic compounds congeners of Schiff bases [59] .", [["chloramine", "CHEMICAL", 54, 64], ["imine", "CHEMICAL", 101, 106], ["carbon dioxide", "CHEMICAL", 126, 140], ["sodium chloride", "CHEMICAL", 145, 160], ["\u03b1-amino acids", "CHEMICAL", 191, 204], ["N-Metallo-Imines", "CHEMICAL", 232, 248], ["[58]N-metallo-imines", "CHEMICAL", 313, 333], ["chloramine", "CHEMICAL", 54, 64], ["imine", "CHEMICAL", 101, 106], ["carbon dioxide", "CHEMICAL", 126, 140], ["sodium chloride", "CHEMICAL", 145, 160], ["\u03b1-amino acids", "CHEMICAL", 191, 204], ["imines", "CHEMICAL", 210, 216], ["N-Metallo-Imines", "CHEMICAL", 232, 248], ["Schiff Bases", "CHEMICAL", 300, 312], ["[58]N-metallo-imines", "CHEMICAL", 313, 333], ["Schiff bases", "CHEMICAL", 401, 413], ["chloramine", "SIMPLE_CHEMICAL", 54, 64], ["imine", "SIMPLE_CHEMICAL", 101, 106], ["carbon dioxide", "SIMPLE_CHEMICAL", 126, 140], ["sodium chloride [57]", "SIMPLE_CHEMICAL", 145, 165], ["\u03b1-amino acids", "SIMPLE_CHEMICAL", 191, 204], ["imines", "SIMPLE_CHEMICAL", 210, 216], ["N-Metallo-Imines", "SIMPLE_CHEMICAL", 232, 248], ["N-Unsubstituted Schiff Bases [58]N-metallo-imines", "SIMPLE_CHEMICAL", 284, 333], ["Schiff", "SIMPLE_CHEMICAL", 401, 407], ["this reaction", "PROBLEM", 18, 31], ["a chloramine intermediate", "TREATMENT", 52, 77], ["carbon dioxide", "TEST", 126, 140], ["sodium chloride", "TEST", 145, 160], ["\u03b1-amino acids into imines", "TREATMENT", 191, 216], ["N-Metallo-Imines", "TREATMENT", 232, 248], ["Schiff Bases", "TEST", 300, 312], ["metallo-imines", "TREATMENT", 319, 333]]], ["They have been found synthetic applications in the last few decades as relatively stable analogues of the corresponding Schiff bases.", [["Schiff bases", "CHEMICAL", 120, 132], ["synthetic applications", "TREATMENT", 21, 43], ["synthetic", "OBSERVATION_MODIFIER", 21, 30], ["stable", "OBSERVATION", 82, 88], ["Schiff bases", "OBSERVATION", 120, 132]]], ["Their elaborations to azadiene have been fully explored by the Barluenga [60] [61] [62] , Ghosez [63, 64] and Panunzio groups [65] [66] [67] [68] [69] .", [["azadiene", "CHEMICAL", 22, 30], ["azadiene", "CHEMICAL", 22, 30], ["Barluenga [60] [61] [62]", "CHEMICAL", 63, 87], ["Panunzio", "CHEMICAL", 110, 118], ["azadiene", "SIMPLE_CHEMICAL", 22, 30], ["Barluenga [60] [61] [62]", "SIMPLE_CHEMICAL", 63, 87], ["Ghosez [63, 64]", "SIMPLE_CHEMICAL", 90, 105], ["Panunzio groups [65] [66] [67] [68] [69]", "SIMPLE_CHEMICAL", 110, 150], ["azadiene", "TREATMENT", 22, 30], ["Ghosez", "TEST", 90, 96]]], ["Generally speaking, they are monomeric compounds reasonably stable under anhydrous conditions.", [["anhydrous", "CHEMICAL", 73, 82]]], ["Since the metal-nitrogen bond is easily hydrolysed, the N-metalloimines may be considered a protected, stabilized form of the corresponding elusive imines of ammonia, which are known to be very unstable readily trimerizing to triazines [11] .", [["metal-nitrogen", "CHEMICAL", 10, 24], ["N-metalloimines", "CHEMICAL", 56, 71], ["ammonia", "CHEMICAL", 158, 165], ["triazines", "CHEMICAL", 226, 235], ["nitrogen", "CHEMICAL", 16, 24], ["N-metalloimines", "CHEMICAL", 56, 71], ["imines", "CHEMICAL", 148, 154], ["ammonia", "CHEMICAL", 158, 165], ["triazines", "CHEMICAL", 226, 235], ["N-metalloimines", "SIMPLE_CHEMICAL", 56, 71], ["ammonia", "SIMPLE_CHEMICAL", 158, 165], ["triazines [11]", "SIMPLE_CHEMICAL", 226, 240], ["metalloimines", "TREATMENT", 58, 71]]], ["Although some metalloimines, e.g., the silylimines of certain aldehydes, can be isolated in a pure form by distillation under reduced pressure, for synthetic purposes it is in general more convenient to prepare them in situ just before the use.", [["metalloimines", "CHEMICAL", 14, 27], ["aldehydes", "CHEMICAL", 62, 71], ["metalloimines", "CHEMICAL", 14, 27], ["silylimines", "CHEMICAL", 39, 50], ["aldehydes", "CHEMICAL", 62, 71], ["metalloimines", "SIMPLE_CHEMICAL", 14, 27], ["silylimines", "SIMPLE_CHEMICAL", 39, 50], ["aldehydes", "SIMPLE_CHEMICAL", 62, 71], ["some metalloimines", "PROBLEM", 9, 27], ["certain aldehydes", "TREATMENT", 54, 71], ["synthetic purposes", "TREATMENT", 148, 166], ["some", "OBSERVATION_MODIFIER", 9, 13], ["metalloimines", "OBSERVATION", 14, 27], ["reduced", "OBSERVATION_MODIFIER", 126, 133], ["pressure", "OBSERVATION_MODIFIER", 134, 142]]], ["In this case it is possible to ascertain their structure by a combined use of IR, 1 H-NMR, 13 Among different metalloimines, N-trialkylsilyl imines must be considered the most popular and the most used intermediates in the preparation of nitrogen containing organic compounds, with special emphasis to the potentially bioactive ones [67, 86] .", [["metalloimines", "CHEMICAL", 110, 123], ["N-trialkylsilyl imines", "CHEMICAL", 125, 147], ["nitrogen", "CHEMICAL", 238, 246], ["H", "CHEMICAL", 84, 85], ["metalloimines", "CHEMICAL", 110, 123], ["N-trialkylsilyl imines", "CHEMICAL", 125, 147], ["nitrogen", "CHEMICAL", 238, 246], ["metalloimines", "SIMPLE_CHEMICAL", 110, 123], ["N-trialkylsilyl imines", "SIMPLE_CHEMICAL", 125, 147], ["nitrogen", "SIMPLE_CHEMICAL", 238, 246], ["NMR", "TEST", 86, 89], ["different metalloimines", "TREATMENT", 100, 123], ["N-trialkylsilyl imines", "TREATMENT", 125, 147], ["nitrogen containing organic compounds", "TREATMENT", 238, 275]]], ["Silyl imines have been prepared, for the first time, by Rochow [84] starting from aromatic aldehydes and nonenolizable ketones by treatment of the carbonyl compounds with one equivalent of lithium hexamethyldisilylamide in tetrahydrofuran [86] .", [["Silyl imines", "CHEMICAL", 0, 12], ["Rochow [84]", "CHEMICAL", 56, 67], ["aromatic aldehydes", "CHEMICAL", 82, 100], ["nonenolizable ketones", "CHEMICAL", 105, 126], ["carbonyl", "CHEMICAL", 147, 155], ["lithium hexamethyldisilylamide", "CHEMICAL", 189, 219], ["tetrahydrofuran", "CHEMICAL", 223, 238], ["Silyl imines", "CHEMICAL", 0, 12], ["aromatic aldehydes", "CHEMICAL", 82, 100], ["nonenolizable ketones", "CHEMICAL", 105, 126], ["carbonyl", "CHEMICAL", 147, 155], ["lithium hexamethyldisilylamide", "CHEMICAL", 189, 219], ["tetrahydrofuran", "CHEMICAL", 223, 238], ["Silyl imines", "SIMPLE_CHEMICAL", 0, 12], ["Rochow [84]", "SIMPLE_CHEMICAL", 56, 67], ["aromatic aldehydes", "SIMPLE_CHEMICAL", 82, 100], ["nonenolizable ketones", "SIMPLE_CHEMICAL", 105, 126], ["carbonyl compounds", "SIMPLE_CHEMICAL", 147, 165], ["lithium hexamethyldisilylamide", "SIMPLE_CHEMICAL", 189, 219], ["tetrahydrofuran [86]", "SIMPLE_CHEMICAL", 223, 243], ["Silyl imines", "TREATMENT", 0, 12], ["aromatic aldehydes", "TEST", 82, 100], ["nonenolizable ketones", "PROBLEM", 105, 126], ["the carbonyl compounds", "TREATMENT", 143, 165], ["lithium hexamethyldisilylamide in tetrahydrofuran", "TREATMENT", 189, 238]]], ["The reaction proceeds by an addition-elimination sequence probably involving a four centers cyclic transition state (Scheme 12).Scheme 12.", [["The reaction", "PROBLEM", 0, 12], ["an addition-elimination sequence", "TEST", 25, 57]]], ["Preparation of N-silylimines via reaction of lithium hexalkyldisilylamide.Ketones, bearing a hydrogen atom in \u03b1-position to the carbonyl group, failed to produce the silylimines since in this case the strongly basic organometallic reagent attacks an \u03b1-hydrogen affording the corresponding lithium enolate.", [["N-silylimines", "CHEMICAL", 15, 28], ["lithium hexalkyldisilylamide", "CHEMICAL", 45, 73], ["Ketones", "CHEMICAL", 74, 81], ["carbonyl", "CHEMICAL", 128, 136], ["silylimines", "CHEMICAL", 166, 177], ["\u03b1-hydrogen", "CHEMICAL", 250, 260], ["lithium enolate", "CHEMICAL", 289, 304], ["N-silylimines", "CHEMICAL", 15, 28], ["lithium hexalkyldisilylamide", "CHEMICAL", 45, 73], ["Ketones", "CHEMICAL", 74, 81], ["hydrogen", "CHEMICAL", 93, 101], ["carbonyl", "CHEMICAL", 128, 136], ["silylimines", "CHEMICAL", 166, 177], ["\u03b1-hydrogen", "CHEMICAL", 250, 260], ["lithium enolate", "CHEMICAL", 289, 304], ["N-silylimines", "SIMPLE_CHEMICAL", 15, 28], ["lithium hexalkyldisilylamide", "SIMPLE_CHEMICAL", 45, 73], ["Ketones", "SIMPLE_CHEMICAL", 74, 81], ["\u03b1-position", "SIMPLE_CHEMICAL", 110, 120], ["carbonyl", "SIMPLE_CHEMICAL", 128, 136], ["silylimines", "SIMPLE_CHEMICAL", 166, 177], ["\u03b1-hydrogen", "SIMPLE_CHEMICAL", 250, 260], ["lithium enolate", "SIMPLE_CHEMICAL", 289, 304], ["N", "TREATMENT", 15, 16], ["silylimines", "TREATMENT", 17, 28], ["lithium hexalkyldisilylamide", "TREATMENT", 45, 73], ["Ketones", "TEST", 74, 81], ["a hydrogen atom", "TREATMENT", 91, 106], ["an \u03b1-hydrogen", "TREATMENT", 247, 260], ["the corresponding lithium enolate", "TREATMENT", 271, 304], ["lithium enolate", "OBSERVATION", 289, 304]]], ["Enolizable aldehydes were supposed to behave in the same way [85] .Scheme 12.", [["aldehydes", "CHEMICAL", 11, 20], ["aldehydes", "CHEMICAL", 11, 20], ["aldehydes", "SIMPLE_CHEMICAL", 11, 20], ["Enolizable aldehydes", "PROBLEM", 0, 20], ["aldehydes", "OBSERVATION", 11, 20]]], ["Preparation of N-silylimines via reaction of lithium hexalkyldisilylamide.This notwithstanding the preparation of such silyl imines is easier than one might expect [87] .", [["N-silylimines", "CHEMICAL", 15, 28], ["lithium hexalkyldisilylamide", "CHEMICAL", 45, 73], ["silyl imines", "CHEMICAL", 119, 131], ["N-silylimines", "CHEMICAL", 15, 28], ["lithium hexalkyldisilylamide", "CHEMICAL", 45, 73], ["silyl imines", "CHEMICAL", 119, 131], ["N-silylimines", "SIMPLE_CHEMICAL", 15, 28], ["lithium hexalkyldisilylamide", "SIMPLE_CHEMICAL", 45, 73], ["silyl imines", "SIMPLE_CHEMICAL", 119, 131], ["N", "TREATMENT", 15, 16], ["silylimines", "TREATMENT", 17, 28], ["lithium hexalkyldisilylamide", "TREATMENT", 45, 73], ["such silyl imines", "TREATMENT", 114, 131]]], ["Few competitive methods, to the above cited, have been reported in the last few years on the preparation of N-alkylsilyl imines.", [["N-alkylsilyl imines", "CHEMICAL", 108, 127], ["N-alkylsilyl imines", "CHEMICAL", 108, 127], ["N-alkylsilyl imines", "SIMPLE_CHEMICAL", 108, 127], ["N-alkylsilyl imines", "TREATMENT", 108, 127], ["competitive", "OBSERVATION_MODIFIER", 4, 15], ["methods", "OBSERVATION", 16, 23]]], ["Very recently Nikonov and co-workers [88] reported an elegant preparation of N-silyl-aldimines 42 via a chemoselective hydrosilylation of nitriles 35 catalysed by ruthenium complex (Scheme 13).", [["N-silyl-aldimines 42", "CHEMICAL", 77, 97], ["nitriles 35", "CHEMICAL", 138, 149], ["ruthenium", "CHEMICAL", 163, 172], ["N-silyl-aldimines", "CHEMICAL", 77, 94], ["nitriles", "CHEMICAL", 138, 146], ["ruthenium", "CHEMICAL", 163, 172], ["N-silyl-aldimines 42", "SIMPLE_CHEMICAL", 77, 97], ["nitriles 35", "SIMPLE_CHEMICAL", 138, 149], ["ruthenium complex", "SIMPLE_CHEMICAL", 163, 180], ["N-silyl-aldimines", "TREATMENT", 77, 94], ["a chemoselective hydrosilylation of nitriles", "TREATMENT", 102, 146]]], ["N-alkylsilyl imines via hydrosilylation of nitrile.", [["N-alkylsilyl imines", "CHEMICAL", 0, 19], ["nitrile", "CHEMICAL", 43, 50], ["N-alkylsilyl imines", "CHEMICAL", 0, 19], ["nitrile", "CHEMICAL", 43, 50], ["N-alkylsilyl imines", "SIMPLE_CHEMICAL", 0, 19], ["nitrile", "SIMPLE_CHEMICAL", 43, 50], ["alkylsilyl imines", "TREATMENT", 2, 19], ["hydrosilylation of nitrile", "TREATMENT", 24, 50]]], ["[89, 90] In analogy of classical preparation of Schiff Bases silyl-imines 45 may be prepared by elimination of vicinal substituents as shown in (Scheme 14).Scheme 14.", [["silyl-imines", "CHEMICAL", 61, 73], ["Schiff Bases silyl-imines", "CHEMICAL", 48, 73], ["Schiff Bases silyl-imines 45", "SIMPLE_CHEMICAL", 48, 76], ["vicinal substituents", "SIMPLE_CHEMICAL", 111, 131], ["Schiff Bases silyl-imines", "TREATMENT", 48, 73], ["vicinal substituents", "TREATMENT", 111, 131]]], ["Formation of silylimines via elimination of vicinal groups. (a) from N-chlorosilylamines; (b) from \u03b1-cyano silylamines.Preparation of N-tin-Imines via Reaction of Carbonyl Compounds with Tris(trimethylstannyl)amine [91]This method allows the preparation of tin imines from enolizable and non enolizable aldehydes and ketones, in good yield and under very mild conditions (Scheme 15) [91] .", [["silylimines", "CHEMICAL", 13, 24], ["N-chlorosilylamines", "CHEMICAL", 69, 88], ["\u03b1-cyano silylamines", "CHEMICAL", 99, 118], ["N-tin-Imines", "CHEMICAL", 134, 146], ["Tris(trimethylstannyl)amine", "CHEMICAL", 187, 214], ["tin imines", "CHEMICAL", 257, 267], ["aldehydes", "CHEMICAL", 303, 312], ["ketones", "CHEMICAL", 317, 324], ["silylimines", "CHEMICAL", 13, 24], ["N-chlorosilylamines", "CHEMICAL", 69, 88], ["\u03b1-cyano silylamines", "CHEMICAL", 99, 118], ["N-tin-Imines", "CHEMICAL", 134, 146], ["Carbonyl", "CHEMICAL", 163, 171], ["Tris(trimethylstannyl)amine", "CHEMICAL", 187, 214], ["tin imines", "CHEMICAL", 257, 267], ["aldehydes", "CHEMICAL", 303, 312], ["ketones", "CHEMICAL", 317, 324], ["silylimines", "SIMPLE_CHEMICAL", 13, 24], ["N-chlorosilylamines", "SIMPLE_CHEMICAL", 69, 88], ["\u03b1-cyano silylamines", "SIMPLE_CHEMICAL", 99, 118], ["N-tin-Imines", "SIMPLE_CHEMICAL", 134, 146], ["Carbonyl Compounds", "SIMPLE_CHEMICAL", 163, 181], ["Tris(trimethylstannyl)amine [91]", "SIMPLE_CHEMICAL", 187, 219], ["tin imines", "SIMPLE_CHEMICAL", 257, 267], ["enolizable", "SIMPLE_CHEMICAL", 273, 283], ["non enolizable aldehydes", "SIMPLE_CHEMICAL", 288, 312], ["ketones", "SIMPLE_CHEMICAL", 317, 324], ["silylimines via elimination of vicinal groups", "TREATMENT", 13, 58], ["cyano silylamines", "TREATMENT", 101, 118], ["N-tin-Imines", "TREATMENT", 134, 146], ["Carbonyl Compounds with Tris(trimethylstannyl)amine", "TREATMENT", 163, 214], ["tin imines", "TREATMENT", 257, 267], ["non enolizable aldehydes", "PROBLEM", 288, 312], ["ketones", "TEST", 317, 324], ["very mild conditions", "PROBLEM", 350, 370]]], ["The reaction involves an addition-elimination reaction of the type discussed for the Rochow's procedure.", [["The reaction", "PROBLEM", 0, 12], ["the Rochow's procedure", "TREATMENT", 81, 103]]], ["The organometallic reagent is, in this case, the tris(trimethylstanny1)amines which can be easily prepared from trimethyl tin chloride and lithium amide.", [["tris(trimethylstanny1)amines", "CHEMICAL", 49, 77], ["trimethyl tin chloride", "CHEMICAL", 112, 134], ["lithium amide", "CHEMICAL", 139, 152], ["tris(trimethylstanny1)amines", "CHEMICAL", 49, 77], ["trimethyl tin chloride", "CHEMICAL", 112, 134], ["lithium amide", "CHEMICAL", 139, 152], ["tris(trimethylstanny1)amines", "SIMPLE_CHEMICAL", 49, 77], ["trimethyl tin chloride", "SIMPLE_CHEMICAL", 112, 134], ["lithium amide", "SIMPLE_CHEMICAL", 139, 152], ["the tris(trimethylstanny1)amines", "TREATMENT", 45, 77], ["trimethyl tin chloride", "TREATMENT", 112, 134], ["lithium amide", "TREATMENT", 139, 152], ["organometallic reagent", "OBSERVATION", 4, 26]]], ["Since the tris(trimethylstanny1)amine does not show strong basic properties, the \u03b1-deprotonation is completely suppressed thus allowing a facile preparation of tin-imines even in the case of enolizable ketones and aldehydes.", [["tris(trimethylstanny1)amine", "CHEMICAL", 10, 37], ["tin-imines", "CHEMICAL", 160, 170], ["enolizable ketones", "CHEMICAL", 191, 209], ["aldehydes", "CHEMICAL", 214, 223], ["tris(trimethylstanny1)amine", "CHEMICAL", 10, 37], ["tin-imines", "CHEMICAL", 160, 170], ["ketones", "CHEMICAL", 202, 209], ["aldehydes", "CHEMICAL", 214, 223], ["tris(trimethylstanny1)amine", "SIMPLE_CHEMICAL", 10, 37], ["tin-imines", "SIMPLE_CHEMICAL", 160, 170], ["enolizable ketones", "SIMPLE_CHEMICAL", 191, 209], ["aldehydes", "SIMPLE_CHEMICAL", 214, 223], ["a facile preparation of tin-imines", "TREATMENT", 136, 170], ["enolizable ketones and aldehydes", "PROBLEM", 191, 223]]], ["An interesting feature of the tin-imines is the possibility to undergo transmetallation reactions with trialkylsilyl chlorides (e.g., chloro tert-butyldimethylsilane) to give the corresponding N-silylimine and tris(trimethyltin)onium chloride that spontaneously precipitates from the solution.", [["trialkylsilyl chlorides", "CHEMICAL", 103, 126], ["chloro tert-butyldimethylsilane", "CHEMICAL", 134, 165], ["N-silylimine", "CHEMICAL", 193, 205], ["tris(trimethyltin)onium chloride", "CHEMICAL", 210, 242], ["tin-imines", "CHEMICAL", 30, 40], ["trialkylsilyl chlorides", "CHEMICAL", 103, 126], ["chloro tert-butyldimethylsilane", "CHEMICAL", 134, 165], ["N-silylimine", "CHEMICAL", 193, 205], ["tris(trimethyltin)onium chloride", "CHEMICAL", 210, 242], ["tin-imines", "SIMPLE_CHEMICAL", 30, 40], ["trialkylsilyl chlorides", "SIMPLE_CHEMICAL", 103, 126], ["chloro tert-butyldimethylsilane", "SIMPLE_CHEMICAL", 134, 165], ["N-silylimine", "SIMPLE_CHEMICAL", 193, 205], ["tris(trimethyltin)onium chloride", "SIMPLE_CHEMICAL", 210, 242], ["transmetallation reactions", "PROBLEM", 71, 97], ["trialkylsilyl chlorides", "TREATMENT", 103, 126], ["chloro tert-butyldimethylsilane)", "TREATMENT", 134, 166], ["the corresponding N-silylimine and tris(trimethyltin)onium chloride", "TREATMENT", 175, 242]]], ["Removal of this precipitate by filtration allows the preparation of almost pure solution of silylimines [91] .Preparation of N-tin-Imines via Reaction of Carbonyl Compounds with Tris(trimethylstannyl)amine [91]Scheme 15.", [["silylimines", "CHEMICAL", 92, 103], ["N-tin-Imines", "CHEMICAL", 125, 137], ["Tris(trimethylstannyl)amine", "CHEMICAL", 178, 205], ["silylimines", "CHEMICAL", 92, 103], ["N-tin-Imines", "CHEMICAL", 125, 137], ["Carbonyl", "CHEMICAL", 154, 162], ["Tris(trimethylstannyl)amine", "CHEMICAL", 178, 205], ["silylimines [91]", "SIMPLE_CHEMICAL", 92, 108], ["N-tin-Imines", "SIMPLE_CHEMICAL", 125, 137], ["Carbonyl Compounds", "SIMPLE_CHEMICAL", 154, 172], ["Tris(trimethylstannyl)amine [91]Scheme 15", "SIMPLE_CHEMICAL", 178, 219], ["Removal", "TREATMENT", 0, 7], ["almost pure solution of silylimines", "TREATMENT", 68, 103], ["N-tin-Imines", "TREATMENT", 125, 137], ["Carbonyl Compounds with Tris(trimethylstannyl)amine", "TREATMENT", 154, 205]]], ["Synthesis of N-tin imines.Schiff Bases as Precursors of Countless Versatile Organic Processes for the Production of Intermediates/ProductsAs a versatile precursor for organic syntheses, we can identify, in an oversimplification, four different types of reactions in which Schiff bases have been found extremely important applications: (a) addition of organometallic reagents or hydride to C=N bond to afford compounds of structure 52; (b) hetero Diels-Alder reaction to furnish six membered nitrogen containing heterocyclic compounds of general formula 53; (c) skeletons for the building-up scaffolds, as the very famous salen scaffold, to be used as \"privileged ligand\" [92] for the formation of the corresponding chiral salen metal complexes 54; (d) Staudinger reaction with ketene to furnish biologically important \u03b2-lactam ring 55 (Chart 1).", [["N-tin imines", "CHEMICAL", 13, 25], ["hydride", "CHEMICAL", 378, 385], ["nitrogen", "CHEMICAL", 491, 499], ["ketene", "CHEMICAL", 777, 783], ["N-tin imines", "CHEMICAL", 13, 25], ["Schiff bases", "CHEMICAL", 272, 284], ["hydride", "CHEMICAL", 378, 385], ["C=N", "CHEMICAL", 389, 392], ["nitrogen", "CHEMICAL", 491, 499], ["salen metal", "CHEMICAL", 722, 733], ["ketene", "CHEMICAL", 777, 783], ["\u03b2-lactam", "CHEMICAL", 818, 826], ["N-tin imines", "SIMPLE_CHEMICAL", 13, 25], ["hydride", "SIMPLE_CHEMICAL", 378, 385], ["C=N bond", "SIMPLE_CHEMICAL", 389, 397], ["(c) skeletons", "SIMPLE_CHEMICAL", 557, 570], ["(d) Staudinger", "SIMPLE_CHEMICAL", 748, 762], ["ketene", "SIMPLE_CHEMICAL", 777, 783], ["Synthesis of N-tin imines", "TREATMENT", 0, 25], ["Schiff Bases", "TEST", 26, 38], ["organic syntheses", "PROBLEM", 167, 184], ["organometallic reagents", "TREATMENT", 351, 374], ["hydride", "TREATMENT", 378, 385], ["Alder reaction", "PROBLEM", 452, 466], ["furnish six membered nitrogen containing heterocyclic compounds of general formula", "TREATMENT", 470, 552], ["the building-up scaffolds", "TREATMENT", 575, 600], ["the very famous salen scaffold", "TREATMENT", 605, 635], ["the corresponding chiral salen metal complexes", "TREATMENT", 697, 743], ["ketene", "TREATMENT", 777, 783]]], ["It must be underlined for point (c) that we are reporting only the applications of chiral salen complexes [92] [93] [94] [95] [96] .", [["salen", "CHEMICAL", 90, 95], ["[92] [93] [94] [95]", "CHEMICAL", 106, 125], ["salen", "SIMPLE_CHEMICAL", 90, 95], ["[92] [93] [94] [95] [96]", "SIMPLE_CHEMICAL", 106, 130], ["chiral salen complexes", "TREATMENT", 83, 105]]], ["For different complex catalysts, as salophen [97, 98] , or for the use of Schiff bases, different from salen backbone, we refer the interested reader to the following up-to-date survey of extremely good and dedicated reviews on the subject authored by specialists in the field [92, [99] [100] [101] [102] [103] [104] [105] .Schiff Bases as Precursors of Countless Versatile Organic Processes for the Production of Intermediates/ProductsThe same criteria have been used for all the applications reported in Chart 1.", [["salophen", "CHEMICAL", 36, 44], ["salophen", "CHEMICAL", 36, 44], ["Schiff bases", "CHEMICAL", 74, 86], ["salen", "CHEMICAL", 103, 108], ["Schiff bases", "SIMPLE_CHEMICAL", 74, 86], ["salen backbone", "SIMPLE_CHEMICAL", 103, 117], ["different complex catalysts", "TREATMENT", 4, 31], ["salophen", "TEST", 36, 44], ["Schiff bases", "TREATMENT", 74, 86], ["Schiff Bases", "TEST", 324, 336], ["Intermediates/Products", "TREATMENT", 414, 436]]], ["Accordingly we have grouped the references reported in: (a) Reduction of C=N bond, focused on asymmetric formation of carbon-carbon bond [60, [106] [107] [108] [109] ; (b) Hetero Diels-Alder reactions with the formation of heterocyclic compounds [110] [111] [112] [113] [114] [115] [116] ; (c) Use of chiral salen metal complexes in the asymmetric synthesis [92] [93] [94] [95] [96] 117, 118] ; (d) Staudinger reactions for the preparation of \u03b2-lactams [4, [119] [120] [121] [122] .", [["carbon-carbon", "CHEMICAL", 118, 131], ["\u03b2-lactams", "CHEMICAL", 443, 452], ["C=N", "CHEMICAL", 73, 76], ["carbon", "CHEMICAL", 118, 124], ["carbon", "CHEMICAL", 125, 131], ["salen metal", "CHEMICAL", 308, 319], ["\u03b2-lactams", "CHEMICAL", 443, 452], ["C=N bond", "SIMPLE_CHEMICAL", 73, 81], ["carbon-carbon", "SIMPLE_CHEMICAL", 118, 131], ["[106] [107] [108] [109]", "SIMPLE_CHEMICAL", 142, 165], ["b) Hetero Diels-Alder reactions", "SIMPLE_CHEMICAL", 169, 200], ["[110] [111] [112] [113] [114] [115] [116]", "SIMPLE_CHEMICAL", 246, 287], ["chiral salen metal complexes", "SIMPLE_CHEMICAL", 301, 329], ["[92] [93] [94] [95] [96] 117, 118] ; (d) Staudinger", "SIMPLE_CHEMICAL", 358, 409], ["\u03b2-lactams [4, [119] [120] [121] [122]", "SIMPLE_CHEMICAL", 443, 480], ["carbon-carbon bond", "TEST", 118, 136], ["Hetero Diels", "TEST", 172, 184], ["Alder reactions", "PROBLEM", 185, 200], ["heterocyclic compounds", "TEST", 223, 245], ["chiral salen metal complexes", "TEST", 301, 329], ["the asymmetric synthesis", "TEST", 333, 357], ["Staudinger reactions", "TEST", 399, 419], ["\u03b2-lactams", "TEST", 443, 452]]], ["In the following paragraphs we will emphasize the importance of imines, first discovered by the Ugo Schiff, providing the reader with relevant information highlighting the importance of Schiff bases and their applications in a wide range of organic and pharmaceutical chemistry fields.Schiff Bases as Intermediate of Bio-ProcessesThe importance of Schiff bases as intermediates in bio-processes is very well established: suffice it to mention one of the very basic process of life: the transamination reaction (Scheme 16) [123] .Scheme 16.", [["imines", "CHEMICAL", 64, 70], ["Schiff bases", "CHEMICAL", 186, 198], ["Schiff bases", "CHEMICAL", 348, 360], ["Schiff", "SIMPLE_CHEMICAL", 186, 192], ["Schiff", "SIMPLE_CHEMICAL", 348, 354], ["Schiff bases", "TREATMENT", 186, 198], ["Schiff Bases", "PROBLEM", 285, 297], ["Schiff bases", "TREATMENT", 348, 360], ["the transamination reaction", "PROBLEM", 482, 509]]], ["Transamination reaction through Schiff bases from amino-acid to ketoacid and vice versa.Reaction Hetero Diels-Alder Other important bio-processes, that lately are attracting the interest of chemists and biologists, are related to the glycation of albumin that leads to the formation of important biomarkers, which are predictive of type II diabetes [124] or to the reaction between sugars and biologically relevant amines with the formation of Schiff bases.", [["Schiff bases", "CHEMICAL", 32, 44], ["amino-acid", "CHEMICAL", 50, 60], ["ketoacid", "CHEMICAL", 64, 72], ["type II diabetes", "DISEASE", 332, 348], ["amines", "CHEMICAL", 415, 421], ["Schiff bases", "CHEMICAL", 32, 44], ["amino-acid", "CHEMICAL", 50, 60], ["ketoacid", "CHEMICAL", 64, 72], ["sugars", "CHEMICAL", 382, 388], ["amines", "CHEMICAL", 415, 421], ["Schiff bases", "CHEMICAL", 444, 456], ["Schiff bases", "SIMPLE_CHEMICAL", 32, 44], ["amino-acid", "SIMPLE_CHEMICAL", 50, 60], ["ketoacid", "SIMPLE_CHEMICAL", 64, 72], ["albumin", "GENE_OR_GENE_PRODUCT", 247, 254], ["sugars", "SIMPLE_CHEMICAL", 382, 388], ["amines", "SIMPLE_CHEMICAL", 415, 421], ["Schiff bases", "SIMPLE_CHEMICAL", 444, 456], ["albumin", "PROTEIN", 247, 254], ["Transamination reaction", "PROBLEM", 0, 23], ["Schiff bases", "TEST", 32, 44], ["amino-acid", "TREATMENT", 50, 60], ["ketoacid", "TREATMENT", 64, 72], ["the glycation of albumin", "TREATMENT", 230, 254], ["type II diabetes", "PROBLEM", 332, 348], ["the reaction between sugars", "PROBLEM", 361, 388], ["Schiff bases", "OBSERVATION", 32, 44], ["Schiff bases", "OBSERVATION", 444, 456]]], ["These intermediates Schiff bases 66, in turn, evolve to Advanced Glycation Endproducts (AGE) through Amadori compounds (Scheme 17).Scheme 17.", [["AGE", "CHEMICAL", 88, 91], ["Schiff bases", "CHEMICAL", 20, 32], ["Advanced Glycation Endproducts", "SIMPLE_CHEMICAL", 56, 86], ["AGE", "SIMPLE_CHEMICAL", 88, 91], ["Amadori compounds", "SIMPLE_CHEMICAL", 101, 118], ["Schiff bases", "TEST", 20, 32], ["Advanced Glycation Endproducts", "TREATMENT", 56, 86], ["Schiff bases", "OBSERVATION", 20, 32], ["Advanced", "OBSERVATION_MODIFIER", 56, 64], ["Glycation Endproducts", "OBSERVATION", 65, 86]]], ["Protein glycation by glucose.AGEs are involved in many pathological conditions such as cardiovascular disease [125] , Alzheimer [126] and so on.", [["cardiovascular", "ANATOMY", 87, 101], ["glucose", "CHEMICAL", 21, 28], ["AGEs", "CHEMICAL", 29, 33], ["cardiovascular disease", "DISEASE", 87, 109], ["Alzheimer [126]", "DISEASE", 118, 133], ["glucose", "CHEMICAL", 21, 28], ["glucose", "SIMPLE_CHEMICAL", 21, 28], ["AGEs", "SIMPLE_CHEMICAL", 29, 33], ["Protein glycation", "TEST", 0, 17], ["glucose", "TEST", 21, 28], ["many pathological conditions", "PROBLEM", 50, 78], ["cardiovascular disease", "PROBLEM", 87, 109], ["Alzheimer", "PROBLEM", 118, 127]]], ["The following paragraphs will focus on the importance of Schiff discovery and present some examples of compounds featuring the Schiff bases as pharmaceutical garrisons.Some Application of Schiff Bases in Pharmaceutical ResearchThere are numerous publications covering the use of Schiff bases in therapeutic or biological applications either as potential drug candidates or diagnostic probes and analytical tools.", [["Schiff", "CHEMICAL", 57, 63], ["Schiff bases", "CHEMICAL", 127, 139], ["Schiff Bases", "CHEMICAL", 188, 200], ["Schiff bases", "CHEMICAL", 279, 291], ["Schiff", "SIMPLE_CHEMICAL", 57, 63], ["pharmaceutical garrisons", "PROBLEM", 143, 167], ["Schiff Bases", "TREATMENT", 188, 200], ["Pharmaceutical ResearchThere", "TREATMENT", 204, 232], ["Schiff bases", "TREATMENT", 279, 291], ["biological applications", "TREATMENT", 310, 333], ["diagnostic probes", "TEST", 373, 390], ["Schiff bases", "OBSERVATION", 127, 139], ["pharmaceutical garrisons", "OBSERVATION", 143, 167], ["Schiff Bases", "OBSERVATION", 188, 200], ["numerous", "OBSERVATION_MODIFIER", 237, 245], ["publications", "OBSERVATION", 246, 258]]], ["The activity of Schiff bases as anticancer compounds [127, 128] including radioactive nuclide complexes, antibacterial [129] [130] [131] [132] [133] [134] [135] , antifungal [25, 136, 137] , antiviral agents [138] , has been extensively studied.", [["anticancer", "ANATOMY", 32, 42], ["[127, 128", "CHEMICAL", 53, 62], ["[129] [130] [131] [132] [133] [134] [135] , antifungal [25, 136, 137", "CHEMICAL", 119, 187], ["Schiff bases", "CHEMICAL", 16, 28], ["Schiff", "SIMPLE_CHEMICAL", 16, 22], ["anticancer", "CANCER", 32, 42], ["[127, 128]", "SIMPLE_CHEMICAL", 53, 63], ["radioactive nuclide complexes", "SIMPLE_CHEMICAL", 74, 103], ["[129] [130] [131] [132] [133] [134] [135]", "SIMPLE_CHEMICAL", 119, 160], ["antifungal [25, 136, 137]", "SIMPLE_CHEMICAL", 163, 188], ["anticancer compounds", "TEST", 32, 52], ["radioactive nuclide complexes", "TEST", 74, 103], ["antifungal", "TEST", 163, 173], ["antiviral agents", "TREATMENT", 191, 207], ["Schiff bases", "OBSERVATION", 16, 28]]], ["Moreover, Schiff bases are present in various natural, semi-synthetic, and synthetic compounds (see Figure 4 for some examples) and have been demonstrated to be essential for their biological activities [139, 140] .Antiparassitic Schiff BasesMalaria is a severe morbidity of humans and other animals.", [["Schiff bases", "CHEMICAL", 10, 22], ["Schiff bases", "SIMPLE_CHEMICAL", 10, 22], ["humans", "ORGANISM", 275, 281], ["humans", "SPECIES", 275, 281], ["humans", "SPECIES", 275, 281], ["Antiparassitic Schiff BasesMalaria", "PROBLEM", 215, 249], ["a severe morbidity of humans", "PROBLEM", 253, 281], ["Schiff bases", "OBSERVATION", 10, 22], ["various", "OBSERVATION_MODIFIER", 38, 45], ["natural", "OBSERVATION_MODIFIER", 46, 53], ["Schiff BasesMalaria", "OBSERVATION", 230, 249], ["severe", "OBSERVATION_MODIFIER", 255, 261], ["morbidity", "OBSERVATION", 262, 271]]], ["It is caused by protozoa of the genus Plasmodium.", [["protozoa of the genus Plasmodium", "DISEASE", 16, 48], ["Plasmodium", "ORGANISM", 38, 48], ["protozoa", "OBSERVATION", 16, 24], ["genus Plasmodium", "OBSERVATION", 32, 48]]], ["It is initiated by a bite from an infected female Anopheles mosquito, which introduces the Plasmodium through saliva into the circulatory system.", [["circulatory system", "ANATOMY", 126, 144], ["female", "ORGANISM", 43, 49], ["Anopheles mosquito", "ORGANISM", 50, 68], ["Plasmodium", "ORGANISM", 91, 101], ["saliva", "ORGANISM_SUBSTANCE", 110, 116], ["circulatory system", "ANATOMICAL_SYSTEM", 126, 144], ["Anopheles mosquito", "SPECIES", 50, 68], ["Anopheles mosquito", "SPECIES", 50, 68], ["circulatory system", "ANATOMY", 126, 144]]], ["In the blood, the protists travel to the liver to mature and reproduce.", [["blood", "ANATOMY", 7, 12], ["liver", "ANATOMY", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["liver", "ORGAN", 41, 46], ["blood", "ANATOMY", 7, 12], ["liver", "ANATOMY", 41, 46]]], ["Typical symptoms of malaria include fever and headache, which, in severe cases, can progress to coma and eventually death.", [["malaria", "DISEASE", 20, 27], ["fever", "DISEASE", 36, 41], ["headache", "DISEASE", 46, 54], ["coma", "DISEASE", 96, 100], ["death", "DISEASE", 116, 121], ["Typical symptoms", "PROBLEM", 0, 16], ["malaria", "PROBLEM", 20, 27], ["fever", "PROBLEM", 36, 41], ["headache", "PROBLEM", 46, 54], ["malaria", "OBSERVATION", 20, 27], ["fever", "OBSERVATION", 36, 41]]], ["The imino-group of Schiff bases has been shown to be valuable function to confer antimalarial activity.", [["Schiff bases", "CHEMICAL", 19, 31], ["Schiff bases", "OBSERVATION", 19, 31]]], ["For example, ancistrocladidine (68, Figure 4) , a secondary metabolite produced by plants belonging to the families Ancistrocladaceae and Dioncophyllaceae, features an imine group in its structure.", [["ancistrocladidine", "CHEMICAL", 13, 30], ["imine", "CHEMICAL", 168, 173], ["ancistrocladidine", "CHEMICAL", 13, 30], ["imine", "CHEMICAL", 168, 173], ["ancistrocladidine", "SIMPLE_CHEMICAL", 13, 30], ["Ancistrocladaceae", "GENE_OR_GENE_PRODUCT", 116, 133], ["Dioncophyllaceae", "SIMPLE_CHEMICAL", 138, 154], ["imine", "SIMPLE_CHEMICAL", 168, 173], ["ancistrocladidine", "TEST", 13, 30], ["a secondary metabolite", "PROBLEM", 48, 70], ["Dioncophyllaceae", "TREATMENT", 138, 154], ["imine group", "OBSERVATION", 168, 179]]], ["The compound has shown potent activity against P. falciparum K1.", [["P. falciparum", "DISEASE", 47, 60], ["P. falciparum", "ORGANISM", 47, 60], ["K1", "ORGANISM", 61, 63], ["P. falciparum", "SPECIES", 47, 60], ["P. falciparum", "SPECIES", 47, 60], ["P. falciparum K1", "PROBLEM", 47, 63], ["potent activity", "OBSERVATION_MODIFIER", 23, 38]]], ["Some novel aldimine and hydrazone isoquinoline derivatives, prepared by reacting 1-formyl-5-nitroisoquinoline with amines (Scheme 18), showed activity against a chloroquine-resistant Plasmodium falciparum strain (ACC Niger).", [["aldimine", "CHEMICAL", 11, 19], ["hydrazone isoquinoline", "CHEMICAL", 24, 46], ["1-formyl-5-nitroisoquinoline", "CHEMICAL", 81, 109], ["amines", "CHEMICAL", 115, 121], ["chloroquine", "CHEMICAL", 161, 172], ["Plasmodium falciparum", "DISEASE", 183, 204], ["aldimine", "CHEMICAL", 11, 19], ["hydrazone isoquinoline", "CHEMICAL", 24, 46], ["1-formyl-5-nitroisoquinoline", "CHEMICAL", 81, 109], ["amines", "CHEMICAL", 115, 121], ["chloroquine", "CHEMICAL", 161, 172], ["aldimine", "SIMPLE_CHEMICAL", 11, 19], ["hydrazone isoquinoline derivatives", "SIMPLE_CHEMICAL", 24, 58], ["1-formyl-5-nitroisoquinoline", "SIMPLE_CHEMICAL", 81, 109], ["amines", "SIMPLE_CHEMICAL", 115, 121], ["Scheme 18)", "SIMPLE_CHEMICAL", 123, 133], ["chloroquine", "SIMPLE_CHEMICAL", 161, 172], ["Plasmodium falciparum", "ORGANISM", 183, 204], ["Plasmodium falciparum", "SPECIES", 183, 204], ["Plasmodium falciparum", "SPECIES", 183, 204], ["Some novel aldimine and hydrazone isoquinoline derivatives", "TREATMENT", 0, 58], ["a chloroquine", "TREATMENT", 159, 172], ["resistant Plasmodium falciparum strain", "PROBLEM", 173, 211], ["aldimine", "OBSERVATION", 11, 19]]], ["In particular the corresponding Schiff base of formyl-5-nitroisoquinoline (E)-N-((5-nitroisoquinolin-1-yl)-methylene)-1-(2-(trifluoromethyl)-phenyl)methanamine (73, Scheme 18) showed an IC 50 of 0.7 \u00b5g/mL against P. falciparium [137] .Antiparassitic Schiff BasesScheme 18.", [["formyl-5-nitroisoquinoline", "CHEMICAL", 47, 73], ["E)-N-((5-nitroisoquinolin-1-yl)-methylene)-1-(2-(trifluoromethyl)-phenyl)methanamine", "CHEMICAL", 75, 159], ["Schiff base", "CHEMICAL", 32, 43], ["formyl-5-nitroisoquinoline (E)-N-((5-nitroisoquinolin-1-yl)-methylene)-1-(2-(trifluoromethyl)-phenyl)methanamine", "CHEMICAL", 47, 159], ["Schiff BasesScheme 18", "CHEMICAL", 250, 271], ["Schiff", "SIMPLE_CHEMICAL", 32, 38], ["formyl-5-nitroisoquinoline (E)-N-((5-nitroisoquinolin-1-yl)-methylene)-1-(2-(trifluoromethyl)-phenyl)methanamine", "SIMPLE_CHEMICAL", 47, 159], ["P. falciparium", "SPECIES", 213, 227], ["P. falciparium", "SPECIES", 213, 227], ["the corresponding Schiff base of formyl", "TREATMENT", 14, 53], ["nitroisoquinoline (E)", "TREATMENT", 56, 77], ["nitroisoquinolin", "TREATMENT", 84, 100], ["methylene)", "TREATMENT", 107, 117], ["(trifluoromethyl)-phenyl)methanamine", "TREATMENT", 123, 159], ["an IC", "TREATMENT", 183, 188], ["Schiff BasesScheme", "OBSERVATION", 250, 268]]], ["Synthesis of some 5-nitroisoquinolines Schiff bases.Salicylidene Amines as Bioactive CompoundsSalicylidenebenzylamine derivatives have been studied extensively for their biological activities [121] [122] [123] .", [["5-nitroisoquinolines", "CHEMICAL", 18, 38], ["Salicylidene Amines", "CHEMICAL", 52, 71], ["Salicylidenebenzylamine", "CHEMICAL", 94, 117], ["5-nitroisoquinolines", "CHEMICAL", 18, 38], ["Schiff bases", "CHEMICAL", 39, 51], ["Salicylidene Amines", "CHEMICAL", 52, 71], ["Salicylidenebenzylamine", "CHEMICAL", 94, 117], ["5-nitroisoquinolines Schiff bases", "SIMPLE_CHEMICAL", 18, 51], ["Salicylidene Amines", "SIMPLE_CHEMICAL", 52, 71], ["Salicylidenebenzylamine derivatives", "SIMPLE_CHEMICAL", 94, 129], ["Synthesis", "TREATMENT", 0, 9], ["Salicylidene Amines", "TREATMENT", 52, 71], ["Bioactive CompoundsSalicylidenebenzylamine derivatives", "TREATMENT", 75, 129], ["bases", "ANATOMY_MODIFIER", 46, 51]]], ["Schiff base complexes derived from 4-hydroxysalicylaldehyde and amines have strong anticancer activity, e.g., against Ehrlich ascites carcinoma (EAC) [141] .", [["anticancer", "ANATOMY", 83, 93], ["Ehrlich ascites carcinoma", "ANATOMY", 118, 143], ["EAC", "ANATOMY", 145, 148], ["4-hydroxysalicylaldehyde", "CHEMICAL", 35, 59], ["amines", "CHEMICAL", 64, 70], ["Ehrlich ascites carcinoma", "DISEASE", 118, 143], ["Schiff base", "CHEMICAL", 0, 11], ["4-hydroxysalicylaldehyde", "CHEMICAL", 35, 59], ["amines", "CHEMICAL", 64, 70], ["Schiff", "SIMPLE_CHEMICAL", 0, 6], ["4-hydroxysalicylaldehyde", "SIMPLE_CHEMICAL", 35, 59], ["amines", "SIMPLE_CHEMICAL", 64, 70], ["anticancer", "CANCER", 83, 93], ["Ehrlich ascites carcinoma", "CANCER", 118, 143], ["EAC", "CANCER", 145, 148], ["Schiff base complexes", "TEST", 0, 21], ["amines", "TREATMENT", 64, 70], ["Ehrlich ascites carcinoma", "PROBLEM", 118, 143], ["carcinoma", "OBSERVATION", 134, 143]]], ["N-(salicylidene)-2-hydroxyaniline, in turn, showed activity against Mycobacterium tuberculosis H37Rv [136] .", [["N-(salicylidene)-2-hydroxyaniline", "CHEMICAL", 0, 33], ["Mycobacterium tuberculosis", "DISEASE", 68, 94], ["N-(salicylidene)-2-hydroxyaniline", "CHEMICAL", 0, 33], ["N-(salicylidene)-2-hydroxyaniline", "SIMPLE_CHEMICAL", 0, 33], ["Mycobacterium tuberculosis", "ORGANISM", 68, 94], ["Mycobacterium tuberculosis H37Rv", "SPECIES", 68, 100], ["Mycobacterium tuberculosis H37Rv", "SPECIES", 68, 100], ["salicylidene)", "TREATMENT", 3, 16], ["hydroxyaniline", "TREATMENT", 19, 33], ["Mycobacterium tuberculosis H37Rv", "PROBLEM", 68, 100]]], ["The antibacterial activity of a series of 5-chlorosalicylaldehyde-Shiff bases (Scaffolds 74 and 75 Figure 5 ) was studied against several strains including Escherichia coli and Staphylococcus aureus [142] .", [["5-chlorosalicylaldehyde", "CHEMICAL", 42, 65], ["Scaffolds 74 and 75 Figure 5", "CHEMICAL", 79, 107], ["5-chlorosalicylaldehyde-Shiff bases", "CHEMICAL", 42, 77], ["5-chlorosalicylaldehyde-Shiff bases", "SIMPLE_CHEMICAL", 42, 77], ["Escherichia coli", "ORGANISM", 156, 172], ["Staphylococcus aureus", "ORGANISM", 177, 198], ["Escherichia coli", "SPECIES", 156, 172], ["Staphylococcus aureus", "SPECIES", 177, 198], ["Escherichia coli", "SPECIES", 156, 172], ["Staphylococcus aureus", "SPECIES", 177, 198], ["5-chlorosalicylaldehyde-Shiff bases (Scaffolds", "TREATMENT", 42, 88], ["several strains", "PROBLEM", 130, 145], ["Escherichia coli", "PROBLEM", 156, 172], ["Staphylococcus aureus", "PROBLEM", 177, 198], ["antibacterial activity", "OBSERVATION", 4, 26], ["Escherichia coli", "OBSERVATION", 156, 172], ["Staphylococcus aureus", "OBSERVATION", 177, 198]]], ["Cu(II) and Cd(II) complexes 76 ( Figure 6 ) of more highly functionalized salicylidenebenzylamines present higher activity with respect to the free molecules [143] .Other Antibacterial Schiff BasesSchiff bases characterized by a 2,4-dichloro-5-fluorophenyl moiety (Figure 7 ) completely inhibited the growth of S. aureus, E. coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae with MIC values ranging from 6.3 to 12.5 \u00b5g/mL, which are comparable to ciprofloxacin [134] .", [["Cu(II", "CHEMICAL", 0, 5], ["Cd", "CHEMICAL", 11, 13], ["salicylidenebenzylamines", "CHEMICAL", 74, 98], ["2,4-dichloro-5-fluorophenyl", "CHEMICAL", 229, 256], ["ciprofloxacin", "CHEMICAL", 453, 466], ["Cu(II)", "CHEMICAL", 0, 6], ["Cd(II)", "CHEMICAL", 11, 17], ["salicylidenebenzylamines", "CHEMICAL", 74, 98], ["Schiff BasesSchiff bases", "CHEMICAL", 185, 209], ["2,4-dichloro-5-fluorophenyl", "CHEMICAL", 229, 256], ["ciprofloxacin", "CHEMICAL", 453, 466], ["Cu(II)", "SIMPLE_CHEMICAL", 0, 6], ["Cd(II)", "SIMPLE_CHEMICAL", 11, 17], ["salicylidenebenzylamines", "SIMPLE_CHEMICAL", 74, 98], ["2,4-dichloro-5-fluorophenyl moiety", "SIMPLE_CHEMICAL", 229, 263], ["S. aureus", "ORGANISM", 311, 320], ["E. coli", "ORGANISM", 322, 329], ["Pseudomonas aeruginosa", "ORGANISM", 331, 353], ["Klebsiella pneumoniae", "ORGANISM", 359, 380], ["ciprofloxacin", "SIMPLE_CHEMICAL", 453, 466], ["S. aureus", "SPECIES", 311, 320], ["E. coli", "SPECIES", 322, 329], ["Pseudomonas aeruginosa", "SPECIES", 331, 353], ["Klebsiella pneumoniae", "SPECIES", 359, 380], ["S. aureus", "SPECIES", 311, 320], ["E. coli", "SPECIES", 322, 329], ["Pseudomonas aeruginosa", "SPECIES", 331, 353], ["Klebsiella pneumoniae", "SPECIES", 359, 380], ["Cd(II) complexes", "TEST", 11, 27], ["Figure", "TEST", 33, 39], ["Other Antibacterial Schiff BasesSchiff bases", "TEST", 165, 209], ["dichloro", "TEST", 233, 241], ["S. aureus", "PROBLEM", 311, 320], ["E. coli", "PROBLEM", 322, 329], ["Pseudomonas aeruginosa", "PROBLEM", 331, 353], ["Klebsiella pneumoniae", "PROBLEM", 359, 380], ["MIC values", "TEST", 386, 396], ["ciprofloxacin", "TREATMENT", 453, 466], ["Antibacterial Schiff", "OBSERVATION", 171, 191], ["aureus", "OBSERVATION", 314, 320], ["Klebsiella pneumoniae", "OBSERVATION", 359, 380]]], ["The secondary metabolites of the plant Actinomadura rubra, madurahydroxylactones, have been transformed into the corresponding Schiff bases 80 (Figure 8 ) [144] .", [["madurahydroxylactones", "CHEMICAL", 59, 80], ["madurahydroxylactones", "CHEMICAL", 59, 80], ["Schiff bases", "CHEMICAL", 127, 139], ["Actinomadura rubra", "ORGANISM", 39, 57], ["madurahydroxylactones", "SIMPLE_CHEMICAL", 59, 80], ["Actinomadura rubra", "SPECIES", 39, 57], ["Actinomadura rubra", "SPECIES", 39, 57], ["the plant Actinomadura rubra", "TREATMENT", 29, 57], ["madurahydroxylactones", "TREATMENT", 59, 80], ["Schiff bases", "TEST", 127, 139], ["secondary metabolites", "OBSERVATION", 4, 25], ["Actinomadura rubra", "OBSERVATION", 39, 57]]], ["Madurahydroxylactone-derived compounds inhibited in vitro B. subtilis, Micrococcus flavus, Sarcina lutea, and S. aureus giving MIC values varying from 0.2 to 3.1 \u00b5g/mL [145] .Antifungal Schiff BasesSchiff bases of chitosan 69 and 70 (See Figure 4 ) have shown antifungal activity against Botrytis cinerea and Colletotrichum lagenarium [140] .", [["Sarcina lutea", "ANATOMY", 91, 104], ["Madurahydroxylactone", "CHEMICAL", 0, 20], ["MIC", "CHEMICAL", 127, 130], ["chitosan", "CHEMICAL", 214, 222], ["Madurahydroxylactone", "CHEMICAL", 0, 20], ["Madurahydroxylactone", "SIMPLE_CHEMICAL", 0, 20], ["B. subtilis", "ORGANISM", 58, 69], ["Micrococcus flavus", "ORGANISM", 71, 89], ["Sarcina lutea", "ORGANISM", 91, 104], ["S. aureus", "ORGANISM", 110, 119], ["chitosan 69", "SIMPLE_CHEMICAL", 214, 225], ["Botrytis cinerea", "ORGANISM", 288, 304], ["Colletotrichum lagenarium", "ORGANISM", 309, 334], ["B. subtilis", "SPECIES", 58, 69], ["Micrococcus flavus", "SPECIES", 71, 89], ["Sarcina lutea", "SPECIES", 91, 104], ["S. aureus", "SPECIES", 110, 119], ["Botrytis cinerea", "SPECIES", 288, 304], ["Colletotrichum lagenarium", "SPECIES", 309, 334], ["B. subtilis", "SPECIES", 58, 69], ["Micrococcus flavus", "SPECIES", 71, 89], ["Sarcina lutea", "SPECIES", 91, 104], ["S. aureus", "SPECIES", 110, 119], ["Botrytis cinerea", "SPECIES", 288, 304], ["Colletotrichum lagenarium", "SPECIES", 309, 334], ["Madurahydroxylactone", "TREATMENT", 0, 20], ["Micrococcus flavus", "PROBLEM", 71, 89], ["Sarcina lutea", "PROBLEM", 91, 104], ["S. aureus", "PROBLEM", 110, 119], ["MIC values", "TEST", 127, 137], ["Antifungal Schiff BasesSchiff bases", "TEST", 175, 210], ["chitosan", "TEST", 214, 222], ["antifungal activity", "TREATMENT", 260, 279], ["Botrytis cinerea", "PROBLEM", 288, 304], ["Micrococcus flavus", "OBSERVATION", 71, 89], ["aureus", "OBSERVATION", 113, 119]]], ["Imine derivatives having a 2,4-dichloro-5-fluorophenyl moiety (see Figure 7 ) and the Schiff bases 82, reported in Figure 9 , inhibited the growth of fungal clinical isolates, such as Aspergillus fumigatus, Aspergillus flavus, Penicillium marneffei, Trichophyton mentagrophytes.", [["Imine", "CHEMICAL", 0, 5], ["2,4-dichloro-5-fluorophenyl", "CHEMICAL", 27, 54], ["Aspergillus fumigatus", "DISEASE", 184, 205], ["Aspergillus flavus", "DISEASE", 207, 225], ["Imine", "CHEMICAL", 0, 5], ["2,4-dichloro-5-fluorophenyl", "CHEMICAL", 27, 54], ["Schiff bases", "CHEMICAL", 86, 98], ["Imine derivatives", "SIMPLE_CHEMICAL", 0, 17], ["2,4-dichloro-5-fluorophenyl moiety", "SIMPLE_CHEMICAL", 27, 61], ["Schiff bases 82", "SIMPLE_CHEMICAL", 86, 101], ["Aspergillus fumigatus", "ORGANISM", 184, 205], ["Aspergillus flavus", "ORGANISM", 207, 225], ["Penicillium marneffei", "ORGANISM", 227, 248], ["Trichophyton mentagrophytes", "ORGANISM", 250, 277], ["Aspergillus fumigatus", "SPECIES", 184, 205], ["Aspergillus flavus", "SPECIES", 207, 225], ["Penicillium marneffei", "SPECIES", 227, 248], ["Trichophyton mentagrophytes", "SPECIES", 250, 277], ["Aspergillus fumigatus", "SPECIES", 184, 205], ["Aspergillus flavus", "SPECIES", 207, 225], ["Penicillium marneffei", "SPECIES", 227, 248], ["Trichophyton mentagrophytes", "SPECIES", 250, 277], ["Imine derivatives", "PROBLEM", 0, 17], ["a 2,4-dichloro-5-fluorophenyl moiety", "TREATMENT", 25, 61], ["the Schiff bases", "TEST", 82, 98], ["fungal clinical isolates", "PROBLEM", 150, 174], ["Aspergillus fumigatus", "PROBLEM", 184, 205], ["Aspergillus flavus", "PROBLEM", 207, 225], ["Penicillium marneffei", "PROBLEM", 227, 248], ["Trichophyton mentagrophytes", "PROBLEM", 250, 277], ["Aspergillus fumigatus", "OBSERVATION", 184, 205], ["Aspergillus flavus", "OBSERVATION", 207, 225], ["Penicillium marneffei", "OBSERVATION", 227, 248], ["Trichophyton mentagrophytes", "OBSERVATION", 250, 277]]], ["The compounds showed MIC values in the range of 6.3-12.5 \u00b5g/mL, which is comparable to that of fluconazole [134] .", [["MIC", "CHEMICAL", 21, 24], ["fluconazole", "CHEMICAL", 95, 106], ["fluconazole", "CHEMICAL", 95, 106], ["MIC", "SIMPLE_CHEMICAL", 21, 24], ["fluconazole", "SIMPLE_CHEMICAL", 95, 106], ["The compounds", "TEST", 0, 13], ["MIC values", "TEST", 21, 31], ["fluconazole", "TREATMENT", 95, 106]]], ["The isatin-derived Schiff bases 83-86 ( Figure 10 ) showed an interesting activity against Microsporum audouinii (MIC range 2.4-9.7 \u00b5g/mL) and Microsporum gypseum (MIC range 1.2-9.7 \u00b5g/mL) [43] .", [["isatin", "CHEMICAL", 4, 10], ["Schiff bases 83-86", "CHEMICAL", 19, 37], ["isatin", "CHEMICAL", 4, 10], ["Schiff bases", "CHEMICAL", 19, 31], ["isatin", "SIMPLE_CHEMICAL", 4, 10], ["Schiff bases 83-86", "SIMPLE_CHEMICAL", 19, 37], ["Microsporum audouinii", "ORGANISM", 91, 112], ["Microsporum gypseum", "ORGANISM", 143, 162], ["Microsporum audouinii", "SPECIES", 91, 112], ["Microsporum gypseum", "SPECIES", 143, 162], ["Microsporum audouinii", "SPECIES", 91, 112], ["Microsporum gypseum", "SPECIES", 143, 162], ["The isatin", "TEST", 0, 10], ["Schiff bases", "TEST", 19, 31], ["Microsporum audouinii", "TEST", 91, 112], ["MIC range", "TEST", 114, 123], ["Microsporum gypseum", "TEST", 143, 162], ["MIC range", "TEST", 164, 173]]], ["The compounds reported inhibited also Candida albicans, Aspergillus niger, Cryptococcus neoformans, T. mentagrophytes, E. floccosum, and Histoplasma capsulatum (MIC range 10-79 \u00b5g/mL [146] .Antiviral Schiff BasesThe Schiff bases of modified 3-hydroxyguanidines [147, 148] , have been prepared and tested against mouse hepatitis virus (MHV), in particular, compound 87 ( Figure 11 ) inhibited the viral replication by 50% when used at a concentration of 3.2 \u00b5M.", [["Candida albicans", "DISEASE", 38, 54], ["Cryptococcus neoformans", "DISEASE", 75, 98], ["Histoplasma capsulatum", "DISEASE", 137, 159], ["3-hydroxyguanidines", "CHEMICAL", 241, 260], ["147, 148]", "CHEMICAL", 262, 271], ["mouse hepatitis virus", "DISEASE", 312, 333], ["Schiff bases", "CHEMICAL", 216, 228], ["3-hydroxyguanidines", "CHEMICAL", 241, 260], ["Candida albicans", "ORGANISM", 38, 54], ["Aspergillus niger", "ORGANISM", 56, 73], ["Cryptococcus neoformans", "ORGANISM", 75, 98], ["T. mentagrophytes", "ORGANISM", 100, 117], ["E. floccosum", "ORGANISM", 119, 131], ["Histoplasma capsulatum", "ORGANISM", 137, 159], ["3-hydroxyguanidines [147, 148]", "SIMPLE_CHEMICAL", 241, 271], ["mouse hepatitis virus", "ORGANISM", 312, 333], ["MHV", "ORGANISM", 335, 338], ["Candida albicans", "SPECIES", 38, 54], ["Aspergillus niger", "SPECIES", 56, 73], ["Cryptococcus neoformans", "SPECIES", 75, 98], ["T. mentagrophytes", "SPECIES", 100, 117], ["E. floccosum", "SPECIES", 119, 131], ["Histoplasma capsulatum", "SPECIES", 137, 159], ["mouse", "SPECIES", 312, 317], ["hepatitis virus", "SPECIES", 318, 333], ["Candida albicans", "SPECIES", 38, 54], ["Aspergillus niger", "SPECIES", 56, 73], ["Cryptococcus neoformans", "SPECIES", 75, 98], ["T. mentagrophytes", "SPECIES", 100, 117], ["E. floccosum", "SPECIES", 119, 131], ["Histoplasma capsulatum", "SPECIES", 137, 159], ["mouse hepatitis virus", "SPECIES", 312, 333], ["MHV", "SPECIES", 335, 338], ["Candida albicans", "PROBLEM", 38, 54], ["Aspergillus niger", "TEST", 56, 73], ["Cryptococcus neoformans", "PROBLEM", 75, 98], ["T. mentagrophytes", "TEST", 100, 117], ["E. floccosum", "TEST", 119, 131], ["Histoplasma capsulatum", "TEST", 137, 159], ["Antiviral Schiff Bases", "TREATMENT", 190, 212], ["mouse hepatitis virus", "PROBLEM", 312, 333], ["the viral replication", "TREATMENT", 392, 413], ["Candida albicans", "OBSERVATION", 38, 54], ["Cryptococcus neoformans", "OBSERVATION", 75, 98], ["Schiff Bases", "OBSERVATION", 200, 212], ["Schiff bases", "OBSERVATION", 216, 228], ["viral replication", "OBSERVATION", 396, 413]]], ["Similarly, a set of imine derivatives of abacavir [148] have been prepared and tested for their antiviral activity.", [["imine", "CHEMICAL", 20, 25], ["abacavir", "CHEMICAL", 41, 49], ["imine", "CHEMICAL", 20, 25], ["abacavir", "CHEMICAL", 41, 49], ["imine derivatives", "SIMPLE_CHEMICAL", 20, 37], ["abacavir [148]", "SIMPLE_CHEMICAL", 41, 55], ["a set of imine derivatives of abacavir", "TREATMENT", 11, 49]]], ["Compounds 88-90 in Figure 12 were highly effective against the human immunodeficiency virus-type 1 (HIV-1).", [["Compounds 88-90", "CHEMICAL", 0, 15], ["human immunodeficiency virus-type", "DISEASE", 63, 96], ["human immunodeficiency virus-type 1", "ORGANISM", 63, 98], ["HIV-1", "ORGANISM", 100, 105], ["human immunodeficiency virus-type 1", "SPECIES", 63, 98], ["HIV-1", "SPECIES", 100, 105], ["human immunodeficiency virus-type 1", "SPECIES", 63, 98], ["HIV-1", "SPECIES", 100, 105], ["Compounds", "TEST", 0, 9], ["the human immunodeficiency virus", "PROBLEM", 59, 91]]], ["The molecules, which are reported to be Abacavir prodrugs, showed a 50% protection of human leukemic cells (CEM) at micromolar and even nanomolar concentration (compound 87, EC 50 = 50 nM).Hybrid StructuresThe use of hybrid structures to achieve new pharmacological activities is widely used in medicinal chemistry.", [["leukemic cells", "ANATOMY", 92, 106], ["CEM", "ANATOMY", 108, 111], ["Abacavir", "CHEMICAL", 40, 48], ["Abacavir prodrugs", "SIMPLE_CHEMICAL", 40, 57], ["human", "ORGANISM", 86, 91], ["leukemic cells", "CELL", 92, 106], ["CEM", "CELL", 108, 111], ["human leukemic cells", "CELL_TYPE", 86, 106], ["CEM", "CELL_LINE", 108, 111], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["Abacavir prodrugs", "TREATMENT", 40, 57], ["human leukemic cells", "PROBLEM", 86, 106], ["CEM", "TEST", 108, 111], ["micromolar", "TEST", 116, 126], ["nanomolar concentration", "TEST", 136, 159], ["EC", "TEST", 174, 176], ["hybrid structures", "TREATMENT", 217, 234], ["leukemic cells", "OBSERVATION", 92, 106]]], ["In an attempt to achieve novel antitumor compounds, Schiff and Mannich bases of fluoroquinolones have been prepared and tested in cell line [149] (Figure 13 ).", [["antitumor", "ANATOMY", 31, 40], ["cell line", "ANATOMY", 130, 139], ["fluoroquinolones", "CHEMICAL", 80, 96], ["Schiff", "CHEMICAL", 52, 58], ["Mannich bases", "CHEMICAL", 63, 76], ["fluoroquinolones", "CHEMICAL", 80, 96], ["antitumor", "CANCER", 31, 40], ["Schiff", "SIMPLE_CHEMICAL", 52, 58], ["fluoroquinolones", "SIMPLE_CHEMICAL", 80, 96], ["cell line [149", "CELL", 130, 144], ["novel antitumor compounds", "TREATMENT", 25, 50], ["Schiff and Mannich bases", "TREATMENT", 52, 76], ["fluoroquinolones", "TREATMENT", 80, 96]]], ["In particular compounds 92 depicted in Figure 13 showed potent activity against L1210, HL60 and CHO tumor cells in the MTT assay.ConclusionsOn typing \"Schiff bases\" in any chemistry database a countless number of records appears as proof of the importance of such derivatives in chemistry.", [["L1210", "ANATOMY", 80, 85], ["HL60", "ANATOMY", 87, 91], ["CHO tumor cells", "ANATOMY", 96, 111], ["tumor", "DISEASE", 100, 105], ["MTT", "CHEMICAL", 119, 122], ["Schiff bases", "CHEMICAL", 151, 163], ["L1210", "CELL", 80, 85], ["HL60", "CELL", 87, 91], ["CHO tumor cells", "CELL", 96, 111], ["L1210", "CELL_LINE", 80, 85], ["HL60", "CELL_LINE", 87, 91], ["CHO tumor cells", "CELL_LINE", 96, 111], ["HL60", "TEST", 87, 91], ["CHO tumor cells", "PROBLEM", 96, 111], ["the MTT assay", "TEST", 115, 128], ["ConclusionsOn typing", "TEST", 129, 149], ["Schiff bases", "PROBLEM", 151, 163], ["such derivatives", "TREATMENT", 259, 275], ["potent activity", "OBSERVATION_MODIFIER", 56, 71], ["tumor cells", "OBSERVATION", 100, 111]]], ["They are present as reactants in umpteen synthetic organic processes, as important scaffolds in organometallic chemistry, as backbones of precious catalysts and as pharmaceutical presidiums against a series of different diseases and pathological states.", [["organometallic chemistry", "TEST", 96, 120], ["precious catalysts", "TREATMENT", 138, 156], ["different diseases and pathological states", "PROBLEM", 210, 252]]], ["According to the scope of this review we have tried to give simple headlines not pretending to account the multidisciplinary applications of Schiff Bases.", [["Schiff Bases", "OBSERVATION", 141, 153]]], ["The short section on N-metalloimines has been included because they must be considered as synthetic equivalents of the Schiff base arising from aldehydes/ketones and the simplest amine: ammonia.", [["N-metalloimines", "CHEMICAL", 21, 36], ["aldehydes/ketones", "CHEMICAL", 144, 161], ["amine", "CHEMICAL", 179, 184], ["ammonia", "CHEMICAL", 186, 193], ["N-metalloimines", "CHEMICAL", 21, 36], ["Schiff base", "CHEMICAL", 119, 130], ["aldehydes", "CHEMICAL", 144, 153], ["ketones", "CHEMICAL", 154, 161], ["amine", "CHEMICAL", 179, 184], ["ammonia", "CHEMICAL", 186, 193], ["N-metalloimines", "SIMPLE_CHEMICAL", 21, 36], ["Schiff", "SIMPLE_CHEMICAL", 119, 125], ["aldehydes", "SIMPLE_CHEMICAL", 144, 153], ["ketones", "SIMPLE_CHEMICAL", 154, 161], ["amine", "SIMPLE_CHEMICAL", 179, 184], ["ammonia", "SIMPLE_CHEMICAL", 186, 193], ["metalloimines", "TREATMENT", 23, 36], ["the Schiff base", "TEST", 115, 130], ["aldehydes/ketones", "TEST", 144, 161]]]]}